UCB [ADDRESS_764506] Number: 2017-000957- 37
IND Number: 128708
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Protocol/Amendment number Date Type of amendment
Final protocol 19 Apr 2017 Not applicable
Protocol amendment 1 30 May 2017 Nonsubstantial
Protocol amendment 1.1 (CZ) 07 Sep 2017 Substantial
Protocol amendment 1.1 (DE) [ADDRESS_764507] 2017 Nonsubstantial
Protocol amendment 1.1 (NL) 18 Sep 2017 Substantial
Protocol amendment 2 05 Mar 2018 Substantial
Protocol amendment 2.1 (CZ) 07 Mar 2018 Substantial
Protocol amendment 2.2 (DE) 07 Mar 2018 Substantial
Protocol amendment 2.3 (NL) 27 Apr 2018 Substantial
Protocol amendment 2.4 (CZ) 03 Jul 2018 Substantial
Protocol amendment 3 27Feb 2019 Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.PUBLIC COPY Sponsor:
PUBLIC COPY Sponsor:
UCB Biopharma SPRL
PUBLIC COPY UCB Biopharma SPRL
Allée de la Recherche 60
PUBLIC COPY Allée de la Recherche 60
1070 Brussels
PUBLIC COPY 1070 Brussels
PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization N SUBJECTS 
This document cannot be used to support any marketing authorization N SUBJECTS 
UCB Biopharma SPRL
This document cannot be used to support any marketing authorization UCB Biopharma SPRL
Allée de la Recherche 60
This document cannot be used to support any marketing authorization Allée de la Recherche 60
1070 Brussels
This document cannot be used to support any marketing authorization 1070 Brussels
BELGIUM
This document cannot be used to support any marketing authorization BELGIUM
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Protocol amendment 1.1 (NL)
This document cannot be used to support any marketing authorization Protocol amendment 1.1 (NL)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Protocol amendment 2.1 (CZ)
This document cannot be used to support any marketing authorization Protocol amendment 2.1 (CZ)
This document cannot be used to support any marketing authorization Protocol amendment 2.2 (DE)
This document cannot be used to support any marketing authorization Protocol amendment 2.2 (DE)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Protocol amendment 2.3 (NL)
This document cannot be used to support any marketing authorization Protocol amendment 2.3 (NL)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Protocol amendment 2.4 (CZ)
This document cannot be used to support any marketing authorization Protocol amendment 2.4 (CZ)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Protocol amendment 3
This document cannot be used to support any marketing authorization Protocol amendment 3
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.BELGIUM
application and any extensions or variations thereof.BELGIUM
Date
application and any extensions or variations thereof.Date
application and any extensions or variations thereof.19 Apr 2017
application and any extensions or variations thereof.19 Apr 2017
application and any extensions or variations thereof.30 May 2017
application and any extensions or variations thereof.30 May 2017
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Protocol amendment 2.2 (DE)
application and any extensions or variations thereof.Protocol amendment 2.2 (DE)
application and any extensions or variations thereof.application and any extensions or variations thereof.Protocol amendment 2.3 (NL)
application and any extensions or variations thereof.Protocol amendment 2.3 (NL)
application and any extensions or variations thereof.application and any extensions or variations thereof.Protocol amendment 2.4 (CZ)
application and any extensions or variations thereof.Protocol amendment 2.4 (CZ)
application and any extensions or variations thereof.application and any extensions or variations thereof.Protocol amendment [ADDRESS_764508] INFORMATION
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Sponsor Study Physician
Name:
[CONTACT_2761]: UCB Celltech, [ADDRESS_764509], Slough, Berkshire, SL1 3WE, [LOCATION_006]
Phone:
Fax:
Exploratory Project Manager
Name:
[CONTACT_2761]: Alfred-Nobel-Str 10, [ZIP_CODE] Monheim, [LOCATION_013]
Phone:
Fax:
Clinical Trial Biostatistician
Name:
[CONTACT_2761]: UCB Celltech, [ADDRESS_764510], Slough, Berkshire, SL1 3WE, [LOCATION_006]
Phone:
Fax:
Clinical Monitoring Contract Research Organization
Name: [CONTACT_352338] (IRL) Limited
Address: One Kilmainham Square, Inchicore Road, Kilmainham, Dublin 8, Ireland
Phone: [PHONE_12055]
Fax: [PHONE_12056]PUBLIC COPY PUBLIC COPY PUBLIC COPY Str 10, [ADDRESS_764511] Research Organization
Name:
[CONTACT_581733]:
This document cannot be used to support any marketing authorization Address:
This document cannot be used to support any marketing authorization Address:
This document cannot be used to support any marketing authorization Phone:
This document cannot be used to support any marketing authorization Phone:
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Fax:
This document cannot be used to support any marketing authorization Fax:
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.application and any extensions or variations thereof.UCB Celltech, [ADDRESS_764512] Research Organization
PAREXEL International (IRL) Limited
application and any extensions or variations thereof.PAREXEL International (IRL) Limited
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 3 of 136SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: [PHONE_301] 21
US and Canada: +[PHONE_299] or +[PHONE_300]
Email Global: [EMAIL_311] 
PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB [ADDRESS_764513] OF ABBREVIATIONS..................................................................................................10
1 SUMMARY.....................................................................................................................15
2 INTRODUCTION ...........................................................................................................16
2.1 Axial spondyloarthritis.....................................................................................................16
2.2 Bimekizumab ...................................................................................................................17
2.2.1 Clinical experience with bimekizumab................................................................18
2.2.2 Nonclinical studies with bimekizumab................................................................19
2.3 Certolizumab pegol..........................................................................................................19
2.3.1 Clinical experience with CZP..............................................................................20
2.4 Study rationale .................................................................................................................20
3 STUDY OBJECTIVE(S) .................................................................................................21
3.1 Primary objective .............................................................................................................21
3.2 Secondary objective .........................................................................................................21
3.3 Other exploratory objectives............................................................................................21
4 STUD Y VARIABLES.....................................................................................................21
4.1 Efficacy variables.............................................................................................................21
4.1.1 Primary efficacy variable.....................................................................................21
4.1.2 Secondary efficacy variables ...............................................................................21
4.1.3 Other efficacy variables.......................................................................................22
4.2 Safety variables................................................................................................................22
4.2.1 Primary safety variables ......................................................................................22
4.2.2 Other safety variables ..........................................................................................22
4.3 Other PK and PD variables ..............................................................................................22
4.3.1 Other PK variables...............................................................................................22
4.3.2 Other PD variables...............................................................................................22
4.4 Other immunological variable(s) .....................................................................................23
4.5 Other nonhereditary pharmacogenomic variables ...........................................................23
4.6 Other pharmacogenetic variables.....................................................................................23
5 STUDY DESIGN.............................................................................................................23
5.1 Study description .............................................................................................................23
5.1.1 Screening Period (minimum of 2 and up to 4 weeks)..........................................24
5.1.2 Treatment Period (Week 0 to Week 12) ..............................................................24
5.1.3 Treatment Extension Period (Week 12 to Week 48) ...........................................24
5.1.4 Safety Follow-up Period (Week 48 to Week 64).................................................[ADDRESS_764514]................................................................................................25PUBLIC COPY ................................
PUBLIC COPY ................................ ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
Secondary efficacy variables
PUBLIC COPY Secondary efficacy variables ................................
PUBLIC COPY ................................
Other efficacy variables
PUBLIC COPY Other efficacy variables ................................
PUBLIC COPY ................................
................................PUBLIC COPY ................................
ty variablesPUBLIC COPY ty variables
This document cannot be used to support any marketing authorization 17
This document cannot be used to support any marketing authorization 17
................................
This document cannot be used to support any marketing authorization ................................ 18
This document cannot be used to support any marketing authorization 18
................................
This document cannot be used to support any marketing authorization ................................ 19
This document cannot be used to support any marketing authorization 19
................................
This document cannot be used to support any marketing authorization ................................ ..........
This document cannot be used to support any marketing authorization ..........
................................
This document cannot be used to support any marketing authorization ................................ ..............
This document cannot be used to support any marketing authorization ..............
................................
This document cannot be used to support any marketing authorization ................................ .................
This document cannot be used to support any marketing authorization .................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
Other safety variables
This document cannot be used to support any marketing authorization Other safety variables ................................
This document cannot be used to support any marketing authorization ................................
Other PK and PD variables
This document cannot be used to support any marketing authorization Other PK and PD variables ................................
This document cannot be used to support any marketing authorization ................................
Other PK variables
This document cannot be used to support any marketing authorization Other PK variables ................................
This document cannot be used to support any marketing authorization ................................
variables
This document cannot be used to support any marketing authorization variables
Other immunological variable(s)
This document cannot be used to support any marketing authorization Other immunological variable(s)
Other nonhereditary pharmacogenomic variables
This document cannot be used to support any marketing authorization Other nonhereditary pharmacogenomic variables
Other pharmacogenetic variables
This document cannot be used to support any marketing authorization Other pharmacogenetic variables
STUDY DESIGN
This document cannot be used to support any marketing authorization STUDY DESIGN
Study description
This document cannot be used to support any marketing authorization Study description
5.1.1
This document cannot be used to support any marketing authorization 5.1.1
5.1.2
This document cannot be used to support any marketing authorization 5.1.2
5.1.3
This document cannot be used to support any marketing authorization 5.1.3application and any extensions or variations thereof.19
application and any extensions or variations thereof.19
..............
application and any extensions or variations thereof............... 20
application and any extensions or variations thereof.20
.................
application and any extensions or variations thereof.................. 20
application and any extensions or variations thereof.20
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. .............
application and any extensions or variations thereof..............
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. ............................
application and any extensions or variations thereof.............................
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
Other immunological variable(s)
application and any extensions or variations thereof.Other immunological variable(s)
Other nonhereditary pharmacogenomic variables
application and any extensions or variations thereof.Other nonhereditary pharmacogenomic variables
Other pharmacogenetic variables
application and any extensions or variations thereof.Other pharmacogenetic variables
STUDY DESIGN
application and any extensions or variations thereof.STUDY DESIGN ................................
application and any extensions or variations thereof.................................
Study description
application and any extensions or variations thereof.Study description
Screening Period (minimum of 2 and up to 4 weeks)application and any extensions or variations thereof.Screening Period (minimum of 2 and up to 4 weeks)application and any extensions or variations thereof.Treatment Period (Week 0 to Week 12)application and any extensions or variations thereof.Treatment Period (Week 0 to Week 12)
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 5 of 1365.5 Planned number of subjects and site(s)............................................................................25
5.6 Anticipated regions and countries....................................................................................25
5.7 Schedule of assessments ..................................................................................................26
5.8 Schematic diagram...........................................................................................................31
5.9 Rationale for study design and selection of dose.............................................................32
6 SELECTION AND WITHDRAWAL OF SUBJECTS...................................................33
6.1 Inclusion criteria ..............................................................................................................33
6.2 Exclusion criteria .............................................................................................................35
6.3 Withdrawal criteria ..........................................................................................................38
6.3.1 Potential drug-induced liver injury IMP discontinuation criteria........................40
6.4 Study stoppi[INVESTIGATOR_004].........................................................................................................41
6.5 Retesting/rescreening.......................................................................................................41
7 STUDY TREATMENT(S) ..............................................................................................[ADDRESS_764515](s)........................................................42
7.2 Treatment(s) to be administered ......................................................................................[ADDRESS_764516] compliance................................................................44
7.8 Concomitant medication(s)/treatment(s)..........................................................................44
7.8.1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) ..........................45
7.8.2 Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) .........................457.8.3 Rescue medication ...............................................................................................47
7.9 Blinding............................................................................................................................47
7.9.1 Procedures for maintaining and breaking the treatment blind.............................47
[IP_ADDRESS] Maintenance of study treatment blind .......................................................[IP_ADDRESS] Breaking the treatment blind in an emergency situation ...........................48
7.10 Randomization and numbering of subjects......................................................................48
8 STUDY PROCEDURES BY [CONTACT_16990] ...............................................................................49
8.1 Screening Visit (Visit 1) ..................................................................................................49
8.2 Baseline (Visit 2, Week 0) ...............................................................................................51
8.3 Week 2 (Visit 3)...............................................................................................................52
8.4 Week 4 (Visit 4)...............................................................................................................52
8.5 Week 6 (Visit 5)...............................................................................................................53
8.6 Week 8 (Visit 6)...............................................................................................................53
8.7 Week 10 (Visit 7).............................................................................................................54
8.8 Week 12 (Visit 8).............................................................................................................54PUBLIC COPY ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................ ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
PUBLIC COPY ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................ ................................
PUBLIC COPY ................................
Procedures for monitoring subject compliance
PUBLIC COPY Procedures for monitoring subject compliance
Concomitant medication(s)/treatment(s)
PUBLIC COPY Concomitant medication(s)/treatment(s)
Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) PUBLIC COPY Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
This document cannot be used to support any marketing authorization ..............
This document cannot be used to support any marketing authorization .............. [ADDRESS_764517] compliance ................................
This document cannot be used to support any marketing authorization ................................
Concomitant medication(s)/treatment(s)
This document cannot be used to support any marketing authorization Concomitant medication(s)/treatment(s) ................................
This document cannot be used to support any marketing authorization ................................
Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
This document cannot be used to support any marketing authorization Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
Prohibited concomitant treatments (medications and thera
This document cannot be used to support any marketing authorization Prohibited concomitant treatments (medications and thera
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
This document cannot be used to support any marketing authorization Procedures for maint
This document cannot be used to support any marketing authorization Procedures for maint
Maintenance of study treatment blind
This document cannot be used to support any marketing authorization Maintenance of study treatment blind
Breaking the treatment blind in an emergency situation
This document cannot be used to support any marketing authorization Breaking the treatment blind in an emergency situation
Randomization and numbering of subjects
This document cannot be used to support any marketing authorization Randomization and numbering of subjects
STUDY PROCEDURES BY 
[CONTACT_581573] (Visit 1)
This document cannot be used to support any marketing authorization Screening Visit (Visit 1)
Baseline (Visit 2, Week 0)
This document cannot be used to support any marketing authorization Baseline (Visit 2, Week 0)
8.3
This document cannot be used to support any marketing authorization 8.3 Week
This document cannot be used to support any marketing authorization Week
8.4
This document cannot be used to support any marketing authorization 8.4 Week 4 (Visit 4)
This document cannot be used to support any marketing authorization Week 4 (Visit 4)
8.5
This document cannot be used to support any marketing authorization 8.5application and any extensions or variations thereof.38
application and any extensions or variations thereof.38
........................
application and any extensions or variations thereof......................... 40
application and any extensions or variations thereof.40
.........
application and any extensions or variations thereof.......... 41
application and any extensions or variations thereof.41
................................
application and any extensions or variations thereof................................. .......
application and any extensions or variations thereof........
..............................
application and any extensions or variations thereof...............................
................................
application and any extensions or variations thereof................................. ........................
application and any extensions or variations thereof.........................
................................
application and any extensions or variations thereof................................. ......................
application and any extensions or variations thereof.......................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
application and any extensions or variations thereof.................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
application and any extensions or variations thereof.Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
Prohibited concomitant treatments (medications and thera
application and any extensions or variations thereof.Prohibited concomitant treatments (medications and thera
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
application and any extensions or variations thereof.Procedures for maint
application and any extensions or variations thereof.Procedures for maint aining and breaking the treatment blind
application and any extensions or variations thereof.aining and breaking the treatment blind
Maintenance of study treatment blind
application and any extensions or variations thereof.Maintenance of study treatment blind
Breaking the treatment blind in an emergency situation
application and any extensions or variations thereof.Breaking the treatment blind in an emergency situation
Randomization and numbering of subjects
application and any extensions or variations thereof.Randomization and numbering of subjects
STUDY PROCEDURES BY 
[INVESTIGATOR_581504].STUDY PROCEDURES BY 
[CONTACT_159337] (Visit 1)
application and any extensions or variations thereof.Screening Visit (Visit 1)
Baseline (Visit 2, Week 0)
application and any extensions or variations thereof.Baseline (Visit 2, Week 0)
application and any extensions or variations thereof.Weekapplication and any extensions or variations thereof.Week 2 (Visit 3)application and any extensions or variations thereof.2 (Visit 3)
Week 4 (Visit 4)application and any extensions or variations thereof.Week 4 (Visit 4)
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 6 of 1368.9 Week 16 (Visit 9), Week 20 (Visit 10), Week 28 (Visit 12), Week 32 (Visit 13), Week 
40 (Visit 15), and Week 44 (Visit 16)..............................................................................55
8.10 Week 24 (Visit 11) and Week 36 (Visit 14) ....................................................................56
8.11 Week 48 (Visit 17)/Early Withdrawal Visit ....................................................................57
8.12 Safety Follow-Up Visit (Week 64, Visit 18, 20 weeks after the final dose of IMP) .......58
8.13 Early Withdrawal Visit ....................................................................................................58
8.14 Unscheduled Visit............................................................................................................58
9 ASSESSMENT OF EFFICA CY......................................................................................59
9.1 ASDAS ............................................................................................................................59
9.2 ASAS20, ASAS40, and ASAS partial remission ............................................................60
9.3 BASDAI...........................................................................................................................60
9.4 Inflammation – BASDAI (mean of Questions 5 and 6) ..................................................61
9.5 Function – BASFI ............................................................................................................61
9.6 Patient global assessment (PGADA) ...............................................................................[ADDRESS_764518] scan...............................................................................................62
10 ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/ PHARMACOGENETIC 
VARIABLE(S) ................................................................................................................62
10.1 Pharmacokinetic variables ...............................................................................................62
10.2 Pharmacodynamic variables ............................................................................................63
10.3 Nonhereditary pharmacogenomic variables.....................................................................63
10.4 Pharmacogenetic variables...............................................................................................63
11 ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S) ............................................63
12 ASSESSMENT OF SAFETY..........................................................................................64
12.1 Adverse events .................................................................................................................64
12.1.1 Definitions ...........................................................................................................64
[IP_ADDRESS] Adverse event ............................................................................................64
[IP_ADDRESS] Serious adverse event ................................................................................64
[IP_ADDRESS] Adverse events of special interest .............................................................66
[IP_ADDRESS] Adverse events for special monitoring......................................................67
12.1.2 Procedures for reporting and recording adverse events.......................................67
[IP_ADDRESS] Description of adverse events....................................................................67
[IP_ADDRESS] Rule for repetition of an adverse event......................................................6812.1.2.3 Additional procedures for reporting serious adverse events .....................68
12.1.3 Follow up of adverse events ................................................................................68PUBLIC COPY ................................
PUBLIC COPY ................................ ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................ ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................ ................................
PUBLIC COPY ................................
Hospi[INVESTIGATOR_581489] ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
COKINETIC/ 
PUBLIC COPY COKINETIC/ 
PHARMACODYNAMIC/PHAR
PUBLIC COPY PHARMACODYNAMIC/PHAR MACOGENOMIC/ PHARMAC
PUBLIC COPY MACOGENOMIC/ PHARMAC
................................PUBLIC COPY ................................
This document cannot be used to support any marketing authorization 58
This document cannot be used to support any marketing authorization 58
......................
This document cannot be used to support any marketing authorization ...................... 59
This document cannot be used to support any marketing authorization 59
............................
This document cannot be used to support any marketing authorization ............................ 59
This document cannot be used to support any marketing authorization 59
............................
This document cannot be used to support any marketing authorization ............................
...........................
This document cannot be used to support any marketing authorization ...........................
................................
This document cannot be used to support any marketing authorization ................................ ..................
This document cannot be used to support any marketing authorization ..................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
COKINETIC/ 
This document cannot be used to support any marketing authorization COKINETIC/ 
MACOGENOMIC/ PHARMAC
This document cannot be used to support any marketing authorization MACOGENOMIC/ PHARMAC
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
Pharmacodynamic variables
This document cannot be used to support any marketing authorization Pharmacodynamic variables ................................
This document cannot be used to support any marketing authorization ................................
Nonhereditary pharmacogenomic variables
This document cannot be used to support any marketing authorization Nonhereditary pharmacogenomic variables
Pharmacogenetic variables
This document cannot be used to support any marketing authorization Pharmacogenetic variables ................................
This document cannot be used to support any marketing authorization ................................
ASSESSMENT OF IMMUNO
This document cannot be used to support any marketing authorization ASSESSMENT OF IMMUNO
ASSESSMENT OF SAFETY
This document cannot be used to support any marketing authorization ASSESSMENT OF SAFETY
Adverse events
This document cannot be used to support any marketing authorization Adverse events ................................
This document cannot be used to support any marketing authorization ................................
Definitions
This document cannot be used to support any marketing authorization Definitions
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS]
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS]
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS]
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS]
12.1.2
This document cannot be used to support any marketing authorization 12.1.2application and any extensions or variations thereof.59
application and any extensions or variations thereof.59
............................
application and any extensions or variations thereof............................. 60
application and any extensions or variations thereof.60
...........................
application and any extensions or variations thereof............................ 60
application and any extensions or variations thereof.60
..................
application and any extensions or variations thereof...................
................................
application and any extensions or variations thereof................................. ............
application and any extensions or variations thereof.............
................................
application and any extensions or variations thereof................................. ...............
application and any extensions or variations thereof................
................................
application and any extensions or variations thereof................................. ..........................
application and any extensions or variations thereof...........................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
MACOGENOMIC/ PHARMAC
application and any extensions or variations thereof.MACOGENOMIC/ PHARMAC
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
Nonhereditary pharmacogenomic variables
application and any extensions or variations thereof.Nonhereditary pharmacogenomic variables
................................
application and any extensions or variations thereof.................................
ASSESSMENT OF IMMUNO
application and any extensions or variations thereof.ASSESSMENT OF IMMUNO LOGICAL VARIABLE(S)
application and any extensions or variations thereof.LOGICAL VARIABLE(S)
ASSESSMENT OF SAFETY
application and any extensions or variations thereof.ASSESSMENT OF SAFETY ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
Definitions
application and any extensions or variations thereof.Definitions ................................
application and any extensions or variations thereof.................................
Adverse event
application and any extensions or variations thereof.Adverse event
[IP_ADDRESS]
application and any extensions or variations thereof.[IP_ADDRESS] Serious
application and any extensions or variations thereof.Serious
12.1.1.3application and any extensions or variations thereof.[IP_ADDRESS] Adverse events of special interestapplication and any extensions or variations thereof.Adverse events of special interest
12.1.1.4application and any extensions or variations thereof. [IP_ADDRESS]
UCB [ADDRESS_764519] ...............................................................70
12.5 Safety signal detection .....................................................................................................70
12.6 Laboratory measurements................................................................................................70
12.6.1 Evaluation of PDILI ............................................................................................72
[IP_ADDRESS] Consultation with Medical Monitor and local hepatologist ......................77
[IP_ADDRESS] Immediate action: Determination of IMP discontinuation........................77
[IP_ADDRESS] Testing: Identification/exclusion of alternative etiology...........................77
[IP_ADDRESS] Follow-up evaluation.................................................................................79
12.7 Other safety measurements ..............................................................................................79
12.7.1 Vital signs ............................................................................................................79
12.7.2 Body weight and height .......................................................................................80
12.7.3 Physical examination ...........................................................................................80
12.7.4 12-lead electrocardiogram ...................................................................................80
12.7.5 Tuberculosis and TB risk factor assessment and management ...........................80
[IP_ADDRESS] Tuberculosis assessment by [CONTACT_18406]............................................................8212.7.5.[ADDRESS_764520] X-ray for tuberculosis......................................................................82
[IP_ADDRESS] Tuberculosis questionnaire........................................................................83
[IP_ADDRESS] Tuberculosis management.........................................................................[ADDRESS_764521] Screening and Enrollment log/Subject Identification Code list..............[ADDRESS_764522] privacy.................................................................................................................94
16.5 Protocol amendments.......................................................................................................94
17 FINANCE, INSURANCE, AND PUBLICATION .........................................................94
18 REFERENCES ................................................................................................................94
19 APPENDICES .................................................................................................................99
19.1 Modified [LOCATION_001] (mNY) Classification Criteria for AS ............................................99
19.2 Markedly abnormal laboratory values ...........................................................................100
19.3 Protocol Amendment 1 ..................................................................................................101
19.4 Protocol Amendment 2 ..................................................................................................107
19.5 Protocol Amendment 3 ..................................................................................................117
20 DECLARATION AND SIGNATURE [CONTACT_163601] .....................................135
21 SPONSOR DECLARATION ........................................................................................136PUBLIC COPY ................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
................................
PUBLIC COPY ................................
Handling of dropouts or missing data
PUBLIC COPY Handling of dropouts or missing data ................................
PUBLIC COPY ................................
Planned interim analysis and data monitoring
PUBLIC COPY Planned interim analysis and data monitoring
Determination of sample size
PUBLIC COPY Determination of sample size ................................
PUBLIC COPY ................................
ETHICS AND REGULATOR
PUBLIC COPY ETHICS AND REGULATOR Y REQUIREMENTS
PUBLIC COPY Y REQUIREMENTS
................................PUBLIC COPY ................................
This document cannot be used to support any marketing authorization ......
This document cannot be used to support any marketing authorization ......89
This document cannot be used to support any marketing authorization 89
................................
This document cannot be used to support any marketing authorization ................................ 89
This document cannot be used to support any marketing authorization 89
............................
This document cannot be used to support any marketing authorization ............................ 89
This document cannot be used to support any marketing authorization 89
................................
This document cannot be used to support any marketing authorization ................................ ..........
This document cannot be used to support any marketing authorization ..........
.......................
This document cannot be used to support any marketing authorization .......................
...............................
This document cannot be used to support any marketing authorization ...............................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
Planned interim analysis and data monitoring
This document cannot be used to support any marketing authorization Planned interim analysis and data monitoring
................................
This document cannot be used to support any marketing authorization ................................
Y REQUIREMENTS
This document cannot be used to support any marketing authorization Y REQUIREMENTS
................................
This document cannot be used to support any marketing authorization ................................ ................................
This document cannot be used to support any marketing authorization ................................
................................
This document cannot be used to support any marketing authorization ................................
Institutional Review Boards and Independent Ethics Committees
This document cannot be used to support any marketing authorization Institutional Review Boards and Independent Ethics Committees
................................
This document cannot be used to support any marketing authorization ................................
Protocol amendments
This document cannot be used to support any marketing authorization Protocol amendments ................................
This document cannot be used to support any marketing authorization ................................
INSURANCE, AND PUBLI
This document cannot be used to support any marketing authorization INSURANCE, AND PUBLI
REFERENCES
This document cannot be used to support any marketing authorization REFERENCES ................................
This document cannot be used to support any marketing authorization ................................
APPENDICES
This document cannot be used to support any marketing authorization APPENDICES ................................
This document cannot be used to support any marketing authorization ................................
Modified [LOCATION_001] (mNY) Classification Criteria for AS
This document cannot be used to support any marketing authorization Modified [LOCATION_001] (mNY) Classification Criteria for AS
Markedly abnormal laboratory values
This document cannot be used to support any marketing authorization Markedly abnormal laboratory values
19.3
This document cannot be used to support any marketing authorization 19.3 Protocol Amendment 1
This document cannot be used to support any marketing authorization Protocol Amendment 1
19.4
This document cannot be used to support any marketing authorization 19.4 Protocol Amendment 2
This document cannot be used to support any marketing authorization Protocol Amendment 2
19.5
This document cannot be used to support any marketing authorization 19.5 Protocol Amendment 3
This document cannot be used to support any marketing authorization Protocol Amendment 3
20
This document cannot be used to support any marketing authorization 20application and any extensions or variations thereof.89
application and any extensions or variations thereof.89
..........
application and any extensions or variations thereof........... 90
application and any extensions or variations thereof.90
.......................
application and any extensions or variations thereof........................ 90
application and any extensions or variations thereof.90
...............................
application and any extensions or variations thereof................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
Y REQUIREMENTS
application and any extensions or variations thereof.Y REQUIREMENTS ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
Institutional Review Boards and Independent Ethics Committees
application and any extensions or variations thereof.Institutional Review Boards and Independent Ethics Committees
................................
application and any extensions or variations thereof................................. ................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
INSURANCE, AND PUBLI
application and any extensions or variations thereof.INSURANCE, AND PUBLI
................................
application and any extensions or variations thereof.................................
................................
application and any extensions or variations thereof.................................
Modified [LOCATION_001] (mNY) Classification Criteria for AS
application and any extensions or variations thereof.Modified [LOCATION_001] (mNY) Classification Criteria for AS
Markedly abnormal laboratory values
application and any extensions or variations thereof.Markedly abnormal laboratory values
Protocol Amendment [ADDRESS_764523] OF TABLES
Table 5‒1: Schedule of assessments ..................................................................................26
Table 5‒2: Exposure to bimekizumab by [CONTACT_2715] ..................................................................33
Table 7‒1: Treatments administered..................................................................................43
Table 7‒2: Prohibited or restricted medications and required wash-out periods prior 
to Baseline........................................................................................................45
Table 12‒1: Anticipated serious adverse events for the population of subjects with AS ....65
Table 12‒2: Laboratory measurements................................................................................71
Table 12‒3: Required investigations and follow-up for PDILI ...........................................74
Table 12‒4: PDILI laboratory measurements ......................................................................77
Table 12‒5: PDILI information to be collected ...................................................................79
Table 19‒1: Modified [LOCATION_001] (mNY) Classification Criteria for AS ............................99
Table 19‒2: Definitions of markedly abnormal hematology values..................................100
Table 19‒3: Definitions of markedly abnormal biochemistry values................................[ADDRESS_764524] OF FIGURES
Figure 5‒1: Schematic diagram...........................................................................................[ADDRESS_764525]
AESM adverse event for special monitoring
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AS ankylosing spondylitis
ASAS Assessment of SpondyloArthritis International Society
ASAS20, 40, 5/6 Assessment in SpondyloArthritis International Society 20%, 40%, [ADDRESS_764526] research organization
CRP C-reactive protein
CSR clinical study reportPUBLIC COPY Ankylosing Spondylitis Disease Activity Score major improvement
PUBLIC COPY Ankylosing Spondylitis Disease Activity Score major improvement
Bath Ankylosing Spondylitis Disease Activity Index
PUBLIC COPY Bath Ankylosing Spondylitis Disease Activity Index
Bath Ankylosing Spondylitis Functional Index
PUBLIC COPY Bath Ankylosing Spondylitis Functional Index
Bacille CalmettePUBLIC COPY Bacille Calmette
This document cannot be used to support any marketing authorization Assessment in SpondyloArthritis International Society 20%, 40%, 5
This document cannot be used to support any marketing authorization Assessment in SpondyloArthritis International Society 20%, 40%, 5
Ankylosing Spondylitis Disease Activity Score inactive disease
This document cannot be used to support any marketing authorization Ankylosing Spondylitis Disease Activity Score inactive disease
Ankylosing Spondylitis Disease Activity Score major improvement
This document cannot be used to support any marketing authorization Ankylosing Spondylitis Disease Activity Score major improvement
Bath Ankylosing Spondylitis Disease Activity Index
This document cannot be used to support any marketing authorization Bath Ankylosing Spondylitis Disease Activity Index
Bath Ankylosing Spondylitis Functional Index
This document cannot be used to support any marketing authorization Bath Ankylosing Spondylitis Functional Index
Bacille Calmette
This document cannot be used to support any marketing authorization Bacille Calmette -
This document cannot be used to support any marketing authorization -Guérin
This document cannot be used to support any marketing authorization Guérin
body mass index
This document cannot be used to support any marketing authorization body mass index
blood pressure
This document cannot be used to support any marketing authorization blood pressure
body surface area
This document cannot be used to support any marketing authorization body surface area
This document cannot be used to support any marketing authorization cluster of differentiation
This document cannot be used to support any marketing authorization cluster of differentiation
Centers for Disease Control 
This document cannot be used to support any marketing authorization Centers for Disease Control 
COX
This document cannot be used to support any marketing authorization COX -
This document cannot be used to support any marketing authorization -2 inhibitor
This document cannot be used to support any marketing authorization 2 inhibitor
CPM
This document cannot be used to support any marketing authorization CPM
CPMP
This document cannot be used to support any marketing authorization CPMPapplication and any extensions or variations thereof.Assessment in SpondyloArthritis International Society 20%, 40%, 5
application and any extensions or variations thereof.Assessment in SpondyloArthritis International Society 20%, 40%, [ADDRESS_764527] Manager
ES Enrolled Set
FAS Full Analysis Set
FDA Food and Drug Administration
FSH follicle -stimulation hormone
GCP Good Clinical Practice
GFR glomerular filtration rate
GI gastrointestinal
GMP Good Manufacturing Practice
HADS Hospi[INVESTIGATOR_581490] -A Hospi[INVESTIGATOR_5620]—Anxiety 
HADS -D Hospi[INVESTIGATOR_5620]—De pression 
HbcAg hepatitis B core antibody
HbsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
HLA human leukocyte antigen
hs-CRP high sensitivity C-reactive protein
hPDSC human periosteum-derived stem cell
IB Investigator’s Brochure
IBD inflammatory bowel disease
ICH International Council for Harmonisation
ICF Informed Consent form
IEC Independent Ethics CommitteePUBLIC COPY glomerular filtration rate
PUBLIC COPY glomerular filtration rate
Good Manufacturing Practice
PUBLIC COPY Good Manufacturing Practice
Hospi[INVESTIGATOR_581491] B core antibody
This document cannot be used to support any marketing authorization hepatitis B core antibody
hepatitis B surface antigen
This document cannot be used to support any marketing authorization hepatitis B surface antigen
hepatitis B virus
This document cannot be used to support any marketing authorization hepatitis B virus
hepatitis C virus
This document cannot be used to support any marketing authorization hepatitis C virus
CRP
This document cannot be used to support any marketing authorization CRP
hPDSC
This document cannot be used to support any marketing authorization hPDSC
IB
This document cannot be used to support any marketing authorization IB
IBD
This document cannot be used to support any marketing authorization IBDapplication and any extensions or variations thereof.Hospi[INVESTIGATOR_581492].Hospi[INVESTIGATOR_581493].Hospi[INVESTIGATOR_581493].Hospi[INVESTIGATOR_581494] B core antibody
application and any extensions or variations thereof.hepatitis B core antibody
hepatitis B surface antigen
application and any extensions or variations thereof.hepatitis B surface antigen
hepatitis B virus
application and any extensions or variations thereof.hepatitis B virus
hepatitis C virus
application and any extensions or variations thereof.hepatitis C virus
human immunodeficiency virus
application and any extensions or variations thereof.human immunodeficiency virus
human leukocyte antigen
application and any extensions or variations thereof.human leukocyte antigen
high sensitivity C
application and any extensions or variations thereof.high sensitivity C
UCB [ADDRESS_764528]
IUD intrauterine device
IUS intrauterine hormone-releasing system
im intramuscular
iv intravenous
IRT interactive response technology
LTB latent tuberculosis
LTBI latent tuberculosis infection 
MAR missing at random
MCID minimal clinically important difference
MCP-Mod multiple comparison procedure – modeling
MCS mental component summary
MedDRA®Medical Dictionary for Regulatory Activities
MI multiple imputation
MMP matrix metalloproteinase
mNY Modified [LOCATION_001] (criteria)
MOS Medical Outcomes Study
MRI magnetic resonance imaging
MTB mycobacterium tuberculosis 
MTX methotrexate
nr-axSpA nonradiographic-axial spondyloarthritis
NRI nonresponder imputation
NRS numeric rating scale
NSAID nonsteroidal anti-inflammatory drug
NTMB nontuberculous mycobacteria
NYHA [LOCATION_001] Heart Association
OPV oral polio vaccine
PCS physical component summary
PD pharmacodynamicsPUBLIC COPY minimal clinically important difference
PUBLIC COPY minimal clinically important difference
multiple comparison procedure 
PUBLIC COPY multiple comparison procedure 
mental component summary
PUBLIC COPY mental component summary
Medical Dictionary for Regulatory 
PUBLIC COPY Medical Dictionary for Regulatory 
multiple imputation
PUBLIC COPY multiple imputation
matrix metalloproteinasePUBLIC COPY matrix metalloproteinase
This document cannot be used to support any marketing authorization minimal clinically important difference
This document cannot be used to support any marketing authorization minimal clinically important difference
–
This document cannot be used to support any marketing authorization –modeling
This document cannot be used to support any marketing authorization modeling
mental component summary
This document cannot be used to support any marketing authorization mental component summary
Medical Dictionary for Regulatory 
This document cannot be used to support any marketing authorization Medical Dictionary for Regulatory 
multiple imputation
This document cannot be used to support any marketing authorization multiple imputation
matrix metalloproteinase
This document cannot be used to support any marketing authorization matrix metalloproteinase
Modified [LOCATION_001] (criteria)
This document cannot be used to support any marketing authorization Modified [LOCATION_001] (criteria)
This document cannot be used to support any marketing authorization Medical Outcomes Study
This document cannot be used to support any marketing authorization Medical Outcomes Study
magnetic resonance imaging
This document cannot be used to support any marketing authorization magnetic resonance imaging
mycobacterium tuberculosis 
This document cannot be used to support any marketing authorization mycobacterium tuberculosis 
methotrexate
This document cannot be used to support any marketing authorization methotrexate
This document cannot be used to support any marketing authorization NSAID
This document cannot be used to support any marketing authorization NSAID
NTMB
This document cannot be used to support any marketing authorization NTMB
NYHA
This document cannot be used to support any marketing authorization NYHAapplication and any extensions or variations thereof.modeling
application and any extensions or variations thereof.modeling
Medical Dictionary for Regulatory 
application and any extensions or variations thereof.Medical Dictionary for Regulatory Activities
application and any extensions or variations thereof.Activities
matrix metalloproteinase
application and any extensions or variations thereof.matrix metalloproteinase
Modified [LOCATION_001] (criteria)
application and any extensions or variations thereof.Modified [LOCATION_001] (criteria)
application and any extensions or variations thereof.Medical Outcomes Study
application and any extensions or variations thereof.Medical Outcomes Study
magnetic resonance imaging
application and any extensions or variations thereof.magnetic resonance imaging
mycobacterium tuberculosis 
application and any extensions or variations thereof.mycobacterium tuberculosis 
methotrexate
application and any extensions or variations thereof.methotrexate
nonradiographic
application and any extensions or variations thereof.nonradiographic
nonresponder imputation
application and any extensions or variations thereof.nonresponder imputation
numeric rating scale
application and any extensions or variations thereof.numeric rating scale
UCB [ADDRESS_764529] positron-emission tomography – computed tomography
PET-MRI positron-emission tomography – magnetic resonance imaging
PFS pre-filled syringe
PGADA Patient’s Global Assessment of Disease Activity
PhGADA Physician’s Global Assessment of Disease Activity
PK pharmacokinetics
PK-PPS Pharmacokinetics Per-Protocol Set
PPS Per-Protocol Set
PS Patient Safety
PsA psoriatic arthritis
PSO psoriasis
Q2W every 2 weeks
Q4W every 4 weeks (monthly)
QTcF QT interval corrected for heart rate using Fridericia’s formula 
RA rheumatoid arthritis
RCTC Rheumatology Common Toxicity Criteria
RIF mycobacterium tuberculosis rifampin
RNA ribonucleic acid
RS Randomized Set
RUV residual unexplained variability
SAE serious adverse event
SAP Statistical Analysis Plan
sc subcutaneous(ly)
SD standard deviation
SFU Safety Follow-up
SI sacroiliac
SpA spondyloarthritis
SOP standard operating procedure
SS Safety Set
SSZ sulfasalazine
STIR short-tau-inversion recoveryPUBLIC COPY weeks (monthly)
PUBLIC COPY weeks (monthly)
QT interval corrected for heart rate using Fridericia’s formula 
PUBLIC COPY QT interval corrected for heart rate using Fridericia’s formula 
rheumatoid arthritis
PUBLIC COPY rheumatoid arthritis
Rheumatology Common Toxicity Criteria
PUBLIC COPY Rheumatology Common Toxicity Criteria
mycobacterium tuberculosis PUBLIC COPY mycobacterium tuberculosis 
This document cannot be used to support any marketing authorization QT interval corrected for heart rate using Fridericia’s formula 
This document cannot be used to support any marketing authorization QT interval corrected for heart rate using Fridericia’s formula 
Rheumatology Common Toxicity Criteria
This document cannot be used to support any marketing authorization Rheumatology Common Toxicity Criteria
mycobacterium tuberculosis 
This document cannot be used to support any marketing authorization mycobacterium tuberculosis 
ribonucleic acid
This document cannot be used to support any marketing authorization ribonucleic acid
Randomized Set
This document cannot be used to support any marketing authorization Randomized Set
residual unexplained variability
This document cannot be used to support any marketing authorization residual unexplained variability
serious adverse event
This document cannot be used to support any marketing authorization serious adverse event
Statistical Analysis Plan
This document cannot be used to support any marketing authorization Statistical Analysis Plan
SpA
This document cannot be used to support any marketing authorization SpA
SOP
This document cannot be used to support any marketing authorization SOPapplication and any extensions or variations thereof.QT interval corrected for heart rate using Fridericia’s formula 
application and any extensions or variations thereof.QT interval corrected for heart rate using Fridericia’s formula 
Rheumatology Common Toxicity Criteria
application and any extensions or variations thereof.Rheumatology Common Toxicity Criteria
mycobacterium tuberculosis 
application and any extensions or variations thereof.mycobacterium tuberculosis rifampin
application and any extensions or variations thereof.rifampin
residual unexplained variability
application and any extensions or variations thereof.residual unexplained variability
serious adverse event
application and any extensions or variations thereof.serious adverse event
Statistical Analysis Plan
application and any extensions or variations thereof.Statistical Analysis Plan
subcutaneous(ly)
application and any extensions or variations thereof.subcutaneous(ly)
standard deviation
application and any extensions or variations thereof.standard deviation
Safety Follow
application and any extensions or variations thereof.Safety Follow
UCB [ADDRESS_764530]-blind, investigator-blind, parallel-group, 
study to investigate the efficacy and safety of bimekizumab (also known as UCB4940) and 
certolizumab pegol ([CZP]; Cimzia®) in adult subjects with active ankylosing spondylitis (AS).
Eligible subjects will have active AS, determined by [CONTACT_58943] (X- ray) 
fulfilling the Modified [LOCATION_001] criteria for AS (van der Linden et al, 1984), including symptoms for ≥3 months and age of onset <[ADDRESS_764531] moderate to severe active disease at Screening (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] ≥4 and spi[INVESTIGATOR_18172] ≥4 [BASDAI Question 2]). 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objective of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS-ID) and ASDAS major 
improvement (ASDAS-MI) at Week 12. Primary safety variables include the incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from investigational medicinal product (IMP).
Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP on 
changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
bimekizumab, to obtain additional biomarkers and clinical and imaging data as applicable, and to 
assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Treatment Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize at 
least 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
The study consists of a Screening Period (2 to4 weeks), Treatment Period (12 weeks), Treatment 
Extension Period (36 weeks), and a Safety Follow-up (SFU) Period (20 weeks after the final 
dose of the IMP). Therefore, the maximum duration of the study is [ADDRESS_764532] for a minimum of 2 weeks and up to 4 weeks. During the 
Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion and exclusion criteria. The Screening Period will also enable washout of any medications not 
permitted for use during the study. PUBLIC COPY MI) at Week 12. Primary safety variables include the incidence of 
PUBLIC COPY MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
PUBLIC COPY adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
Other exploratory objectives of the study are to 
PUBLIC COPY Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP on 
PUBLIC COPY evaluate the effect of bimekizumab or CZP on 
changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
PUBLIC COPY changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
obtain additional biomarkers and clinical and imaging 
PUBLIC COPY obtain additional biomarkers and clinical and imaging 
assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
PUBLIC COPY assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Multiple sites in North America, Europe, and the Asian PUBLIC COPY Multiple sites in North America, Europe, and the Asian
This document cannot be used to support any marketing authorization months and age of onset <[ADDRESS_764533] moderate 
This document cannot be used to support any marketing authorization months and age of onset <[ADDRESS_764534] moderate 
to severe active disease at Screening (Bath Ankylosing Spondylitis Disease Activity Index 
This document cannot be used to support any marketing authorization to severe active disease at Screening (Bath Ankylosing Spondylitis Disease Activity Index 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
This document cannot be used to support any marketing authorization The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
This document cannot be used to support any marketing authorization subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
e is the change from Baseline in 
This document cannot be used to support any marketing authorization e is the change from Baseline in 
(ASDAS) at Week 12. The secondary objective 
This document cannot be used to support any marketing authorization (ASDAS) at Week 12. The secondary objective 
of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
This document cannot be used to support any marketing authorization of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
SDAS inactive disease (ASDAS
This document cannot be used to support any marketing authorization SDAS inactive disease (ASDAS -
This document cannot be used to support any marketing authorization -ID) and ASDAS major 
This document cannot be used to support any marketing authorization ID) and ASDAS major 
MI) at Week 12. Primary safety variables include the incidence of 
This document cannot be used to support any marketing authorization MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
This document cannot be used to support any marketing authorization adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
evaluate the effect of bimekizumab or CZP on 
This document cannot be used to support any marketing authorization evaluate the effect of bimekizumab or CZP on 
changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
This document cannot be used to support any marketing authorization changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
obtain additional biomarkers and clinical and imaging 
This document cannot be used to support any marketing authorization obtain additional biomarkers and clinical and imaging 
assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
This document cannot be used to support any marketing authorization assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Multiple sites in North America, Europe, and the Asian
This document cannot be used to support any marketing authorization Multiple sites in North America, Europe, and the Asian
in a 2:1 ratio to receive either bimekizumab or CZP. 
This document cannot be used to support any marketing authorization in a 2:1 ratio to receive either bimekizumab or CZP. 
The study consists of a Screening Period (2
This document cannot be used to support any marketing authorization The study consists of a Screening Period (2
Extension Period (36 weeks), and a Safety Follow
This document cannot be used to support any marketing authorization Extension Period (36 weeks), and a Safety Follow
dose of the IMP). Therefore, the maximum duration of the study is 68
This document cannot be used to support any marketing authorization dose of the IMP). Therefore, the maximum duration of the study is [ADDRESS_764535] for a minimum of 2 weeks and up to 4 weeks. During the 
Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion 
This document cannot be used to support any marketing authorization Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion 
and exclusion criteria. The Screening Perio
This document cannot be used to support any marketing authorization and exclusion criteria. The Screening Perio
This document cannot be used to support any marketing authorization permitted for use during the study. 
This document cannot be used to support any marketing authorization permitted for use during the study. 
application and any extensions or variations thereof.The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
application and any extensions or variations thereof.The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
application and any extensions or variations thereof.subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
e is the change from Baseline in 
application and any extensions or variations thereof.e is the change from Baseline in 
(ASDAS) at Week 12. The secondary objective 
application and any extensions or variations thereof.(ASDAS) at Week 12. The secondary objective 
of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
application and any extensions or variations thereof.of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
ID) and ASDAS major 
application and any extensions or variations thereof.ID) and ASDAS major 
MI) at Week 12. Primary safety variables include the incidence of 
application and any extensions or variations thereof.MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
application and any extensions or variations thereof.adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
evaluate the effect of bimekizumab or CZP on 
application and any extensions or variations thereof.evaluate the effect of bimekizumab or CZP on 
changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
application and any extensions or variations thereof.changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
obtain additional biomarkers and clinical and imaging 
application and any extensions or variations thereof.obtain additional biomarkers and clinical and imaging 
assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
application and any extensions or variations thereof.assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Multiple sites in North America, Europe, and the Asian
application and any extensions or variations thereof.Multiple sites in North America, Europe, and the Asian
in a 2:1 ratio to receive either bimekizumab or CZP. 
application and any extensions or variations thereof.in a 2:1 ratio to receive either bimekizumab or CZP. 
The study consists of a Screening Period (2
application and any extensions or variations thereof.The study consists of a Screening Period (2 to
application and any extensions or variations thereof.to4 weeks), Treatment Period (12
application and any extensions or variations thereof.4 weeks), Treatment Period (12
Extension Period (36 weeks), and a Safety Follow
application and any extensions or variations thereof.Extension Period (36 weeks), and a Safety Follow
dose of the IMP). Therefore, the maximum duration of the study is 68
application and any extensions or variations thereof.dose of the IMP). Therefore, the maximum duration of the study is [ADDRESS_764536] for a minimum of 2 weeks and up to 4 weeks. During the 
Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion 
application and any extensions or variations thereof.Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion 
and exclusion criteria. The Screening Perio
application and any extensions or variations thereof.and exclusion criteria. The Screening Perio
application and any extensions or variations thereof.permitted for use during the study. 
application and any extensions or variations thereof.permitted for use during the study. 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 16of 136Treatment Period
At Baseline/Day 1, subjects will be randomized in a 2:1 ratio to receive the following blinded 
study treatments during the Treatment Period:
Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
Certolizumab pegol 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks 6 to10.
The IMP will be administered sc in the clinic by [CONTACT_1146]. 
Treatment Extension Period
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment 
Extension Period and will receive the following treatments:
Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc every 4 weeks (Q4W) from Week 12 to Week 44. 
Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W from Week 12 to Week 44. 
Subjects not responding to treatment will be withdrawn from the study as per Investigator’s discretion.
Safety Follow-Up Period
All subjects who complete the study or who discontinue early, including those withdrawn from 
study treatment, will have a SFU Visit at 20 weeks after their final dose of IMP. 
2 INTRODUCTION
2.1 Axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term applied to a family of rheumatic diseases (including axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
common with each other and distinct from other inflammatory arthritides, particularly 
rheumatoid arthritis (RA). 
Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the exact prevalence of axSpA; however, recent 
data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). 
The Assessment of SpondyloArthritis International Society (ASAS) working group established 
classification criteria to distinguish [ADDRESS_764537] categories of SpA: peripheral SpA and axSpA (Rudwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 2009b). This division is based on the 
body part predominantly involved in the inflammatory process. Therefore, peripheral SpA 
includes diseases affecting mainly peripheral joints, such as reactive arthritis and PsA, whereas axSpA comprises those diseases with mainly axial involvement (sacroiliac [SI] joints and spi[INVESTIGATOR_050]), including AS diagnosed with radiographic involvement and nonradiographic axSpA (nr-axSpA). PUBLIC COPY weeks (Q4W) from Week 12 to Week 44
PUBLIC COPY weeks (Q4W) from Week 12 to Week 44
Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
PUBLIC COPY Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
PUBLIC COPY Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
complete the study or who discontinue early, including those withdrawn from 
PUBLIC COPY complete the study or who discontinue early, including those withdrawn from 
study treatment, will have a SFU Visit at [ADDRESS_764538] a SFU Visit at 20 weeks after their final dose of IMP. 
This document cannot be used to support any marketing authorization Certolizumab pegol 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_581574] 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_581575] 400mg Q4W 
This document cannot be used to support any marketing authorization Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
This document cannot be used to support any marketing authorization Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
complete the study or who discontinue early, including those withdrawn from 
This document cannot be used to support any marketing authorization complete the study or who discontinue early, including those withdrawn from 
study treatment, will have a SFU Visit at [ADDRESS_764539] a SFU Visit at 20 weeks after their final dose of IMP. 
INTRODUCTION
This document cannot be used to support any marketing authorization INTRODUCTION
Axial spondyloarthritis
This document cannot be used to support any marketing authorization Axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term applied to a fam
This document cannot be used to support any marketing authorization Spondyloarthritis (SpA) is an umbrella term applied to a fam
axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
This document cannot be used to support any marketing authorization axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
This document cannot be used to support any marketing authorization inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
This document cannot be used to support any marketing authorization common with each other and
This document cannot be used to support any marketing authorization common with each other and
rheumatoid arthritis (RA). 
This document cannot be used to support any marketing authorization rheumatoid arthritis (RA). 
Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
This document cannot be used to support any marketing authorization Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the exact prevalence of axSpA; ho
This document cannot be used to support any marketing authorization population. Limited evidence exists regarding the exact prevalence of axSpA; ho
data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 
This document cannot be used to support any marketing authorization data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 
0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). 
This document cannot be used to support any marketing authorization 0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). 
The 
This document cannot be used to support any marketing authorization The Assessment of SpondyloArthritis International Society
This document cannot be used to support any marketing authorization Assessment of SpondyloArthritis International Society
classification criteria to distinguish [ADDRESS_764540] categories of SpA: peripheral SpA and axSpA 
This document cannot be used to support any marketing authorization classification criteria to distinguish [ADDRESS_764541] categories of SpA: peripheral SpA and axSpA 
(Rudwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 2009b). This division is based on the This document cannot be used to support any marketing authorization (Rudwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 2009b). This division is based on the application and any extensions or variations thereof.week Treatment 
application and any extensions or variations thereof.week Treatment 
Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
application and any extensions or variations thereof.Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
application and any extensions or variations thereof.Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
application and any extensions or variations thereof.Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
complete the study or who discontinue early, including those withdrawn from 
application and any extensions or variations thereof.complete the study or who discontinue early, including those withdrawn from 
study treatment, will have a SFU Visit at [ADDRESS_764542] a SFU Visit at 20 weeks after their final dose of IMP. 
Axial spondyloarthritis
application and any extensions or variations thereof.Axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term applied to a fam
application and any extensions or variations thereof.Spondyloarthritis (SpA) is an umbrella term applied to a fam
axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
application and any extensions or variations thereof.axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
application and any extensions or variations thereof.inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
application and any extensions or variations thereof.common with each other and
application and any extensions or variations thereof.common with each other and distinct from other inflammatory arthritides, particularly 
application and any extensions or variations thereof.distinct from other inflammatory arthritides, particularly 
rheumatoid arthritis (RA). 
application and any extensions or variations thereof.rheumatoid arthritis (RA). 
Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
application and any extensions or variations thereof.Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the exact prevalence of axSpA; ho
application and any extensions or variations thereof.population. Limited evidence exists regarding the exact prevalence of axSpA; ho
data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 
application and any extensions or variations thereof.data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 
0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). application and any extensions or variations thereof.0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). 
Assessment of SpondyloArthritis International Societyapplication and any extensions or variations thereof.Assessment of SpondyloArthritis International Society
UCB [ADDRESS_764543] inflammatory back pain. The disease typi[INVESTIGATOR_58888], then progresses to the spi[INVESTIGATOR_050]. In the sacroiliac joints and the spi[INVESTIGATOR_050], a ctive 
inflammation results in erosions, sclerosis, and fatty lesions seen on an magnetic resonance 
imaging (MRI). However, the most characteristic feature is new bone formation leading to 
ankylosis of the SI joints and syndesmophytes attached to the vertebral bodies. As a result of 
extended syndesmophyte formation, over time the spi[INVESTIGATOR_58889]. Objective signs of inflammation (such as enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic features (such 
as the presence of human leukocyte antigen [HLA] B27), and laboratory parameters (such as 
elevated C-reactive protein [CRP]) may also be present (Braun, 2012; Rudwaleit et al, 2009a; Braun and Sieper, 2007). Disability in axSpA is related to both the degree of inflammatory 
activity, causing pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
ankylosis, causing loss of spi[INVESTIGATOR_18171]. Patients with AS show radiographic progression of 
disease with X-ray identified sacroiliitis, while "Bamboo spi[INVESTIGATOR_050]" may develop when the outer 
fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
marginal syndesmophytes between adjoining vertebrae.
Nonsteroidal anti-inflammatory drugs are often rapi[INVESTIGATOR_58890] (pain and 
stiffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. Conventional disease-modifying antirheumatic drugs (DMARDs, eg, methotrexate [MTX] and 
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, DMARDs are recommended only in patients with predominantly peripheral manifestations 
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to nonsteroidal 
anti-inflammatory drugs (NSAIDs), or those in whom NSAIDs are contraindicated, have 
approved treatment options such as tumor necrosis factor (TNF) inhibitors.
Recently, the interleukin (IL)-17 cytokine family has been identified as a therapeutic target in 
axSpA and secukinumab, an IL-17A monoclonal antibody, has recently been approved as a treatment option in active AS. 
Treatment with tumor necrosis factor alpha (TNFα)-antagonists has demonstrated marked 
improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the processes which lead to inflammation and subsequent damage, as in RA, are driven by 
[CONTACT_581576]α production, including extracellular matrix degradation due to matrix 
metalloproteinase (MMP) production (Davis and Mease, 2008).
2.2 Bimekizumab
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of immunoglobulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity 
for human IL-17A and human IL-17F and selectively and potently inhibits the activity of both 
isoforms in vitro. Interleukin-17A and IL-17F are key proinflammatory cytokines believed to play important roles in autoimmune and inflammatory diseases. Therefore, bimekizumab permits 
an evaluation of the potential for additional efficacy, which may be conferred by [CONTACT_581577], in patients suffering from diseases in which both cytokines are active. Bimekizumab is being developed for the treatment of patients with inflammatory diseases such as PsA, psoriasis (PSO), and axSpA. PUBLIC COPY ffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
PUBLIC COPY ffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. 
PUBLIC COPY have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. 
modifying antirheumatic drugs (DMARDs, eg, methotr
PUBLIC COPY modifying antirheumatic drugs (DMARDs, eg, methotr
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
PUBLIC COPY sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
PUBLIC COPY peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
DMARDs are recommended only in patients with predo
PUBLIC COPY DMARDs are recommended only in patients with predo
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to 
PUBLIC COPY (Braun et al, 2011). Patients who are intolerant of or have inadequately responded to 
(NSAIDs), or those in whom NSAIDs are contraindicated, have 
PUBLIC COPY (NSAIDs), or those in whom NSAIDs are contraindicated, have 
approved treatment options such as tumPUBLIC COPY approved treatment options such as tum
17 cytokine family has been identified as a therapeutic target in PUBLIC COPY 17 cytokine family has been identified as a therapeutic target in 
This document cannot be used to support any marketing authorization inflammation (such as enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic features (such 
This document cannot be used to support any marketing authorization inflammation (such as enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic features (such 
antigen [HLA] B27), and laboratory parameters (such as 
This document cannot be used to support any marketing authorization antigen [HLA] B27), and laboratory parameters (such as 
reactive protein [CRP]) may also be present (Braun, 2012; Rudwaleit et al, 2009a; 
This document cannot be used to support any marketing authorization reactive protein [CRP]) may also be present (Braun, 2012; Rudwaleit et al, 2009a; 
Braun and Sieper, 2007). Disability in axSpA is related to both the degree of inflammatory 
This document cannot be used to support any marketing authorization Braun and Sieper, 2007). Disability in axSpA is related to both the degree of inflammatory 
g pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
This document cannot be used to support any marketing authorization g pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
ankylosis, causing loss of spi[INVESTIGATOR_18171]. Patients with AS show radiographic progression of 
This document cannot be used to support any marketing authorization ankylosis, causing loss of spi[INVESTIGATOR_18171]. Patients with AS show radiographic progression of 
ray identified sacroiliitis, while "Bamboo spi[INVESTIGATOR_050]" may develop when
This document cannot be used to support any marketing authorization ray identified sacroiliitis, while "Bamboo spi[INVESTIGATOR_050]" may develop when the outer 
This document cannot be used to support any marketing authorization the outer 
fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
This document cannot be used to support any marketing authorization fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
inflammatory drugs are often rapi[INVESTIGATOR_58890] (pain and 
This document cannot be used to support any marketing authorization inflammatory drugs are often rapi[INVESTIGATOR_58890] (pain and 
ffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
This document cannot be used to support any marketing authorization ffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. 
This document cannot be used to support any marketing authorization have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. 
modifying antirheumatic drugs (DMARDs, eg, methotr
This document cannot be used to support any marketing authorization modifying antirheumatic drugs (DMARDs, eg, methotr
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
This document cannot be used to support any marketing authorization sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
This document cannot be used to support any marketing authorization peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
DMARDs are recommended only in patients with predo
This document cannot be used to support any marketing authorization DMARDs are recommended only in patients with predo minantly peripheral manifestations 
This document cannot be used to support any marketing authorization minantly peripheral manifestations 
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to 
This document cannot be used to support any marketing authorization (Braun et al, 2011). Patients who are intolerant of or have inadequately responded to 
(NSAIDs), or those in whom NSAIDs are contraindicated, have 
This document cannot be used to support any marketing authorization (NSAIDs), or those in whom NSAIDs are contraindicated, have 
or necrosis factor (TNF) inhibitors.
This document cannot be used to support any marketing authorization or necrosis factor (TNF) inhibitors.
17 cytokine family has been identified as a therapeutic target in 
This document cannot be used to support any marketing authorization 17 cytokine family has been identified as a therapeutic target in 
17A monoclonal antibody, has recently been approved as a 
This document cannot be used to support any marketing authorization 17A monoclonal antibody, has recently been approved as a 
tment with tumor necrosis factor alpha (TNFα)
This document cannot be used to support any marketing authorization tment with tumor necrosis factor alpha (TNFα)
improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the 
This document cannot be used to support any marketing authorization improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the 
This document cannot be used to support any marketing authorization processes which lead to inflammation and subsequent damage, as in RA, are driv
This document cannot be used to support any marketing authorization processes which lead to inflammation and subsequent damage, as in RA, are driv
dysregulated TNFα production, including extracellular matrix degradation due to matrix 
This document cannot be used to support any marketing authorization dysregulated TNFα production, including extracellular matrix degradation due to matrix 
metalloproteinase (MMP) production (Davis and Mease, 2008).
This document cannot be used to support any marketing authorization metalloproteinase (MMP) production (Davis and Mease, 2008).
Bimekizumab
This document cannot be used to support any marketing authorization Bimekizumab
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of 
This document cannot be used to support any marketing authorization Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of 
immuno
This document cannot be used to support any marketing authorization immuno globulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a 
This document cannot be used to support any marketing authorization globulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a 
genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity 
This document cannot be used to support any marketing authorization genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity 
for human IL
This document cannot be used to support any marketing authorization for human IL
isoforms in vitro. Interleukin
This document cannot be used to support any marketing authorization isoforms in vitro. Interleukin
play important roles in autoimmune and inflammatory diseases. Therefore, bimekizumab permits This document cannot be used to support any marketing authorization play important roles in autoimmune and inflammatory diseases. Therefore, bimekizumab permits application and any extensions or variations thereof.g pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
application and any extensions or variations thereof.g pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
ankylosis, causing loss of spi[INVESTIGATOR_18171]. Patients with AS show radiographic progression of 
application and any extensions or variations thereof.ankylosis, causing loss of spi[INVESTIGATOR_18171]. Patients with AS show radiographic progression of 
the outer 
application and any extensions or variations thereof.the outer 
fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
application and any extensions or variations thereof.fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
inflammatory drugs are often rapi[INVESTIGATOR_58890] (pain and 
application and any extensions or variations thereof.inflammatory drugs are often rapi[INVESTIGATOR_58890] (pain and 
ffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
application and any extensions or variations thereof.ffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. 
application and any extensions or variations thereof.have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. 
modifying antirheumatic drugs (DMARDs, eg, methotr
application and any extensions or variations thereof.modifying antirheumatic drugs (DMARDs, eg, methotr
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
application and any extensions or variations thereof.sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
application and any extensions or variations thereof.peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
minantly peripheral manifestations 
application and any extensions or variations thereof.minantly peripheral manifestations 
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to 
application and any extensions or variations thereof.(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to 
(NSAIDs), or those in whom NSAIDs are contraindicated, have 
application and any extensions or variations thereof.(NSAIDs), or those in whom NSAIDs are contraindicated, have 
or necrosis factor (TNF) inhibitors.
application and any extensions or variations thereof.or necrosis factor (TNF) inhibitors.
17 cytokine family has been identified as a therapeutic target in 
application and any extensions or variations thereof.17 cytokine family has been identified as a therapeutic target in 
17A monoclonal antibody, has recently been approved as a 
application and any extensions or variations thereof.17A monoclonal antibody, has recently been approved as a 
tment with tumor necrosis factor alpha (TNFα)
application and any extensions or variations thereof.tment with tumor necrosis factor alpha (TNFα)
improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the 
application and any extensions or variations thereof.improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the 
application and any extensions or variations thereof.processes which lead to inflammation and subsequent damage, as in RA, are driv
application and any extensions or variations thereof.processes which lead to inflammation and subsequent damage, as in RA, are driv
dysregulated TNFα production, including extracellular matrix degradation due to matrix 
application and any extensions or variations thereof.dysregulated TNFα production, including extracellular matrix degradation due to matrix 
metalloproteinase (MMP) production (Davis and Mease, 2008).
application and any extensions or variations thereof.metalloproteinase (MMP) production (Davis and Mease, 2008).
Bimekizumab
application and any extensions or variations thereof.Bimekizumab
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of 
application and any extensions or variations thereof.Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of 
globulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a 
application and any extensions or variations thereof.globulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a 
genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity application and any extensions or variations thereof.genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity 
for human IL application and any extensions or variations thereof. for human IL -application and any extensions or variations thereof.-17A and human ILapplication and any extensions or variations thereof.17A and human IL
UCB [ADDRESS_764544] been completed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
and UP0031 in 12 healthy volunteers. 
UP0008 was a Phase 1, First- in-Human (FIH) randomized, subject-blind, investigator-blind, 
placebo-controlled, single-dose, dose-escalating study in 39 subjects with mild- to-moderate 
plaque PSO. In this study bimekizumab was administered by [CONTACT_33980] (iv) infusion of 
single ascending doses and was well tolerated at doses of up to 640mg. The maximum tolerated dose was not reached, and no safety issues were identified. Dose-proportional PK 
was displayed between bimekizumab 8mg and 640mg. The median t½ ranged between 
17.[ADDRESS_764545] were observed after bimekizumab administration for all features of 
plaque PSO in the study. 
RA0124 was an open-label, parallel-group, single-dose study to evaluate the absolute bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of bimekizumab given by [CONTACT_581578] 30 healthy subjects. Similar BA was observed for the 2 doses tested (0.656 and 0.631 for the 
bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
were observed versus previous studies when bimekizumab was administered sc as a single dose of 80mg or 160mg, or iv at a dose of 160mg.
PA0007 was a randomized, subject-blind, investigator-blind, placebo-controlled, 
multiple-dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
response to at least 1 nonbiologic disease-modifying antirheumatic drug (DMARD) and/or 
[ADDRESS_764546]. Bimekizumab was administered to 4 cohorts of subjects as a loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 3-weekly intervals of 160mg, 40mg, 80mg, or 320mg, respectively. There were no unexpected clinically relevant safety findings and all doses were well tolerated.
UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab formulations (a histidine-based formulation 2x80mg and an acetate-based formulation 1x160mg) administered by [CONTACT_580662]. Results showed similar geometric means for AUC between the 2 bimekizumab formulations 
(2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL) and the relative BA for the 
bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
size in UP0031.
Additional studies of bimekizumab are ongoing. RA0123 is a Phase 2a, double-blind, randomized, placebo-controlled, multiple dose study to evaluate the safety, PK, PD, and efficacy 
of multiple doses of bimekizumab administered as add-on therapy to stable CZP therapy in 
subjects with moderate to severe RA. UC0011 is a Phase 2a study, which will evaluate the efficacy, safety, tolerability, and PK of an iv loading dose and 2 sc maintenance doses of 
bimekizumab in subjects with moderate to severe active ulcerative colitis. PS0010, PS0011, 
PS0016, and PS0018 are Phase 2 studies, which will evaluate the PD, PK, safety, and/or efficacy PUBLIC COPY bimekizumab given by [CONTACT_581578] 30 healthy 
PUBLIC COPY bimekizumab given by [CONTACT_581578] 30 healthy 
subjects. Similar BA was observed for the 2 doses tested (0
PUBLIC COPY subjects. Similar BA was observed for the 2 doses tested (0
bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
PUBLIC COPY bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
were observed versus previous studies when bimekizumab was administered sc as a single 
PUBLIC COPY were observed versus previous studies when bimekizumab was administered sc as a single 
dose of 80mg or 160mg, or iv at a dose of 160mg.
PUBLIC COPY dose of 80mg or 160mg, or iv at a dose of 160mg.
ndomized, subject
PUBLIC COPY ndomized, subject blind, investigator
PUBLIC COPY blind, investigator
dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
PUBLIC COPY dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
PUBLIC COPY profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
PUBLIC COPY t least [ADDRESS_764547]. Bimekizumab was administered to 4 cohorts of subjects as a 
This document cannot be used to support any marketing authorization moderate 
This document cannot be used to support any marketing authorization moderate 
plaque PSO. In this study bimekizumab was administered by [CONTACT_33980] (iv) infusion of 
This document cannot be used to support any marketing authorization plaque PSO. In this study bimekizumab was administered by [CONTACT_33980] (iv) infusion of 
es and was well tolerated at doses of up to 640mg. The maximum 
This document cannot be used to support any marketing authorization es and was well tolerated at doses of up to 640mg. The maximum 
proportional PK 
This document cannot be used to support any marketing authorization proportional PK 
was displayed between bimekizumab 8mg and 640mg. The median t½ ranged between 
This document cannot be used to support any marketing authorization was displayed between bimekizumab 8mg and 640mg. The median t½ ranged between 
dependent improvements in the 
This document cannot be used to support any marketing authorization dependent improvements in the 
psoriatic lesion of interest were observed after bimekizumab administration for all features of 
This document cannot be used to support any marketing authorization psoriatic lesion of interest were observed after bimekizumab administration for all features of 
dose study to evalu
This document cannot be used to support any marketing authorization dose study to evalu ate the absolute 
This document cannot be used to support any marketing authorization ate the absolute 
bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of 
This document cannot be used to support any marketing authorization bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of 
bimekizumab given by [CONTACT_581578] 30 healthy 
This document cannot be used to support any marketing authorization bimekizumab given by [CONTACT_581578] 30 healthy 
subjects. Similar BA was observed for the 2 doses tested (0
This document cannot be used to support any marketing authorization subjects. Similar BA was observed for the 2 doses tested (0 .656 and 0.631 for the 
This document cannot be used to support any marketing authorization .656 and 0.631 for the 
bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
This document cannot be used to support any marketing authorization bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
were observed versus previous studies when bimekizumab was administered sc as a single 
This document cannot be used to support any marketing authorization were observed versus previous studies when bimekizumab was administered sc as a single 
dose of 80mg or 160mg, or iv at a dose of 160mg.
This document cannot be used to support any marketing authorization dose of 80mg or 160mg, or iv at a dose of 160mg.
blind, investigator
This document cannot be used to support any marketing authorization blind, investigator
dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
This document cannot be used to support any marketing authorization dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
This document cannot be used to support any marketing authorization profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
This document cannot be used to support any marketing authorization t least [ADDRESS_764548] 1 nonbiologic disease -
This document cannot be used to support any marketing authorization -modifying antirheumatic drug (DMARD) and/or 
This document cannot be used to support any marketing authorization modifying antirheumatic drug (DMARD) and/or 
approved biologic DMARD. Bimekizumab was administered to [ADDRESS_764549]. Bimekizumab was administered to 4 cohorts of subjects as a 
loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 
This document cannot be used to support any marketing authorization loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 
ls of 160mg, 40mg, 80mg, or 320mg, respectively. There were no 
This document cannot be used to support any marketing authorization ls of 160mg, 40mg, 80mg, or 320mg, respectively. There were no 
unexpected clinically relevant safety findings and all doses were well tolerated.
This document cannot be used to support any marketing authorization unexpected clinically relevant safety findings and all doses were well tolerated.
UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab 
This document cannot be used to support any marketing authorization UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab 
formulations (a histid
This document cannot be used to support any marketing authorization formulations (a histid ine
This document cannot be used to support any marketing authorization inebased formulation 2x80mg and an acetate
This document cannot be used to support any marketing authorization based formulation 2x80mg and an acetate
This document cannot be used to support any marketing authorization 1x160mg) administered by [CONTACT_580662]. Results showed similar 
This document cannot be used to support any marketing authorization 1x160mg) administered by [CONTACT_580662]. Results showed similar 
geometric means for AUC between the 2 bimekizumab formulations 
This document cannot be used to support any marketing authorization geometric means for AUC between the 2 bimekizumab formulations 
(2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL)
This document cannot be used to support any marketing authorization (2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL)
bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
This document cannot be used to support any marketing authorization bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
This document cannot be used to support any marketing authorization confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
size in UP0031.
This document cannot be used to support any marketing authorization size in UP0031.
This document cannot be used to support any marketing authorization Additional studies of bimekizumab are 
This document cannot be used to support any marketing authorization Additional studies of bimekizumab are 
randomized, placebo
This document cannot be used to support any marketing authorization randomized, placebo
of multiple doses of bimekizumab administered as add
This document cannot be used to support any marketing authorization of multiple doses of bimekizumab administered as addapplication and any extensions or variations thereof.dependent improvements in the 
application and any extensions or variations thereof.dependent improvements in the 
psoriatic lesion of interest were observed after bimekizumab administration for all features of 
application and any extensions or variations thereof.psoriatic lesion of interest were observed after bimekizumab administration for all features of 
ate the absolute 
application and any extensions or variations thereof.ate the absolute 
bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of 
application and any extensions or variations thereof.bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of 
bimekizumab given by [CONTACT_581578] 30 healthy 
application and any extensions or variations thereof.bimekizumab given by [CONTACT_581578] 30 healthy 
.656 and 0.631 for the 
application and any extensions or variations thereof..656 and 0.631 for the 
bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
application and any extensions or variations thereof.bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
were observed versus previous studies when bimekizumab was administered sc as a single 
application and any extensions or variations thereof.were observed versus previous studies when bimekizumab was administered sc as a single 
blind, investigator
application and any extensions or variations thereof.blind, investigator -
application and any extensions or variations thereof.-blind, placebo
application and any extensions or variations thereof.blind, placebo
dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
application and any extensions or variations thereof.dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
application and any extensions or variations thereof.profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
application and any extensions or variations thereof.modifying antirheumatic drug (DMARD) and/or 
application and any extensions or variations thereof.modifying antirheumatic drug (DMARD) and/or 
approved biologic DMARD. Bimekizumab was administered to [ADDRESS_764550]. Bimekizumab was administered to 4 cohorts of subjects as a 
loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 
application and any extensions or variations thereof.loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 
ls of 160mg, 40mg, 80mg, or 320mg, respectively. There were no 
application and any extensions or variations thereof.ls of 160mg, 40mg, 80mg, or 320mg, respectively. There were no 
unexpected clinically relevant safety findings and all doses were well tolerated.
application and any extensions or variations thereof.unexpected clinically relevant safety findings and all doses were well tolerated.
UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab 
application and any extensions or variations thereof.UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab 
based formulation 2x80mg and an acetate
application and any extensions or variations thereof.based formulation 2x80mg and an acetate
application and any extensions or variations thereof.1x160mg) administered by [CONTACT_580662]. Results showed similar 
application and any extensions or variations thereof.1x160mg) administered by [CONTACT_580662]. Results showed similar 
geometric means for AUC between the 2 bimekizumab formulations 
application and any extensions or variations thereof.geometric means for AUC between the 2 bimekizumab formulations 
(2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL)
application and any extensions or variations thereof.(2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL)
bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
application and any extensions or variations thereof.bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
application and any extensions or variations thereof.confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
size in UP0031.
application and any extensions or variations thereof.size in UP0031.
application and any extensions or variations thereof. Additional studies of bimekizumab are application and any extensions or variations thereof. Additional studies of bimekizumab are 
randomized, placeboapplication and any extensions or variations thereof.
randomized, placebo
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 19of 136of bimekizumab administered sc to subjects with PSO. PA0008 and AS0008 are Phase 2b 
double-blind, randomized, placebo-controlled, multiple-dose studies to evaluate the efficacy and 
safety of bimekizumab in subjects with active PsA or AS, respectively.
Additional information on the clinical data for bimekizumab is available in the current version of 
the Investigator’s Brochure (IB).
2.2.[ADDRESS_764551] level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the mucosa associated lymphoid tissue via a pharmacologically-related mechanism. In a second 
repeat -dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa ( Balantidium coli ) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, the gut associated lymph node lesions observed in the first study are considered to be accidental and/or linked to exaggerated pharmacology and proliferation of Balantidium coli and are considered to 
be the result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.
2.[ADDRESS_764552] all features 
of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
inflammation and subsequent damage, as in RA, are driven by [CONTACT_581576]α production, 
including extracellular matrix degradation due to matrix metalloproteinase (MMP) production (Davis and Mease, 2008). 
The RAPID-axSpA study enrolled subjects with active axSpA with objective signs of 
inflammation, and the results indicated that baseline disease burden was similar between the AS and nr-axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID-axSpA 
study it was shown that CZP rapi[INVESTIGATOR_18188] [ADDRESS_764553] axSpA population, including in the AS and the nr-axSpA 
subpopulations, and that the responses to the treatment were similar in both subpopulations 
(Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; 
Sieper et al, 2014).
Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant 
(KD) of 90pM. Tumor necrosis factor alpha (TNFα) is a key pro-inflammatory cytokine with a 
central role in inflammatory processes. 
Certolizumab pegol does not contain a fragment crystallizable (Fc) region, which is normally 
present in a complete antibody, and therefore does not fix complement or cause PUBLIC COPY lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
PUBLIC COPY lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa (
PUBLIC COPY (20mg/kg/week), a slightly higher number of protozoa ( Balantidium coli
PUBLIC COPY Balantidium coli
he control animals and low dose animals. Therefore, the gut 
PUBLIC COPY he control animals and low dose animals. Therefore, the gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
PUBLIC COPY associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of 
PUBLIC COPY linked to exaggerated pharmacology and proliferation of 
he result of a change in local mucosal immunity. 
PUBLIC COPY he result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
PUBLIC COPY Additional information on the nonclinical data for bimekizumab is available in the current 
Certolizumab pegol PUBLIC COPY Certolizumab pegol
This document cannot be used to support any marketing authorization 17F has shown potent effects in a variety of animal models 
This document cannot be used to support any marketing authorization 17F has shown potent effects in a variety of animal models 
of inflammatory disease. Intravenously administered bimekizumab was well tolerated in repeat 
This document cannot be used to support any marketing authorization of inflammatory disease. Intravenously administered bimekizumab was well tolerated in repeat 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
This document cannot be used to support any marketing authorization 200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
This document cannot be used to support any marketing authorization enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
inding was not associated with 
This document cannot be used to support any marketing authorization inding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
This document cannot be used to support any marketing authorization hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
related mechanism. In a second 
This document cannot be used to support any marketing authorization related mechanism. In a second 
s/necrosis findings observed in gut associated 
This document cannot be used to support any marketing authorization s/necrosis findings observed in gut associated 
lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
This document cannot be used to support any marketing authorization lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
Balantidium coli
This document cannot be used to support any marketing authorization Balantidium coli
he control animals and low dose animals. Therefore, the gut 
This document cannot be used to support any marketing authorization he control animals and low dose animals. Therefore, the gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
This document cannot be used to support any marketing authorization associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of 
This document cannot be used to support any marketing authorization linked to exaggerated pharmacology and proliferation of Balantidium coli
This document cannot be used to support any marketing authorization Balantidium coli
he result of a change in local mucosal immunity. 
This document cannot be used to support any marketing authorization he result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
This document cannot be used to support any marketing authorization Additional information on the nonclinical data for bimekizumab is available in the current 
Certolizumab pegol
This document cannot be used to support any marketing authorization Certolizumab pegol
antagonists has demonstrated marked improvement in almost all features 
This document cannot be used to support any marketing authorization antagonists has demonstrated marked improvement in almost all features 
This document cannot be used to support any marketing authorization of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
This document cannot be used to support any marketing authorization of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
inflammation and subsequent damage, as in RA, are driven by [CONTACT_581576]α pr
This document cannot be used to support any marketing authorization inflammation and subsequent damage, as in RA, are driven by [CONTACT_581576]α pr
including extracellular matrix degradation due to matrix metalloproteinase (MMP) production 
This document cannot be used to support any marketing authorization including extracellular matrix degradation due to matrix metalloproteinase (MMP) production 
(Davis and Mease, 2008). 
This document cannot be used to support any marketing authorization (Davis and Mease, 2008). 
axSpA study enrolled subjects with active axSpA with objective signs of 
This document cannot be used to support any marketing authorization axSpA study enrolled subjects with active axSpA with objective signs of 
inflammation, and the results indicated that b
This document cannot be used to support any marketing authorization inflammation, and the results indicated that b
axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID
This document cannot be used to support any marketing authorization axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID
study it was shown that CZP rapi[INVESTIGATOR_18188] 24 weeks of 
This document cannot be used to support any marketing authorization study it was shown that CZP rapi[INVESTIGATOR_18188] 24 weeks of 
-
This document cannot be used to support any marketing authorization -blind treatment
This document cannot be used to support any marketing authorization blind treatment
This document cannot be used to support any marketing authorization subpopulations, and that the responses to the treatment were similar in both subpopulations 
This document cannot be used to support any marketing authorization subpopulations, and that the responses to the treatment were similar in both subpopulations 
(Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; 
This document cannot be used to support any marketing authorization (Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; 
Sie
This document cannot be used to support any marketing authorization Sieper et al, 2014).
This document cannot be used to support any marketing authorization per et al, 2014).
Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant 
This document cannot be used to support any marketing authorization Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant application and any extensions or variations thereof.200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
application and any extensions or variations thereof.200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
application and any extensions or variations thereof.enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
inding was not associated with 
application and any extensions or variations thereof.inding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
application and any extensions or variations thereof.hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
related mechanism. In a second 
application and any extensions or variations thereof.related mechanism. In a second 
s/necrosis findings observed in gut associated 
application and any extensions or variations thereof.s/necrosis findings observed in gut associated 
lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
application and any extensions or variations thereof.lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
Balantidium coli
application and any extensions or variations thereof.Balantidium coli ) was observed in the 
application and any extensions or variations thereof.) was observed in the 
he control animals and low dose animals. Therefore, the gut 
application and any extensions or variations thereof.he control animals and low dose animals. Therefore, the gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
application and any extensions or variations thereof.associated lymph node lesions observed in the first study are considered to be accidental and/or 
Balantidium coli
application and any extensions or variations thereof.Balantidium coli
Additional information on the nonclinical data for bimekizumab is available in the current 
application and any extensions or variations thereof.Additional information on the nonclinical data for bimekizumab is available in the current 
antagonists has demonstrated marked improvement in almost all features 
application and any extensions or variations thereof.antagonists has demonstrated marked improvement in almost all features 
application and any extensions or variations thereof.of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
application and any extensions or variations thereof.of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
inflammation and subsequent damage, as in RA, are driven by [CONTACT_581576]α pr
application and any extensions or variations thereof.inflammation and subsequent damage, as in RA, are driven by [CONTACT_581576]α pr
including extracellular matrix degradation due to matrix metalloproteinase (MMP) production 
application and any extensions or variations thereof.including extracellular matrix degradation due to matrix metalloproteinase (MMP) production 
axSpA study enrolled subjects with active axSpA with objective signs of 
application and any extensions or variations thereof.axSpA study enrolled subjects with active axSpA with objective signs of 
inflammation, and the results indicated that b
application and any extensions or variations thereof.inflammation, and the results indicated that b
axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID
application and any extensions or variations thereof.axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID
study it was shown that CZP rapi[INVESTIGATOR_18188] [ADDRESS_764554] axSpA population, including in the AS and the nr
subpopulations, and that the responses to the treatment were similar in both subpopulations 
application and any extensions or variations thereof.subpopulations, and that the responses to the treatment were similar in both subpopulations 
(Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; application and any extensions or variations thereof.(Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; 
per et al, 2014).application and any extensions or variations thereof. per et al, 2014).
UCB [ADDRESS_764555] TNF blockers used for the treatment of patients with active AS showed great promise. 
(Brandt et al, 2000). However, despi[INVESTIGATOR_581495], C-reactive protein 
and inflammation as detected by [CONTACT_9268], the TNFα inhibitors did not appear to prevent new bone 
formation in the spi[INVESTIGATOR_050] (van der Heijde et al, 2008). A 12-year longitudinal study shows that the 
higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
inflammation and new bone formation are related (Ramiro et al, 2014). Understanding the role of different cytokines in driving new bone formation allows for improved treatments for AS 
patients. There is a growing association, and interest, for the involvement of IL-17 signaling in 
bone pathology during spondyloarthritis disease progression. The role of IL-17A in driving bone loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
demonstrated that mesenchymal cells incubated in the presence of IL 17A and bone 
differentiation medium leads to the formation of extracellular calcified bone matrix with an 
increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL-17A may have a 
role not only in bone destruction, but under the right conditions in driving new bone formation. 
Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
IL-17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
inflammation leads to bone destruction, however in the absence of these, the same inflammation 
will induce new bone formation. In the AS patient at the syndesmophytes when mesenchymal 
cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
induce new bone formation (Miossec, 2017). Recently, IL 17-producing γδ-T cells have been associated with periosteal bone formation for fracture repair (Ono et al, 2016); the periosteum is 
also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
human periosteum-derived stem cell (hPDSC) model of osteogenic differentiation demonstrated 
that either/both IL-17A or/and IL-17F are able to drive pathologic bone formation (Shah et al, 
2017). Inhibiting both IL-17A and IL-17F has the potential to impact the pathophysiology of 
new bone formation in AS patients.
AS0013, the current subject-blind and investigator-blind study has been designed to evaluate the 
efficacy and safety of bimekizumab in a clinical setting in subjects with AS. The features of bone 
lesions are both erosive and neo-appositive and it is not clear if the inflammatory and erosive process precedes the new formation of bone. 18F-fluoride positron-emission tomography –
computed tomography (PET-CT) or 18F-fluoride positron-emission tomography – magnetic 
resonance imaging (PET-MRI) will be used to investigate the effects of bimekizumab on the PUBLIC COPY higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
PUBLIC COPY higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
nd new bone formation are related (Ramiro et al, 2014). Understanding the role of 
PUBLIC COPY nd new bone formation are related (Ramiro et al, 2014). Understanding the role of 
different cytokines in driving new bone formation allows for improved treatments for AS 
PUBLIC COPY different cytokines in driving new bone formation allows for improved treatments for AS 
patients. There is a growing association, and interest, for the involvement of IL
PUBLIC COPY patients. There is a growing association, and interest, for the involvement of IL
bone pathology during spondyloarthritis disease progression. The role of IL
PUBLIC COPY bone pathology during spondyloarthritis disease progression. The role of IL
loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
PUBLIC COPY loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
demonstrated that mesenchymal cells incubated in the 
PUBLIC COPY demonstrated that mesenchymal cells incubated in the 
differentiation medium leads to the formation of extracellular calcified bone matrix with an 
PUBLIC COPY differentiation medium leads to the formation of extracellular calcified bone matrix with an 
increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that ILPUBLIC COPY increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL
role not only in bone destruction, bu PUBLIC COPY role not only in bone destruction, bu
This document cannot be used to support any marketing authorization dose, the recommended maintenance dose of CZP for adult subjects with AS is 
This document cannot be used to support any marketing authorization dose, the recommended maintenance dose of CZP for adult subjects with AS is 
Additional information on the clinical data for CZP is available in the current version of the IB 
This document cannot be used to support any marketing authorization Additional information on the clinical data for CZP is available in the current version of the IB 
The first TNF blockers used for the treatment of patients with active AS showed great promise. 
This document cannot be used to support any marketing authorization The first TNF blockers used for the treatment of patients with active AS showed great promise. 
(Brandt et al, 2000). However, despi[INVESTIGATOR_581495], C
This document cannot be used to support any marketing authorization (Brandt et al, 2000). However, despi[INVESTIGATOR_581495], C -
This document cannot be used to support any marketing authorization -reactive protein 
This document cannot be used to support any marketing authorization reactive protein 
inhibitors did not appear to prevent new bone 
This document cannot be used to support any marketing authorization inhibitors did not appear to prevent new bone 
year longitudinal study shows that the 
This document cannot be used to support any marketing authorization year longitudinal study shows that the 
higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
This document cannot be used to support any marketing authorization higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
nd new bone formation are related (Ramiro et al, 2014). Understanding the role of 
This document cannot be used to support any marketing authorization nd new bone formation are related (Ramiro et al, 2014). Understanding the role of 
different cytokines in driving new bone formation allows for improved treatments for AS 
This document cannot be used to support any marketing authorization different cytokines in driving new bone formation allows for improved treatments for AS 
patients. There is a growing association, and interest, for the involvement of IL
This document cannot be used to support any marketing authorization patients. There is a growing association, and interest, for the involvement of IL
bone pathology during spondyloarthritis disease progression. The role of IL
This document cannot be used to support any marketing authorization bone pathology during spondyloarthritis disease progression. The role of IL
loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
This document cannot be used to support any marketing authorization loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
demonstrated that mesenchymal cells incubated in the 
This document cannot be used to support any marketing authorization demonstrated that mesenchymal cells incubated in the 
differentiation medium leads to the formation of extracellular calcified bone matrix with an 
This document cannot be used to support any marketing authorization differentiation medium leads to the formation of extracellular calcified bone matrix with an 
increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL
This document cannot be used to support any marketing authorization increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL
t under the right conditions in driving new bone formation. 
This document cannot be used to support any marketing authorization t under the right conditions in driving new bone formation. 
Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in 
This document cannot be used to support any marketing authorization Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in 
This document cannot be used to support any marketing authorization osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
This document cannot be used to support any marketing authorization osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
This document cannot be used to support any marketing authorization 17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
inflammation leads to bone destruction, however in the absence of these, the same inflammation 
This document cannot be used to support any marketing authorization inflammation leads to bone destruction, however in the absence of these, the same inflammation 
will induce new bone formation. In the AS patient at the syndesmo
This document cannot be used to support any marketing authorization will induce new bone formation. In the AS patient at the syndesmo
cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
This document cannot be used to support any marketing authorization cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
induce new bone formation (Miossec, 2017). Recently, IL 17
This document cannot be used to support any marketing authorization induce new bone formation (Miossec, 2017). Recently, IL 17
associated with periosteal bone formation for fr
This document cannot be used to support any marketing authorization associated with periosteal bone formation for fr
also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
This document cannot be used to support any marketing authorization also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
human periosteum
This document cannot be used to support any marketing authorization human periosteum
This document cannot be used to support any marketing authorization that either/both IL
This document cannot be used to support any marketing authorization that either/both IL
2017). Inhibiting both IL
This document cannot be used to support any marketing authorization 2017). Inhibiting both IL
new bone formation in AS patients.
This document cannot be used to support any marketing authorization new bone formation in AS patients.
AS0013, the current subject
This document cannot be used to support any marketing authorization AS0013, the current subject
efficacy and safety of bimekizumab in a clinical setting in subjects with AS. The features of bone This document cannot be used to support any marketing authorization efficacy and safety of bimekizumab in a clinical setting in subjects with AS. The features of bone application and any extensions or variations thereof.The first TNF blockers used for the treatment of patients with active AS showed great promise. 
application and any extensions or variations thereof.The first TNF blockers used for the treatment of patients with active AS showed great promise. 
reactive protein 
application and any extensions or variations thereof.reactive protein 
inhibitors did not appear to prevent new bone 
application and any extensions or variations thereof.inhibitors did not appear to prevent new bone 
year longitudinal study shows that the 
application and any extensions or variations thereof.year longitudinal study shows that the 
higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
application and any extensions or variations thereof.higher the disease activity, the more the structural damage in the spi[INVESTIGATOR_050], and thus concluding that 
nd new bone formation are related (Ramiro et al, 2014). Understanding the role of 
application and any extensions or variations thereof.nd new bone formation are related (Ramiro et al, 2014). Understanding the role of 
different cytokines in driving new bone formation allows for improved treatments for AS 
application and any extensions or variations thereof.different cytokines in driving new bone formation allows for improved treatments for AS 
patients. There is a growing association, and interest, for the involvement of IL
application and any extensions or variations thereof.patients. There is a growing association, and interest, for the involvement of IL
bone pathology during spondyloarthritis disease progression. The role of IL
application and any extensions or variations thereof.bone pathology during spondyloarthritis disease progression. The role of IL
loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
application and any extensions or variations thereof.loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
presence of IL 17A and bone 
application and any extensions or variations thereof.presence of IL 17A and bone 
differentiation medium leads to the formation of extracellular calcified bone matrix with an 
application and any extensions or variations thereof.differentiation medium leads to the formation of extracellular calcified bone matrix with an 
increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL
application and any extensions or variations thereof.increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL
t under the right conditions in driving new bone formation. 
application and any extensions or variations thereof.t under the right conditions in driving new bone formation. 
Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in 
application and any extensions or variations thereof.Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in 
application and any extensions or variations thereof.osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
application and any extensions or variations thereof.osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
application and any extensions or variations thereof.17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
inflammation leads to bone destruction, however in the absence of these, the same inflammation 
application and any extensions or variations thereof.inflammation leads to bone destruction, however in the absence of these, the same inflammation 
will induce new bone formation. In the AS patient at the syndesmo
application and any extensions or variations thereof.will induce new bone formation. In the AS patient at the syndesmo
cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
application and any extensions or variations thereof.cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
induce new bone formation (Miossec, 2017). Recently, IL 17
application and any extensions or variations thereof.induce new bone formation (Miossec, 2017). Recently, IL 17
associated with periosteal bone formation for fr
application and any extensions or variations thereof.associated with periosteal bone formation for fr
also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
application and any extensions or variations thereof.also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
human periosteum
application and any extensions or variations thereof.human periosteum -
application and any extensions or variations thereof.-derived stem cell (hPDSC) model of osteogenic differentiation demonstrated 
application and any extensions or variations thereof.derived stem cell (hPDSC) model of osteogenic differentiation demonstrated 
application and any extensions or variations thereof.that either/both IL
application and any extensions or variations thereof.that either/both IL -
application and any extensions or variations thereof.-17A or/and IL
application and any extensions or variations thereof.17A or/and IL
2017). Inhibiting both ILapplication and any extensions or variations thereof.2017). Inhibiting both IL
new bone formation in AS patients. application and any extensions or variations thereof.new bone formation in AS patients.
UCB [ADDRESS_764556] activity between bimekizumab and CZP. 
3 STUDY OBJECTIVE(S)
This is a Phase 2a, multicenter, randomized, subject-blind and investigator-blind, parallel-group study to evaluate the efficacy and safety of bimekizumab compared to CZP in subjects with active AS. The effect of study treatments on the process of osteoproliferation will be evaluated in 
a subgroup of subjects at selected sites.
3.1 Primary objective
The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc Q2W for 12 weeks compared to CZP in the treatment of subjects with active AS.
3.2 Secondary objective
The secondary objective of the study is as follows:
To assess the safety and tolerability of bimekizumab
3.3 Other exploratory objectives
The other exploratory objectives of the study are as follows:To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
4 STUDY VARIABLES
4.1 Efficacy variables
4.1.1 Primary efficacy variable
The primary efficacy variable for this study is as follows:
Change from Baseline in ASDAS at Week 12
4.1.2 Secondary efficacy variables
The secondary efficacy variables for this study are as follows:ASDAS-ID at Week 12
ASDAS-MI at Week 12PUBLIC COPY To assess the safety and tolerability of bimekizumab
PUBLIC COPY To assess the safety and tolerability of bimekizumab
Other exploratory objectives
PUBLIC COPY Other exploratory objectives
of the study are as follows:
PUBLIC COPY of the study are as follows:
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
PUBLIC COPY To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
PUBLIC COPY To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as availablePUBLIC COPY To assess additional biomarker, clinical, and imaging data as available
This document cannot be used to support any marketing authorization group 
This document cannot be used to support any marketing authorization group 
study to evaluate the efficacy and safety of bimekizumab compared to CZP in subjects with 
This document cannot be used to support any marketing authorization study to evaluate the efficacy and safety of bimekizumab compared to CZP in subjects with 
AS. The effect of study treatments on the process of osteoproliferation will be evaluated in 
This document cannot be used to support any marketing authorization AS. The effect of study treatments on the process of osteoproliferation will be evaluated in 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc 
This document cannot be used to support any marketing authorization The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc 
12 weeks compared to CZP in the treatment of subjects with active AS.
This document cannot be used to support any marketing authorization 12 weeks compared to CZP in the treatment of subjects with active AS.
of the study are as follows:
This document cannot be used to support any marketing authorization of the study are as follows:
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
This document cannot be used to support any marketing authorization To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
This document cannot be used to support any marketing authorization To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
This document cannot be used to support any marketing authorization To assess additional biomarker, clinical, and imaging data as available
afety of bimekizumab or CZP during the Treatment Extension 
This document cannot be used to support any marketing authorization afety of bimekizumab or CZP during the Treatment Extension 
STUDY VARIABLES
This document cannot be used to support any marketing authorization STUDY VARIABLES
Efficacy variables
This document cannot be used to support any marketing authorization Efficacy variables
This document cannot be used to support any marketing authorization Primary efficacy variable
This document cannot be used to support any marketing authorization Primary efficacy variable
The primary efficacy variable for this study is as follows:
This document cannot be used to support any marketing authorization The primary efficacy variable for this study is as follows:
Change from Baseline in ASDAS at Week 12
This document cannot be used to support any marketing authorization Change from Baseline in ASDAS at Week 12
The secondary efficacy variables for this study are as follows:
This document cannot be used to support any marketing authorization The secondary efficacy variables for this study are as follows:

This document cannot be used to support any marketing authorization ASDAS
This document cannot be used to support any marketing authorization ASDAS

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc 
application and any extensions or variations thereof.The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc 
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
application and any extensions or variations thereof.To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
application and any extensions or variations thereof.To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
application and any extensions or variations thereof.To assess additional biomarker, clinical, and imaging data as available
afety of bimekizumab or CZP during the Treatment Extension 
application and any extensions or variations thereof.afety of bimekizumab or CZP during the Treatment Extension 
STUDY VARIABLES
application and any extensions or variations thereof.STUDY VARIABLES
Efficacy variables
application and any extensions or variations thereof.Efficacy variables
application and any extensions or variations thereof.Primary efficacy variable
application and any extensions or variations thereof.Primary efficacy variable
The primary efficacy variable for this study is as follows:
application and any extensions or variations thereof.The primary efficacy variable for this study is as follows:
Change from Baseline in ASDAS at Week 12
application and any extensions or variations thereof.Change from Baseline in ASDAS at Week 12
Secondary efficacy variables
application and any extensions or variations thereof.Secondary efficacy variables
The secondary efficacy variables for this study are as follows:application and any extensions or variations thereof.The secondary efficacy variables for this study are as follows:
ID at Week 12application and any extensions or variations thereof.ID at Week 12
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 22of 1364.1.3 Other efficacy variables 
Assessment time points for the other efficacy variables are specified in Table 5‒1. The following 
efficacy variables are exploratory and are assessed over the Treatment Period and Treatment 
Extension Period, as applicable:
Change from Baseline in ASDAS
ASAS20 response
ASAS40 response
Time to ASAS20 response
Time to ASAS40 response
ASAS partial remission
Change from Baseline in BASDAI
Changes in bone formation as measured by [CONTACT_581579] (SUV AUC) and derived from PET-MRI or PET-CT at Baseline, Week 12, and Week 48 
4.2 Safety variables
4.2.1 Primary safety variables
The primary safety variables for this study are as follows:
Incidence of AEs and SAEs
Adverse events leading to withdrawal from IMP
4.2.2 Other safety variables
The other safety variables for this study are as follows:Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
weight
Change from Baseline in physical examination
Change from Baseline in standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS, QT, and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 
Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
urinalysis)
4.3 Other PK and PD variables
4.3.1 Other PK variables
The PK variables are plasma concentrations of bimekizumab and CZP.
4.3.2 Other PD variables
The PD variables assessed at time points specified in Table 5‒1 are the blood or blood derivative 
(eg, plasma) concentrations of cytokines and chemokines of relevance to IL-17A/F signaling PUBLIC COPY The primary safety variables for this study are as follows:
PUBLIC COPY The primary safety variables for this study are as follows:
Adverse events leading to withdrawal from IMP
PUBLIC COPY Adverse events leading to withdrawal from IMP
Other safety variables PUBLIC COPY Other safety variables
This document cannot be used to support any marketing authorization Changes in bone formation as measured by [CONTACT_581580] e, Week 12, and Week 48 
This document cannot be used to support any marketing authorization e, Week 12, and Week 48 
The primary safety variables for this study are as follows:
This document cannot be used to support any marketing authorization The primary safety variables for this study are as follows:
Adverse events leading to withdrawal from IMP
This document cannot be used to support any marketing authorization Adverse events leading to withdrawal from IMP
Other safety variables
This document cannot be used to support any marketing authorization Other safety variables
The other safety variables for thi
This document cannot be used to support any marketing authorization The other safety variables for thi s study are as follows:
This document cannot be used to support any marketing authorization s study are as follows:
Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
This document cannot be used to support any marketing authorization Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
Change from Baseline in physical examination
This document cannot be used to support any marketing authorization Change from Baseline in physical examination
Change from Baseline in standard [ADDRESS_764557] 12
and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 
This document cannot be used to support any marketing authorization and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 
Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
This document cannot be used to support any marketing authorization Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
urinalysis)
This document cannot be used to support any marketing authorization urinalysis)
4.3
This document cannot be used to support any marketing authorization 4.3
4.3.1
This document cannot be used to support any marketing authorization 4.3.1
The PK variables are plasma concentrati
This document cannot be used to support any marketing authorization The PK variables are plasma concentratiapplication and any extensions or variations thereof.Changes in bone formation as measured by [CONTACT_581581].Changes in bone formation as measured by [CONTACT_581582] 
e, Week 12, and Week 48 
application and any extensions or variations thereof.e, Week 12, and Week 48 
Adverse events leading to withdrawal from IMP
application and any extensions or variations thereof.Adverse events leading to withdrawal from IMP
s study are as follows:
application and any extensions or variations thereof.s study are as follows:
Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
application and any extensions or variations thereof.Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
Change from Baseline in physical examination
application and any extensions or variations thereof.Change from Baseline in physical examination
Change from Baseline in standard [ADDRESS_764558] 12
and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 
application and any extensions or variations thereof.and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 
Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
application and any extensions or variations thereof.Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
Other PK and PD variablesapplication and any extensions or variations thereof.Other PK and PD variables
UCB [ADDRESS_764559], AS biology, and bone metabolism. Additional variables may 
include, but will not be limited to, serum complement concentrations and mononucle ar cell 
subtypes.
4.4 Other immunological variable(s)
Immunological variables will allow evaluation of immunogenicity as well as immunological 
biomarkers. Anti-bimekizumab antibody and anti-CZP antibody detection prior to and following 
study treatment will be evaluated.
4.5 Other nonhereditary pharmacogenomic variables
Where local regulations permit, blood and urine will be collected at specific time points specified 
in Table 5‒1 and stored for up to 20 years to allow for potential exploratory analyses of 
ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
and the inflammatory and immune response processes. The nature and format of these tentative analyses will be determined at a later stage. 
4.6 Other pharmacogenetic variables 
Additional blood samples will be collected from subjects who consent to participate in the 
pharmacogenetic substudy at specific time points specified in Table 5‒1 and stored at -80°C for 
up to [ADDRESS_764560] meet the following key inclusion criteria: 
Subjects will have active adult-onset AS, meeting Modified [LOCATION_001] criteria for AS with: 
BASDAI score ≥4
Spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). 
hs-CRP levels should be above the upper limit of normal (ULN) at the Screening Visit. One 
re-test of hs-CRP is permitted during the Screening Period upon discretion of the 
Investigator.
Subject must have had an inadequate response to, have a contraindication to, or has been intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack of response to at least [ADDRESS_764561] tolerated dose of the administered NSAID.) If taking NSAIDs at study entry, subjects must be on a stable dose for 2 weeks prior to Baseline. PUBLIC COPY Additional blood samples will be collected from subjects who consent to participate in the 
PUBLIC COPY Additional blood samples will be collected from subjects who consent to participate in the 
ic substudy at specific time points specified in 
PUBLIC COPY ic substudy at specific time points specified in 
up to 20 years. Pharmacogenetic biomarkers may be measured to evaluat
PUBLIC COPY up to 20 years. Pharmacogenetic biomarkers may be measured to evaluat
response to treatment with bimekizumab, AS disease biology, bone metabolism, and 
PUBLIC COPY response to treatment with bimekizumab, AS disease biology, bone metabolism, and 
inflammatory and immune response processes. The nature and format of these tentative 
PUBLIC COPY inflammatory and immune response processes. The nature and format of these tentative 
study analyses will be determined when the results of the main s
PUBLIC COPY study analyses will be determined when the results of the main s
STUDY DESIGN
PUBLIC COPY STUDY DESIGN
Study descriptionPUBLIC COPY Study description
This document cannot be used to support any marketing authorization CZP antibody detection prior to and following 
This document cannot be used to support any marketing authorization CZP antibody detection prior to and following 
Where local regulations permit, blood and urine will be collected at specific time points specified 
This document cannot be used to support any marketing authorization Where local regulations permit, blood and urine will be collected at specific time points specified 
and stored for up to 20 years to allow for potential exploratory analyses of 
This document cannot be used to support any marketing authorization and stored for up to 20 years to allow for potential exploratory analyses of 
ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
This document cannot be used to support any marketing authorization ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
and immune response processes. The nature and format of these tentative 
This document cannot be used to support any marketing authorization and immune response processes. The nature and format of these tentative 
Additional blood samples will be collected from subjects who consent to participate in the 
This document cannot be used to support any marketing authorization Additional blood samples will be collected from subjects who consent to participate in the 
ic substudy at specific time points specified in 
This document cannot be used to support any marketing authorization ic substudy at specific time points specified in Table
This document cannot be used to support any marketing authorization Table [ADDRESS_764562] meet the following key inclusion criteria: 
This document cannot be used to support any marketing authorization To be eligible to participate, subjects must meet the following key inclusion criteria: 
Subjects will have active adult
This document cannot be used to support any marketing authorization Subjects will have active adult
BASDAI score 
This document cannot be used to support any marketing authorization BASDAI score ≥
This document cannot be used to support any marketing authorization ≥4
This document cannot be used to support any marketing authorization 4
Spi[INVESTIGATOR_581496] (ULN) at the Screening Visit. One 
This document cannot be used to support any marketing authorization CRP levels should be above the upper limit of normal (ULN) at the Screening Visit. One 
re
This document cannot be used to support any marketing authorization re-
This document cannot be used to support any marketing authorization -test of hs
This document cannot be used to support any marketing authorization test of hs
Investigator.
This document cannot be used to support any marketing authorization Investigator.

This document cannot be used to support any marketing authorization Subject must have had an inadequate response to, have a contraindication
This document cannot be used to support any marketing authorization Subject must have had an inadequate response to, have a contraindicationapplication and any extensions or variations thereof.Where local regulations permit, blood and urine will be collected at specific time points specified 
application and any extensions or variations thereof.Where local regulations permit, blood and urine will be collected at specific time points specified 
ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
application and any extensions or variations thereof.ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
and immune response processes. The nature and format of these tentative 
application and any extensions or variations thereof.and immune response processes. The nature and format of these tentative 
Additional blood samples will be collected from subjects who consent to participate in the 
application and any extensions or variations thereof.Additional blood samples will be collected from subjects who consent to participate in the 
5
application and any extensions or variations thereof.5‒
application and any extensions or variations thereof.‒[ADDRESS_764563] meet the following key inclusion criteria: 
application and any extensions or variations thereof.To be eligible to participate, subjects must meet the following key inclusion criteria: 
Subjects will have active adult
application and any extensions or variations thereof.Subjects will have active adult -
application and any extensions or variations thereof.-onset AS, meeting Modified [LOCATION_001] criteria for AS with: 
application and any extensions or variations thereof.onset AS, meeting Modified [LOCATION_001] criteria for AS with: 
4
application and any extensions or variations thereof.4
Spi[INVESTIGATOR_581497].Spi[INVESTIGATOR_463121] ≥
application and any extensions or variations thereof.≥4 (from BASDAI Question
application and any extensions or variations thereof.4 (from BASDAI Question
CRP levels should be above the upper limit of normal (ULN) at the Screening Visit. One 
application and any extensions or variations thereof.CRP levels should be above the upper limit of normal (ULN) at the Screening Visit. One 
test of hs
application and any extensions or variations thereof.test of hs -
application and any extensions or variations thereof.-CRP is permitted during the Screening Period upon discretion of the 
application and any extensions or variations thereof.CRP is permitted during the Screening Period upon discretion of the 
Investigator.application and any extensions or variations thereof.Investigator.
Subject must have had an inadequate response to, have a contraindicationapplication and any extensions or variations thereof. Subject must have had an inadequate response to, have a contraindication
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 24of 136In addition, the subject may not have been exposed to more than [ADDRESS_764564] therapy (defined as no response within the first [ADDRESS_764565] 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will receive either bimekizumab or CZP up to Week 44 (final dose of IMP). 
AS0013 will include a Screening Period of 2 to 4 weeks, a 12-week Treatment Period, a 36-week 
Treatment Extension Period, and a 20-week Safety Follow-up Period (after the final dose of 
IMP). 
In approximately [ADDRESS_764566] scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET-positive 
lesions were observed in the previous scan.
5.1.1 Screening Period (minimum of 2 and up to 4 weeks)
Assessments of eligibility as described in Section 6will be initiated during the 2- to 4-week 
Screening Period. The informed consent will be obtained as described in Section 8.1. The 
Screening Period will also enable the washout of medications not permitted for use during the 
study.
The assessments at the Screening Visit are presented in Table 5‒1.
5.1.2 Treatment Period (Week 0 to Week 12)
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
treatments: 
Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks 6to10.
Study treatments will be prepared and administered by [CONTACT_581583]. 
5.1.3 Treatment Extension Period (Week 12 to Week 48)
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment 
Extension Period and will receive the following treatments:
Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc Q4W from Week 12 to Week 44. 
Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
from Week 12 to Week 44. 
Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discretion and will not enter the Treatment Extension Period.
The assessments during the Treatment Extension Period are presented in Table 5‒1.PUBLIC COPY Screening Period will also enable the washout of medications not permitted for use during the 
PUBLIC COPY Screening Period will also enable the washout of medications not permitted for use during the 
The assessments at the Screening Visit are presented in 
PUBLIC COPY The assessments at the Screening Visit are presented in Table
PUBLIC COPY Table
PUBLIC COPY Treatment Period (Week 0 to Week 12)
PUBLIC COPY Treatment Period (Week 0 to Week 12)
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
PUBLIC COPY Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
Bimekizumab 160mg sc Q2W 
PUBLIC COPY Bimekizumab 160mg sc Q2W from Week 0 through Week
PUBLIC COPY from Week 0 through Week
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in PUBLIC COPY placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. PUBLIC COPY order to maintain the blind vs the CZP loading dose at these visits. 
This document cannot be used to support any marketing authorization week 
This document cannot be used to support any marketing authorization week 
up Period (after the final dose of 
This document cannot be used to support any marketing authorization up Period (after the final dose of 
CT scan will be performed at 
This document cannot be used to support any marketing authorization CT scan will be performed at 
creening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET
This document cannot be used to support any marketing authorization creening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET -
This document cannot be used to support any marketing authorization -positive 
This document cannot be used to support any marketing authorization positive 
Screening Period (minimum of 2 and up to 4 weeks)
This document cannot be used to support any marketing authorization Screening Period (minimum of 2 and up to 4 weeks)
will be initiated during the 2
This document cannot be used to support any marketing authorization will be initiated during the 2
Screening Period. The informed consent will be obtained as described in 
This document cannot be used to support any marketing authorization Screening Period. The informed consent will be obtained as described in Section
This document cannot be used to support any marketing authorization Section
Screening Period will also enable the washout of medications not permitted for use during the 
This document cannot be used to support any marketing authorization Screening Period will also enable the washout of medications not permitted for use during the 
Table
This document cannot be used to support any marketing authorization Table 5
This document cannot be used to support any marketing authorization 5‒
This document cannot be used to support any marketing authorization ‒1
This document cannot be used to support any marketing authorization 1
This document cannot be used to support any marketing authorization Treatment Period (Week 0 to Week 12)
This document cannot be used to support any marketing authorization Treatment Period (Week 0 to Week 12)
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
This document cannot be used to support any marketing authorization Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
from Week 0 through Week
This document cannot be used to support any marketing authorization from Week 0 through Week
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
This document cannot be used to support any marketing authorization placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 
This document cannot be used to support any marketing authorization order to maintain the blind vs the CZP loading dose at these visits. 
CZP 400mg sc Q2W at Weeks 0, 2, and 4
This document cannot be used to support any marketing authorization CZP 400mg sc Q2W at Weeks 0, 2, and 4
Study treatments will be prepared and administered by [CONTACT_581584] (Week 12 to Week 48)
This document cannot be used to support any marketing authorization Treatment Extension Period (Week 12 to Week 48)
After completing the 12
This document cannot be used to support any marketing authorization After completing the 12
This document cannot be used to support any marketing authorization Extension Period and will receive the following treatments:
This document cannot be used to support any marketing authorization Extension Period and will receive the following treatments:
Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
This document cannot be used to support any marketing authorization Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc Q4W from Week 12 to Week 44. 
This document cannot be used to support any marketing authorization 320mg sc Q4W from Week 12 to Week 44. 

This document cannot be used to support any marketing authorization Subjects randomized t
This document cannot be used to support any marketing authorization Subjects randomized t
from Week [ADDRESS_764567] scan will be performed at 
positive 
application and any extensions or variations thereof.positive 
will be initiated during the 2
application and any extensions or variations thereof.will be initiated during the 2 -
application and any extensions or variations thereof.-to 4
application and any extensions or variations thereof.to 4-
application and any extensions or variations thereof.-week 
application and any extensions or variations thereof.week 
Section
application and any extensions or variations thereof.Section 8.1
application and any extensions or variations thereof.8.1. The 
application and any extensions or variations thereof.. The 
Screening Period will also enable the washout of medications not permitted for use during the 
application and any extensions or variations thereof.Screening Period will also enable the washout of medications not permitted for use during the 
application and any extensions or variations thereof.Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
application and any extensions or variations thereof.Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
from Week 0 through Week
application and any extensions or variations thereof.from Week 0 through Week
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
application and any extensions or variations thereof.placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 
application and any extensions or variations thereof.order to maintain the blind vs the CZP loading dose at these visits. 
CZP 400mg sc Q2W at Weeks 0, 2, and 4
application and any extensions or variations thereof.CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
application and any extensions or variations thereof.(loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Study treatments will be prepared and administered by [CONTACT_581585].Study treatments will be prepared and administered by [CONTACT_581586] (Week 12 to Week 48)
application and any extensions or variations thereof.Treatment Extension Period (Week 12 to Week 48)
After completing the 12
application and any extensions or variations thereof.After completing the 12 -
application and any extensions or variations thereof.-
application and any extensions or variations thereof.week Treatment 
application and any extensions or variations thereof.week Treatment 
Extension Period and will receive the following treatments:
application and any extensions or variations thereof.Extension Period and will receive the following treatments:
Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
application and any extensions or variations thereof.Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc Q4W from Week 12 to Week 44. 
application and any extensions or variations thereof.320mg sc Q4W from Week 12 to Week 44. 
Subjects randomized tapplication and any extensions or variations thereof.Subjects randomized t
from Week 12 to Week 44. application and any extensions or variations thereof.from Week 12 to Week 44. 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 25of 1365.1.4 Safety Follow-up Period (Week 48 to Week 64)
All subjects who complete the study or who discontinue from the study early, including those 
withdrawn from the IMP treatment, will have a SFU Visit at 20 weeks after their final dose of 
IMP. The assessments at the SFU Visit are presented in Table 5‒1.
5.2 Safety monitoring strategy
An independent Data Monitoring Committee (DMC) will review study safety data on an ongoing basis. Details will be available in the DMC charter. Cardiovascular and Neuropsychiatric Adjudication Committees will review and monitor cardiovascular and neuropsychiatric events. Further details are provided in Section 12.5.
5.[ADDRESS_764568] scan of the entire spi[INVESTIGATOR_581498] 25 subjects at Screening, and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET-positive lesions were observed in the previous scan. 
The PET-MRI or PET-CT scan should be performed after confirmation of eligibility for the 
study based on screening assessments. All subjects at selected sites are eligible provided that a 
separate Informed Consent form (ICF) for the imaging evaluation has been signed.
5.[ADDRESS_764569] a maximum of up to 68 weeks, as follows:
Screening Period: minimum of 2 weeks and up to 4 weeks
Treatment Period: 12 weeks
Treatment Extension Period: 36 weeks
Safety Follow-up Period: [ADDRESS_764570] in the study.
5.5 Planned number of subjects and site(s)
It is anticipated that approximately [ADDRESS_764571] or PET-MRI substudy at multiple sites.
5.6 Anticipated regions and countries
The study sites will be located in North America, Europe, and APAC countries with possible extension to other regions.PUBLIC COPY study based on screening assessments. All subjects at selected sites are eligible provided that a 
PUBLIC COPY study based on screening assessments. All subjects at selected sites are eligible provided that a 
separate Informed Consent form (ICF) for the imaging evaluation has been signed.
PUBLIC COPY separate Informed Consent form (ICF) for the imaging evaluation has been signed.
Study duration per subject
PUBLIC COPY Study duration per subject
r each subject, the study will last a maximum of up to 68 weeks, as follows:
PUBLIC COPY r each subject, the study will last a maximum of up to 68 weeks, as follows:
Screening Period: minimum of 2 weeks and up to 4 weeks
PUBLIC COPY Screening Period: minimum of 2 weeks and up to 4 weeks
Treatment Extension Period: 36 weeksPUBLIC COPY Treatment Extension Period: 36 weeks
This document cannot be used to support any marketing authorization An independent Data Monitoring Committee (DMC) will review study safety data on an ongoing 
This document cannot be used to support any marketing authorization An independent Data Monitoring Committee (DMC) will review study safety data on an ongoing 
hiatric events. 
This document cannot be used to support any marketing authorization hiatric events. 
e spi[INVESTIGATOR_581499] e spi[INVESTIGATOR_581500] 25 subjects at Screening, and during the study at Week 12 and 
This document cannot be used to support any marketing authorization at selected sites in approximately 25 subjects at Screening, and during the study at Week 12 and 
positive lesions were observed in the previous scan. 
This document cannot be used to support any marketing authorization positive lesions were observed in the previous scan. 
ormed after confirmation of eligibility for the 
This document cannot be used to support any marketing authorization ormed after confirmation of eligibility for the 
study based on screening assessments. All subjects at selected sites are eligible provided that a 
This document cannot be used to support any marketing authorization study based on screening assessments. All subjects at selected sites are eligible provided that a 
separate Informed Consent form (ICF) for the imaging evaluation has been signed.
This document cannot be used to support any marketing authorization separate Informed Consent form (ICF) for the imaging evaluation has been signed.
r each subject, the study will last a maximum of up to 68 weeks, as follows:
This document cannot be used to support any marketing authorization r each subject, the study will last a maximum of up to 68 weeks, as follows:
Screening Period: minimum of 2 weeks and up to 4 weeks
This document cannot be used to support any marketing authorization Screening Period: minimum of 2 weeks and up to 4 weeks
Treatment Extension Period: 36 weeks
This document cannot be used to support any marketing authorization Treatment Extension Period: 36 weeks
This document cannot be used to support any marketing authorization up Period: 20 weeks after the final dose of IM
This document cannot be used to support any marketing authorization up Period: [ADDRESS_764572] in the study.
Planned number of subjects and site(s
This document cannot be used to support any marketing authorization Planned number of subjects and site(s
It is anticipated that approximately [ADDRESS_764573] 25 subjects in the PET
multiple sites.
This document cannot be used to support any marketing authorization multiple sites.
This document cannot be used to support any marketing authorization Anticipated regions and countries
This document cannot be used to support any marketing authorization Anticipated regions and countries
The study sites w
This document cannot be used to support any marketing authorization The study sites w
This document cannot be used to support any marketing authorization extension to other regions.
This document cannot be used to support any marketing authorization extension to other regions.application and any extensions or variations thereof.e spi[INVESTIGATOR_581501].e spi[INVESTIGATOR_581500] 25 subjects at Screening, and during the study at Week 12 and 
application and any extensions or variations thereof.at selected sites in approximately 25 subjects at Screening, and during the study at Week 12 and 
positive lesions were observed in the previous scan. 
application and any extensions or variations thereof.positive lesions were observed in the previous scan. 
ormed after confirmation of eligibility for the 
application and any extensions or variations thereof.ormed after confirmation of eligibility for the 
study based on screening assessments. All subjects at selected sites are eligible provided that a 
application and any extensions or variations thereof.study based on screening assessments. All subjects at selected sites are eligible provided that a 
separate Informed Consent form (ICF) for the imaging evaluation has been signed.
application and any extensions or variations thereof.separate Informed Consent form (ICF) for the imaging evaluation has been signed.
r each subject, the study will last a maximum of up to 68 weeks, as follows:
application and any extensions or variations thereof.r each subject, the study will last a maximum of up to 68 weeks, as follows:
Screening Period: minimum of 2 weeks and up to 4 weeks
application and any extensions or variations thereof.Screening Period: minimum of 2 weeks and up to 4 weeks
application and any extensions or variations thereof.up Period: 20 weeks after the final dose of IM
application and any extensions or variations thereof.up Period: [ADDRESS_764574] in the study.
Planned number of subjects and site(s
application and any extensions or variations thereof.Planned number of subjects and site(s
It is anticipated that approximately [ADDRESS_764575] 25 subjects in the PET
application and any extensions or variations thereof.Anticipated regions and countries
application and any extensions or variations thereof.Anticipated regions and countries
The study sites w
application and any extensions or variations thereof.The study sites w ill be located in North America, Europe, and APAC countries with possible 
application and any extensions or variations thereof.ill be located in North America, Europe, and APAC countries with possible 
application and any extensions or variations thereof.extension to other regions.application and any extensions or variations thereof.extension to other regions.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 26of 1365.7 Schedule of assessments
Table 5 ‒1: Schedule of assessments
Study Period SCr Treatment Period Treatment Extension Period SFUa
Visitb/Week 
(Visit window ±3 days)V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18
Procedures SV BL 
W0W2 W4 W6 W8 W10 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48
/WDW64
Written informed 
consentcX
Demographic data X
AS history X
Inclusion/exclusion criteria X X
d
Significant past medical history and concomitant 
diseasesX X
e
Prior and concomitant 
medicationsfX X X X X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X X X X X
C-SSRS X X X X X X X X X X X X X X X X X
HADS X X X X X X X X X X X X X X
BASDAI X X X X X X X X X X X X X X X X X
BASFI X X X X X X X X X X X X X X X X X
PGADA X X X X X X X X X X X X X X X X
PhGADA X X X X X X X X X X X X X X X X
Total and nocturnal 
spi[INVESTIGATOR_18172] (NRS)X X X X X X X X X X X X X X X X XPUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY XPUBLIC COPY XPUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization V13
This document cannot be used to support any marketing authorization V13 V14
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W28
This document cannot be used to support any marketing authorization W28 W32
This document cannot be used to support any marketing authorization W32
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Treatment Extension Period
application and any extensions or variations thereof.Treatment Extension Period
V14
application and any extensions or variations thereof.V14 V15
application and any extensions or variations thereof.V15
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.W32
application and any extensions or variations thereof.W32 W36
application and any extensions or variations thereof.W36
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 27of 136Table 5 ‒1: Schedule of assessments
Study Period SCr Treatment Period Treatment Extension Period SFUa
Visitb/Week 
(Visit window ±3 days)V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18
Procedures SV BL 
W0W2 W4 W6 W8 W10 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48
/WDW64
Physical examination 
(incl. height and 
weight)gX X X X X
Vital signs (BP, pulse, temperature)
hX X X X X X X X X X X X X X X X X X
12-lead ECG (local) X X X X X X X X X X X X X X X
Tuberculosis questionnaireX X X X X X
IGRA TB testiX X
Pregnancy testjX X X X X X X X X X X X X X X
Hematology/biochemistry/urinalysis
kX X X X X X X X X X X X
Serology (HIV, Hepatitis B and C, HLA- B27)
k, lX
Blood samples for cytokines, complement, and biomarker analysis
kX X X X X X X
Blood sampling for bimekizumab and CZP plasma concentrations
kX X X X X X X
Bimekizumab and CZP antibody detection
kX X X X X X XPUBLIC COPY X
PUBLIC COPY X
PUBLIC COPY PUBLIC COPY X
PUBLIC COPY X X
PUBLIC COPY X
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY X
PUBLIC COPY X
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY X
PUBLIC COPY X
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY XPUBLIC COPY XPUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W32
This document cannot be used to support any marketing authorization W32 W36
This document cannot be used to support any marketing authorization W36
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.V15
application and any extensions or variations thereof.V15
application and any extensions or variations thereof.application and any extensions or variations thereof.W36
application and any extensions or variations thereof.W36 W40
application and any extensions or variations thereof.W40
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 28of 136Table 5 ‒1: Schedule of assessments
Study Period SCr Treatment Period Treatment Extension Period SFUa
Visitb/Week 
(Visit window ±3 days)V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18
Procedures SV BL 
W0W2 W4 W6 W8 W10 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48
/WDW64
Blood sample for 
hs-CRPkX X X X X X X X X X X X X X X
Blood samples for 
pharmacogenetic variablesX X X
Blood samples for nonhereditary pharmacogenomic variablesX X X X X
Urine samples for 
biomarker researchX X X X
Chest X- ray or CT scan 
of chest mX X
Sacroiliac joint X- raynX
PET-MRI or PET- CT 
scan as a substudy at 
selected sitesoX X X
Contact [CONTACT_6606] X X X X X X X X X X X X X X X X X X
IMP administrationpX X X X X X X X X X X X X X X
AS=ankylosing spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
BL=Baseline; BP=blood pressure; CT=computed tomography; C-SSRS=Columbia Suicide Severity Rating Scale; CZP=certolizumab pegol; ECG=e lectrocardiogram; HADS=Hospi[INVESTIGATOR_5620]; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA- B27=human 
leukocyten antigen B27; hs-CRP=high sensitivity C-reactive protein; IGRA=Interferon-Gamma Release Assay; IMP=investigational medicinal product; 
IRT=interactive response technology; NRS=numeric rating scale; PET-CT=positron-emission tomography-computer tomography; PET- MRI=positron -emission 
tomography – magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Activity; PhGADA=Physician’s Global Assessment of Disease 
Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow -Up; SV=Screening Visit; TB=tuberculosis; V=Visit; W=Week; PUBLIC COPY PUBLIC COPY PUBLIC COPY X
PUBLIC COPY X
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W32
This document cannot be used to support any marketing authorization W32 W36
This document cannot be used to support any marketing authorization W36
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
This document cannot be used to support any marketing authorization spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
BL=Baseline; BP=blood pressure; CT=computed tomography; C
This document cannot be used to support any marketing authorization BL=Baseline; BP=blood pressure; CT=computed tomography; C
lectrocardiogram; HADS=Hospi[INVESTIGATOR_5620]; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA
This document cannot be used to support any marketing authorization lectrocardiogram; HADS=Hospi[INVESTIGATOR_5620]; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA
CRP=high sensitivity C
This document cannot be used to support any marketing authorization CRP=high sensitivity C
IRT=interactive response technology; NRS=numeric rating scale; PET
This document cannot be used to support any marketing authorization IRT=interactive response technology; NRS=numeric rating scale; PET
magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Act
This document cannot be used to support any marketing authorization magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Act
Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow
This document cannot be used to support any marketing authorization Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.V15
application and any extensions or variations thereof.V15
application and any extensions or variations thereof.application and any extensions or variations thereof.W36
application and any extensions or variations thereof.W36 W40
application and any extensions or variations thereof.W40
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
application and any extensions or variations thereof.spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
BL=Baseline; BP=blood pressure; CT=computed tomography; C
application and any extensions or variations thereof.BL=Baseline; BP=blood pressure; CT=computed tomography; C
lectrocardiogram; HADS=Hospi[INVESTIGATOR_5620]; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA
application and any extensions or variations thereof.lectrocardiogram; HADS=Hospi[INVESTIGATOR_5620]; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA
CRP=high sensitivity C
application and any extensions or variations thereof.CRP=high sensitivity C
IRT=interactive response technology; NRS=numeric rating scale; PET
application and any extensions or variations thereof.IRT=interactive response technology; NRS=numeric rating scale; PET
magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Actapplication and any extensions or variations thereof.magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Act
Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow application and any extensions or variations thereof.Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 29of 136Table 5 ‒1: Schedule of assessments
Study Period SCr Treatment Period Treatment Extension Period SFUa
Visitb/Week 
(Visit window ±3 days)V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18
Procedures SV BL 
W0W2 W4 W6 W8 W10 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48
/WDW64
WD=Early Withdrawal Visit; WHO=World Health Organization
aSafety Follow -Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including tho se withdrawn from 
study treatment. 
bVisit windows of ±[ADDRESS_764576] dose at all visits through Week 48. The SFU Visit window is -3 and +7 days from the final dose.
cA separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 1) with biomarker, pharmacogenetic and nonhereditary 
pharmacogenomic blood-samples and 2) PET-MRI or PET- CT scans.
dEnsure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
eEnsure that there are no significant changes in the medical history.
fPrior and concomitant medication at Screening and Baseline; concomitant medication only at all other visits.
gThe physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screening only) and weight (Screening, Week 12 and Week 48/WD only).
hVital signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at 30 minutes and 1 hour after dosing at 
Baseline/Day 1.
iQuantiFERON TB test or another WHO-validated IGRA test such as Elispot test, if QuantiFERON TB test is not locally available. 
jPregnancy testing will performed on serum at Screening and on urine at all other visits. Pregnancy test results must be negative prior to administering IMP. 
kAt dosing visits, all blood samples are taken prior to dosing. Blood samples for IMP and anti-IMP antibody detection will be processed as per instructions in the 
laboratory manual. After Screening, until Week 12, hs-CRP data will not be sent to the Investigator to protect the blinded nature of the treatment assignments.
lSubjects who have evidence of or test positive for hepatitis B by [CONTACT_28782]: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) are excluded; a positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
mIf a subject has had a recent radiograph or CT scan of the chest within [ADDRESS_764577] X-ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB-test).
nIf subjects have a previous X-ray documenting AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by [CONTACT_581587]. If no X -ray is available one must be performed at Screening. If the previous X-ray is more than [ADDRESS_764578] scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET-positive lesions are 
observed in the previous scan. If a subject withdraws from the study early, the PET-MRI or PET-CT scan must be repeated at the WD visit only, if the prior 
examination was done more than 12 weeks prior to the WD visit and the previous PET-scan showed positive lesions.
pCZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks [ADDRESS_764579] been completed. Subjects randomized to bimekizumab will recei ve 1 placebo injection at Baseline PUBLIC COPY studies: 1) with biomarker, pharmacogenetic and nonhereditary 
PUBLIC COPY studies: 1) with biomarker, pharmacogenetic and nonhereditary 
Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
PUBLIC COPY Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
d Baseline; concomitant medication only at all other visits.
PUBLIC COPY d Baseline; concomitant medication only at all other visits.
The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screeni
PUBLIC COPY The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screeni
l signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at 30
PUBLIC COPY l signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at [ADDRESS_764580] be negat
n prior to dosing. Blood samples for IMP and anti PUBLIC COPY n prior to dosing. Blood samples for IMP and anti
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialTreatment Extension Period
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W32
This document cannot be used to support any marketing authorization W32 W36
This document cannot be used to support any marketing authorization W36
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including tho
This document cannot be used to support any marketing authorization Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including tho
FU Visit window is 
This document cannot be used to support any marketing authorization FU Visit window is -
This document cannot be used to support any marketing authorization -3 and +7 days from the final dose.
This document cannot be used to support any marketing authorization 3 and +7 days from the final dose.
studies: 1) with biomarker, pharmacogenetic and nonhereditary 
This document cannot be used to support any marketing authorization studies: 1) with biomarker, pharmacogenetic and nonhereditary 
Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
This document cannot be used to support any marketing authorization Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
d Baseline; concomitant medication only at all other visits.
This document cannot be used to support any marketing authorization d Baseline; concomitant medication only at all other visits.
The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screeni
This document cannot be used to support any marketing authorization The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screeni
l signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at 30
This document cannot be used to support any marketing authorization l signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at [ADDRESS_764581] positive for hepatitis B by [CONTACT_28782]: 1) positive for hepatitis B 
This document cannot be used to support any marketing authorization Subjects who have evidence of or test positive for hepatitis B by [CONTACT_28782]: 1) positive for hepatitis B 
hepatitis B core antibody (HBcAb+) are excluded; a positive 
This document cannot be used to support any marketing authorization hepatitis B core antibody (HBcAb+) are excluded; a positive 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
This document cannot be used to support any marketing authorization positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
If a subject has had a recent radiograph or CT scan of the che
This document cannot be used to support any marketing authorization If a subject has had a recent radiograph or CT scan of the che
ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB
This document cannot be used to support any marketing authorization ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB
ray documenti
This document cannot be used to support any marketing authorization ray documenti ng AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by [CONTACT_581588], they are eligible for study entry after reconfirming their eligibility by [CONTACT_581589]. If the previous X
This document cannot be used to support any marketing authorization ray is available one must be performed at Screening. If the previous X
ray may be performed if permitted by [CONTACT_13144].
This document cannot be used to support any marketing authorization ray may be performed if permitted by [CONTACT_13144].
CT scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET
This document cannot be used to support any marketing authorization CT scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET
observed in the previous scan. If a subject withdraws from the study early, the PET
This document cannot be used to support any marketing authorization observed in the previous scan. If a subject withdraws from the study early, the PET
examination was done more than 12 weeks prior to the WD visit and the previous PET
This document cannot be used to support any marketing authorization examination was done more than 12 weeks prior to the WD visit and the previous PET
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks 6 to 10 and 400mg Q4W from Week 12
This document cannot be used to support any marketing authorization CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks [ADDRESS_764582] been completed. Subjects randomized to bimekizumab will receiapplication and any extensions or variations thereof.V15
application and any extensions or variations thereof.V15
application and any extensions or variations thereof.application and any extensions or variations thereof.W36
application and any extensions or variations thereof.W36 W40
application and any extensions or variations thereof.W40
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including tho
application and any extensions or variations thereof.Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including tho
3 and +7 days from the final dose.
application and any extensions or variations thereof.3 and +7 days from the final dose.
studies: 1) with biomarker, pharmacogenetic and nonhereditary 
application and any extensions or variations thereof.studies: 1) with biomarker, pharmacogenetic and nonhereditary 
Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
application and any extensions or variations thereof.Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
d Baseline; concomitant medication only at all other visits.
application and any extensions or variations thereof.d Baseline; concomitant medication only at all other visits.
The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screeni
application and any extensions or variations thereof.The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screeni
l signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at 30
application and any extensions or variations thereof.l signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at [ADDRESS_764583] positive for hepatitis B by [CONTACT_28782]: 1) positive for hepatitis B 
application and any extensions or variations thereof.Subjects who have evidence of or test positive for hepatitis B by [CONTACT_28782]: 1) positive for hepatitis B 
hepatitis B core antibody (HBcAb+) are excluded; a positive 
application and any extensions or variations thereof.hepatitis B core antibody (HBcAb+) are excluded; a positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti
application and any extensions or variations thereof.test for HCV is defined as: 1) positive for hepatitis C antibody (anti
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
application and any extensions or variations thereof.positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
If a subject has had a recent radiograph or CT scan of the che
application and any extensions or variations thereof.If a subject has had a recent radiograph or CT scan of the che st within [ADDRESS_764584] X
ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB
application and any extensions or variations thereof.ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB
ng AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by [CONTACT_581590].ng AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by [CONTACT_581589]. If the previous X
application and any extensions or variations thereof.ray is available one must be performed at Screening. If the previous X
ray may be performed if permitted by [CONTACT_13144].
application and any extensions or variations thereof.ray may be performed if permitted by [CONTACT_13144].
CT scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET
application and any extensions or variations thereof.CT scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET
observed in the previous scan. If a subject withdraws from the study early, the PET
application and any extensions or variations thereof.observed in the previous scan. If a subject withdraws from the study early, the PET
examination was done more than 12 weeks prior to the WD visit and the previous PET
application and any extensions or variations thereof.examination was done more than 12 weeks prior to the WD visit and the previous PET
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks 6 to 10 and 400mg Q4W from Week 12
application and any extensions or variations thereof.CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks [ADDRESS_764585] been completed. Subjects randomized to bimekizumab will recei
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 30of 136Table 5 ‒1: Schedule of assessments
Study Period SCr Treatment Period Treatment Extension Period SFUa
Visitb/Week 
(Visit window ±3 days)V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18
Procedures SV BL 
W0W2 W4 W6 W8 W10 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48
/WDW64
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialTreatment Extension Period
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization V14
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W32
This document cannot be used to support any marketing authorization W32 W36
This document cannot be used to support any marketing authorization W36
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.V15
application and any extensions or variations thereof.V15
application and any extensions or variations thereof.application and any extensions or variations thereof.W36
application and any extensions or variations thereof.W36 W40
application and any extensions or variations thereof.W40
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 31of 1365.8 Schematic diagram
Figure 5 ‒1: Schematic diagram
CZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety Follow- up, W=week
aSubjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discretion and will not enter the 
Treatment Extension Period.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialCZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety F
This document cannot be used to support any marketing authorization CZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety F
Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discr
This document cannot be used to support any marketing authorization Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discr
Treatment Extension Period.
This document cannot be used to support any marketing authorization Treatment Extension Period.
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.CZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety F
application and any extensions or variations thereof.CZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety F
Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discr
application and any extensions or variations thereof.Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discr
application and any extensions or variations thereof.

UCB [ADDRESS_764586]-blind and investigator-blind study to 
evaluate the efficacy and safety of bimekizumab and CZP in adult subjects with active AS. 
AS0013 includes a 12–week Treatmen t Period, a 36-week Treatment Extension Period, and a 
20-week SFU Period. Rationales for the study design, selected population, and bimekizumab doses are provided below.
Study design
AS0013 was designed to evaluate the efficacy, safety and the process of osteoproliferation using 
PET imaging techniques at Screening and after [ADDRESS_764587] reached 
Week 12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
IMP for subjects responding to treatment. This extension also allows further evaluation of the 
inhibition of the osteoproliferative effect of bimekizumab and CZP at Week 48 and to compare this to Baseline and Week 12.
Population
AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
formation in subjects at risk of new bone formation (disease progression) and comparing the 
outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
safety risk were they to participate in this investigational study program. Active AS is defined by 
a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of inclusion and exclusion criteria is provided in Section 6.
Dose selection
The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment Period:
Bimekizumab 160mg sc Q2W from Week 0 through Week 10 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Weeks 6to10.
Exposure levels up to 8-fold greater than 160mg Q2W have been previously studied in the development of bimekizumab. In the single ascending dose study UP0008, a single dose of bimekizumab 640mg was tested. In the multiple dose study PA0007, a bimekizumab 560mg 
loading dose followed by 2 subsequent 320mg doses every 3 weeks was tested. At exposure 
levels achieved at these doses, the compound had no significant safety concerns. Additionally, in the above clinical studies (UP0008 and PA0007), bimekizumab was administered iv and the 
current study proposes to administer the compound sc. The exposure of the drug is expected to 
be lower than after iv administration due to lower bioavailability following sc administration and, therefore, the dose regimens are expected to be safe. No safety concerns have been reported 
in ongoing clinical studies evaluating cumulative monthly doses of bimekizumab 320mg in other PUBLIC COPY effect of bimekizumab and CZP at Week [ADDRESS_764588] of bimekizumab and CZP at Week 48 and to compare 
AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
PUBLIC COPY AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
formation in subjects at risk of new bone formation (disease progression)
PUBLIC COPY formation in subjects at risk of new bone formation (disease progression)
outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
PUBLIC COPY outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
PUBLIC COPY Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
safety risk were they to participate in this invesPUBLIC COPY safety risk were they to participate in this inves
a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of PUBLIC COPY a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of 
This document cannot be used to support any marketing authorization steoproliferation using 
This document cannot be used to support any marketing authorization steoproliferation using 
PET imaging techniques at Screening and after [ADDRESS_764589] reached 
12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
This document cannot be used to support any marketing authorization 12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
IMP for subjects responding to treatment. This extension also allows further evaluation of the 
This document cannot be used to support any marketing authorization IMP for subjects responding to treatment. This extension also allows further evaluation of the 
effect of bimekizumab and CZP at Week [ADDRESS_764590] of bimekizumab and CZP at Week 48 and to compare 
AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
This document cannot be used to support any marketing authorization AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
formation in subjects at risk of new bone formation (disease progression)
This document cannot be used to support any marketing authorization formation in subjects at risk of new bone formation (disease progression)
outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
This document cannot be used to support any marketing authorization outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
This document cannot be used to support any marketing authorization Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
safety risk were they to participate in this inves
This document cannot be used to support any marketing authorization safety risk were they to participate in this inves tigational study program. Active AS is defined by 
[CONTACT_581591]. Active AS is defined by 
a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of 
This document cannot be used to support any marketing authorization a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of 
inclusion and exclusion criteria is provided in 
This document cannot be used to support any marketing authorization inclusion and exclusion criteria is provided in 
The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment 
This document cannot be used to support any marketing authorization The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment 
Bimekizumab 160mg sc Q2W from Week 0 through Week
This document cannot be used to support any marketing authorization Bimekizumab 160mg sc Q2W from Week 0 through Week
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (lo
This document cannot be used to support any marketing authorization CZP 400mg sc Q2W at Weeks 0, 2, and 4 (lo
[ADDRESS_764591] reached 
12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
application and any extensions or variations thereof.12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
IMP for subjects responding to treatment. This extension also allows further evaluation of the 
application and any extensions or variations thereof.IMP for subjects responding to treatment. This extension also allows further evaluation of the 
effect of bimekizumab and CZP at Week [ADDRESS_764592] of bimekizumab and CZP at Week 48 and to compare 
AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
application and any extensions or variations thereof.AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
formation in subjects at risk of new bone formation (disease progression)
application and any extensions or variations thereof.formation in subjects at risk of new bone formation (disease progression)
outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
application and any extensions or variations thereof.outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
application and any extensions or variations thereof.Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
tigational study program. Active AS is defined by 
[INVESTIGATOR_581504].tigational study program. Active AS is defined by 
a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of 
application and any extensions or variations thereof.a BASDAI score ≥4 and a spi[INVESTIGATOR_463121] ≥4 (from BASDAI Question 2). The full list of 
inclusion and exclusion criteria is provided in 
application and any extensions or variations thereof.inclusion and exclusion criteria is provided in Section
application and any extensions or variations thereof.Section
The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment 
application and any extensions or variations thereof.The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment 
Bimekizumab 160mg sc Q2W from Week 0 through Week
application and any extensions or variations thereof.Bimekizumab 160mg sc Q2W from Week 0 through Week
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (lo
application and any extensions or variations thereof.CZP 400mg sc Q2W at Weeks 0, 2, and 4 (lo
Exposure levels up to [ADDRESS_764593] the dose response of ASAS20/40 at 
Week 12, ie, for a different endpoint than the primary efficacy endpoint being proposed in this 
study (Diderichsen and Cox, 2016). These simulations indicated that increasing doses above bimekizumab 320mg Q4W may not provide additional benefit in terms of efficacy. 
The dose selected in the current study is bimekizumab 160mg Q2W instead of 320mg Q4W. 
Given that the PK of bimekizumab has been established to be linear in the exposure range 
(UP0008 and PA0007), the proposed dose of bimekizumab 160mg Q2W is expected to provide similar overall exposure and hence response compared to a dose of 320mg Q4W. Table 5‒2
shows a comparable AUC
taubetween bimekizumab 320Q4W and 160mg Q2W calculated over a 
period of similar time (14 days). In conclusion, the existing data suggest that at the proposed dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is achieved at this exposure level.
Table 5 ‒2: Exposure to bimekizumab by [CONTACT_581592]
160mg Q2W sc 320mg Q4W sc 640mg SD iv from 
UP0008
AUC tauor AUC 0-inf(µg*day/mL) 442a,b445a,b3787c,d
Cmax(µg/mL) 33a38a260c
iv=intravenous; Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
aMedian model predicted 
bCalculated over a period of 14 days 
cMedian observed in UP0008 
dAUC 0-inf
The dose and regimen proposed for CZP is one of the currently approved dose regimens in 
axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose of CZP has been tested in Phase [ADDRESS_764594] be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by [CONTACT_423]. 
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, and medication intake according to the judgment of the 
Investigator.PUBLIC COPY Bimekizumab dose
PUBLIC COPY Bimekizumab dose
PUBLIC COPY 160mg Q2W sc
PUBLIC COPY 160mg Q2W sc
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 442
PUBLIC COPY 442a,b
PUBLIC COPY a,b
PUBLIC COPY PUBLIC COPY 33
PUBLIC COPY 33
PUBLIC COPY PUBLIC COPY Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
PUBLIC COPY Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
Calculated over a period of 14 days PUBLIC COPY Calculated over a period of 14 days PUBLIC COPY 
This document cannot be used to support any marketing authorization nstead of 320mg Q4W. 
This document cannot be used to support any marketing authorization nstead of 320mg Q4W. 
Given that the PK of bimekizumab has been established to be linear in the exposure range 
This document cannot be used to support any marketing authorization Given that the PK of bimekizumab has been established to be linear in the exposure range 
(UP0008 and PA0007), the proposed dose of bimekizumab 160mg Q2W is expected to provide 
This document cannot be used to support any marketing authorization (UP0008 and PA0007), the proposed dose of bimekizumab 160mg Q2W is expected to provide 
Table
This document cannot be used to support any marketing authorization Table 5
This document cannot be used to support any marketing authorization 5‒
This document cannot be used to support any marketing authorization ‒[ADDRESS_764595] that at the proposed 
dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is 
This document cannot be used to support any marketing authorization dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is 
Bimekizumab dose
This document cannot be used to support any marketing authorization Bimekizumab dose
This document cannot be used to support any marketing authorization 320mg Q4W sc
This document cannot be used to support any marketing authorization 320mg Q4W sc
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
This document cannot be used to support any marketing authorization Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
This document cannot be used to support any marketing authorization The dose and regimen proposed for CZP is one of the currently approved dose 
This document cannot be used to support any marketing authorization The dose and regimen proposed for CZP is one of the currently approved dose 
axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
This document cannot be used to support any marketing authorization axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose 
This document cannot be used to support any marketing authorization tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose 
of CZP has been tested in Phase [ADDRESS_764596] (IRB)/Independent Ethics Committee (IEC) approved written 
This document cannot be used to support any marketing authorization An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written application and any extensions or variations thereof.between bimekizumab 320Q4W and 160mg Q2W calculated over a 
application and any extensions or variations thereof.between bimekizumab 320Q4W and 160mg Q2W calculated over a 
onclusion, the existing data suggest that at the proposed 
application and any extensions or variations thereof.onclusion, the existing data suggest that at the proposed 
dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is 
application and any extensions or variations thereof.dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is 
Bimekizumab dose
application and any extensions or variations thereof.Bimekizumab dose
application and any extensions or variations thereof.320mg Q4W sc
application and any extensions or variations thereof.320mg Q4W sc
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.445
application and any extensions or variations thereof.445a,b
application and any extensions or variations thereof.a,b
application and any extensions or variations thereof.application and any extensions or variations thereof.38
application and any extensions or variations thereof.38
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
application and any extensions or variations thereof.Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.The dose and regimen proposed for CZP is one of the currently approved dose 
application and any extensions or variations thereof.The dose and regimen proposed for CZP is one of the currently approved dose 
axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
application and any extensions or variations thereof.axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose 
application and any extensions or variations thereof.tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose 
of CZP has been tested in Phase [ADDRESS_764597] (IRB)/Independent Ethics Committee (IEC) approved written application and any extensions or variations thereof.An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
UCB [ADDRESS_764598] has a documented diagnosis of adult-onset AS as defined by [CONTACT_581593] (X-ray) fulfilling the Modified [LOCATION_001] criteria for AS (1984) of at least 
3 months’ symptom duration and age of onset <[ADDRESS_764599] has moderate to severe active disease at the Screening Visit as defined by [CONTACT_581594]:
BASDAI score ≥4
Spi[INVESTIGATOR_463121] ≥4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
6. Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack o f 
response to at least [ADDRESS_764600] tolerated dose of the 
administered NSAID).
7. Subject may not have been exposed to more than [ADDRESS_764601] therapy (defined as no response within the first [ADDRESS_764602] be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than [ADDRESS_764603] menstrual period), permanently 
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656]) or, if of childbearing 
potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till [ADDRESS_764604] at Visit 1 (Screening) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and correctly.
combined (estrogen and progestogen) hormonal contraception associated with inhibition 
of ovulation (oral, intravaginal or transdermal)
progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
intrauterine device (IUD)
intrauterine hormone-releasing system (IUS)
bilateral tubal occlusion
vasectomized partner (where postvasectomy testing had demonstrated sperm clearance)
sexual abstinence if it is in accordance with a subject’s preferred and common lifestyle. Subjects who use abstinence as a form of birth control must agree to abstain from heterosexual intercourse until 20 weeks after the final dose of IMP (anticipated 5 
half-lifes of bimekizumab). Study personnel must confirm the continued use of 
abstinence is still in accordance with the subject’s lifestyle at regular intervals during the study.PUBLIC COPY within the first [ADDRESS_764605] be postmenopausal (at least 1 year; to be confirmed hormonally as part 
PUBLIC COPY subjects must be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than [ADDRESS_764606] menstrual period), permanently 
PUBLIC COPY of the screening process, if less than [ADDRESS_764607] menstrual period), permanently 
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpi
[INVESTIGATOR_581502] (eg, tubal occlusion, hysterectomy, bilateral salpi
[CONTACT_104434] (and engaged in sexual activity that could result in procreation), must be willing to 
PUBLIC COPY potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till [ADDRESS_764608] a negative pregnancy
This document cannot be used to support any marketing authorization Spi[INVESTIGATOR_463121] ≥4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
This document cannot be used to support any marketing authorization Spi[INVESTIGATOR_463121] ≥4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
Subject must have had an inadequate response to, have a contraindication to, or has been 
This document cannot be used to support any marketing authorization Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack o
This document cannot be used to support any marketing authorization intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack o
response to at least [ADDRESS_764609] therapy (defined as no response 
This document cannot be used to support any marketing authorization agonist therapy (defined as no response 
within the first [ADDRESS_764610] be postmenopausal (at least 1 year; to be confirmed hormonally as part 
This document cannot be used to support any marketing authorization subjects must be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than [ADDRESS_764611] menstrual period), permanently 
This document cannot be used to support any marketing authorization of the screening process, if less than [ADDRESS_764612] menstrual period), permanently 
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpi
[INVESTIGATOR_581503] (eg, tubal occlusion, hysterectomy, bilateral salpi
[CONTACT_104434] (and engaged in sexual activity that could result in procreation), must be willing to 
This document cannot be used to support any marketing authorization potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till [ADDRESS_764613] at Visit 1 (Screening) and immediately prior to first 
This document cannot be used to support any marketing authorization test at Visit 1 (Screening) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and 
This document cannot be used to support any marketing authorization dose. The following methods are considered highly effective when used consistently and 
combined (estrogen and progestogen) hormonal contraception associated with inhibition 
This document cannot be used to support any marketing authorization combined (estrogen and progestogen) hormonal contraception associated with inhibition 
(oral, intravaginal or transdermal)
This document cannot be used to support any marketing authorization (oral, intravaginal or transdermal)
This document cannot be used to support any marketing authorization progestogen
This document cannot be used to support any marketing authorization progestogen only hormonal contraception associated with inhibition of ovulation (oral, 
This document cannot be used to support any marketing authorization only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable)
This document cannot be used to support any marketing authorization injectable, implantable)
intrauterine device (IUD)
This document cannot be used to support any marketing authorization intrauterine device (IUD)
intrauterine hormone
This document cannot be used to support any marketing authorization intrauterine hormone

This document cannot be used to support any marketing authorization bilateral tubal occlusion
This document cannot be used to support any marketing authorization bilateral tubal occlusion

This document cannot be used to support any marketing authorization vasectomize
This document cannot be used to support any marketing authorization vasectomizeapplication and any extensions or variations thereof.Subject must have had an inadequate response to, have a contraindication to, or has been 
application and any extensions or variations thereof.Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack o
application and any extensions or variations thereof.intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack o f 
application and any extensions or variations thereof.f 
response to at least [ADDRESS_764614] therapy (defined as no response 
application and any extensions or variations thereof.agonist therapy (defined as no response 
CRP levels above the ULN at the Screening Visit. One re
application and any extensions or variations thereof.CRP levels above the ULN at the Screening Visit. One re
permitted during the Screening Period upon discretion of the In
application and any extensions or variations thereof.permitted during the Screening Period upon discretion of the In vestigator. 
application and any extensions or variations thereof.vestigator. 
subjects must be postmenopausal (at least 1 year; to be confirmed hormonally as part 
application and any extensions or variations thereof.subjects must be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than [ADDRESS_764615] menstrual period), permanently 
application and any extensions or variations thereof.of the screening process, if less than [ADDRESS_764616] menstrual period), permanently 
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpi
[INVESTIGATOR_581504].sterilized (eg, tubal occlusion, hysterectomy, bilateral salpi [INVESTIGATOR_1656]) or, if of childbearing 
application and any extensions or variations thereof.ngectomy) or, if of childbearing 
potential (and engaged in sexual activity that could result in procreation), must be willing to 
application and any extensions or variations thereof.potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till [ADDRESS_764617] at Visit 1 (Screening) and immediately prior to first 
application and any extensions or variations thereof.test at Visit 1 (Screening) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and 
application and any extensions or variations thereof.dose. The following methods are considered highly effective when used consistently and 
combined (estrogen and progestogen) hormonal contraception associated with inhibition 
application and any extensions or variations thereof.combined (estrogen and progestogen) hormonal contraception associated with inhibition 
(oral, intravaginal or transdermal)
application and any extensions or variations thereof.(oral, intravaginal or transdermal)
application and any extensions or variations thereof.only hormonal contraception associated with inhibition of ovulation (oral, 
application and any extensions or variations thereof.only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable)
application and any extensions or variations thereof.injectable, implantable)
intrauterine device (IUD)
application and any extensions or variations thereof.intrauterine device (IUD)
intrauterine hormone
application and any extensions or variations thereof.intrauterine hormone
application and any extensions or variations thereof.bilateral tubal occlusion
application and any extensions or variations thereof.bilateral tubal occlusion
application and any extensions or variations thereof.vasectomizeapplication and any extensions or variations thereof.vasectomize
UCB [ADDRESS_764618] administration of IMP (anticipated 5 half-
lives).
6.2 Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria is met:
1. Female subject who is breastfeeding, pregnant, or planning to become pregnant during the 
study or within [ADDRESS_764619] has received previous treatment with a polyethylene glycolylated (PEGylated) 
compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
6. Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic arthritis, or reactive arthritis. 
Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they have no active symptomatic disease at Screening or Baseline.
7. Subject has a secondary, noninflammatory condition (eg, osteoarthritis, fibromyalgia) that in 
the Investigator’s opi[INVESTIGATOR_581505]’s primary diagnosis of active AS.
8. Subject has received previous or current biological treatment other than TNFα inhibitor 
treatment.
9. Subjects must not have used medications in the manner as detailed by [CONTACT_581595] 7‒2.
10. Subject has: 
a history of chronic or recurrent infections (eg, more than 3 epi[INVESTIGATOR_581506]). Minor illnesses like common cold or 
transient, localized infections that may have been treated with a short course of antibiotic 
therapy (up to 7 days) need not count in this assessment.
a serious or life-threatening infection within the 6 months prior to the Baseline Visit 
(including herpes zoster) or hospi[INVESTIGATOR_581507] 6 months.
any current sign or symptom that may indicate an active infection (except for common cold), or has had an infection requiring systemic antibiotics within 2 weeks prior to Baseline.
a high risk of infection in the Investigator’s opi[INVESTIGATOR_1649] (eg, subjects with leg ulcers, indwelling urinary catheter, prior prosthetic joint infection at any time, subjects who are permanently bedridden or wheelchair assisted).PUBLIC COPY compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
PUBLIC COPY compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
PUBLIC COPY Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic a
PUBLIC COPY eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic a
Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
PUBLIC COPY Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
have no active symptomatic disease at Screening or Baseline.
PUBLIC COPY have no active symptomatic disease at Screening or Baseline.
Subject has a secondary, noninflammatory condition (eg, osteoarthri
PUBLIC COPY Subject has a secondary, noninflammatory condition (eg, osteoarthri
the Investigator’s opi[INVESTIGATOR_581508]’s opi[INVESTIGATOR_581509]’s primary diagnosis of active AS.PUBLIC COPY study drug on the subject’s primary diagnosis of active AS.
This document cannot be used to support any marketing authorization Female subject who is breastfeeding, pregnant, or planning to become pregnant during the 
This document cannot be used to support any marketing authorization Female subject who is breastfeeding, pregnant, or planning to become pregnant during the 
study or within [ADDRESS_764620] has received previous treatment with a polyethylene glycolylated (
This document cannot be used to support any marketing authorization Subject has received previous treatment with a polyethylene glycolylated (
compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
This document cannot be used to support any marketing authorization compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
This document cannot be used to support any marketing authorization Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic a
This document cannot be used to support any marketing authorization eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic a
Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
This document cannot be used to support any marketing authorization Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
have no active symptomatic disease at Screening or Baseline.
This document cannot be used to support any marketing authorization have no active symptomatic disease at Screening or Baseline.
Subject has a secondary, noninflammatory condition (eg, osteoarthri
This document cannot be used to support any marketing authorization Subject has a secondary, noninflammatory condition (eg, osteoarthri
the Investigator’s opi[INVESTIGATOR_581510]’s opi[INVESTIGATOR_581509]’s primary diagnosis of active AS.
This document cannot be used to support any marketing authorization study drug on the subject’s primary diagnosis of active AS.
Subject has received previous or current biological treatment other than T
This document cannot be used to support any marketing authorization Subject has received previous or current biological treatment other than T
Subjects must not have used medications in the manner as detailed by [CONTACT_581596] (eg, more than 3 epi[INVESTIGATOR_581511] (eg, more than 3 epi[INVESTIGATOR_581512]). Minor illnesses like common cold or 
This document cannot be used to support any marketing authorization antibiotics or antivirals during the preceding year). Minor illnesses like common cold or 
This document cannot be used to support any marketing authorization transient, localized infections that may have been treated with a short course of 
This document cannot be used to support any marketing authorization transient, localized infections that may have been treated with a short course of 
therapy (up to 7 days) need not count in this assessment.
This document cannot be used to support any marketing authorization therapy (up to 7 days) need not count in this assessment.

This document cannot be used to support any marketing authorization a serious or life
This document cannot be used to support any marketing authorization a serious or life
(including herpes zoster) or hospi[INVESTIGATOR_581507] 6 months.
This document cannot be used to support any marketing authorization (including herpes zoster) or hospi[INVESTIGATOR_581507] 6 months.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject has participated in another study of a medication under investigation within the last [ADDRESS_764621] has received previous treatment with a polyethylene glycolylated (
application and any extensions or variations thereof.Subject has received previous treatment with a polyethylene glycolylated ( PEGylated) 
application and any extensions or variations thereof.PEGylated) 
compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
application and any extensions or variations thereof.compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
application and any extensions or variations thereof.Subject has a total ankylosis of the spi[INVESTIGATOR_283958] a diagnosis of any other inflammatory arthritis 
eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic a
application and any extensions or variations thereof.eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic a rthritis, or reactive arthritis. 
application and any extensions or variations thereof.rthritis, or reactive arthritis. 
Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
application and any extensions or variations thereof.Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
have no active symptomatic disease at Screening or Baseline.
application and any extensions or variations thereof.have no active symptomatic disease at Screening or Baseline.
Subject has a secondary, noninflammatory condition (eg, osteoarthri
application and any extensions or variations thereof.Subject has a secondary, noninflammatory condition (eg, osteoarthri
the Investigator’s opi[INVESTIGATOR_581513].the Investigator’s opi[INVESTIGATOR_581509]’s primary diagnosis of active AS.
application and any extensions or variations thereof.study drug on the subject’s primary diagnosis of active AS.
Subject has received previous or current biological treatment other than T
application and any extensions or variations thereof.Subject has received previous or current biological treatment other than T
Subjects must not have used medications in the manner as detailed by [CONTACT_581597].Subjects must not have used medications in the manner as detailed by [CONTACT_581598] (eg, more than 3 epi[INVESTIGATOR_581514].ory of chronic or recurrent infections (eg, more than 3 epi[INVESTIGATOR_581512]). Minor illnesses like common cold or 
application and any extensions or variations thereof.antibiotics or antivirals during the preceding year). Minor illnesses like common cold or 
application and any extensions or variations thereof.transient, localized infections that may have been treated with a short course of 
application and any extensions or variations thereof.transient, localized infections that may have been treated with a short course of 
therapy (up to 7 days) need not count in this assessment.
application and any extensions or variations thereof.therapy (up to 7 days) need not count in this assessment.
a serious or life
application and any extensions or variations thereof.a serious or life
(including herpes zoster) or hospi[INVESTIGATOR_581507] 6 months.application and any extensions or variations thereof.(including herpes zoster) or hospi[INVESTIGATOR_581507] [ADDRESS_764622] has a history of or current clinically active infection with Histoplasma, Coccidiodes, 
Paracoccidioides, Pneumocystis, nontuberculous mycobacteria (NTMB), Blastomyces, or 
Aspergillus or current active Candidiasis (local or systemic)
12. Subject has acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) 
infection. Subjects who have evidence of, or test positive for, hepatitis B or hepatitis C are excluded as follows: 
A positive test for the hepatitis B virus (HBV) is defined as: 1) positive for hepatitis B 
surface antigen (HBsAg+), or 2) positive for anti-hepatitis B core antibody (HBcAb+). 
A positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction).
13. Subjects with known TB infection, at high risk of acquiring TB infection, with latent TB 
infection (LTBI), or current or history of NTMB infection (refer to Section 12.7.5 for details 
on determining full TB exclusion criteria). 
14. Subject has a primary immunosuppressive condition, including taking immunosuppressive 
therapy following an organ transplant or has had a splenectomy.
15. Subjects with concurrent malignancy or a history of malignancy (including surgically 
resected uterine/cervical carcinoma- in-situ) during the past 5 years will be excluded with the 
following exceptions that may be included:
a.≤3 excised or ablated basal cell carcinomas of the skin
b. One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised or 
ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
recurrence or metastases for more than 2 years prior to Screening
c.Actinic keratosis(- es)
d. Squamous cell carcinoma- in-situ of the skin successfully excised or ablated more than 
[ADDRESS_764623] has a history of demyelinating disease (including myelitis) or neurologic symptoms 
suggestive of demyelinating disease.
18. Subject has a current or recent history, as determined by [CONTACT_737], of severe, 
progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, card iac 
(eg, congestive heart failure [LOCATION_001] Heart Association [NYHA] Grade 3 and 4), 
gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects with a history of peptic ulcer disease are allowed), or neurological disease.
19. Subjects has a history of uncompensated heart failure, fluid overload, or myocardial 
infarction, or evidence of new-onset ischemic heart disease or in the opi[INVESTIGATOR_581515], within [ADDRESS_764624] has a primary immunosuppressive condition, including taking immunosuppressive 
therapy following an organ transplant or has had a splenectomy.
PUBLIC COPY therapy following an organ transplant or has had a splenectomy.
Subjects with concurrent malignancy or a history of malignancy (including 
PUBLIC COPY Subjects with concurrent malignancy or a history of malignancy (including 
situ) during the past 5 years will be excluded with the 
PUBLIC COPY situ) during the past 5 years will be excluded with the 
following exceptions that may be included:
PUBLIC COPY following exceptions that may be included:
≤3 excised or ablated basal cell carcinomas of the skin
PUBLIC COPY ≤3 excised or ablated basal cell carcinomas of the skin
One squamous cell carcinoma of the skin (stage T1 m
PUBLIC COPY One squamous cell carcinoma of the skin (stage T1 m
ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of PUBLIC COPY ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
recurrence or metastases for more than [ADDRESS_764625] for the hepatitis B virus (HBV) is defined as: 1) positive for hepatitis B 
This document cannot be used to support any marketing authorization A positive test for the hepatitis B virus (HBV) is defined as: 1) positive for hepatitis B 
hepatitis B core antibody (HBcAb+). 
This document cannot be used to support any marketing authorization hepatitis B core antibody (HBcAb+). 
positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
This document cannot be used to support any marketing authorization positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
HCV Ab), and 2) positive via a confirmatory test for HCV (for example, 
This document cannot be used to support any marketing authorization HCV Ab), and 2) positive via a confirmatory test for HCV (for example, 
acquiring TB infection, with latent TB 
This document cannot be used to support any marketing authorization acquiring TB infection, with latent TB 
infection (LTBI), or current or history of NTMB infection (refer to Section 
This document cannot be used to support any marketing authorization infection (LTBI), or current or history of NTMB infection (refer to Section 12.7.[ADDRESS_764626] has a primary immunosuppressive condition, including taking immunosuppressive 
therapy following an organ transplant or has had a splenectomy.
This document cannot be used to support any marketing authorization therapy following an organ transplant or has had a splenectomy.
Subjects with concurrent malignancy or a history of malignancy (including 
This document cannot be used to support any marketing authorization Subjects with concurrent malignancy or a history of malignancy (including 
situ) during the past 5 years will be excluded with the 
This document cannot be used to support any marketing authorization situ) during the past 5 years will be excluded with the 
≤3 excised or ablated basal cell carcinomas of the skin
This document cannot be used to support any marketing authorization ≤3 excised or ablated basal cell carcinomas of the skin
One squamous cell carcinoma of the skin (stage T1 m
This document cannot be used to support any marketing authorization One squamous cell carcinoma of the skin (stage T1 m
ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
This document cannot be used to support any marketing authorization ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
recurrence or metastases for more than [ADDRESS_764627] has a history of demyelinating disease (
This document cannot be used to support any marketing authorization Subject has a history of demyelinating disease (
suggestive of demyelinating disease.
This document cannot be used to support any marketing authorization suggestive of demyelinating disease.
This document cannot be used to support any marketing authorization Subject has a current or recent history, as determined by [CONTACT_737], of severe, 
This document cannot be used to support any marketing authorization Subject has a current or recent history, as determined by [CONTACT_737], of severe, 
progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, card
This document cannot be used to support any marketing authorization progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, card
(eg, congestive heart failure [LOCATION_001] Heart Association [NYHA] Grade 3 and 4), 
This document cannot be used to support any marketing authorization (eg, congestive heart failure [LOCATION_001] Heart Association [NYHA] Grade 3 and 4), 
gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects 
This document cannot be used to support any marketing authorization gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects 
with a history of peptic ulcer disease are allowed), or neurological disease.
This document cannot be used to support any marketing authorization with a history of peptic ulcer disease are allowed), or neurological disease.
19.This document cannot be used to support any marketing authorization 19.application and any extensions or variations thereof.positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
application and any extensions or variations thereof.positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
HCV Ab), and 2) positive via a confirmatory test for HCV (for example, 
application and any extensions or variations thereof.HCV Ab), and 2) positive via a confirmatory test for HCV (for example, 
acquiring TB infection, with latent TB 
application and any extensions or variations thereof.acquiring TB infection, with latent TB 
12.7.[ADDRESS_764628] has a primary immunosuppressive condition, including taking immunosuppressive 
Subjects with concurrent malignancy or a history of malignancy (including 
application and any extensions or variations thereof.Subjects with concurrent malignancy or a history of malignancy (including 
situ) during the past 5 years will be excluded with the 
application and any extensions or variations thereof.situ) during the past 5 years will be excluded with the 
≤3 excised or ablated basal cell carcinomas of the skin
application and any extensions or variations thereof.≤3 excised or ablated basal cell carcinomas of the skin
One squamous cell carcinoma of the skin (stage T1 m
application and any extensions or variations thereof.One squamous cell carcinoma of the skin (stage T1 m
ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
application and any extensions or variations thereof.ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
recurrence or metastases for more than [ADDRESS_764629] has a history of demyelinating disease (
application and any extensions or variations thereof.Subject has a history of demyelinating disease (
suggestive of demyelinating disease.
application and any extensions or variations thereof.suggestive of demyelinating disease.
application and any extensions or variations thereof.Subject has a current or recent history, as determined by [CONTACT_737], of severe, 
application and any extensions or variations thereof.Subject has a current or recent history, as determined by [CONTACT_737], of severe, 
progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, card
application and any extensions or variations thereof.progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, card
(eg, congestive heart failure [LOCATION_001] Heart Association [NYHA] Grade 3 and 4), application and any extensions or variations thereof.(eg, congestive heart failure [LOCATION_001] Heart Association [NYHA] Grade 3 and 4), 
gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects application and any extensions or variations thereof.gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects 
with a history of peptic ulcer disease are allowed), or neurological disease.application and any extensions or variations thereof.with a history of peptic ulcer disease are allowed), or neurological disease.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 37of [ZIP_CODE]. Subjects with presence of significant uncontrolled neuropsychiatric disorder, active suicidal 
ideation, or positive suicide behavior using the “Baseline” version of the Columbia-Suicide 
Severity Rating Scale (C-SSRS) and the Hospi[INVESTIGATOR_5620] (HADS) with either of the following criteria:
Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
a positive response (“Yes”) to either question 4 or question 5 of the “Screening/Baseline” 
version of the C-SSRS at screening.
HADS Depression score ≥10 or Anxiety score ≥15.
21. Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), *alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
an identified exclusionary medical condition.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, AST, or ALP remain above the thresholds defined above, should not be randomized. 
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).
If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor.
22. Subjects with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
neutropenia <1.5x10
9/L, hemoglobin <8.5g/dL, lymphocytes <1.0 x109/L, white blood cell 
(WBC) count <3.0x109, platelets <100 x109/L). Individual screening tests for which the 
results are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
once for confirmation during the Screening Period if they are within 25% of the exclusion 
limit. Upon retesting, subjects whose results remain outside this threshold should not be 
randomized. 
23. Subject has an estimated glomerular filtration rate (GFR) as measured by [CONTACT_18984][INVESTIGATOR_10444] <60mL/min/1.73m2
24. Subject has a 12-lead ECG with changes considered to be clinically significant upon medical 
review (eg, QT corrected for heart rate [QTc] using Fridericia’s correction [QTcF] >450ms, bundle branch block, evidence of myocardial ischemia).PUBLIC COPY Tests that result in ALT, AST, or ALP up to 25% above the exc
PUBLIC COPY Tests that result in ALT, AST, or ALP up to 25% above the exc
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
PUBLIC COPY once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
AST, or ALP remain above the thresholds defined above, should not be randomized. 
PUBLIC COPY AST, or ALP remain above the thresholds defined above, should not be randomized. 
For randomized subjects with a Baseline result >ULN for AL
PUBLIC COPY For randomized subjects with a Baseline result >ULN for AL
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
PUBLIC COPY a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).
PUBLIC COPY understood and recorded in the electronic Case Report form (eCRF).
If a subject has >ULN ALT, AST, or ALP that does not meet the exclusionPUBLIC COPY If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing PUBLIC COPY Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
This document cannot be used to support any marketing authorization attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
[CONTACT_581599], or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
) to either question 4 or question 5 of the “Screening/Baseline” 
This document cannot be used to support any marketing authorization ) to either question 4 or question 5 of the “Screening/Baseline” 
Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
This document cannot be used to support any marketing authorization Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
ate aminotransferase (AST), *alkaline phosphatase (ALP), or 
This document cannot be used to support any marketing authorization ate aminotransferase (AST), *alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
This document cannot be used to support any marketing authorization >ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
This document cannot be used to support any marketing authorization elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
e undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
This document cannot be used to support any marketing authorization e undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
This document cannot be used to support any marketing authorization *An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
Tests that result in ALT, AST, or ALP up to 25% above the exc
This document cannot be used to support any marketing authorization Tests that result in ALT, AST, or ALP up to 25% above the exc
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
This document cannot be used to support any marketing authorization once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
AST, or ALP remain above the thresholds defined above, should not be randomized. 
This document cannot be used to support any marketing authorization AST, or ALP remain above the thresholds defined above, should not be randomized. 
For randomized subjects with a Baseline result >ULN for AL
This document cannot be used to support any marketing authorization For randomized subjects with a Baseline result >ULN for AL
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
This document cannot be used to support any marketing authorization a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).
This document cannot be used to support any marketing authorization understood and recorded in the electronic Case Report form (eCRF).
If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion
This document cannot be used to support any marketing authorization If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
This document cannot be used to support any marketing authorization Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
This document cannot be used to support any marketing authorization clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor.
This document cannot be used to support any marketing authorization must be discussed with the Medical Monitor.
with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
This document cannot be used to support any marketing authorization with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
neutropenia <1.5x10
This document cannot be used to support any marketing authorization neutropenia <1.5x109
This document cannot be used to support any marketing authorization 9/L, hemoglobin <8.5g/dL, lymphocytes <1.0 x10
This document cannot be used to support any marketing authorization /L, hemoglobin <8.5g/dL, lymphocytes <1.0 x10
This document cannot be used to support any marketing authorization (WBC) count <3.0x10
This document cannot be used to support any marketing authorization (WBC) count <3.0x109
This document cannot be used to support any marketing authorization 9platelets <100
This document cannot be used to support any marketing authorization platelets <100
sults are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
This document cannot be used to support any marketing authorization sults are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
once for confirmation during the Screening Period if they are within 25% of the exclusion 
This document cannot be used to support any marketing authorization once for confirmation during the Screening Period if they are within 25% of the exclusion 
limit. Upon retesting, subjects whose results remain outside this thresho
This document cannot be used to support any marketing authorization limit. Upon retesting, subjects whose results remain outside this thresho
randomized. 
This document cannot be used to support any marketing authorization randomized. 
Subject has an estimated glomerular filtration rate (GFR) as measured by [CONTACT_581600] (GFR) as measured by [CONTACT_18984][INVESTIGATOR_10444] <60mL/min/1.73m
This document cannot be used to support any marketing authorization Disease Epi[INVESTIGATOR_10444] <60mL/min/1.73m
24.
This document cannot be used to support any marketing authorization 24.Subject has a [ADDRESS_764630] has a 12application and any extensions or variations thereof.ate aminotransferase (AST), *alkaline phosphatase (ALP), or 
application and any extensions or variations thereof.ate aminotransferase (AST), *alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
application and any extensions or variations thereof.>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
application and any extensions or variations thereof.elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
e undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
application and any extensions or variations thereof.e undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
application and any extensions or variations thereof.*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
Tests that result in ALT, AST, or ALP up to 25% above the exc
application and any extensions or variations thereof.Tests that result in ALT, AST, or ALP up to 25% above the exc lusion limit may be repeated 
application and any extensions or variations thereof.lusion limit may be repeated 
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
application and any extensions or variations thereof.once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
AST, or ALP remain above the thresholds defined above, should not be randomized. 
application and any extensions or variations thereof.AST, or ALP remain above the thresholds defined above, should not be randomized. 
For randomized subjects with a Baseline result >ULN for AL
application and any extensions or variations thereof.For randomized subjects with a Baseline result >ULN for AL T, AST, ALP, or total bilirubin, 
application and any extensions or variations thereof.T, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
application and any extensions or variations thereof.a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).
application and any extensions or variations thereof.understood and recorded in the electronic Case Report form (eCRF).
If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion
application and any extensions or variations thereof.If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
application and any extensions or variations thereof.Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
application and any extensions or variations thereof.clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor.
application and any extensions or variations thereof.must be discussed with the Medical Monitor.
with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
application and any extensions or variations thereof.with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
/L, hemoglobin <8.5g/dL, lymphocytes <1.0 x10
application and any extensions or variations thereof./L, hemoglobin <8.5g/dL, lymphocytes <1.0 x10
application and any extensions or variations thereof.platelets <100
application and any extensions or variations thereof.platelets <100
sults are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
application and any extensions or variations thereof.sults are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
once for confirmation during the Screening Period if they are within 25% of the exclusion 
application and any extensions or variations thereof.once for confirmation during the Screening Period if they are within 25% of the exclusion 
limit. Upon retesting, subjects whose results remain outside this thresho
application and any extensions or variations thereof.limit. Upon retesting, subjects whose results remain outside this thresho
Subject has an estimated glomerular filtration rate (GFR) as measured by [CONTACT_581601].Subject has an estimated glomerular filtration rate (GFR) as measured by [CONTACT_18984][INVESTIGATOR_10444] <60mL/min/1.73mapplication and any extensions or variations thereof.Disease Epi[INVESTIGATOR_10444] <60mL/min/1.73m
Subject has a 12application and any extensions or variations thereof.Subject has a 12
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 38of [ZIP_CODE]. Subjects has received any live (includes attenuated) vaccination within the 8 weeks prior to 
Baseline (12 months prior to Baseline for the TB Bacille Calmette-Guérin [BCG] vaccine) 
(eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza vaccination is not permitted). Live vaccines are not allowed during the study or for 20 weeks 
after the final dose of IMP. 
Live vaccines include, but are not limited to the following: 
Anthrax vaccine
Intranasal influenza vaccine
Measles-mumps-rubella (MMR) vaccine
Polio live oral vaccine (OPV)
Smallpox vaccine
Tuberculosis BCG vaccine (within 12 months prior to Baseline)
Typhoid live oral vaccine
Varicella vaccine
Yellow fever vaccine
26. Subject has a history of chronic alcohol or drug abuse within the previous 6 months.
27. Subjects has any other condition which, in the Investigator's judgment, would make the 
subject unsuitable for inclusion in the study.
28. Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.
29. Subject is a UCB employee or is an employee of a third-party organization involved in the 
study.
6.3 Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued care.
Subjects should be withdrawn from the study and encouraged to come for the SFU Visit 
([ADDRESS_764631] received dose of IMP) if any of the following events occur:
1. Subject withdraws his/her consent.
2. The sponsor or a regulatory agency requests withdrawal of the subject.
3. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test.
4. Subject develops an illness that would interfere with his/her continued participation.PUBLIC COPY Subject has a history of chronic alcohol or drug abuse within the previous [ADDRESS_764632] has a history of chronic alcohol or drug abuse within the previous 6 months.
Subjects has any other condition which, in the Investigator's judgment, would ma
PUBLIC COPY Subjects has any other condition which, in the Investigator's judgment, would ma
subject unsuitable for inclusion in the study.
PUBLIC COPY subject unsuitable for inclusion in the study.
Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
PUBLIC COPY Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether PUBLIC COPY families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
This document cannot be used to support any marketing authorization months prior to Baseline)
This document cannot be used to support any marketing authorization months prior to Baseline)
Subject has a history of chronic alcohol or drug abuse within the previous [ADDRESS_764633] has a history of chronic alcohol or drug abuse within the previous 6 months.
Subjects has any other condition which, in the Investigator's judgment, would ma
This document cannot be used to support any marketing authorization Subjects has any other condition which, in the Investigator's judgment, would ma
subject unsuitable for inclusion in the study.
This document cannot be used to support any marketing authorization subject unsuitable for inclusion in the study.
Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
This document cannot be used to support any marketing authorization Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
This document cannot be used to support any marketing authorization families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
Subject is a UCB employee or is an employee of a third
This document cannot be used to support any marketing authorization Subject is a UCB employee or is an employee of a third
Withdrawal criteria
This document cannot be used to support any marketing authorization Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
This document cannot be used to support any marketing authorization Subjects are free to withdraw from the study at any time, without prejudice to their continued 
Subjects should be withdr
This document cannot be used to support any marketing authorization Subjects should be withdr
weeks after the last received dose of IMP) if any of the following events occur:
This document cannot be used to support any marketing authorization weeks after the last received dose of IMP) if any of the following events occur:
Subject withdraws his/her consent.
This document cannot be used to support any marketing authorization Subject withdraws his/her consent.
This document cannot be used to support any marketing authorization The sponsor or a regulatory agency requests withdrawal of the subject.
This document cannot be used to support any marketing authorization The sponsor or a regulatory agency requests withdrawal of the subject.
3.
This document cannot be used to support any marketing authorization 3.There
This document cannot be used to support any marketing authorization Thereapplication and any extensions or variations thereof.Subject has a history of chronic alcohol or drug abuse within the previous [ADDRESS_764634] has a history of chronic alcohol or drug abuse within the previous 6 months.
Subjects has any other condition which, in the Investigator's judgment, would ma
application and any extensions or variations thereof.Subjects has any other condition which, in the Investigator's judgment, would ma
Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
application and any extensions or variations thereof.Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
application and any extensions or variations thereof.families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
Subject is a UCB employee or is an employee of a third
application and any extensions or variations thereof.Subject is a UCB employee or is an employee of a third
Withdrawal criteria
application and any extensions or variations thereof.Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
application and any extensions or variations thereof.Subjects are free to withdraw from the study at any time, without prejudice to their continued 
Subjects should be withdr
application and any extensions or variations thereof.Subjects should be withdr awn from the study and encouraged to come for the SFU Visit 
application and any extensions or variations thereof.awn from the study and encouraged to come for the SFU Visit 
weeks after the last received dose of IMP) if any of the following events occur:
application and any extensions or variations thereof.weeks after the last received dose of IMP) if any of the following events occur:
Subject withdraws his/her consent.
application and any extensions or variations thereof.Subject withdraws his/her consent.
application and any extensions or variations thereof.The sponsor or a regulatory agency requests withdrawal of the subject.application and any extensions or variations thereof.The sponsor or a regulatory agency requests withdrawal of the subject.
is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy application and any extensions or variations thereof.is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
UCB [ADDRESS_764635] considered as having either a suspected new LTBI or who develops active TB or 
NTMB infection during the study (including but not limited to, conversion demonstrated by 
[CONTACT_14234]-gamma release assay [IGRA] or other diagnostic means) must be immediately discontinued from IMP, and an Early Withdrawal Visit must be scheduled as soon as possible, but not later than the next regular visit.
Confirmed active TB is a serious adverse event (SAE) and must be captured on an SAE 
Report Form and provided to the Sponsor in accordance with SAE reporting requirements. 
As with all SAEs, periodic follow-up reports should be completed as per protocol 
requirements until such time as the TB infection resolves. 
Additional information on TB policies are provided Section 12.7.5.
6. Subject is noncompliant with the study procedures or medications in the opi[INVESTIGATOR_684].
7. Subject uses prohibited concomitant medications as defined in this protocol (see 
Section 7.8.2) that may present a risk to the safety of the subject in the opi[INVESTIGATOR_286098]/or the Medical Monitor.
8. Subject develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
AST as defined in Section Section 6.3.1; neutropenia <0.5x10
9/L; lymphopenia <0.5x109/L. 
Any laboratory value or change judged to be clinically significant by [CONTACT_59008]. For clarification, 
laboratory values that are markedly abnormal as per Table 19‒2 and Table 19‒3 will be 
flagged to the Investigator and to the medical monitor but do not trigger mandatory 
withdrawal unless listed above (Refer to Section 6.3.1 for withdrawal criteria in relation to 
potential drug-induced liver injury [PDILI].)
9. Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
Questions 4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
self-rated C-SSRS. The subject should be referred immediately to a Mental Healthcare 
Professional and must be withdrawn from the study.
10. Subjects with a Hospi[INVESTIGATOR_5620]—Depression (HADS-D) score ≥[ADDRESS_764636] who develops a HADS-D score of ≥[ADDRESS_764637]:
Be referred, as appropriate, to a health care professional treating IBD, such as a gastroenterologist
Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
[CONTACT_580666]’s suitability for continued participation in the study.PUBLIC COPY Subject develops laboratory abnormalities (with or
PUBLIC COPY Subject develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
PUBLIC COPY without clinical symptoms) of ALT or 
; neutropenia <0.5x10
PUBLIC COPY ; neutropenia <0.5x10
Any laboratory value or change judged to be clinically significant by [CONTACT_581602]. For clarification, 
PUBLIC COPY prompt consideration of whether the subject should continue on IMP. For clarification, 
laboratory values that are markedly abnormal as per 
PUBLIC COPY laboratory values that are markedly abnormal as per 
flagged to the Investigator and to 
PUBLIC COPY flagged to the Investigator and to the medical monitor but do not trigger mandatory 
PUBLIC COPY the medical monitor but do not trigger mandatory 
withdrawal unless listed above (Refer to 
PUBLIC COPY withdrawal unless listed above (Refer to 
induced liver injury [PDILI].)PUBLIC COPY induced liver injury [PDILI].)
Subject has active suicidal ideation as indicated by a positive response (“Yes”) to PUBLIC COPY Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
This document cannot be used to support any marketing authorization Report Form and provided to the Sponsor in accordance with SAE reporting requirements. 
This document cannot be used to support any marketing authorization Report Form and provided to the Sponsor in accordance with SAE reporting requirements. 
Subject is noncompliant with the study procedures or medications in the opi[INVESTIGATOR_581516] (see 
This document cannot be used to support any marketing authorization Subject uses prohibited concomitant medications as defined in this protocol (see 
) that may present a risk to the safety of the subject in the opi[INVESTIGATOR_581517] ) that may present a risk to the safety of the subject in the opi[INVESTIGATOR_581518]) of ALT or 
This document cannot be used to support any marketing authorization without clinical symptoms) of ALT or 
; neutropenia <0.5x10
This document cannot be used to support any marketing authorization ; neutropenia <0.5x109
This document cannot be used to support any marketing authorization [ADDRESS_764638] should continue on IMP. For clarification, 
laboratory values that are markedly abnormal as per 
This document cannot be used to support any marketing authorization laboratory values that are markedly abnormal as per Table
This document cannot be used to support any marketing authorization Table
the medical monitor but do not trigger mandatory 
This document cannot be used to support any marketing authorization the medical monitor but do not trigger mandatory 
withdrawal unless listed above (Refer to 
This document cannot be used to support any marketing authorization withdrawal unless listed above (Refer to Section
This document cannot be used to support any marketing authorization Section
induced liver injury [PDILI].)
This document cannot be used to support any marketing authorization induced liver injury [PDILI].)
Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
This document cannot be used to support any marketing authorization Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
This document cannot be used to support any marketing authorization 4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
This document cannot be used to support any marketing authorization 4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
SSRS. The subject shou
This document cannot be used to support any marketing authorization SSRS. The subject shou
Professional and must be withdrawn from the study.
This document cannot be used to support any marketing authorization Professional and must be withdrawn from the study.
Hospi[INVESTIGATOR_581519]. Any subject who develops a HADS
This document cannot be used to support any marketing authorization must be withdrawn. Any subject who develops a HADS
should be referred immediately to a Mental Healthcare Professional for further evaluation 
This document cannot be used to support any marketing authorization should be referred immediately to a Mental Healthcare Professional for further evaluation 
and potential withdrawal by [CONTACT_737].
This document cannot be used to support any marketing authorization and potential withdrawal by [CONTACT_737].
Subjects with newly diagnosed IBD or with IBD flares during the study must:
This document cannot be used to support any marketing authorization Subjects with newly diagnosed IBD or with IBD flares during the study must:
Be referred, as appropriate, to 
This document cannot be used to support any marketing authorization Be referred, as appropriate, to 
gastroenterologist
This document cannot be used to support any marketing authorization gastroenterologist

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Subject is noncompliant with the study procedures or medications in the opi[INVESTIGATOR_581520].Subject is noncompliant with the study procedures or medications in the opi[INVESTIGATOR_581521] (see 
application and any extensions or variations thereof.Subject uses prohibited concomitant medications as defined in this protocol (see 
) that may present a risk to the safety of the subject in the opi[INVESTIGATOR_581520].) that may present a risk to the safety of the subject in the opi[INVESTIGATOR_581518]) of ALT or 
application and any extensions or variations thereof.without clinical symptoms) of ALT or 
/L; lymphopenia <0.5x10
application and any extensions or variations thereof./L; lymphopenia <0.5x10
Any laboratory value or change judged to be clinically significant by [CONTACT_581603].Any laboratory value or change judged to be clinically significant by [CONTACT_59008]. For clarification, 
application and any extensions or variations thereof.prompt consideration of whether the subject should continue on IMP. For clarification, 
Table
application and any extensions or variations thereof.Table 19
application and any extensions or variations thereof.19‒
application and any extensions or variations thereof.‒
the medical monitor but do not trigger mandatory 
application and any extensions or variations thereof.the medical monitor but do not trigger mandatory 
Section
application and any extensions or variations thereof.Section 6.3.[ADDRESS_764639] has active suicidal ideation as indicated by a positive response (“Yes”) to 
application and any extensions or variations thereof.Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
application and any extensions or variations thereof.4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
application and any extensions or variations thereof.4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
SSRS. The subject shou
application and any extensions or variations thereof.SSRS. The subject shou ld be referred immediately to a Mental Healthcare 
application and any extensions or variations thereof.ld be referred immediately to a Mental Healthcare 
Professional and must be withdrawn from the study.
application and any extensions or variations thereof.Professional and must be withdrawn from the study.
Hospi[INVESTIGATOR_581492].Hospi[INVESTIGATOR_581522]. Any subject who develops a HADS
application and any extensions or variations thereof.must be withdrawn. Any subject who develops a HADS
should be referred immediately to a Mental Healthcare Professional for further evaluation 
application and any extensions or variations thereof.should be referred immediately to a Mental Healthcare Professional for further evaluation 
and potential withdrawal by [CONTACT_737].
application and any extensions or variations thereof.and potential withdrawal by [CONTACT_737].
Subjects with newly diagnosed IBD or with IBD flares during the study must:
application and any extensions or variations thereof.Subjects with newly diagnosed IBD or with IBD flares during the study must:
Be referred, as appropriate, to 
application and any extensions or variations thereof.Be referred, as appropriate, to 
gastroenterologist
application and any extensions or variations thereof.gastroenterologist
Discontinue IMP and be followedapplication and any extensions or variations thereof. Discontinue IMP and be followed
UCB [ADDRESS_764640] data from 
subjects who withdraw early from the study (NRC, 2010). If a subject withdraws from study 
treatment for any of the above criteria prior to Week 48, they will be asked to return for the study termination assessments as laid down at the Week 48/WD Visit and for the SFU Visit (20 weeks 
after final dose administration). All subjects who withdraw from the study due to an AE must be 
followed until resolution of the event or until the event is considered stable. All subjects who withdraw from the study due to development of a laboratory abnormality must be closely 
monitored. If a subject at any time has had an ALT and/or AST >5xULN, additional monitoring 
of hepatic markers will be performed every week or [ADDRESS_764641] to follow up, the Investigator should make an 
effort (at least [ADDRESS_764642]), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a narrative description of the reason(s) for removing the subject, must be recorded in the source documents. The eCRF must document the primary reason for withdrawal or discontinuation.
Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
of a subject in advance.
6.3.1 Potential drug -induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
The PDILI criteria below require immediate discontinuation of IMP: 
Subjects with either of the following:
ALT or AST ≥5ULN
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator. 
Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 12.6.1. 
If subjects are unable to comply with the applicable monitoring schedule, IMP must be discontinued immediately.PUBLIC COPY documents. The eCRF must document the primary reason for withdrawal or discontinuation.
PUBLIC COPY documents. The eCRF must document the primary reason for withdrawal or discontinuation.
Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
PUBLIC COPY Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
induced liver injury IMP discontinuation criteria
PUBLIC COPY induced liver injury IMP discontinuation criteria
induced liver injury (PDILI) must be asse
PUBLIC COPY induced liver injury (PDILI) must be asse
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
PUBLIC COPY must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
PUBLIC COPY not medically necessary should also be discontinued. 
The PDILI criteria below require immediate discontinuation of IMP: PUBLIC COPY The PDILI criteria below require immediate discontinuation of IMP: 
This document cannot be used to support any marketing authorization >5xULN, additional monitoring 
This document cannot be used to support any marketing authorization >5xULN, additional monitoring 
resolution of the event, the 
This document cannot be used to support any marketing authorization resolution of the event, the 
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
This document cannot be used to support any marketing authorization Investigators should attempt to obtain information on subjects in the case of withdrawal or 
up, the Investigator should make an 
This document cannot be used to support any marketing authorization up, the Investigator should make an 
effort (at least [ADDRESS_764643]), and document his/her effort 
This document cannot be used to support any marketing authorization effort (at least [ADDRESS_764644]), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
This document cannot be used to support any marketing authorization (date and summary of the phone call and copy of the written message in the source documents), 
tion. All results of these evaluations and observations, together with a 
This document cannot be used to support any marketing authorization tion. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
This document cannot be used to support any marketing authorization narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must document the primary reason for withdrawal or discontinuation.
This document cannot be used to support any marketing authorization documents. The eCRF must document the primary reason for withdrawal or discontinuation.
Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
This document cannot be used to support any marketing authorization Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
induced liver injury IMP discontinuation criteria
This document cannot be used to support any marketing authorization induced liver injury IMP discontinuation criteria
induced liver injury (PDILI) must be asse
This document cannot be used to support any marketing authorization induced liver injury (PDILI) must be asse
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
This document cannot be used to support any marketing authorization must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
This document cannot be used to support any marketing authorization not medically necessary should also be discontinued. 
The PDILI criteria below require immediate discontinuation of IMP: 
This document cannot be used to support any marketing authorization The PDILI criteria below require immediate discontinuation of IMP: 
either of the following:
This document cannot be used to support any marketing authorization either of the following:
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
This document cannot be used to support any marketing authorization ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
This document cannot be used to support any marketing authorization Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomi
This document cannot be used to support any marketing authorization hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomi
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
This document cannot be used to support any marketing authorization upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
This document cannot be used to support any marketing authorization alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
This document cannot be used to support any marketing authorization The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigato
This document cannot be used to support any marketing authorization Investigato r. 
This document cannot be used to support any marketing authorization r. 
Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN,
This document cannot be used to support any marketing authorization Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN,
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
This document cannot be used to support any marketing authorization <2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
This document cannot be used to support any marketing authorization fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of This document cannot be used to support any marketing authorization Evaluation of application and any extensions or variations thereof.Investigators should attempt to obtain information on subjects in the case of withdrawal or 
application and any extensions or variations thereof.Investigators should attempt to obtain information on subjects in the case of withdrawal or 
up, the Investigator should make an 
application and any extensions or variations thereof.up, the Investigator should make an 
effort (at least [ADDRESS_764645]), and document his/her effort 
application and any extensions or variations thereof.effort (at least [ADDRESS_764646]), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
application and any extensions or variations thereof.(date and summary of the phone call and copy of the written message in the source documents), 
tion. All results of these evaluations and observations, together with a 
application and any extensions or variations thereof.tion. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
application and any extensions or variations thereof.narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must document the primary reason for withdrawal or discontinuation.
application and any extensions or variations thereof.documents. The eCRF must document the primary reason for withdrawal or discontinuation.
Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
application and any extensions or variations thereof.Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
induced liver injury IMP discontinuation criteria
application and any extensions or variations thereof.induced liver injury IMP discontinuation criteria
induced liver injury (PDILI) must be asse
application and any extensions or variations thereof.induced liver injury (PDILI) must be asse
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
application and any extensions or variations thereof.must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
application and any extensions or variations thereof.not medically necessary should also be discontinued. 
The PDILI criteria below require immediate discontinuation of IMP: 
application and any extensions or variations thereof.The PDILI criteria below require immediate discontinuation of IMP: 
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
application and any extensions or variations thereof.ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
application and any extensions or variations thereof.Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomi
application and any extensions or variations thereof.hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomi
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
application and any extensions or variations thereof.upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
application and any extensions or variations thereof.alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
application and any extensions or variations thereof.The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
application and any extensions or variations thereof.Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN,application and any extensions or variations thereof.Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN,
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, application and any extensions or variations thereof. <2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 41of 136Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.
6.4 Study stoppi[INVESTIGATOR_417688], planned dosing and procedures may be discontinued or suspended for all subjects in any part of the study and appropriate follow-up procedures established. Where it is possible to do so without threatening the safety of subjects, such discontinuation/suspension should be discussed with the UCB Study Physician prior to its implementation.
Possible reasons for discontinuation or suspension of the study include (but are not limited to):
A pattern of AEs occurs that contraindicates the further dosing of enrolled/additional 
subjects, including (but not limited to):
More than [ADDRESS_764647] meets any individual Withdrawal Criteria # 5, #9, ro #10 , or (as 
provided in Section 6.3), regardless of whether they met the same or different criteria.
Once a second subject meets any of those criteria, referral to the DMC may not be 
delayed while awaiting the outcome of either case.
If the above criteria are reached, the DMC will meet as soon as possible to determine whether discontinuation or suspension of the study should occur and to determine what investigations, 
analyses, procedural amendments, or other actions should occur, before making any 
recommendation regarding the possibility of recommencing the study. Further details on the role 
of the DMC are provided in Section 12.5. 
If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other reasons consistent with applicable laws, regulations, and Good Clinical Practice (GCP).
6.5 Retesting/rescreening
In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
may be repeated on [ADDRESS_764648] meets any individual Withdrawal Criteria #
PUBLIC COPY More than [ADDRESS_764649] meets any individual Withdrawal Criteria #
), regardless of whether they met the same or different criteria.
PUBLIC COPY ), regardless of whether they met the same or different criteria.
subject meets any of those criteria, referral to the DMC may not be 
PUBLIC COPY subject meets any of those criteria, referral to the DMC may not be 
delayed while awaiting the outcome of either case.
PUBLIC COPY delayed while awaiting the outcome of either case.
If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
PUBLIC COPY If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
discontinuation or suspension of the study 
PUBLIC COPY discontinuation or suspension of the study should occur and to determine what investigations, 
PUBLIC COPY should occur and to determine what investigations, 
PUBLIC COPY analyses, procedural amendments, or other actions should occur, before making any 
PUBLIC COPY analyses, procedural amendments, or other actions should occur, before making any 
recommendation regarding the possibility of recommencing the study. Further details on the role 
PUBLIC COPY recommendation regarding the possibility of recommencing the study. Further details on the role 
SectionPUBLIC COPY Section
This document cannot be used to support any marketing authorization During the study, planned dosing and procedures may be discontinued or suspended for all 
This document cannot be used to support any marketing authorization During the study, planned dosing and procedures may be discontinued or suspended for all 
up procedures established. Where it is 
This document cannot be used to support any marketing authorization up procedures established. Where it is 
subjects, such discontinuation/suspension 
This document cannot be used to support any marketing authorization subjects, such discontinuation/suspension 
Possible reasons for discontinuation or suspension of the study include (but are not limited to):
This document cannot be used to support any marketing authorization Possible reasons for discontinuation or suspension of the study include (but are not limited to):
icates the further dosing of enrolled/additional 
This document cannot be used to support any marketing authorization icates the further dosing of enrolled/additional 
More than [ADDRESS_764650] meets any individual Withdrawal Criteria #
This document cannot be used to support any marketing authorization More than [ADDRESS_764651] meets any individual Withdrawal Criteria # 5
This document cannot be used to support any marketing authorization 5, #
This document cannot be used to support any marketing authorization , #
), regardless of whether they met the same or different criteria.
This document cannot be used to support any marketing authorization ), regardless of whether they met the same or different criteria.
subject meets any of those criteria, referral to the DMC may not be 
This document cannot be used to support any marketing authorization subject meets any of those criteria, referral to the DMC may not be 
delayed while awaiting the outcome of either case.
This document cannot be used to support any marketing authorization delayed while awaiting the outcome of either case.
If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
This document cannot be used to support any marketing authorization If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
should occur and to determine what investigations, 
This document cannot be used to support any marketing authorization should occur and to determine what investigations, 
This document cannot be used to support any marketing authorization analyses, procedural amendments, or other actions should occur, before making any 
This document cannot be used to support any marketing authorization analyses, procedural amendments, or other actions should occur, before making any 
recommendation regarding the possibility of recommencing the study. Further details on the role 
This document cannot be used to support any marketing authorization recommendation regarding the possibility of recommencing the study. Further details on the role 
12.5
This document cannot be used to support any marketing authorization 12.5. 
This document cannot be used to support any marketing authorization . 
If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other 
This document cannot be used to support any marketing authorization If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws
This document cannot be used to support any marketing authorization reasons consistent with applicable laws
Retesting/rescreening
This document cannot be used to support any marketing authorization Retesting/rescreening
In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
This document cannot be used to support any marketing authorization In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
may be repeated on [ADDRESS_764652] maybe enrolled. 
This document cannot be used to support any marketing authorization Subjects whose Screening Period expi[INVESTIGATOR_581523], up to a maximum of 10 subje
This document cannot be used to support any marketing authorization Subjects who withdraw from the study may be replaced, up to a maximum of 10 subje
application and any extensions or variations thereof.subjects, such discontinuation/suspension 
application and any extensions or variations thereof.subjects, such discontinuation/suspension 
Possible reasons for discontinuation or suspension of the study include (but are not limited to):
application and any extensions or variations thereof.Possible reasons for discontinuation or suspension of the study include (but are not limited to):
icates the further dosing of enrolled/additional 
application and any extensions or variations thereof.icates the further dosing of enrolled/additional 
, #
application and any extensions or variations thereof., #9
application and any extensions or variations thereof.9, ro 
application and any extensions or variations thereof., ro #
application and any extensions or variations thereof.#
), regardless of whether they met the same or different criteria.
application and any extensions or variations thereof.), regardless of whether they met the same or different criteria.
subject meets any of those criteria, referral to the DMC may not be 
application and any extensions or variations thereof.subject meets any of those criteria, referral to the DMC may not be 
If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
application and any extensions or variations thereof.If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
should occur and to determine what investigations, 
application and any extensions or variations thereof.should occur and to determine what investigations, 
application and any extensions or variations thereof.analyses, procedural amendments, or other actions should occur, before making any 
application and any extensions or variations thereof.analyses, procedural amendments, or other actions should occur, before making any 
recommendation regarding the possibility of recommencing the study. Further details on the role 
application and any extensions or variations thereof.recommendation regarding the possibility of recommencing the study. Further details on the role 
If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other 
application and any extensions or variations thereof.If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws
application and any extensions or variations thereof.reasons consistent with applicable laws , regulations, and Good Clinical Practice (GCP).
application and any extensions or variations thereof., regulations, and Good Clinical Practice (GCP).
Retesting/rescreening
application and any extensions or variations thereof.Retesting/rescreening
In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
application and any extensions or variations thereof.In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
may be repeated on [ADDRESS_764653] maybe enrolled. 
application and any extensions or variations thereof.Subjects whose Screening Period expi[INVESTIGATOR_581524].Subjects whose Screening Period expi[INVESTIGATOR_581524].Subjects who withdraw from the study may be replaced, up to a maximum of 10 subje
application and any extensions or variations thereof.Subjects who withdraw from the study may be replaced, up to a maximum of 10 subje
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 42of 1367 STUDY TREATMENT(S)
7.[ADDRESS_764654](s)
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a vial or in a pre -filled syringe (PFS) form as described below: 
Vial: a clear to opalescent, colorless to slightly brown, sterile, preservative -free solution in 
2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
and sealed with an aluminum cap overseal. Each single -use dose vial will contain 160mg/mL 
bimekiz umab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
pH 
PFS: 1mL PFS at a concentration of 160mg/mL ( mM sodium acetate, mM glycine, 
 polysorbate 80 at pH ) for sc injection.
Certolizumab pegol will be supplied as a sterile, clear, colorless -to-slightly yellow solution at 
pH  in 1mL single -use glass PFS for sc injection. Each syringe contains an extractable volume 
of 1.0mL at a concentration of CZP 200mg/mL in mM sodium acetate buffer and mM 
sodium chloride as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
from light.
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe an Pharmacopoeia) 
quality appropriate for injection.
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
7.2 Treatment(s) to be administered
The IMP is to be administered in the clinic by [CONTACT_581604] [ADDRESS_764655].
The IMP (bimekizumab or CZP) will be administered at time points indicated in Table 5‒1.
At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
CZP treatment arms and will receive IMP as shown in Table 7‒1.PUBLIC COPY as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
PUBLIC COPY as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
PUBLIC COPY Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe
PUBLIC COPY preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
PUBLIC COPY Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
Treatment(s) to be administeredPUBLIC COPY Treatment(s) to be administered
The IMP is to be administered in the clinic by [CONTACT_581604] 2 PUBLIC COPY The IMP is to be administered in the clinic by [CONTACT_581604] 2 
This document cannot be used to support any marketing authorization 2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
This document cannot be used to support any marketing authorization 2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
use dose vial will contain 160mg/mL 
This document cannot be used to support any marketing authorization use dose vial will contain 160mg/mL 
umab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
This document cannot be used to support any marketing authorization umab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
PFS: 1mL PFS at a concentration of 160mg/mL ( mM sodium acetate, mM glycine, 
This document cannot be used to support any marketing authorization PFS: 1mL PFS at a concentration of 160mg/mL ( mM sodium acetate, mM glycine, 
slightly yellow solution at 
This document cannot be used to support any marketing authorization slightly yellow solution at 
use glass PFS for sc injection. Each syringe contains an extractable volume 
This document cannot be used to support any marketing authorization use glass PFS for sc injection. Each syringe contains an extractable volume 
of 1.0mL at a concentration of CZP 200mg/mL in mM sodium acetate buffer and mM 
This document cannot be used to support any marketing authorization of 1.0mL at a concentration of CZP 200mg/mL in mM sodium acetate buffer and mM 
This document cannot be used to support any marketing authorization as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
This document cannot be used to support any marketing authorization as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
This document cannot be used to support any marketing authorization Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe
This document cannot be used to support any marketing authorization preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
This document cannot be used to support any marketing authorization Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
Treatment(s) to be administered
This document cannot be used to support any marketing authorization Treatment(s) to be administered
The IMP is to be administered in the clinic by [CONTACT_581604] 2 
This document cannot be used to support any marketing authorization The IMP is to be administered in the clinic by [CONTACT_581604] 2 
areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
This document cannot be used to support any marketing authorization areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
This document cannot be used to support any marketing authorization visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
should be rotated and injections s
This document cannot be used to support any marketing authorization should be rotated and injections s hould not be given into areas where the skin is tender, bruised, 
This document cannot be used to support any marketing authorization hould not be given into areas where the skin is tender, bruised, 
The IMP (bimekizumab or CZP) will be administered at time points indicated in 
This document cannot be used to support any marketing authorization The IMP (bimekizumab or CZP) will be administered at time points indicated in 
At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
This document cannot be used to support any marketing authorization At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
CZP treatment arms and will receive IMP as shown in 
This document cannot be used to support any marketing authorization CZP treatment arms and will receive IMP as shown in 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.umab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
application and any extensions or variations thereof.umab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
PFS: 1mL PFS at a concentration of 160mg/mL ( mM sodium acetate, mM glycine, 
application and any extensions or variations thereof.PFS: 1mL PFS at a concentration of 160mg/mL ( mM sodium acetate, mM glycine, 
slightly yellow solution at 
application and any extensions or variations thereof.slightly yellow solution at 
use glass PFS for sc injection. Each syringe contains an extractable volume 
application and any extensions or variations thereof.use glass PFS for sc injection. Each syringe contains an extractable volume 
of 1.0mL at a concentration of CZP 200mg/mL in mM sodium acetate buffer and mM 
application and any extensions or variations thereof.of 1.0mL at a concentration of CZP 200mg/mL in mM sodium acetate buffer and mM 
application and any extensions or variations thereof.as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
application and any extensions or variations thereof.as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
application and any extensions or variations thereof.Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe
application and any extensions or variations thereof.preservative free) of pharmacopoeia ([LOCATION_002] Pharmacopoeia/Europe
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
application and any extensions or variations thereof.Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
Treatment(s) to be administered
application and any extensions or variations thereof.Treatment(s) to be administered
The IMP is to be administered in the clinic by [CONTACT_581604] 2 
application and any extensions or variations thereof.The IMP is to be administered in the clinic by [CONTACT_581604] 2 
areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
application and any extensions or variations thereof.areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
application and any extensions or variations thereof.visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
hould not be given into areas where the skin is tender, bruised, 
application and any extensions or variations thereof.hould not be given into areas where the skin is tender, bruised, 
The IMP (bimekizumab or CZP) will be administered at time points indicated in 
application and any extensions or variations thereof.The IMP (bimekizumab or CZP) will be administered at time points indicated in 
At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
application and any extensions or variations thereof.At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
CZP treatment arms and will receive IMP as shown in 
application and any extensions or variations thereof.CZP treatment arms and will receive IMP as shown in 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 43of 136Table 7 ‒1:Treatments administered
IMP Study period
Treatment Period Treatment Extension Period 
Bimekizumab 160mg sc Q2Wa320mg sc Q4W
CZP Loading doses of 400mg sc Q2W at Weeks 0, 2, 
and 4 followed by [CONTACT_18322] 200mg sc Q2W400mg sc Q4W
CZP=certolizumab pegol; IMP=investigational medicinal product, Q2W=every 2 weeks; Q4W=every 4 weeks; 
sc=subcutaneous
aIn addition, subjects will receive 1 placebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
blind vs the CZP loading dose at these visits.
The minimum time between doses should be no less than 10 days during the Treatment Period 
and no less than 22 days during the Treatment Extension Period. 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.
7.3 Packaging
Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
way as to protect the product from deterioration during transport and storage. Further information regarding storage and transport conditions are provided in the IMP Handling 
Manual.
7.4 Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be translated into the local language.
7.[ADDRESS_764656] be stored under refrigerated conditions (2ºC to 8ºC) protected from light. The IMP must not be frozen.
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_58951] a secured area with 
limited access according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensured either by [CONTACT_261497] (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temperature log in accordance with local requirements on a regular basis (eg, once a week), showing actual and minimum/maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately reported as per instruction s 
contained in the IMP Handling Manual.PUBLIC COPY Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
PUBLIC COPY Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
PUBLIC COPY (GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
way as to protect the product from deterioratio
PUBLIC COPY way as to protect the product from deterioratio n during transport and storage. Further 
PUBLIC COPY n during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
PUBLIC COPY information regarding storage and transport conditions are provided in the IMP Handling 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization CZP=certolizumab pegol; IMP=investigational medicinal product, Q2W=every 2 weeks; Q4W=every 4 weeks; 
This document cannot be used to support any marketing authorization CZP=certolizumab pegol; IMP=investigational medicinal product, Q2W=every 2 weeks; Q4W=every 4 weeks; 
acebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
This document cannot be used to support any marketing authorization acebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization days during the Treatment Period 
This document cannot be used to support any marketing authorization days during the Treatment Period 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
This document cannot be used to support any marketing authorization An IMP Handling Manual will be provided to each site containing instructions regarding drug 
Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
This document cannot be used to support any marketing authorization Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
This document cannot be used to support any marketing authorization (GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
n during transport and storage. Further 
This document cannot be used to support any marketing authorization n during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
This document cannot be used to support any marketing authorization information regarding storage and transport conditions are provided in the IMP Handling 
Clinical drug supplies will be labeled in accordance with the current International Council for 
This document cannot be used to support any marketing authorization Clinical drug supplies will be labeled in accordance with the current International Council for 
ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
This document cannot be used to support any marketing authorization ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be translated into the local language.
This document cannot be used to support any marketing authorization locally required statements. If necessary, labels will be translated into the local language.
Handling and storage requirements
This document cannot be used to support any marketing authorization Handling and storage requirements
Investigational Medicinal Product must be stored un
This document cannot be used to support any marketing authorization Investigational Medicinal Product must be stored un
protected from light. The IMP must not be frozen.
This document cannot be used to support any marketing authorization protected from light. The IMP must not be frozen.
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
This document cannot be used to support any marketing authorization The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_581605].
This document cannot be used to support any marketing authorization limited access according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensured either by [CONTACT_261497] (eg, room, 
This document cannot be used to support any marketing authorization Appropriate storage conditions must be ensured either by [CONTACT_261497] (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temperature 
This document cannot be used to support any marketing authorization refrigeration unit) or by [CONTACT_37142] a temperature 
on a regular basis (eg,
This document cannot be used to support any marketing authorization on a regular basis (eg,
reached over the time interval.
This document cannot be used to support any marketing authorization reached over the time interval.application and any extensions or variations thereof.acebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
application and any extensions or variations thereof.acebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
days during the Treatment Period 
application and any extensions or variations thereof.days during the Treatment Period 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
application and any extensions or variations thereof.An IMP Handling Manual will be provided to each site containing instructions regarding drug 
Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
application and any extensions or variations thereof.Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
application and any extensions or variations thereof.(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
n during transport and storage. Further 
application and any extensions or variations thereof.n during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
application and any extensions or variations thereof.information regarding storage and transport conditions are provided in the IMP Handling 
Clinical drug supplies will be labeled in accordance with the current International Council for 
application and any extensions or variations thereof.Clinical drug supplies will be labeled in accordance with the current International Council for 
ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
application and any extensions or variations thereof.ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be translated into the local language.
application and any extensions or variations thereof.locally required statements. If necessary, labels will be translated into the local language.
Handling and storage requirements
application and any extensions or variations thereof.Handling and storage requirements
Investigational Medicinal Product must be stored un
application and any extensions or variations thereof.Investigational Medicinal Product must be stored un
protected from light. The IMP must not be frozen.
application and any extensions or variations thereof.protected from light. The IMP must not be frozen.
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
application and any extensions or variations thereof.The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_581606].Investigational medicinal product stored by [CONTACT_581606].limited access according to the storage conditions mentioned on the label.
application and any extensions or variations thereof.limited access according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensured either by [CONTACT_261497] (eg, room, 
application and any extensions or variations thereof.Appropriate storage conditions must be ensured either by [CONTACT_261497] (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temperature application and any extensions or variations thereof.refrigeration unit) or by [CONTACT_37142] a temperature 
on a regular basis (eg,application and any extensions or variations thereof.on a regular basis (eg,
UCB [ADDRESS_764657], damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. All supplies and pharmacy documentation must be made available throughout the study for UCB (or designee) to review.
In order to maintain the blind, all IMP documentation (eg, shippi[INVESTIGATOR_18220], drug accountability 
logs, and interactive response technology [IRT] randomization materials) must be maintained and accessed by [CONTACT_58953], trained site personnel only. Designated, unblinded site personnel must be appropriately trained and licensed (per country guidelines) to administer injections.
The packaging identifies each kit by a unique number. Unblinded study staff will be responsible 
for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including recording the administration information on source document.
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_581525], regulations, and UCB standard operating procedures 
(SOPs). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
7.[ADDRESS_764658] be recorded on the Drug Accountability Form.
7.8 Concomitant medication(s)/treatment(s)
All concomitant medications, including over the counter products, herbal, traditional remedies, 
vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
recorded in the subject’s source documentation (eg, clinical chart) and on the electronic Case 
Report Form (eCRF). This record should include the name [CONTACT_18467], the dose, the route and date(s) of administration, and the indication for use.
The Investigator should examine the acceptability of all concomitant procedures, medications, 
topi[INVESTIGATOR_581526], and if necessary, discuss with the Medical Monitor.
In order to ensure that appropriate concomitant therapy is administered, subjects will be 
instructed to consult with the Investigator prior to taking any medication (either PUBLIC COPY The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
PUBLIC COPY The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
The Investigator must ensure that the IMP is us
PUBLIC COPY The Investigator must ensure that the IMP is us ed only in accordance with the protocol.
PUBLIC COPY ed only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
PUBLIC COPY Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_581527])/partially used, unused, damaged, and/or expi[INVESTIGATOR_581528], regulations, and UCB standard operating procedures 
PUBLIC COPY ing to local laws, regulations, and UCB standard operating procedures 
(SOPs). Investigational medicinal product intended for the study cannot be used for any other PUBLIC COPY (SOPs). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol. PUBLIC COPY purpose than that described in this protocol.
This document cannot be used to support any marketing authorization throughout the study for UCB 
This document cannot be used to support any marketing authorization throughout the study for UCB 
In order to maintain the blind, all IMP documentation (eg, shippi[INVESTIGATOR_18220], drug accountability 
This document cannot be used to support any marketing authorization In order to maintain the blind, all IMP documentation (eg, shippi[INVESTIGATOR_18220], drug accountability 
logs, and interactive response technology [IRT] randomization materials) must be maintained 
This document cannot be used to support any marketing authorization logs, and interactive response technology [IRT] randomization materials) must be maintained 
by [CONTACT_58953], trained site personnel only. Designated, unblinded site personnel 
This document cannot be used to support any marketing authorization by [CONTACT_58953], trained site personnel only. Designated, unblinded site personnel 
must be appropriately trained and licensed (per country guidelines) to administer injections.
This document cannot be used to support any marketing authorization must be appropriately trained and licensed (per country guidelines) to administer injections.
The packaging identifies each kit by a unique number. Unblinded study staff will 
This document cannot be used to support any marketing authorization The packaging identifies each kit by a unique number. Unblinded study staff will be responsible 
This document cannot be used to support any marketing authorization be responsible 
for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
This document cannot be used to support any marketing authorization for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
The Investigator (or designee) is responsible for retaining all used, unused, 
This document cannot be used to support any marketing authorization The Investigator (or designee) is responsible for retaining all used, unused, 
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
This document cannot be used to support any marketing authorization The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
ed only in accordance with the protocol.
This document cannot be used to support any marketing authorization ed only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
This document cannot be used to support any marketing authorization Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_581529])/partially used, unused, damaged, and/or expi[INVESTIGATOR_581528], regulations, and UCB standard operating procedures 
This document cannot be used to support any marketing authorization ing to local laws, regulations, and UCB standard operating procedures 
(SOPs). Investigational medicinal product intended for the study cannot be used for any other 
This document cannot be used to support any marketing authorization (SOPs). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
This document cannot be used to support any marketing authorization purpose than that described in this protocol.
Procedures for monitoring subject compliance
This document cannot be used to support any marketing authorization Procedures for monitoring subject compliance
uring theTreatment Period and the Treatment Extension Period, IMP will be administered in 
This document cannot be used to support any marketing authorization uring theTreatment Period and the Treatment Extension Period, IMP will be administered in 
the clinic and compliance will be determined at the visit by [CONTACT_3462]. Drug accountability 
This document cannot be used to support any marketing authorization the clinic and compliance will be determined at the visit by [CONTACT_3462]. Drug accountability 
must be recorded on the Drug Accountability Form.
This document cannot be used to support any marketing authorization must be recorded on the Drug Accountability Form.
Concomitant 
This document cannot be used to support any marketing authorization Concomitant 
All concomitant medications, including over the counter products, herbal, traditional remedies, 
This document cannot be used to support any marketing authorization All concomitant medications, including over the counter products, herbal, traditional remedies, 
vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
This document cannot be used to support any marketing authorization vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
recorded in the subject’s source docum
This document cannot be used to support any marketing authorization recorded in the subject’s source docum
Report Form (eCRF). This record should include the name [CONTACT_18467], the dose, the route and 
This document cannot be used to support any marketing authorization Report Form (eCRF). This record should include the name [CONTACT_18467], the dose, the route and 
date(s) of administration, and the indication for use.
This document cannot be used to support any marketing authorization date(s) of administration, and the indication for use.
The Investigator should examine the acceptability o
This document cannot be used to support any marketing authorization The Investigator should examine the acceptability o
topi[INVESTIGATOR_581526], and if 
This document cannot be used to support any marketing authorization topi[INVESTIGATOR_581526], and if application and any extensions or variations thereof.by [CONTACT_58953], trained site personnel only. Designated, unblinded site personnel 
application and any extensions or variations thereof.by [CONTACT_58953], trained site personnel only. Designated, unblinded site personnel 
must be appropriately trained and licensed (per country guidelines) to administer injections.
application and any extensions or variations thereof.must be appropriately trained and licensed (per country guidelines) to administer injections.
be responsible 
application and any extensions or variations thereof.be responsible 
for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
application and any extensions or variations thereof.for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
The Investigator (or designee) is responsible for retaining all used, unused, 
application and any extensions or variations thereof.The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
application and any extensions or variations thereof.and partially used 
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
application and any extensions or variations thereof.The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
ed only in accordance with the protocol.
application and any extensions or variations thereof.ed only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
application and any extensions or variations thereof.Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_581530].containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_581528], regulations, and UCB standard operating procedures 
application and any extensions or variations thereof.ing to local laws, regulations, and UCB standard operating procedures 
(SOPs). Investigational medicinal product intended for the study cannot be used for any other 
application and any extensions or variations thereof.(SOPs). Investigational medicinal product intended for the study cannot be used for any other 
Procedures for monitoring subject compliance
application and any extensions or variations thereof.Procedures for monitoring subject compliance
uring theTreatment Period and the Treatment Extension Period, IMP will be administered in 
application and any extensions or variations thereof.uring theTreatment Period and the Treatment Extension Period, IMP will be administered in 
the clinic and compliance will be determined at the visit by [CONTACT_3462]. Drug accountability 
application and any extensions or variations thereof.the clinic and compliance will be determined at the visit by [CONTACT_3462]. Drug accountability 
must be recorded on the Drug Accountability Form.
application and any extensions or variations thereof.must be recorded on the Drug Accountability Form.
Concomitant 
application and any extensions or variations thereof.Concomitant medication(s)/treatment(s)
application and any extensions or variations thereof.medication(s)/treatment(s)
All concomitant medications, including over the counter products, herbal, traditional remedies, 
application and any extensions or variations thereof.All concomitant medications, including over the counter products, herbal, traditional remedies, 
vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
application and any extensions or variations thereof.vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
recorded in the subject’s source docum
application and any extensions or variations thereof.recorded in the subject’s source docum
Report Form (eCRF). This record should include the name [CONTACT_18467], the dose, the route and 
application and any extensions or variations thereof.Report Form (eCRF). This record should include the name [CONTACT_18467], the dose, the route and 
date(s) of administration, and the indication for use.application and any extensions or variations thereof.date(s) of administration, and the indication for use.
The Investigator should examine the acceptability o application and any extensions or variations thereof.The Investigator should examine the acceptability o
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 45of 136self-administered non-prescription drugs or prescription therapy prescribed by [CONTACT_3213]).
7.8.1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:
Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:
Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after Week 12.
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following conditions:
No change in dose or dose regimen of these agents is allowed during the study except for 
reasons of intolerance/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No combinations of DMARDs are permitted during the study.
7.8.2 Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
The following concomitant medications are prohibited during the study:
Table 7 ‒2: Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class Dose Exclusion criteria
Analgesics, including opi[INVESTIGATOR_2467] 
(acetaminophen/paracetamol, etc)Any dose Any ad hoc use in the 24 hours prior to any study visit. 
Stable doses of analgesics permitted.
NSAIDs/COX-2 inhibitors Any dose regimen Any change in dose/dose regimen in the 
14days prior to the Baseline Visit
Oral corticosteroids Any dose regimen Any change in dose/dose regimen in the 
14days prior to the Baseline Visit
Intramuscular (im)/intravenous (iv)/
intra-articular (ia) corticosteroids/bursal 
corticosteroids Any dose Use in the 28 days prior to the Baseline 
Visit. PUBLIC COPY Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
PUBLIC COPY Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
No change in dose or dose regimen of these agents is allowed during the study except for 
PUBLIC COPY No change in dose or dose regimen of these agents is allowed during the study except for 
ce/AEs. No increase of the dose is permitted. No change is permitted in 
PUBLIC COPY ce/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
PUBLIC COPY the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
PUBLIC COPY recommended that subjects taking MTX are also taking folic acid supplements. No 
ARDs are permitted during the study.
PUBLIC COPY ARDs are permitted during the study.
Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])PUBLIC COPY Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
This document cannot be used to support any marketing authorization Subjects who are already receiving an established NSAID regimen and have been on a stable 
This document cannot be used to support any marketing authorization Subjects who are already receiving an established NSAID regimen and have been on a stable 
eline may continue their use during the study. However, 
This document cannot be used to support any marketing authorization eline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
This document cannot be used to support any marketing authorization initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
This document cannot be used to support any marketing authorization history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
subjects are permitted to 
This document cannot be used to support any marketing authorization subjects are permitted to 
/or alter their regimen only after 
This document cannot be used to support any marketing authorization /or alter their regimen only after 
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
This document cannot be used to support any marketing authorization Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
No change in dose or dose regimen of these agents is allowed during the study except for 
This document cannot be used to support any marketing authorization No change in dose or dose regimen of these agents is allowed during the study except for 
ce/AEs. No increase of the dose is permitted. No change is permitted in 
This document cannot be used to support any marketing authorization ce/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
This document cannot be used to support any marketing authorization the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
This document cannot be used to support any marketing authorization recommended that subjects taking MTX are also taking folic acid supplements. No 
ARDs are permitted during the study.
This document cannot be used to support any marketing authorization ARDs are permitted during the study.
Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
This document cannot be used to support any marketing authorization Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
The following concomitant medications are prohibited during the study:
This document cannot be used to support any marketing authorization The following concomitant medications are prohibited during the study:
Prohibited or restricted medications and required wash
This document cannot be used to support any marketing authorization Prohibited or restricted medications and required wash
prior to Baseline
This document cannot be used to support any marketing authorization prior to Baseline
This document cannot be used to support any marketing authorization Analgesics, including opi[INVESTIGATOR_581531], including opi[INVESTIGATOR_2467] 
(acetaminophen/paracetamol, etc)
This document cannot be used to support any marketing authorization (acetaminophen/paracetamol, etc)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization NSAIDs/COX
This document cannot be used to support any marketing authorization NSAIDs/COX -
This document cannot be used to support any marketing authorization -2 inhibitors
This document cannot be used to support any marketing authorization 2 inhibitors
This document cannot be used to support any marketing authorization Oral corticosteroids
This document cannot be used to support any marketing authorization Oral corticosteroids
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.subjects are permitted to 
application and any extensions or variations thereof.subjects are permitted to 
/or alter their regimen only after 
application and any extensions or variations thereof./or alter their regimen only after 
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
application and any extensions or variations thereof.Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
No change in dose or dose regimen of these agents is allowed during the study except for 
application and any extensions or variations thereof.No change in dose or dose regimen of these agents is allowed during the study except for 
ce/AEs. No increase of the dose is permitted. No change is permitted in 
application and any extensions or variations thereof.ce/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
application and any extensions or variations thereof.the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
application and any extensions or variations thereof.recommended that subjects taking MTX are also taking folic acid supplements. No 
ARDs are permitted during the study.
application and any extensions or variations thereof.ARDs are permitted during the study.
Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
application and any extensions or variations thereof.Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
The following concomitant medications are prohibited during the study:
application and any extensions or variations thereof.The following concomitant medications are prohibited during the study:
Prohibited or restricted medications and required wash
application and any extensions or variations thereof.Prohibited or restricted medications and required wash
prior to Baseline
application and any extensions or variations thereof.prior to Baseline
Dose
application and any extensions or variations thereof.Dose
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Analgesics, including opi[INVESTIGATOR_581532].Analgesics, including opi[INVESTIGATOR_2467] 
(acetaminophen/paracetamol, etc)
application and any extensions or variations thereof.(acetaminophen/paracetamol, etc)
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.2 inhibitors
application and any extensions or variations thereof.2 inhibitors
application and any extensions or variations thereof.Oral corticosteroids application and any extensions or variations thereof.Oral corticosteroids application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 46of 136Table 7 ‒2: Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class Dose Exclusion criteria
Intra -articular hyaluronic acid Any dose Any use in the 6 months prior to the 
Baseline Visit. 
DMARDs:-azathioprine-cyclosporine,
-cyclophosphamide,
-mycophenolic acid,-mycophenylate mofetil-any other small molecule DMARDs 
(eg tofacitinib, apremilast)Any dose Use within 12 weeks prior to the Baseline 
Visit.
MTX, SSZ, and HCQ Maximum allowed: SSZ ≤3g daily 
HCQ ≤400mg daily 
MTX ≤25mg weeklyUse initiated and/or any change in the dose 
regimen in the 28 days prior to the Baseline 
Visit. No change is permitted in the route of 
administration for MTX (im, sc, or oral) in 
the 28 days prior to the Baseline Visit.
DMARDs:-leflunomide Any dose Use in the 6 months prior to the Baseline Visit unless a cholestyramine washout has been performed; in which case, use up to 28days p rior to the Baseline Visit is 
acceptable. 
TNF inhibitors-infliximab (IFX)
-adalimumab (ADA)
-etanercept (ETN)-golimumab (GOL)-certolizumab pegol (CZP)Any dose For IFX, ADA, and GOL, any use within the 12 weeks prior to the Baseline Visit
For ETN, use within the 28 days prior to 
the Baseline Visit.
For CZP, any previous use
This applies to biosimilar versions of any 
TNF inhibitor s.
Any non -TNF biologic medications Any dose Any exposure history.
ADA=adalimumab; ia=intra -articular; COX -2=cyclooxyg enase 2; CZP=certolizumab pegol; 
DMARD=disease -modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
NSAID=nonsteroidal anti -inflammatory drug; sc=subcutaneo us; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
anti-depressant for 12 weeks prior to Baseline.PUBLIC COPY PUBLIC COPY Any dose
PUBLIC COPY Any dose
PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization 12 weeks prior to the Baseline 
This document cannot be used to support any marketing authorization 12 weeks prior to the Baseline 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Use initiated and/or any change in the dose 
This document cannot be used to support any marketing authorization Use initiated and/or any change in the dose 
regimen in the 28 days prior to the Baseline 
This document cannot be used to support any marketing authorization regimen in the 28 days prior to the Baseline 
Visit. No change is permitted in the route
This document cannot be used to support any marketing authorization Visit. No change is permitted in the route
administration for MTX (im, sc, or oral) in 
This document cannot be used to support any marketing authorization administration for MTX (im, sc, or oral) in 
the 28 days prior to the Baseline Visit.
This document cannot be used to support any marketing authorization the 28 days prior to the Baseline Visit.
This document cannot be used to support any marketing authorization Use in the 6 months prior to the Baseline 
This document cannot be used to support any marketing authorization Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has 
This document cannot be used to support any marketing authorization Visit unless a cholestyramine washout has 
been performed; in which case, use up to 
This document cannot be used to support any marketing authorization been performed; in which case, use up to 
28
This document cannot be used to support any marketing authorization 28
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization TNF biologic medications
This document cannot be used to support any marketing authorization TNF biologic medications
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ADA=adalimumab; ia=intra
This document cannot be used to support any marketing authorization ADA=adalimumab; ia=intra
DMARD=disease
This document cannot be used to support any marketing authorization DMARD=disease -
This document cannot be used to support any marketing authorization -modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
This document cannot be used to support any marketing authorization modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
This document cannot be used to support any marketing authorization HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
NSAID=nonsteroidal anti
This document cannot be used to support any marketing authorization NSAID=nonsteroidal anti
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
This document cannot be used to support any marketing authorization Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
anti
This document cannot be used to support any marketing authorization anti-
This document cannot be used to support any marketing authorization -depressant for 12 weeks prior to Baseline.
This document cannot be used to support any marketing authorization depressant for 12 weeks prior to Baseline.application and any extensions or variations thereof.application and any extensions or variations thereof.Use initiated and/or any change in the dose 
application and any extensions or variations thereof.Use initiated and/or any change in the dose 
regimen in the 28 days prior to the Baseline 
application and any extensions or variations thereof.regimen in the 28 days prior to the Baseline 
Visit. No change is permitted in the route
application and any extensions or variations thereof.Visit. No change is permitted in the route
administration for MTX (im, sc, or oral) in 
application and any extensions or variations thereof.administration for MTX (im, sc, or oral) in 
the 28 days prior to the Baseline Visit.
application and any extensions or variations thereof.the 28 days prior to the Baseline Visit.
application and any extensions or variations thereof.Use in the 6 months prior to the Baseline 
application and any extensions or variations thereof.Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has 
application and any extensions or variations thereof.Visit unless a cholestyramine washout has 
been performed; in which case, use up to 
application and any extensions or variations thereof.been performed; in which case, use up to 
28
application and any extensions or variations thereof.28days p
application and any extensions or variations thereof.days p rior to the Baseline Visit is 
application and any extensions or variations thereof.rior to the Baseline Visit is 
acceptable. 
application and any extensions or variations thereof.acceptable. 
application and any extensions or variations thereof.application and any extensions or variations thereof.For IFX, ADA, and GOL, any use within 
application and any extensions or variations thereof.For IFX, ADA, and GOL, any use within 
the 12 weeks prior to the Baseline Visit
application and any extensions or variations thereof.the 12 weeks prior to the Baseline Visit
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.TNF biologic medications
application and any extensions or variations thereof.TNF biologic medications
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.ADA=adalimumab; ia=intra
application and any extensions or variations thereof.ADA=adalimumab; ia=intra -
application and any extensions or variations thereof.-articular; 
application and any extensions or variations thereof.articular; 
modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
application and any extensions or variations thereof.modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
application and any extensions or variations thereof.HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
NSAID=nonsteroidal anti
application and any extensions or variations thereof.NSAID=nonsteroidal anti -
application and any extensions or variations thereof.-inflammatory drug; sc=subcutaneo
application and any extensions or variations thereof.inflammatory drug; sc=subcutaneo
application and any extensions or variations thereof.application and any extensions or variations thereof.Subjects who are receiving an established antidepressant regimen should be on a stable dose of application and any extensions or variations thereof.Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
depressant for 12 weeks prior to Baseline.application and any extensions or variations thereof. depressant for 12 weeks prior to Baseline.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 47of 136Subjects who take prohibited medications, except topi[INVESTIGATOR_12491], may be withdrawn from 
study treatment, but followed until the Safety Follow-Up Visit (20 weeks after the final dose of 
IMP). The decision to withdraw a subject for taking prohibited medications should be made in consultation with the Medical Monitor. As noted above, subjects who use prohibited topi[INVESTIGATOR_581533].
Vaccines
Administration of live, attenuated vaccines is not allowed during the conduct of the study or for 
20 weeks after the final dose of study drug. Subjects receiving BCG vaccinations within 
12 months prior to study drug administration are excluded (see Exclusion Criterion # 25,
Section 6.2).
7.8.3 Rescue medication
There are no absolute restrictions on the use of concomitant medications to “rescue” subjects whose AS deteriorates during the course of the study. While the objectives of the study should be protected as much as possible through observance of the restrictions detailed in Table 7‒2, the 
wellbeing of the subject will always take priority, and subjects should be managed as deemed appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be discussed with the Sponsor's Study Physician first, wherever possible.
7.9 Blinding
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Investigational medicinal product injections will be prepared at the investigational sites by 
[CONTACT_58953], dedicated study personnel. The unblinded personnel will not be involved in the study 
in any way other than assuring the medication is taken from the correct kit and prepared according to the pharmacy manual instructions, and administering the drug to the subjects.
During the study, the Sponsor will provide blinded and unblinded site monitors for the purpos es 
of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
study monitors and study site personnel, blinded to treatment assignment, will not discuss or have access to any study drug-related information.
Further details are provided in the study manuals and site blinding plan. 
7.9.[ADDRESS_764659].PUBLIC COPY appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be 
PUBLIC COPY appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be 
discussed with the Sponsor's Study Physician first, wherever possible.
PUBLIC COPY discussed with the Sponsor's Study Physician first, wherever possible.
es in presentation of the IMPs (bimekizumab and CZP), special precautions will 
PUBLIC COPY es in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
PUBLIC COPY be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the
PUBLIC COPY Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the
Investigational medicinal product injections will be prepared at the investigational sites by [CONTACT_581607], dedicated study personnel. The unblinded personnel will not be involved in the study PUBLIC COPY unblinded, dedicated study personnel. The unblinded personnel will not be involved in the study 
This document cannot be used to support any marketing authorization Administration of live, attenuated vaccines is not allowed during the conduct of the study or
This document cannot be used to support any marketing authorization Administration of live, attenuated vaccines is not allowed during the conduct of the study or for 
This document cannot be used to support any marketing authorization for 
25
This document cannot be used to support any marketing authorization 25,
This document cannot be used to support any marketing authorization ,
There are no absolute restrictions on the use of concomitant medications to “rescue” subjects 
This document cannot be used to support any marketing authorization There are no absolute restrictions on the use of concomitant medications to “rescue” subjects 
whose AS deteriorates during the course of the study. While the objectives of
This document cannot be used to support any marketing authorization whose AS deteriorates during the course of the study. While the objectives of the study should be 
This document cannot be used to support any marketing authorization the study should be 
protected as much as possible through observance of the restrictions detailed in 
This document cannot be used to support any marketing authorization protected as much as possible through observance of the restrictions detailed in 
ys take priority, and subjects should be managed as deemed 
This document cannot be used to support any marketing authorization ys take priority, and subjects should be managed as deemed 
appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be 
This document cannot be used to support any marketing authorization appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be 
discussed with the Sponsor's Study Physician first, wherever possible.
This document cannot be used to support any marketing authorization discussed with the Sponsor's Study Physician first, wherever possible.
es in presentation of the IMPs (bimekizumab and CZP), special precautions will 
This document cannot be used to support any marketing authorization es in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
This document cannot be used to support any marketing authorization be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the
This document cannot be used to support any marketing authorization Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the
Investigational medicinal product injections will be prepared at the investigational sites by 
[CONTACT_581608], dedicated study personnel. The unblinded personnel will not be involved in the study 
This document cannot be used to support any marketing authorization unblinded, dedicated study personnel. The unblinded personnel will not be involved in the study 
than assuring the medication is taken from the correct kit and prepared 
This document cannot be used to support any marketing authorization than assuring the medication is taken from the correct kit and prepared 
according to the pharmacy manual instructions, and administering the drug to the subjects.
This document cannot be used to support any marketing authorization according to the pharmacy manual instructions, and administering the drug to the subjects.
During the study, the Sponsor will provide blinded and unblinded site monitors for the purpos
This document cannot be used to support any marketing authorization During the study, the Sponsor will provide blinded and unblinded site monitors for the purpos
This document cannot be used to support any marketing authorization of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
This document cannot be used to support any marketing authorization of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
study monitors and study site personnel, blinded to treatment assignment, will not discuss or 
This document cannot be used to support any marketing authorization study monitors and study site personnel, blinded to treatment assignment, will not discuss or 
have access to any study drug
This document cannot be used to support any marketing authorization have access to any study drug
ils are provided in the study manuals and site blinding plan. 
This document cannot be used to support any marketing authorization ils are provided in the study manuals and site blinding plan. 
Procedures for maintaining and breaking the treatment blind
This document cannot be used to support any marketing authorization Procedures for maintaining and breaking the treatment blind
The IMP handling manual describes the handling of bimekizumab and CZP. Appropriate training 
This document cannot be used to support any marketing authorization The IMP handling manual describes the handling of bimekizumab and CZP. Appropriate training 
will be given to the site personnel to av
This document cannot be used to support any marketing authorization will be given to the site personnel to av
unblinded for any subject, another assessor will perform the remaining evaluations for that 
This document cannot be used to support any marketing authorization unblinded for any subject, another assessor will perform the remaining evaluations for that 
subject.
This document cannot be used to support any marketing authorization subject.application and any extensions or variations thereof.There are no absolute restrictions on the use of concomitant medications to “rescue” subjects 
application and any extensions or variations thereof.There are no absolute restrictions on the use of concomitant medications to “rescue” subjects 
the study should be 
application and any extensions or variations thereof.the study should be 
protected as much as possible through observance of the restrictions detailed in 
application and any extensions or variations thereof.protected as much as possible through observance of the restrictions detailed in Table
application and any extensions or variations thereof.Table 7
application and any extensions or variations thereof.7
ys take priority, and subjects should be managed as deemed 
application and any extensions or variations thereof.ys take priority, and subjects should be managed as deemed 
appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be 
application and any extensions or variations thereof.appropriate by [CONTACT_737]. If use of any prohibited medications is anticipated, this should be 
discussed with the Sponsor's Study Physician first, wherever possible.
application and any extensions or variations thereof.discussed with the Sponsor's Study Physician first, wherever possible.
es in presentation of the IMPs (bimekizumab and CZP), special precautions will 
application and any extensions or variations thereof.es in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
application and any extensions or variations thereof.be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the
application and any extensions or variations thereof.Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the
Investigational medicinal product injections will be prepared at the investigational sites by 
[INVESTIGATOR_581504].Investigational medicinal product injections will be prepared at the investigational sites by 
[CONTACT_58953], dedicated study personnel. The unblinded personnel will not be involved in the study 
application and any extensions or variations thereof.unblinded, dedicated study personnel. The unblinded personnel will not be involved in the study 
than assuring the medication is taken from the correct kit and prepared 
application and any extensions or variations thereof.than assuring the medication is taken from the correct kit and prepared 
according to the pharmacy manual instructions, and administering the drug to the subjects.
application and any extensions or variations thereof.according to the pharmacy manual instructions, and administering the drug to the subjects.
During the study, the Sponsor will provide blinded and unblinded site monitors for the purpos
application and any extensions or variations thereof.During the study, the Sponsor will provide blinded and unblinded site monitors for the purpos
application and any extensions or variations thereof.of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
application and any extensions or variations thereof.of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
study monitors and study site personnel, blinded to treatment assignment, will not discuss or 
application and any extensions or variations thereof.study monitors and study site personnel, blinded to treatment assignment, will not discuss or 
have access to any study drug
application and any extensions or variations thereof.have access to any study drug -
application and any extensions or variations thereof.-related information.
application and any extensions or variations thereof.related information.
ils are provided in the study manuals and site blinding plan. 
application and any extensions or variations thereof.ils are provided in the study manuals and site blinding plan. 
Procedures for maintaining and breaking the treatment blind
application and any extensions or variations thereof.Procedures for maintaining and breaking the treatment blind
The IMP handling manual describes the handling of bimekizumab and CZP. Appropriate training 
application and any extensions or variations thereof.The IMP handling manual describes the handling of bimekizumab and CZP. Appropriate training 
will be given to the site personnel to avapplication and any extensions or variations thereof.will be given to the site personnel to av
unblinded for any subject, another assessor will perform the remaining evaluations for that application and any extensions or variations thereof. unblinded for any subject, another assessor will perform the remaining evaluations for that 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 48of 136All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP (bimekizumab or CZP) assignment with the following exceptions:
Sponsor Clinical Study Supplies manager and qualified personnel
Sponsor Patient Safety (PS) staff reporting SAEs to the regulatory authorities
Site pharmacist involved in IMP preparation and dispensing
Unblinded monitor who reviews the IMP related documentation and drug accountability
Bioanalytical staff analyzing blood samples for PK and immunogenicity, and biomarkers
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
team.
Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
interim analyses
If necessary, the results of any planned analysis may be shared with key Sponsor’s personnel in order to facilitate additional Clinical Planning or Portfolio Management decisions. Only unblinded summary results will be provided, and individual subject data will be kept blinded. All individuals seeing unblinded summary data will be documented in the Trial Master File (TMF).
[IP_ADDRESS] Maintenance of study treatment blind
All subject treatment details (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581609] (IRT) system.
[IP_ADDRESS] Breaking the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the subject has been allocated by [CONTACT_352237]. All sites will be provided with details of 
how to contact [CONTACT_58958]. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.
The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
is broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by [CONTACT_581610].
7.10 Randomization and numbering of subjects
An IRT will be used for assigning eligible subjects to a treatment regimen (as applicable) based on a predetermined production randomization and/or packaging schedule provided by [CONTACT_18338] (or 
designee). The randomization schedule will be produced by [CONTACT_352240]. The IRT will 
genera te individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. To enroll a subject at Visit 1, the Investigator or designee will contact [CONTACT_581611]. Each subject will receive a 5-digit number 
assigned at screening that serves as the subject identifier throughout the study. The subject number will be required in all communication between the Investigator or designee and the IRT regarding a particular subject. Subject numbers and kit numbers will be tracked via the IRT. PUBLIC COPY order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
PUBLIC COPY order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
unblinded summary results will be provided, and individual subject data will be kept blinded. All 
PUBLIC COPY unblinded summary results will be provided, and individual subject data will be kept blinded. All 
g unblinded summary data will be documented in the Trial Master File (TMF).
PUBLIC COPY g unblinded summary data will be documented in the Trial Master File (TMF).
Maintenance of study treatment blind
PUBLIC COPY Maintenance of study treatment blind
All subject treatment details (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581612] (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581609] (IRT) system.
PUBLIC COPY interactive response technology (IRT) system.
ng the treatment blind in an emergency situation
PUBLIC COPY ng the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose PUBLIC COPY In the event of an emergency, it will be possible to determine to which treatment arm and dose 
This document cannot be used to support any marketing authorization Unblinded monitor who reviews the IMP related documentation and drug accountability
This document cannot be used to support any marketing authorization Unblinded monitor who reviews the IMP related documentation and drug accountability
Bioanalytical staff analyzing blood samples for PK and immunogenicity, and biomarkers
This document cannot be used to support any marketing authorization Bioanalytical staff analyzing blood samples for PK and immunogenicity, and biomarkers
the unblinded 
This document cannot be used to support any marketing authorization the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
This document cannot be used to support any marketing authorization DMC and interim analyses. These individuals will be separate from the main blinded study 
Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
This document cannot be used to support any marketing authorization Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
lysis may be shared with key Sponsor’s personnel in 
This document cannot be used to support any marketing authorization lysis may be shared with key Sponsor’s personnel in 
order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
This document cannot be used to support any marketing authorization order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
unblinded summary results will be provided, and individual subject data will be kept blinded. All 
This document cannot be used to support any marketing authorization unblinded summary results will be provided, and individual subject data will be kept blinded. All 
g unblinded summary data will be documented in the Trial Master File (TMF).
This document cannot be used to support any marketing authorization g unblinded summary data will be documented in the Trial Master File (TMF).
Maintenance of study treatment blind
This document cannot be used to support any marketing authorization Maintenance of study treatment blind
All subject treatment details (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581613] (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581609] (IRT) system.
This document cannot be used to support any marketing authorization interactive response technology (IRT) system.
ng the treatment blind in an emergency situation
This document cannot be used to support any marketing authorization ng the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
This document cannot be used to support any marketing authorization In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the subject has been allocated by [CONTACT_352237]. All sites will be provided with details of 
This document cannot be used to support any marketing authorization the subject has been allocated by [CONTACT_352237]. All sites will be provided with details of 
the system for code breaking at the start of the study. The Medical Monitor or 
This document cannot be used to support any marketing authorization the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.
This document cannot be used to support any marketing authorization equivalent should be consulted prior to unblinding, whenever possible.
The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
This document cannot be used to support any marketing authorization The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
will remain blinded to specific treatment information. Any unblinding of the IMP 
This document cannot be used to support any marketing authorization will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by [CONTACT_581614].
This document cannot be used to support any marketing authorization Termination eCRF page.
Randomization and numbering of subjects
This document cannot be used to support any marketing authorization Randomization and numbering of subjects
An IRT will be used for 
This document cannot be used to support any marketing authorization An IRT will be used for 
This document cannot be used to support any marketing authorization on a predetermined production randomization and/or packaging schedule provided by [CONTACT_18338] (or 
This document cannot be used to support any marketing authorization on a predetermined production randomization and/or packaging schedule provided by [CONTACT_18338] (or 
designee). The randomization schedule will be produced by [CONTACT_352240]. The IRT will 
This document cannot be used to support any marketing authorization designee). The randomization schedule will be produced by [CONTACT_352240]. The IRT will 
genera
This document cannot be used to support any marketing authorization genera te individual assignments for subject kits of IMP, as appropriate, according to the visit 
This document cannot be used to support any marketing authorization te individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. To enroll a subject at Visit 1, the Investigator or designee will contact [CONTACT_581615]. To enroll a subject at Visit 1, the Investigator or designee will contact [CONTACT_581611]. Each subject w
This document cannot be used to support any marketing authorization provide brief details about the subject to be enrolled. Each subject wapplication and any extensions or variations thereof.the unblinded 
application and any extensions or variations thereof.the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
application and any extensions or variations thereof.DMC and interim analyses. These individuals will be separate from the main blinded study 
Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
application and any extensions or variations thereof.Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
lysis may be shared with key Sponsor’s personnel in 
application and any extensions or variations thereof.lysis may be shared with key Sponsor’s personnel in 
order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
application and any extensions or variations thereof.order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
unblinded summary results will be provided, and individual subject data will be kept blinded. All 
application and any extensions or variations thereof.unblinded summary results will be provided, and individual subject data will be kept blinded. All 
g unblinded summary data will be documented in the Trial Master File (TMF).
application and any extensions or variations thereof.g unblinded summary data will be documented in the Trial Master File (TMF).
All subject treatment details (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581616].All subject treatment details (bimekizumab or CZP) will be allocated and maintained by [CONTACT_581617].ng the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
application and any extensions or variations thereof.In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the subject has been allocated by [CONTACT_352237]. All sites will be provided with details of 
application and any extensions or variations thereof.the subject has been allocated by [CONTACT_352237]. All sites will be provided with details of 
the system for code breaking at the start of the study. The Medical Monitor or 
application and any extensions or variations thereof.the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.
application and any extensions or variations thereof.equivalent should be consulted prior to unblinding, whenever possible.
The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
application and any extensions or variations thereof.The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
will remain blinded to specific treatment information. Any unblinding of the IMP 
application and any extensions or variations thereof.will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by [CONTACT_581618].performed by [CONTACT_352239].
application and any extensions or variations thereof.Termination eCRF page.
Randomization and numbering of subjects
application and any extensions or variations thereof.Randomization and numbering of subjects
An IRT will be used for 
application and any extensions or variations thereof.An IRT will be used for 
application and any extensions or variations thereof.assigning eligible subjects to a treatment regimen (as applicable) based 
application and any extensions or variations thereof.assigning eligible subjects to a treatment regimen (as applicable) based 
on a predetermined production randomization and/or packaging schedule provided by [CONTACT_18338] (or 
application and any extensions or variations thereof.on a predetermined production randomization and/or packaging schedule provided by [CONTACT_18338] (or 
designee). The randomization schedule will be produced by [CONTACT_352240]. The IRT will application and any extensions or variations thereof.designee). The randomization schedule will be produced by [CONTACT_352240]. The IRT will 
te individual assignments for subject kits of IMP, as appropriate, according to the visit application and any extensions or variations thereof. te individual assignments for subject kits of IMP, as appropriate, according to the visit 
UCB [ADDRESS_764660]’s randomization number. The IRT will allocate kit numbers to the subject based on the subject number during the course of the study. The randomization number must be incorporated into the eCRF.
8 STUDY PROCEDURES BY [CONTACT_581619] ( Table 5‒1) provides a general overview of study 
assessments. A list of procedures to be completed at each visit is described below.
Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3-day window must be discussed with the Medical Monitor.
For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
3 days prior to the scheduled visit date and within 7 days after the scheduled visit date (-3days to+7days).
8.1 Screening Visit (Visit 1)
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by [CONTACT_58963]/IRB, and that complies with regulatory requirements. 
Subjects will be given adequate time to consider any information concerning the study given to them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
given the opportunity to ask the Investigator any questions regarding potential risks and benefits 
of participation in the study.
Two additional ICFs for substudies will be required:
Where local regulations permit, subjects will also be given the option to participate in the 
pharmacogenetic and pharmacogenomic substudy. Subjects agreeing to participate in the 
substudy will be required to complete a separate ICF. The ICF must be signed prior to 
collecting any samples for the substudy. The substudy will only be conducted where ethically accepted and authorized by [CONTACT_397149]. Refusal to participate in the substudy 
will not affect a subject’s ability to participate in the main AS0013 study.
Subjects will also be given the option to participate in the PET-MRI or PET-CT substudy at 
selected sites. Subjects who decide to participate in the substudy will need to complete a separate ICF following the same procedure and given the same considerations as the main 
ICF. Their willingness to participate in the substudy will be independent from their consent 
to participate in the main AS0013 study.
The following procedures or assessments will be performed at the Screening Visit:
Obtain written informed consent. 
Collect demographic and Baseline characteristics data (including lifestyle and child bearing 
potential as applicable).
Collect AS history. PUBLIC COPY Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
PUBLIC COPY Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by [CONTACT_58963]/IRB, and that complies with
PUBLIC COPY been approved by [CONTACT_58963]/IRB, and that complies with
Subjects will be given adequate time to consider any information concerning the study given to 
PUBLIC COPY Subjects will be given adequate time to consider any information concerning the study given to 
them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
PUBLIC COPY them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
given the opportunity to ask the Inve
PUBLIC COPY given the opportunity to ask the Inve stigator any questions regarding potential risks and benefits 
PUBLIC COPY stigator any questions regarding potential risks and benefits 
Two additional ICFs for substudies will be required: PUBLIC COPY Two additional ICFs for substudies will be required:
This document cannot be used to support any marketing authorization Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
This document cannot be used to support any marketing authorization Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
This document cannot be used to support any marketing authorization Investigator should try to keep the subjects on the original dosing schedule. The window of 
isits. Changes to the dosing 
This document cannot be used to support any marketing authorization isits. Changes to the dosing 
day window must be discussed with the Medical Monitor.
This document cannot be used to support any marketing authorization day window must be discussed with the Medical Monitor.
For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
This document cannot be used to support any marketing authorization For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
7 days after the scheduled visit date 
This document cannot be used to support any marketing authorization 7 days after the scheduled visit date 
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
This document cannot be used to support any marketing authorization Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by [CONTACT_58963]/IRB, and that complies with
This document cannot be used to support any marketing authorization been approved by [CONTACT_58963]/IRB, and that complies with
Subjects will be given adequate time to consider any information concerning the study given to 
This document cannot be used to support any marketing authorization Subjects will be given adequate time to consider any information concerning the study given to 
them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
This document cannot be used to support any marketing authorization them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
stigator any questions regarding potential risks and benefits 
This document cannot be used to support any marketing authorization stigator any questions regarding potential risks and benefits 
Two additional ICFs for substudies will be required:
This document cannot be used to support any marketing authorization Two additional ICFs for substudies will be required:
Where local regulations permit, subjects will also be given the option to participate in the 
This document cannot be used to support any marketing authorization Where local regulations permit, subjects will also be given the option to participate in the 
nd pharmacogenomic substudy. Subjects agreeing to participate in the 
This document cannot be used to support any marketing authorization nd pharmacogenomic substudy. Subjects agreeing to participate in the 
substudy will be required to complete a separate ICF. The ICF must be signed prior to 
This document cannot be used to support any marketing authorization substudy will be required to complete a separate ICF. The ICF must be signed prior to 
collecting any samples for the substudy. The substudy will only be conducted where ethically 
This document cannot be used to support any marketing authorization collecting any samples for the substudy. The substudy will only be conducted where ethically 
and authorized by [CONTACT_397149]. Refusal to participate in the substudy 
This document cannot be used to support any marketing authorization and authorized by [CONTACT_397149]. Refusal to participate in the substudy 
will not affect a subject’s ability to participate in the main AS0013 study.
This document cannot be used to support any marketing authorization will not affect a subject’s ability to participate in the main AS0013 study.
Subjects will also be given the option to participate in the PET
This document cannot be used to support any marketing authorization Subjects will also be given the option to participate in the PET
ted sites. Subjects who decide to participate in the substudy will need to complete a 
This document cannot be used to support any marketing authorization ted sites. Subjects who decide to participate in the substudy will need to complete a 
separate ICF following the same procedure and given the same considerations as the main 
This document cannot be used to support any marketing authorization separate ICF following the same procedure and given the same considerations as the main 
This document cannot be used to support any marketing authorization ICF. Their willingness to participate in the substudy will be independent from the
This document cannot be used to support any marketing authorization ICF. Their willingness to participate in the substudy will be independent from the
to participate in the main AS0013 study.
This document cannot be used to support any marketing authorization to participate in the main AS0013 study.
The following procedures or assessments will be performed at the Screening Visit:
This document cannot be used to support any marketing authorization The following procedures or assessments will be performed at the Screening Visit:

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
application and any extensions or variations thereof.Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
application and any extensions or variations thereof.Investigator should try to keep the subjects on the original dosing schedule. The window of 
isits. Changes to the dosing 
application and any extensions or variations thereof.isits. Changes to the dosing 
day window must be discussed with the Medical Monitor.
application and any extensions or variations thereof.day window must be discussed with the Medical Monitor.
For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
application and any extensions or variations thereof.For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
7 days after the scheduled visit date 
application and any extensions or variations thereof.7 days after the scheduled visit date 
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
application and any extensions or variations thereof.Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by [CONTACT_58963]/IRB, and that complies with
application and any extensions or variations thereof.been approved by [CONTACT_58963]/IRB, and that complies with
Subjects will be given adequate time to consider any information concerning the study given to 
application and any extensions or variations thereof.Subjects will be given adequate time to consider any information concerning the study given to 
them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
application and any extensions or variations thereof.them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be 
stigator any questions regarding potential risks and benefits 
application and any extensions or variations thereof.stigator any questions regarding potential risks and benefits 
Two additional ICFs for substudies will be required:
application and any extensions or variations thereof.Two additional ICFs for substudies will be required:
Where local regulations permit, subjects will also be given the option to participate in the 
application and any extensions or variations thereof.Where local regulations permit, subjects will also be given the option to participate in the 
nd pharmacogenomic substudy. Subjects agreeing to participate in the 
application and any extensions or variations thereof.nd pharmacogenomic substudy. Subjects agreeing to participate in the 
substudy will be required to complete a separate ICF. The ICF must be signed prior to 
application and any extensions or variations thereof.substudy will be required to complete a separate ICF. The ICF must be signed prior to 
collecting any samples for the substudy. The substudy will only be conducted where ethically 
application and any extensions or variations thereof.collecting any samples for the substudy. The substudy will only be conducted where ethically 
and authorized by [CONTACT_397149]. Refusal to participate in the substudy 
application and any extensions or variations thereof.and authorized by [CONTACT_397149]. Refusal to participate in the substudy 
will not affect a subject’s ability to participate in the main AS0013 study.
application and any extensions or variations thereof.will not affect a subject’s ability to participate in the main AS0013 study.
Subjects will also be given the option to participate in the PET
application and any extensions or variations thereof.Subjects will also be given the option to participate in the PET
ted sites. Subjects who decide to participate in the substudy will need to complete a 
application and any extensions or variations thereof.ted sites. Subjects who decide to participate in the substudy will need to complete a 
separate ICF following the same procedure and given the same considerations as the main 
application and any extensions or variations thereof.separate ICF following the same procedure and given the same considerations as the main 
application and any extensions or variations thereof.ICF. Their willingness to participate in the substudy will be independent from the
application and any extensions or variations thereof.ICF. Their willingness to participate in the substudy will be independent from the
to participate in the main AS0013 study.
application and any extensions or variations thereof.to participate in the main AS0013 study.
The following procedures or assessments will be performed at the Screening Visit: application and any extensions or variations thereof.The following procedures or assessments will be performed at the Screening Visit:
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 50of 136Assess if all inclusion criteria and no exclusion criteria are met.
Collect significant past medical history and concomitant diseases.
Record prior and concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the Bath Ankylosing Spondylitis Functional Index (BASFI).
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB, weight and height.
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Administer the tuberculosis questionnaire.
Perform an IGRA tuberculosis test (QuantiFERON TB test).
Perform a serum pregnancy test.
Collect samples for hematology/biochemistry/urinalysis.
Collect samples for hs- CRP.
Collect samples for HIV, hepatitis B and C, and HLA-B27 serology. 
Perform a sacroiliac joint X-ray (if subjects have a previous X-ray documenting AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by 
[CONTACT_18014]. If no X-ray is available one must be performed at the Screening Visit. If the 
previous X-ray is more than 1 year old, and central read criteria for randomization are not 
met, another X-ray may be performed if permitted by [CONTACT_13144]).
Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 2 weeks prior to Baseline.
Obtain a chest radiograph or computer tomography (CT) scan, unless one has been obtained 
within 3 months prior to the Screening Visit.
Register the subject using the interactive response technology (IRT).
Individual screening tests for which the results are borderline for inclusion in the study may be 
repeated if necessary without complete rescreening of all tests.PUBLIC COPY Perform an IGRA tuberculosis test (QuantiFERON TB test).
PUBLIC COPY Perform an IGRA tuberculosis test (QuantiFERON TB test).
ples for hematology/biochemistry/urinalysis.
PUBLIC COPY ples for hematology/biochemistry/urinalysis.
CRP.PUBLIC COPY CRP.
Collect samples for HIV, hepatitis B and C, and HLA PUBLIC COPY Collect samples for HIV, hepatitis B and C, and HLA
This document cannot be used to support any marketing authorization Perform a physical examination, including an evaluation for signs and symptoms of active 
This document cannot be used to support any marketing authorization Perform a physical examination, including an evaluation for signs and symptoms of active 
Perform an IGRA tuberculosis test (QuantiFERON TB test).
This document cannot be used to support any marketing authorization Perform an IGRA tuberculosis test (QuantiFERON TB test).
ples for hematology/biochemistry/urinalysis.
This document cannot be used to support any marketing authorization ples for hematology/biochemistry/urinalysis.
Collect samples for HIV, hepatitis B and C, and HLA
This document cannot be used to support any marketing authorization Collect samples for HIV, hepatitis B and C, and HLA
Perform a sacroiliac joint X
This document cannot be used to support any marketing authorization Perform a sacroiliac joint X -
This document cannot be used to support any marketing authorization -ray (if subjects have a previous X
This document cannot be used to support any marketing authorization ray (if subjects have a previous X
they are eligible for study entry after reconfirming their eligibility by 
[CONTACT_581620]. If no X
This document cannot be used to support any marketing authorization central reading. If no X -
This document cannot be used to support any marketing authorization -ray is available one must be performed at the Screening Visit. If the 
This document cannot be used to support any marketing authorization ray is available one must be performed at the Screening Visit. If the 
ray is more than 1 year old, and central read criteria for randomization are
This document cannot be used to support any marketing authorization ray is more than 1 year old, and central read criteria for randomization are
ray may be performed if permitted by [CONTACT_13144]).
This document cannot be used to support any marketing authorization ray may be performed if permitted by [CONTACT_13144]).
Perform a PET
This document cannot be used to support any marketing authorization Perform a PET -
This document cannot be used to support any marketing authorization -
This document cannot be used to support any marketing authorization MRI or PET
This document cannot be used to support any marketing authorization MRI or PET
weeks prior to Baseline.
This document cannot be used to support any marketing authorization weeks prior to Baseline.
Obtain a chest radiograph or computer tomography (CT) scan, unless
This document cannot be used to support any marketing authorization Obtain a chest radiograph or computer tomography (CT) scan, unless
within [ADDRESS_764661] using the interactive response technology (IRT).
This document cannot be used to support any marketing authorization Register the subject using the interactive response technology (IRT).
Individual screening tests for which the results are borderline for inclusion in the study may be 
This document cannot be used to support any marketing authorization Individual screening tests for which the results are borderline for inclusion in the study may be 
repeated if necessa
This document cannot be used to support any marketing authorization repeated if necessaapplication and any extensions or variations thereof.Perform a physical examination, including an evaluation for signs and symptoms of active 
application and any extensions or variations thereof.Perform a physical examination, including an evaluation for signs and symptoms of active 
Perform an IGRA tuberculosis test (QuantiFERON TB test).
application and any extensions or variations thereof.Perform an IGRA tuberculosis test (QuantiFERON TB test).
ples for hematology/biochemistry/urinalysis.
application and any extensions or variations thereof.ples for hematology/biochemistry/urinalysis.
Collect samples for HIV, hepatitis B and C, and HLA
application and any extensions or variations thereof.Collect samples for HIV, hepatitis B and C, and HLA
ray (if subjects have a previous X
application and any extensions or variations thereof.ray (if subjects have a previous X
they are eligible for study entry after reconfirming their eligibility by 
[INVESTIGATOR_581504].they are eligible for study entry after reconfirming their eligibility by 
[CONTACT_581621]. If the 
application and any extensions or variations thereof.ray is available one must be performed at the Screening Visit. If the 
ray is more than 1 year old, and central read criteria for randomization are
application and any extensions or variations thereof.ray is more than 1 year old, and central read criteria for randomization are
ray may be performed if permitted by [CONTACT_13144]).
application and any extensions or variations thereof.ray may be performed if permitted by [CONTACT_13144]).
application and any extensions or variations thereof.MRI or PET
application and any extensions or variations thereof.MRI or PET
weeks prior to Baseline.
application and any extensions or variations thereof.weeks prior to Baseline.
Obtain a chest radiograph or computer tomography (CT) scan, unless
application and any extensions or variations thereof.Obtain a chest radiograph or computer tomography (CT) scan, unless
within [ADDRESS_764662] using the interactive response technology (IRT).application and any extensions or variations thereof.Register the subject using the interactive response technology (IRT).
Individual screening tests for which the results are borderline for inclusion in the study may be application and any extensions or variations thereof.Individual screening tests for which the results are borderline for inclusion in the study may be 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 51of 1368.2 Baseline (Visit 2, Week 0)
The following procedures or assessments will be performed/recorded prior to administration of 
the IMP:
Verify if all inclusion criteria and no exclusion criteria are met.
Verify significant past medical history and concomitant diseases.
Record prior and concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.
Perform the Patient’s Global Assessment of Disease Activity (PGADA).
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Perform a 12-lead ECG.
Perform a urine pregnancy test.
Collect samples for: 
Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
Anti-bimekizumab and anti-CZP antibody detection.
hs-CRP.
If the respective ICF has been provided collect blood samples for: Cytokines, complement, and biomarker analyses 
Pharmacogenetic variables.
Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided.
Contact [CONTACT_581622].
Administer IMP after all other visit assessments are completed.
Record visit in the IRT.PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at [ADDRESS_764663].
This document cannot be used to support any marketing authorization (PGADA).
This document cannot be used to support any marketing authorization (PGADA).
Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
Hematology/biochemistry/urinalysis.
This document cannot be used to support any marketing authorization Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
This document cannot be used to support any marketing authorization Bimekizumab and CZP plasma concentrations.
bimekizumab and anti
This document cannot be used to support any marketing authorization bimekizumab and anti
If the respective ICF has been provided collect blood samples for: 
This document cannot be used to support any marketing authorization If the respective ICF has been provided collect blood samples for: 
Cytokines, complement, and biomarker a
This document cannot be used to support any marketing authorization Cytokines, complement, and biomarker a
This document cannot be used to support any marketing authorization Pharmacogenetic variables.
This document cannot be used to support any marketing authorization Pharmacogenetic variables.

This document cannot be used to support any marketing authorization Nonhereditary pharmacogenomic variables.
This document cannot be used to support any marketing authorization Nonhereditary pharmacogenomic variables.

This document cannot be used to support any marketing authorization Collect urine samples for biomarker research if the respective ICF has been provided.
This document cannot be used to support any marketing authorization Collect urine samples for biomarker research if the respective ICF has been provided.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.(PGADA).
application and any extensions or variations thereof.(PGADA).
Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
Hematology/biochemistry/urinalysis.
application and any extensions or variations thereof.Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
application and any extensions or variations thereof.Bimekizumab and CZP plasma concentrations.
bimekizumab and anti
application and any extensions or variations thereof.bimekizumab and anti -
application and any extensions or variations thereof.-CZP antibody detection.
application and any extensions or variations thereof.CZP antibody detection.
If the respective ICF has been provided collect blood samples for: 
application and any extensions or variations thereof.If the respective ICF has been provided collect blood samples for: 
Cytokines, complement, and biomarker a
application and any extensions or variations thereof.Cytokines, complement, and biomarker a
application and any extensions or variations thereof.Pharmacogenetic variables.
application and any extensions or variations thereof.Pharmacogenetic variables.
Nonhereditary pharmacogenomic variables.
application and any extensions or variations thereof.Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided.application and any extensions or variations thereof. Collect urine samples for biomarker research if the respective ICF has been provided.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 52of 1368.3 Week 2 (Visit 3)
The following procedures or assessments will be performed/recorded:
Record concomitant medications. 
Assess adverse events.
C-SSRS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Collect samples for hematology/biochemistry/urinalysis.
Administer IMP.
Record visit in the IRT.
8.4 Week 4 (Visit 4)
Record concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Perform a urine pregnancy test.PUBLIC COPY Collect samples for hematology/biochemistry/urinalysis.
PUBLIC COPY Collect samples for hematology/biochemistry/urinalysis.
Record concomitant medications. 
PUBLIC COPY Record concomitant medications. 
This document cannot be used to support any marketing authorization Determine the BASFI.
This document cannot be used to support any marketing authorization Determine the BASFI.
Perform the PGADA.
This document cannot be used to support any marketing authorization Perform the PGADA.
Perform the PhGADA.
This document cannot be used to support any marketing authorization Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
This document cannot be used to support any marketing authorization Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12
This document cannot be used to support any marketing authorization Perform a 12

This document cannot be used to support any marketing authorization Perform a 
This document cannot be used to support any marketing authorization Perform a application and any extensions or variations thereof.Perform the PhGADA.
application and any extensions or variations thereof.Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
application and any extensions or variations thereof.Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
Perform a [ADDRESS_764664].
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 53of 136Collect samples for:
Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
Anti-bimekizumab and anti-CZP antibody detection.
hs-CRP.
If the respective ICF has been provided collect blood samples for:
Cytokines, complement, and biomarker analyses.
Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided.
Administer IMP.
Record visit in the IRT.
8.5 Week 6 (Visit 5)
Record concomitant medications. 
Assess adverse events.
C-SSRS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Collect samples for hematology/biochemistry/urinalysis.
Administer IMP.
Record visit in the IRT.
8.6 Week 8 (Visit 6)
Record concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.PUBLIC COPY 
This document cannot be used to support any marketing authorization Collect urine samples for biomarker research if the respective ICF has been provided.
This document cannot be used to support any marketing authorization Collect urine samples for biomarker research if the respective ICF has been provided.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
This document cannot be used to support any marketing authorization Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
Collect samples for hematology/biochemist
This document cannot be used to support any marketing authorization Collect samples for hematology/biochemist
Administer IMP.
This document cannot be used to support any marketing authorization Administer IMP.
Record visit in the IRT.
This document cannot be used to support any marketing authorization Record visit in the IRT.
Record concomitant medications. 
This document cannot be used to support any marketing authorization Record concomitant medications. 

This document cannot be used to support any marketing authorization Assess adverse events.
This document cannot be used to support any marketing authorization Assess adverse events.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Collect urine samples for biomarker research if the respective ICF has been provided.
application and any extensions or variations thereof.Collect urine samples for biomarker research if the respective ICF has been provided.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
application and any extensions or variations thereof.Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
Collect samples for hematology/biochemist
application and any extensions or variations thereof.Collect samples for hematology/biochemist
Record visit in the IRT.
application and any extensions or variations thereof.Record visit in the IRT.
Week 8 (Visit 6)
application and any extensions or variations thereof.Week 8 (Visit 6)
application and any extensions or variations thereof.Record concomitant medications. application and any extensions or variations thereof.Record concomitant medications. 
Assess adverse events.application and any extensions or variations thereof.Assess adverse events.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 54of 136Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Perform a urine pregnancy test.
Collect samples for: 
Hematology/biochemistry/urinalysis.
hs-CRP.
Administer IMP.
Record visit in the IRT.
8.7 Week 10 (Visit 7)
Record concomitant medications. 
Assess adverse events.
C-SSRS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Collect samples for hematology/biochemistry/urinalysis.
Administer IMP.
Record visit in the IRT.
8.8 Week 12 (Visit 8)
Record concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.PUBLIC COPY 
This document cannot be used to support any marketing authorization Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
This document cannot be used to support any marketing authorization Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
samples for hematology/biochemistry/urinalysis.
This document cannot be used to support any marketing authorization samples for hematology/biochemistry/urinalysis.
Administer IMP.
This document cannot be used to support any marketing authorization Administer IMP.
Record visit in the IRT.
This document cannot be used to support any marketing authorization Record visit in the IRT.
Record concomitant medications. 
This document cannot be used to support any marketing authorization Record concomitant medications. 

This document cannot be used to support any marketing authorization Assess adverse events.
This document cannot be used to support any marketing authorization Assess adverse events.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
application and any extensions or variations thereof.Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
samples for hematology/biochemistry/urinalysis.
application and any extensions or variations thereof.samples for hematology/biochemistry/urinalysis.
Record visit in the IRT.
application and any extensions or variations thereof.Record visit in the IRT.
Week 12 (Visit 8)
application and any extensions or variations thereof.Week 12 (Visit 8)
Record concomitant medications. application and any extensions or variations thereof.Record concomitant medications. 
Assess adverse events.application and any extensions or variations thereof.Assess adverse events.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 55of 136Perform the PGADA.
Perform the PhGA DA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12- lead E CG.
Administer the tuberculosis questionnaire.
Perform a urine pregnancy test.
Collect samples for:
Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
Anti-bimekizumab and anti-CZP antibody detection.
hs-CRP.
If the respective ICF has been provided collect blood samples for:Cytokines, complement, and biomarker analyses.
Pharmacogenetic variables.
Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided.
Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after Week 12 Visit if PET-positive lesions were observed in the previous scan.
Administer IMP.
Record visit in the IRT.
8.9 Week 16 (Visit 9), Week 20 (Visit 10), Week 28 (Visit 12), Week 32 
(Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)
Record concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.PUBLIC COPY CZP antibody detection.
PUBLIC COPY CZP antibody detection.
ICF has been provided collect blood samples for:
PUBLIC COPY ICF has been provided collect blood samples for:
Cytokines, complement, and biomarker analyses.
PUBLIC COPY Cytokines, complement, and biomarker analyses.
Nonhereditary pharmacogenomic variables.PUBLIC COPY Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided. PUBLIC COPY Collect urine samples for biomarker research if the respective ICF has been provided.
This document cannot be used to support any marketing authorization ICF has been provided collect blood samples for:
This document cannot be used to support any marketing authorization ICF has been provided collect blood samples for:
Cytokines, complement, and biomarker analyses.
This document cannot be used to support any marketing authorization Cytokines, complement, and biomarker analyses.
Nonhereditary pharmacogenomic variables.
This document cannot be used to support any marketing authorization Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided.
This document cannot be used to support any marketing authorization Collect urine samples for biomarker research if the respective ICF has been provided.
MRI or PET
This document cannot be used to support any marketing authorization MRI or PET -
This document cannot be used to support any marketing authorization -CT scan in at least [ADDRESS_764665] visit in the IRT.
Week 16 (Visit 9), Week 20 (Visit 10), Week 2
This document cannot be used to support any marketing authorization Week 16 (Visit 9), Week 20 (Visit 10), Week 2
(Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)
This document cannot be used to support any marketing authorization (Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)
Record concomitant medications. 
This document cannot be used to support any marketing authorization Record concomitant medications. 
This document cannot be used to support any marketing authorization Assess adverse events.
This document cannot be used to support any marketing authorization Assess adverse events.

This document cannot be used to support any marketing authorization C
This document cannot be used to support any marketing authorization C-
This document cannot be used to support any marketing authorization -SSRS.
This document cannot be used to support any marketing authorization SSRS.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ICF has been provided collect blood samples for:
application and any extensions or variations thereof.ICF has been provided collect blood samples for:
Nonhereditary pharmacogenomic variables.
application and any extensions or variations thereof.Nonhereditary pharmacogenomic variables.
Collect urine samples for biomarker research if the respective ICF has been provided.
application and any extensions or variations thereof.Collect urine samples for biomarker research if the respective ICF has been provided.
CT scan in at least [ADDRESS_764666] 25 subjects at selected sites within 2
positive lesions were observed in the previous scan.
application and any extensions or variations thereof.positive lesions were observed in the previous scan.
Week 16 (Visit 9), Week 20 (Visit 10), Week 2
application and any extensions or variations thereof.Week 16 (Visit 9), Week 20 (Visit 10), Week 2
(Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)
application and any extensions or variations thereof.(Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)
Record concomitant medications. 
application and any extensions or variations thereof.Record concomitant medications. 
application and any extensions or variations thereof.Assess adverse events.
application and any extensions or variations thereof.Assess adverse events.
SSRS.application and any extensions or variations thereof. SSRS.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 56of 136Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Blood sample for hs-CRP.
Perform a urine pregnancy test.
Administer IMP.
Record visit in the IRT.
8.10 Week 24 (Visit 11) and Week 36 (Visit 14)
Record prior and concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Administer the tuberculosis questionnaire.
Perform a urine pregnancy test.
Collect samples for:
Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
Anti-bimekizumab and anti-CZP antibody detection.
hs-CRP.PUBLIC COPY Total and nocturnal spi[INVESTIGATOR_18172] (NRS). PUBLIC COPY Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
This document cannot be used to support any marketing authorization Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
This document cannot be used to support any marketing authorization Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Perform a physical examination, including an evaluatio
This document cannot be used to support any marketing authorization Perform a physical examination, including an evaluatio
TB and risk for exposure to TB.
This document cannot be used to support any marketing authorization TB and risk for exposure to TB.
Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
lead ECG.
This document cannot be used to support any marketing authorization lead ECG.
Administer the tuberculosis questionnaire.
This document cannot be used to support any marketing authorization Administer the tuberculosis questionnaire.
Perform a urine pregnancy test.
This document cannot be used to support any marketing authorization Perform a urine pregnancy test.
This document cannot be used to support any marketing authorization Collect samples for:
This document cannot be used to support any marketing authorization Collect samples for:

This document cannot be used to support any marketing authorization Hematolo
This document cannot be used to support any marketing authorization Hematolo

This document cannot be used to support any marketing authorization Bimekizumab and CZP plasma concentrations.
This document cannot be used to support any marketing authorization Bimekizumab and CZP plasma concentrations.application and any extensions or variations thereof.Perform a physical examination, including an evaluatio
application and any extensions or variations thereof.Perform a physical examination, including an evaluatio
Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
Administer the tuberculosis questionnaire.
application and any extensions or variations thereof.Administer the tuberculosis questionnaire.
Perform a urine pregnancy test.
application and any extensions or variations thereof.Perform a urine pregnancy test.
Collect samples for:
application and any extensions or variations thereof.Collect samples for:
Hematolo
application and any extensions or variations thereof.Hematolo gy/biochemistry/urinalysis.
application and any extensions or variations thereof.gy/biochemistry/urinalysis.
application and any extensions or variations thereof.Bimekizumab and CZP plasma concentrations.application and any extensions or variations thereof.Bimekizumab and CZP plasma concentrations.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 57of 136If the respective ICF has been provided collect blood samples for:
Cytokines, complement, and biomarker analyses.
Administer IM P.
Record visit in the IRT.
8.11 Week 48 (Visit 17)/Early Withdrawal Visit
Record prior and concomitant medications. 
Assess adverse events.
C-SSRS.
HADS.
Determine the BASDAI. 
Determine the BASFI.
Perform the PGADA.
Perform the PhGADA.
Total and nocturnal spi[INVESTIGATOR_18172] (NRS).
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.
Perform a 12-lead EC G.
Administer the tuberculosis questionnaire.
Perform an IGRA tuberculosis test (QuantiFERON TB test).
Perform a urine pregnancy test.
Collect samples for:
Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
Anti-bimekizumab and anti-CZP antibody detection.
hs-CRP.
If the respective ICF has been provided collect blood samples for:
Cytokines, complement, and biomarker analyses.
Pharmacogenetic variables.
Nonhereditary pharmacogenomic variables.PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure).
PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure).
Perform a physical examination, including an evaluation for signs and symptoms of active 
PUBLIC COPY Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.PUBLIC COPY TB and risk for exposure to TB and weight.
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
Perform a physical examination, including an evaluation for signs and symptoms of active 
This document cannot be used to support any marketing authorization Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.
This document cannot be used to support any marketing authorization TB and risk for exposure to TB and weight.
Administer the tuberculosis questionnaire.
This document cannot be used to support any marketing authorization Administer the tuberculosis questionnaire.
Perform an IGRA tuberculosis test (QuantiFERON TB test).
This document cannot be used to support any marketing authorization Perform an IGRA tuberculosis test (QuantiFERON TB test).
Perform a urine pregnancy test.
This document cannot be used to support any marketing authorization Perform a urine pregnancy test.
Collect samples for:
This document cannot be used to support any marketing authorization Collect samples for:
Hematology/biochemistry/urinalysis.
This document cannot be used to support any marketing authorization Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
This document cannot be used to support any marketing authorization Bimekizumab and CZP plasma concentrations.

This document cannot be used to support any marketing authorization Anti
This document cannot be used to support any marketing authorization Anti bimekizumab and 
This document cannot be used to support any marketing authorization bimekizumab and 

This document cannot be used to support any marketing authorization hs
This document cannot be used to support any marketing authorization hs

This document cannot be used to support any marketing authorization If the respective ICF has been provided collect blood samples for:
This document cannot be used to support any marketing authorization If the respective ICF has been provided collect blood samples for:application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
Perform a physical examination, including an evaluation for signs and symptoms of active 
application and any extensions or variations thereof.Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.
application and any extensions or variations thereof.TB and risk for exposure to TB and weight.
Administer the tuberculosis questionnaire.
application and any extensions or variations thereof.Administer the tuberculosis questionnaire.
Perform an IGRA tuberculosis test (QuantiFERON TB test).
application and any extensions or variations thereof.Perform an IGRA tuberculosis test (QuantiFERON TB test).
Perform a urine pregnancy test.
application and any extensions or variations thereof.Perform a urine pregnancy test.
Hematology/biochemistry/urinalysis.
application and any extensions or variations thereof.Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
application and any extensions or variations thereof.Bimekizumab and CZP plasma concentrations.
bimekizumab and 
application and any extensions or variations thereof.bimekizumab and 
application and any extensions or variations thereof.-application and any extensions or variations thereof.-CRP.application and any extensions or variations thereof.CRP.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 58of 136Collect urine samples for biomarker research if the respective ICF has been provided.
Obtain a X-ray or CT scan of the chest if the QuantiFERON TB test returned a positive 
result. 
Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks after the Week 48/WD Visit if PET-positive lesions were observed in the previous scan. At 
the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET-positive lesions were observed in 
the previous scan.
Record visit in the IRT.
8.12 Safety Follow-Up Visit (Week 64, Visit 18, 20 weeks after the 
final dose of IMP)
Record concomitant medications. 
Assess adverse events.
Measure vital signs (temperature, pulse, and blood pressure).
Perform a 12-lead ECG.
Administer the tuberculosis questionnaire.
Perform a urine pregnancy test.
Collect samples for:
Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
Anti-bimekizumab and anti-CZP antibody detection.
hs-CRP.
If the respective ICF has been provided collect blood samples for:
Cytokines, complement, and biomarker analyses.
Nonhereditary pharmacogenomic variables.
Record visit in the IRT.
8.13 Early Withdrawal Visit
Subjects withdrawing early from the study (see Section 6.3) should undergo the same 
assessments scheduled for the Week 48 Visit (see Section 8.11) as soon as possible after 
withdrawal (as an Early Withdrawal Visit) and then enter the SFU Period, completing study 
participation with the SFU Visit 20 weeks after their final dose of study medication.
8.14 Unscheduled Visit
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well-being. PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure).
PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure).
the tuberculosis questionnaire.
PUBLIC COPY the tuberculosis questionnaire.
Hematology/biochemistry/urinalysis.PUBLIC COPY Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations. PUBLIC COPY Bimekizumab and CZP plasma concentrations.
This document cannot be used to support any marketing authorization positive lesions were observed in 
This document cannot be used to support any marketing authorization positive lesions were observed in 
Up Visit (Week 64, Visit 18, 20 weeks after the 
This document cannot be used to support any marketing authorization Up Visit (Week 64, Visit 18, 20 weeks after the 
Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
Hematology/biochemistry/urinalysis.
This document cannot be used to support any marketing authorization Hematology/biochemistry/urinalysis.
Bimekizumab and CZP plasma concentrations.
This document cannot be used to support any marketing authorization Bimekizumab and CZP plasma concentrations.
bimekizumab and anti
This document cannot be used to support any marketing authorization bimekizumab and anti -
This document cannot be used to support any marketing authorization -CZP antibody detection.
This document cannot be used to support any marketing authorization CZP antibody detection.
If the respective ICF has been pr
This document cannot be used to support any marketing authorization If the respective ICF has been pr
Cytokines, complement, and biomarker analyses.
This document cannot be used to support any marketing authorization Cytokines, complement, and biomarker analyses.
Nonhereditary pharmacogenomic variables.
This document cannot be used to support any marketing authorization Nonhereditary pharmacogenomic variables.
This document cannot be used to support any marketing authorization Record visit in the IRT.
This document cannot be used to support any marketing authorization Record visit in the IRT.
Subjects withdrawing early from the study (see 
This document cannot be used to support any marketing authorization Subjects withdrawing early from the study (see 
assessments scheduled for the Week 48 Visit (see 
This document cannot be used to support any marketing authorization assessments scheduled for the Week 48 Visit (see 
withdrawal (as an Early Withdrawal Visit) and then enter the SFU Period, completing study 
This document cannot be used to support any marketing authorization withdrawal (as an Early Withdrawal Visit) and then enter the SFU Period, completing study 
participation with the SFU Visit 20 weeks after their final dose of study medication.
This document cannot be used to support any marketing authorization participation with the SFU Visit 20 weeks after their final dose of study medication.application and any extensions or variations thereof.Up Visit (Week 64, Visit 18, 20 weeks after the 
application and any extensions or variations thereof.Up Visit (Week 64, Visit 18, [ADDRESS_764667] blood samples for:
application and any extensions or variations thereof.ovided collect blood samples for:
Cytokines, complement, and biomarker analyses.
application and any extensions or variations thereof.Cytokines, complement, and biomarker analyses.
Nonhereditary pharmacogenomic variables.
application and any extensions or variations thereof.Nonhereditary pharmacogenomic variables.
application and any extensions or variations thereof.Record visit in the IRT.
application and any extensions or variations thereof.Record visit in the IRT.
Early Withdrawal Visit
application and any extensions or variations thereof.Early Withdrawal Visit
Subjects withdrawing early from the study (see application and any extensions or variations thereof.Subjects withdrawing early from the study (see 
assessments scheduled for the Week 48 Visit (see application and any extensions or variations thereof. assessments scheduled for the Week 48 Visit (see 
UCB [ADDRESS_764668] during the visit. If an Unscheduled Visit is conducted for reasons 
other than safety or efficacy concerns (eg, repeated collection of a laboratory specimen due to collection or analysis issues), an C-SSRS will not be required at these visits. 
At this visit, any of the following assessments may be performed, depending on the reason for the visit:
Vital signs (temperature, pulse, and blood pressure).
C-SSRS. 
Other patient-reported outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
nocturnal spi[INVESTIGATOR_18172]) as required. 
Administer the tuberculosis questionnaire.
Perform a physical examination, including an evaluation for signs and symptoms of active TB and risk for exposure to TB and weight.
Record 12-lead ECG.
If medically indicated, obtain blood sample(s) for:
Standard safety laboratory tests (hematology, serum chemistry).
The blood sample may also be used for PK/PD assessments, if needed.
Obtain urine sample for standard safety laboratory tests (including urine pregnancy test).
Record concomitant medication.
Record AEs.
9 ASSESSMENT OF EFFICA CY
The timing for all assessments described below is specified in the Schedule of Assessments 
(Table 5‒1).
9.[ADDRESS_764669] and Investigator and multiplied by a validated formula (van der Heijde et al, 2009) as listed:
0.121 x Total spi[INVESTIGATOR_18172] (BASDAI Question 2 result, Section 9.3)
0.058 x Duration of morning stiffness (BASDAI Question 6 result, Section 9.3) 
0.110 x PGADA ( Section 9.6)
0.073 x Peripheral pain/swelling (BASDAI Question 3 result, Section 9.4)
0.579 x (natural logarithm of the CRP [mg/L] + 1)
Spi[INVESTIGATOR_18172], PGADA, duration of morning stiffness, and peripheral pain/swelling are all assessed 
on a numerical scale (0 to 10 units) (Lukas et al, 2009). The results of these calculations are summed to calculate the ASDAS.PUBLIC COPY If medically indicated, obtain blood sample(s) for:
PUBLIC COPY If medically indicated, obtain blood sample(s) for:
Standard safety laboratory tests (hematology, serum chemistry).
PUBLIC COPY Standard safety laboratory tests (hematology, serum chemistry).
The blood sample may also be used for PK/PD assessments, if needed.
PUBLIC COPY The blood sample may also be used for PK/PD assessments, if needed.
Obtain urine sample for standard safe
PUBLIC COPY Obtain urine sample for standard safe ty laboratory tests (including urine pregnancy test).
PUBLIC COPY ty laboratory tests (including urine pregnancy test).
Record concomitant medication.
PUBLIC COPY Record concomitant medication.
This document cannot be used to support any marketing authorization ed outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
This document cannot be used to support any marketing authorization ed outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
Perform a physical examination, including an evaluation for signs and symptoms of active 
This document cannot be used to support any marketing authorization Perform a physical examination, including an evaluation for signs and symptoms of active 
Standard safety laboratory tests (hematology, serum chemistry).
This document cannot be used to support any marketing authorization Standard safety laboratory tests (hematology, serum chemistry).
The blood sample may also be used for PK/PD assessments, if needed.
This document cannot be used to support any marketing authorization The blood sample may also be used for PK/PD assessments, if needed.
ty laboratory tests (including urine pregnancy test).
This document cannot be used to support any marketing authorization ty laboratory tests (including urine pregnancy test).
ASSESSMENT OF EFFICA
This document cannot be used to support any marketing authorization ASSESSMENT OF EFFICA
The timing for all assessments described below is specified in the Schedule of Assessments 
This document cannot be used to support any marketing authorization The timing for all assessments described below is specified in the Schedule of Assessments 
ASDAS
This document cannot be used to support any marketing authorization ASDAS
The ASDAS is comprised of a number of assessments which are scored by [CONTACT_581623] a number of assessments which are scored by [CONTACT_581624] a validated formula (van der Heijde et al, 2009) as listed:
This document cannot be used to support any marketing authorization Investigator and multiplied by a validated formula (van der Heijde et al, 2009) as listed:
0.121 x Total spi[INVESTIGATOR_18172] (BASDAI Question
This document cannot be used to support any marketing authorization 0.121 x Total spi[INVESTIGATOR_18172] (BASDAI Question
0.058 x Duration of morning stiffness (BASDAI Question 6 result, 
This document cannot be used to support any marketing authorization 0.058 x Duration of morning stiffness (BASDAI Question 6 result, 
0.110 x PGADA (
This document cannot be used to support any marketing authorization 0.110 x PGADA (

This document cannot be used to support any marketing authorization 0.073 x 
This document cannot be used to support any marketing authorization 0.073 x 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ed outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
application and any extensions or variations thereof.ed outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
Perform a physical examination, including an evaluation for signs and symptoms of active 
application and any extensions or variations thereof.Perform a physical examination, including an evaluation for signs and symptoms of active 
Standard safety laboratory tests (hematology, serum chemistry).
application and any extensions or variations thereof.Standard safety laboratory tests (hematology, serum chemistry).
The blood sample may also be used for PK/PD assessments, if needed.
application and any extensions or variations thereof.The blood sample may also be used for PK/PD assessments, if needed.
ty laboratory tests (including urine pregnancy test).
application and any extensions or variations thereof.ty laboratory tests (including urine pregnancy test).
ASSESSMENT OF EFFICA
application and any extensions or variations thereof.ASSESSMENT OF EFFICA CY
application and any extensions or variations thereof.CY
The timing for all assessments described below is specified in the Schedule of Assessments 
application and any extensions or variations thereof.The timing for all assessments described below is specified in the Schedule of Assessments 
The ASDAS is comprised of a number of assessments which are scored by [CONTACT_581625].The ASDAS is comprised of a number of assessments which are scored by [CONTACT_581625].Investigator and multiplied by a validated formula (van der Heijde et al, 2009) as listed:
application and any extensions or variations thereof.Investigator and multiplied by a validated formula (van der Heijde et al, 2009) as listed:
0.121 x Total spi[INVESTIGATOR_18172] (BASDAI Question
application and any extensions or variations thereof.0.121 x Total spi[INVESTIGATOR_18172] (BASDAI Question
0.058 x Duration of morning stiffness (BASDAI Question 6 result, 
application and any extensions or variations thereof.0.058 x Duration of morning stiffness (BASDAI Question 6 result, 
0.110 x PGADA (
application and any extensions or variations thereof.0.110 x PGADA (
0.073 x application and any extensions or variations thereof. 0.073 x application and any extensions or variations thereof.Peripheral pain/swelling (BASDAI Questionapplication and any extensions or variations thereof.Peripheral pain/swelling (BASDAI Question
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 60of 136The following definitions apply to ASDAS Disease Activity categories:
ASDAS -Inactive Disease: ASDAS <1.3
ASDAS -Moderate Disease activity: ASDAS ≥1.3, <2.1
ASDAS -High Disease activity: ASDAS ≥2.1; ≤3.5
ASDAS -Very High Disease activity: ASDAS >3.[ADDRESS_764670] 20% and absolute improvement 
of at least [ADDRESS_764671] 3 of the 4 following domains:
PGADA (see Section 9.6)
Pain assessment (the total spi[INVESTIGATOR_18233]; Section 9.8)
Function (represented by [CONTACT_18379], Section 9.5)
Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see Section 9.4] 
concerning morning stiffness intensity and duration)
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of at least 1 unit].
The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
of at least [ADDRESS_764672] 3 of the 4 domains above and no worsening at all 
in the remaining domain.
The ASAS partial remiss ion response is defined as a score of ≤[ADDRESS_764673]’s 
perspective is the BASDAI (Garrett et al, 1 994). The BASDAI is a validated self -reported 
instrument which consists of six 10 unit horizontal NRSs to measure severity of fatigue, spi[INVESTIGATOR_18238], enthesitis, and morning stiffness (both severity and 
duration, respectivel y) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
asks 
 Question 3 of 
the BASDAI asks 
 Question 6 of the BASDAI asks  
The BASDAI is calculated as follows: 
𝐵𝐴𝑆𝐷𝐴𝐼 =Q1+Q2+Q3+Q4+(𝑄5+𝑄6
2)
5PUBLIC COPY concerning morning stiffness intensity and duration)
PUBLIC COPY concerning morning stiffness intensity and duration)
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
PUBLIC COPY and absence of deterioration in the potential remaining domain [deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of
PUBLIC COPY relative worsening of at least 20% and an absolute worsening of
The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
PUBLIC COPY The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
of at least [ADDRESS_764674] 3 of the 4 domains above and no worsening at all 
ion response is defined as a score of ≤2 units on a 0 to 10 unit NRS 
PUBLIC COPY ion response is defined as a score of ≤[ADDRESS_764675] 20% and absolute improvement 
This document cannot be used to support any marketing authorization fined as an improvement of at least 20% and absolute improvement 
Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see 
This document cannot be used to support any marketing authorization Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see 
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
This document cannot be used to support any marketing authorization and absence of deterioration in the potential remaining domain [deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of
This document cannot be used to support any marketing authorization relative worsening of at least 20% and an absolute worsening of
The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
This document cannot be used to support any marketing authorization The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
of at least [ADDRESS_764676] 3 of the 4 domains above and no worsening at all 
ion response is defined as a score of ≤2 units on a 0 to 10 unit NRS 
This document cannot be used to support any marketing authorization ion response is defined as a score of ≤[ADDRESS_764677]’s 
This document cannot be used to support any marketing authorization The most common instrument used to measure the disease activity of AS from the subject’s 
perspective is the BASDAI (Garrett et al, 1
This document cannot be used to support any marketing authorization perspective is the BASDAI (Garrett et al, 1
instrument which consists of six 10 unit horizontal NRSs to measure severity of fatigue, spi[INVESTIGATOR_581534] 10 unit horizontal NRSs to measure severity of fatigue, spi[INVESTIGATOR_18238], enthesitis, and morning stiffness (both severity and 
This document cannot be used to support any marketing authorization and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and 
duration, respectivel
This document cannot be used to support any marketing authorization duration, respectivel y) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
This document cannot be used to support any marketing authorization y) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
This document cannot be used to support any marketing authorization from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
the BASDAI asks 
This document cannot be used to support any marketing authorization the BASDAI asks 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see 
application and any extensions or variations thereof.Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see Section
application and any extensions or variations thereof.Section
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
application and any extensions or variations thereof.and absence of deterioration in the potential remaining domain [deterioration is defined as a 
at least 1 unit].
application and any extensions or variations thereof.at least 1 unit].
The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
application and any extensions or variations thereof.The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
of at least [ADDRESS_764678] 3 of the 4 domains above and no worsening at all 
ion response is defined as a score of ≤2 units on a 0 to 10 unit NRS 
application and any extensions or variations thereof.ion response is defined as a score of ≤[ADDRESS_764679]’s 
application and any extensions or variations thereof.The most common instrument used to measure the disease activity of AS from the subject’s 
perspective is the BASDAI (Garrett et al, 1
application and any extensions or variations thereof.perspective is the BASDAI (Garrett et al, 1 994). The BASDAI is a validated self
application and any extensions or variations thereof.994). The BASDAI is a validated self
instrument which consists of six 10 unit horizontal NRSs to measure severity of fatigue, spi[INVESTIGATOR_581535].instrument which consists of six 10 unit horizontal NRSs to measure severity of fatigue, spi[INVESTIGATOR_18238], enthesitis, and morning stiffness (both severity and 
application and any extensions or variations thereof.and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and 
y) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
application and any extensions or variations thereof.y) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
application and any extensions or variations thereof.from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
the BASDAI asks 
application and any extensions or variations thereof.the BASDAI asks 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 61of 136Fatigue item of the BASDAI
Fatigue as a major symptom of AS can effectively be measured with single -item questions such 
as the BASDAI item (van Tubergen et al, 2002b). This item has shown moderate to good 
reliability and responsiveness (van Tubergen et al, 2002b). The same minimal clinically 
important difference (MCID) will be used for the fatigue item of the BASDAI as for the 
BAS DAI score, ie, a change of 1 unit on the NRS.
9.4 Inflammation –BASDAI (mean of Questions 5 and 6)
Question 5 of the BASDAI (described completely in Section 9.3) measures intensity of morning 
stiffness. The subject considers the previous week and responds to the question, 
The response is indicated on a 10-point NRS in which 0=None and 10=Very severe. Question [ADDRESS_764680] considers the previous week 
and responds to the question, 
The response is indicated on a 10 -point NRS in which 0=0 hours, 5=1 hour, and 10=2 
or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
of Questions 5 and 6. This is used in the definition of the ASAS response variable s defined in 
Section 9.2.
9.5 Function –BASFI
The BASFI is a validated disease -specific instrument for assessing physical function (van der 
Heijde et a l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764681] week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a). The BASFI is the 
mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
analog scale (VAS) or 17.5% of the Baseline score (Pavy et al, 2005); an MCID of 1 unit will be 
used for the NRS version. This is used in the definition of the ASAS response variables defined 
in Section 9.2.
9.6 Patient global assessment (PGADA)
Subjects will provide their global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active” (van Tubergen et al, 2015).
This is used in the calculation of ASDAS ( Section 9.1) and the definition of the ASAS response 
variables defined in Section 9.2.
9.[ADDRESS_764682] to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities. This assessment by [CONTACT_581626].
The subject should be asked to consider bo th joint and skin components in their response to this 
question.PUBLIC COPY of Questions 5 and 6. This is used in the definition of the ASAS response variable
PUBLIC COPY of Questions 5 and 6. This is used in the definition of the ASAS response variable
specific instrument for assessing physical function (van der 
PUBLIC COPY specific instrument for assessing physical function (van der 
l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764683] week. 
PUBLIC COPY l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764684] week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
PUBLIC COPY The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a).
PUBLIC COPY 10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a).
mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating PUBLIC COPY mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual PUBLIC COPY better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
This document cannot be used to support any marketing authorization ) measures intensity of morning 
This document cannot be used to support any marketing authorization ) measures intensity of morning 
This document cannot be used to support any marketing authorization point NRS in which 0=None and 10=Very severe. Question 6 
This document cannot be used to support any marketing authorization point NRS in which 0=None and 10=Very severe. Question [ADDRESS_764685] considers the previous week 
This document cannot be used to support any marketing authorization point NRS in which 0=0 hours, 5=1 hour, and 10=2 
This document cannot be used to support any marketing authorization point NRS in which 0=0 hours, 5=1 hour, and 10=2 
or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
This document cannot be used to support any marketing authorization or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
of Questions 5 and 6. This is used in the definition of the ASAS response variable
This document cannot be used to support any marketing authorization of Questions 5 and 6. This is used in the definition of the ASAS response variable
specific instrument for assessing physical function (van der 
This document cannot be used to support any marketing authorization specific instrument for assessing physical function (van der 
l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764686] week. 
This document cannot be used to support any marketing authorization l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764687] week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
This document cannot be used to support any marketing authorization The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a).
This document cannot be used to support any marketing authorization 10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a).
mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
This document cannot be used to support any marketing authorization mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
This document cannot be used to support any marketing authorization better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
analog scale (VAS) or 17.5% of the Baseline score 
This document cannot be used to support any marketing authorization analog scale (VAS) or 17.5% of the Baseline score 
used for the NRS version. This is used in the definition of the ASAS response variables defined 
This document cannot be used to support any marketing authorization used for the NRS version. This is used in the definition of the ASAS response variables defined 
Patient global assessment (PGADA)
This document cannot be used to support any marketing authorization Patient global assessment (PGADA)
Subjects will provide their global assessment of their disease activity in response to the question 
This document cannot be used to support any marketing authorization Subjects will provide their global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
This document cannot be used to support any marketing authorization “How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is
This document cannot be used to support any marketing authorization “not active” and 10 is “very active” (van Tubergen et al, 2015).
This document cannot be used to support any marketing authorization “very active” (van Tubergen et al, 2015).
This is used in the calculation of ASDAS (
This document cannot be used to support any marketing authorization This is used in the calculation of ASDAS (
variables defined in 
This document cannot be used to support any marketing authorization variables defined in 
The Investigator will assess the overall status of the subject with respect to their AS signs and 
This document cannot be used to support any marketing authorization The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and 
This document cannot be used to support any marketing authorization symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
This document cannot be used to support any marketing authorization limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.point NRS in which 0=None and 10=Very severe. Question 6 
application and any extensions or variations thereof.point NRS in which 0=None and 10=Very severe. Question [ADDRESS_764688] considers the previous week 
application and any extensions or variations thereof.point NRS in which 0=0 hours, 5=1 hour, and 10=2 
application and any extensions or variations thereof.point NRS in which 0=0 hours, 5=1 hour, and 10=2 
or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
application and any extensions or variations thereof.or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
of Questions 5 and 6. This is used in the definition of the ASAS response variable
application and any extensions or variations thereof.of Questions 5 and 6. This is used in the definition of the ASAS response variable
specific instrument for assessing physical function (van der 
application and any extensions or variations thereof.specific instrument for assessing physical function (van der 
l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764689] week. 
application and any extensions or variations thereof.l, 2005; Calin et al, 1994). The BASFI comprises [ADDRESS_764690] week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
application and any extensions or variations thereof.The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a).
application and any extensions or variations thereof.10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a).
mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
application and any extensions or variations thereof.mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
application and any extensions or variations thereof.better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
analog scale (VAS) or 17.5% of the Baseline score 
application and any extensions or variations thereof.analog scale (VAS) or 17.5% of the Baseline score (Pavy et al, 2005); an MCID of 1 unit will be 
application and any extensions or variations thereof.(Pavy et al, 2005); an MCID of 1 unit will be 
used for the NRS version. This is used in the definition of the ASAS response variables defined 
application and any extensions or variations thereof.used for the NRS version. This is used in the definition of the ASAS response variables defined 
Patient global assessment (PGADA)
application and any extensions or variations thereof.Patient global assessment (PGADA)
Subjects will provide their global assessment of their disease activity in response to the question 
application and any extensions or variations thereof.Subjects will provide their global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
application and any extensions or variations thereof.“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“very active” (van Tubergen et al, 2015).
application and any extensions or variations thereof.“very active” (van Tubergen et al, 2015).
This is used in the calculation of ASDAS (
application and any extensions or variations thereof.This is used in the calculation of ASDAS (
variables defined in 
application and any extensions or variations thereof.variables defined in Section
application and any extensions or variations thereof.Section
PhGADA
application and any extensions or variations thereof.PhGADA
The Investigator will assess the overall status of the subject with respect to their AS signs and application and any extensions or variations thereof.The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and application and any extensions or variations thereof.symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 62of 1369.8 Total and nocturnal spi[INVESTIGATOR_581536] 2 separate questions: 1) total 
pain in the spi[INVESTIGATOR_18248] (ie, “How much pain of your spi[INVESTIGATOR_463135]?”); and 2) pain in the spi[INVESTIGATOR_18249] (ie, “How much pain of your spi[INVESTIGATOR_18250]?”) (Sieper et al, 2009; van der Heijde et al, 2005; Committee for Proprietary 
Medicinal Product [CPMP]/EWP/556/95). When responding to each question, the subject is to consider the average amount of pain in the preceding week. The total pain score is used in the definition of the ASAS response variables defined in Section 9.2.
9.[ADDRESS_764691] the blinded nature of the treatment assignments. The hs- CRP 
will be used in the calculation of ASDAS ( Section 9.1).
9.10 Hospi[INVESTIGATOR_58910]-established psychometric properties and its use in clinical research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
higher scores indicating worse state. A score below 8 is considered to be normal whereas a score of 15 and above is considered severe (Snaith and Zigmond, 1994).
9.[ADDRESS_764692] or PET-MRI has a much better spatial resolution and sensitivity (Strobel et al, 2010; Even-Sapir et al, 2007). In the present study, UCB will assess the 
regions of high bone turnover as detected by 18F PET-MRI or 18F PET-CT within the spi[INVESTIGATOR_581537]. 
The 18F-fluoride PET-MRIs of the whole spi[INVESTIGATOR_581538] a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒[ADDRESS_764693] 25 subjects at selected sites.
10 ASSESSMENT OF PHARMA COKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/ 
PHARMACOGENETIC VARI ABLE(S)
Plasma concentrations of bimekizumab and CZP are the PK variables. 
10.1 Pharmacokinetic variables
Blood samples for measurement of PK variables will be collected at the time points specified in 
the Table 5‒1. At dosing visits, blood samples will be drawn prior to dosing, and will be drawn 
at the same time of the sampling for clinical laboratory tests. The time and date of collection will PUBLIC COPY research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
PUBLIC COPY research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
PUBLIC COPY Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
indicating worse state. A score below 8 is considered to be normal whereas a score 
PUBLIC COPY indicating worse state. A score below 8 is considered to be normal whereas a score 
of 15 and above is considered severe (Snaith and Zigmond, 1994).
PUBLIC COPY of 15 and above is considered severe (Snaith and Zigmond, 1994).
CT scan
PUBLIC COPY CT scan
High bone turnover assessed by [CONTACT_581627].
PUBLIC COPY processes regardless of the inflammatory or noninflammatory origin.
While exact localization of regions of radionuclide uptake is difficult with conventional PUBLIC COPY While exact localization of regions of radionuclide uptake is difficult with conventional 
CT or PETPUBLIC COPY CT or PET
This document cannot be used to support any marketing authorization consider the average amount of pain in the preceding week. The total pain score is used in the 
This document cannot be used to support any marketing authorization consider the average amount of pain in the preceding week. The total pain score is used in the 
CRP data will not 
This document cannot be used to support any marketing authorization CRP data will not 
be sent to the Investigator to protect the blinded nature of the treatment assignm
This document cannot be used to support any marketing authorization be sent to the Investigator to protect the blinded nature of the treatment assignm ents. The hs
This document cannot be used to support any marketing authorization ents. The hs
blished psychometric properties and its use in clinical 
This document cannot be used to support any marketing authorization blished psychometric properties and its use in clinical 
research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
This document cannot be used to support any marketing authorization research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
This document cannot be used to support any marketing authorization Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
indicating worse state. A score below 8 is considered to be normal whereas a score 
This document cannot be used to support any marketing authorization indicating worse state. A score below 8 is considered to be normal whereas a score 
of 15 and above is considered severe (Snaith and Zigmond, 1994).
This document cannot be used to support any marketing authorization of 15 and above is considered severe (Snaith and Zigmond, 1994).
High bone turnover assessed by [CONTACT_581628].
This document cannot be used to support any marketing authorization processes regardless of the inflammatory or noninflammatory origin.
While exact localization of regions of radionuclide uptake is difficult with conventional 
This document cannot be used to support any marketing authorization While exact localization of regions of radionuclide uptake is difficult with conventional 
CT or PET
This document cannot be used to support any marketing authorization CT or PET -
This document cannot be used to support any marketing authorization -MRI has a much better spatial resolution and 
This document cannot be used to support any marketing authorization MRI has a much better spatial resolution and 
(Strobel et al, 2010; Even
This document cannot be used to support any marketing authorization (Strobel et al, 2010; Even -
This document cannot be used to support any marketing authorization -Sapir et al, 2007). In the present study, UCB will assess the 
This document cannot be used to support any marketing authorization Sapir et al, 2007). In the present study, UCB will assess the 
regions of high bone turnover as detected by 18F PET
This document cannot be used to support any marketing authorization regions of high bone turnover as detected by 18F PET
MRIs of the whole spi[INVESTIGATOR_581539]/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
This document cannot be used to support any marketing authorization PET/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
This document cannot be used to support any marketing authorization CT system permitting the acquisition of co
This document cannot be used to support any marketing authorization CT system permitting the acquisition of co
session. The PET
This document cannot be used to support any marketing authorization session. The PET -
This document cannot be used to support any marketing authorization -MRI or PET
This document cannot be used to support any marketing authorization MRI or PET
in at least [ADDRESS_764694] 25 subjects at selected sites.
This document cannot be used to support any marketing authorization subjects at selected sites.
ASSESSMENT OF PHARMA
This document cannot be used to support any marketing authorization ASSESSMENT OF PHARMA
Plasma concentrations of bimekizumab and CZP are the PK variables. 
This document cannot be used to support any marketing authorization Plasma concentrations of bimekizumab and CZP are the PK variables. 
10.1
This document cannot be used to support any marketing authorization 10.1application and any extensions or variations thereof.CRP data will not 
application and any extensions or variations thereof.CRP data will not 
ents. The hs
application and any extensions or variations thereof.ents. The hs -
application and any extensions or variations thereof.-CRP 
application and any extensions or variations thereof.CRP 
blished psychometric properties and its use in clinical 
application and any extensions or variations thereof.blished psychometric properties and its use in clinical 
research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
application and any extensions or variations thereof.research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
application and any extensions or variations thereof.Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
indicating worse state. A score below 8 is considered to be normal whereas a score 
application and any extensions or variations thereof.indicating worse state. A score below 8 is considered to be normal whereas a score 
of 15 and above is considered severe (Snaith and Zigmond, 1994).
application and any extensions or variations thereof.of 15 and above is considered severe (Snaith and Zigmond, 1994).
High bone turnover assessed by [CONTACT_581629].High bone turnover assessed by [CONTACT_581630].
application and any extensions or variations thereof.processes regardless of the inflammatory or noninflammatory origin.
While exact localization of regions of radionuclide uptake is difficult with conventional 
application and any extensions or variations thereof.While exact localization of regions of radionuclide uptake is difficult with conventional 
MRI has a much better spatial resolution and 
application and any extensions or variations thereof.MRI has a much better spatial resolution and 
Sapir et al, 2007). In the present study, UCB will assess the 
application and any extensions or variations thereof.Sapir et al, 2007). In the present study, UCB will assess the 
regions of high bone turnover as detected by 18F PET
application and any extensions or variations thereof.regions of high bone turnover as detected by 18F PET
MRIs of the whole spi[INVESTIGATOR_581540].MRIs of the whole spi[INVESTIGATOR_581541]/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
application and any extensions or variations thereof.PET/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
application and any extensions or variations thereof.CT system permitting the acquisition of co
application and any extensions or variations thereof.CT system permitting the acquisition of co
MRI or PET
application and any extensions or variations thereof.MRI or PET -
application and any extensions or variations thereof.-CT scan will be
application and any extensions or variations thereof.CT scan will be
subjects at selected sites.
application and any extensions or variations thereof.subjects at selected sites.
application and any extensions or variations thereof.ASSESSMENT OF PHARMA
application and any extensions or variations thereof.ASSESSMENT OF PHARMA
PHARMACODYNAMIC/PHAR
application and any extensions or variations thereof.PHARMACODYNAMIC/PHAR
PHARMACOGENETIC VARIapplication and any extensions or variations thereof.PHARMACOGENETIC VARI
Plasma concentrations of bimekizumab and CZP are the PK variables. application and any extensions or variations thereof.Plasma concentrations of bimekizumab and CZP are the PK variables. 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 63of 136be recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, 
labeling, and shippi[INVESTIGATOR_58911]. Detailed information 
on sample analysis will be provided in a bioanalytical report.
10.2 Pharmacodynamic variables
Blood samples for measurement of PD variables will be collected at the time points specified in Table 5‒1. Flow cytometry by [CONTACT_74064]-activated cell sorting (FACS) analysis might 
include, but is not limited to: cluster of differentiation (CD)3, CD19, CD4, CD8, and CD69. 
Candidate biomarkers might include, but are not limited to: IL-17A/IL17-F pathway signaling, 
TNF signaling pathway, bone metabolism and AS (eg, IL-17A, IL-17F, IL-23, IL-6, TNF, DC-
STAMP, and circulating osteoclast precursors). At dosing visits, blood samples will be drawn 
prior to dosing, and will be drawn at the same time of the sampling for clinical laboratory tests. 
The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_58911]. Detailed information on sample analysis will be provided in a bioanalytical report.
10.3 Nonhereditary pharmacogenomic variables
Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and metabolites biomarker analysis at the time points specified in Table 5‒1. Where local regulation 
permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
at the time points specified in the schedule of study assessments. Collection of these samples will 
enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone metabolism and inflammatory and immune response processes. Instructions pertaining to sample 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_581542]. The nature and format of these tentative analyses will be determined at a later stage. 
The samples will be stored at the secure long-term storage facility selected by [CONTACT_581631] 20 years. 
10.4 Pharmacogenetic variables
For individuals consenting to the pharmacogenetic substudy, blood samples will be drawn for 
exploratory genetic/epi[INVESTIGATOR_18193], analyses at the time points specified in Table 5‒1. Collection of 
these samples will enable evaluation of genetics/epi[INVESTIGATOR_581543], drug treatment, bone metabolism and inflammatory and immune 
response processes. The nature and format of these tentative analyses will be determined when 
the results of the main study are made available. A separate ICF will be required for those subjects who agree to participate in the pharmacogenetics substudy. The substudy will be 
conducted only where ethically accepted and authorized by [CONTACT_397149]. Refusal to 
participate in the substudy will not affect a subject’s ability to participate in the main study. The samples will be stored at -80°C at the central biorepository for up to 20 years. 
11 ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S)
The immunological variables comprise detection of anti-bimekizumab and anti-CZP antibodies 
related to immunogenicity, serum complement concentrations, mononuclear cell subtypes (analyzed by [CONTACT_4133]/fluorescence-activated cell sorting), and other exploratory biomarkers.PUBLIC COPY Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
PUBLIC COPY Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
points specified in 
PUBLIC COPY points specified in 
permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
PUBLIC COPY permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
t the time points specified in the schedule of study assessments. Collection of these samples will 
PUBLIC COPY t the time points specified in the schedule of study assessments. Collection of these samples will 
enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
PUBLIC COPY enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
metabolism and inflammatory and immune response processes. 
PUBLIC COPY metabolism and inflammatory and immune response processes. 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_581544], processing, storage, labeling, and shippi[INVESTIGATOR_581542]. The nature and format of these tentative analyses will be determined at a later stage. 
PUBLIC COPY this study. The nature and format of these tentative analyses will be determined at a later stage. 
d at the secure longPUBLIC COPY d at the secure long
This document cannot be used to support any marketing authorization include, but is not limited to: cluster of differentiation (CD)3, CD19, CD4, CD8, and CD69. 
This document cannot be used to support any marketing authorization include, but is not limited to: cluster of differentiation (CD)3, CD19, CD4, CD8, and CD69. 
F pathway signaling, 
This document cannot be used to support any marketing authorization F pathway signaling, 
6, TNF, DC
This document cannot be used to support any marketing authorization 6, TNF, DC
STAMP, and circulating osteoclast precursors). At dosing visits, blood samples will be drawn 
This document cannot be used to support any marketing authorization STAMP, and circulating osteoclast precursors). At dosing visits, blood samples will be drawn 
of the sampling for clinical laboratory tests. 
This document cannot be used to support any marketing authorization of the sampling for clinical laboratory tests. 
The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
This document cannot be used to support any marketing authorization The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_581545], processing, storage, labeling, and shippi[INVESTIGATOR_581546] a bioanalytical report.
This document cannot be used to support any marketing authorization ailed information on sample analysis will be provided in a bioanalytical report.
Nonhereditary pharmacogenomic variables
This document cannot be used to support any marketing authorization Nonhereditary pharmacogenomic variables
Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
This document cannot be used to support any marketing authorization Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
points specified in 
This document cannot be used to support any marketing authorization points specified in Table
This document cannot be used to support any marketing authorization Table 5
This document cannot be used to support any marketing authorization 5
permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
This document cannot be used to support any marketing authorization permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
t the time points specified in the schedule of study assessments. Collection of these samples will 
This document cannot be used to support any marketing authorization t the time points specified in the schedule of study assessments. Collection of these samples will 
enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
This document cannot be used to support any marketing authorization enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
metabolism and inflammatory and immune response processes. 
This document cannot be used to support any marketing authorization metabolism and inflammatory and immune response processes. 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_581545], processing, storage, labeling, and shippi[INVESTIGATOR_581542]. The nature and format of these tentative analyses will be determined at a later stage. 
This document cannot be used to support any marketing authorization this study. The nature and format of these tentative analyses will be determined at a later stage. 
d at the secure long
This document cannot be used to support any marketing authorization d at the secure long -
This document cannot be used to support any marketing authorization -term storage facility selected by [CONTACT_581632], blood samples will be drawn for 
This document cannot be used to support any marketing authorization For individuals consenting to the pharmacogenetic substudy, blood samples will be drawn for 
exploratory genetic/epi[INVESTIGATOR_18193], analyses at the time point
This document cannot be used to support any marketing authorization exploratory genetic/epi[INVESTIGATOR_18193], analyses at the time point
these samples will enable evaluation of genetics/epi[INVESTIGATOR_581547]/epi[INVESTIGATOR_581548], drug treatment, bone metabolism and inflammatory and immune 
This document cannot be used to support any marketing authorization ion, drug treatment, bone metabolism and inflammatory and immune 
response processes. The nature and format of these tentative analyses will be determined when 
This document cannot be used to support any marketing authorization response processes. The nature and format of these tentative analyses will be determined when 
the results of the main study are made available. A separate ICF will be required for those 
This document cannot be used to support any marketing authorization the results of the main study are made available. A separate ICF will be required for those 
cts who agree to participate in the pharmacogenetics substudy. The substudy will be 
This document cannot be used to support any marketing authorization cts who agree to participate in the pharmacogenetics substudy. The substudy will be 
conducted only where ethically accepted and authorized by [CONTACT_397149]. Refusal to 
This document cannot be used to support any marketing authorization conducted only where ethically accepted and authorized by [CONTACT_397149]. Refusal to 
participate in the substudy will not affect a subject’s ability to participate
This document cannot be used to support any marketing authorization participate in the substudy will not affect a subject’s ability to participate
This document cannot be used to support any marketing authorization samples will be stored at 
This document cannot be used to support any marketing authorization samples will be stored at 
[ADDRESS_764695] precursors). At dosing visits, blood samples will be drawn 
application and any extensions or variations thereof.STAMP, and circulating osteoclast precursors). At dosing visits, blood samples will be drawn 
of the sampling for clinical laboratory tests. 
application and any extensions or variations thereof.of the sampling for clinical laboratory tests. 
The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
application and any extensions or variations thereof.The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_581549].collection, processing, storage, labeling, and shippi[INVESTIGATOR_581546] a bioanalytical report.
application and any extensions or variations thereof.ailed information on sample analysis will be provided in a bioanalytical report.
Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
application and any extensions or variations thereof.Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
5
application and any extensions or variations thereof.5‒
application and any extensions or variations thereof.‒1
application and any extensions or variations thereof.1. Where local regulation 
application and any extensions or variations thereof.. Where local regulation 
permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
application and any extensions or variations thereof.permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
t the time points specified in the schedule of study assessments. Collection of these samples will 
application and any extensions or variations thereof.t the time points specified in the schedule of study assessments. Collection of these samples will 
enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
application and any extensions or variations thereof.enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
metabolism and inflammatory and immune response processes. 
application and any extensions or variations thereof.metabolism and inflammatory and immune response processes. Instructions pertaining to sample 
application and any extensions or variations thereof.Instructions pertaining to sample 
collection, processing, storage, labeling, and shippi[INVESTIGATOR_581549].collection, processing, storage, labeling, and shippi[INVESTIGATOR_581542]. The nature and format of these tentative analyses will be determined at a later stage. 
application and any extensions or variations thereof.this study. The nature and format of these tentative analyses will be determined at a later stage. 
term storage facility selected by [CONTACT_581633].term storage facility selected by [CONTACT_581633].Pharmacogenetic variables
application and any extensions or variations thereof.Pharmacogenetic variables
For individuals consenting to the pharmacogenetic substudy, blood samples will be drawn for 
application and any extensions or variations thereof.For individuals consenting to the pharmacogenetic substudy, blood samples will be drawn for 
exploratory genetic/epi[INVESTIGATOR_18193], analyses at the time point
application and any extensions or variations thereof.exploratory genetic/epi[INVESTIGATOR_18193], analyses at the time point
these samples will enable evaluation of genetics/epi[INVESTIGATOR_581550].these samples will enable evaluation of genetics/epi[INVESTIGATOR_581551], drug treatment, bone metabolism and inflammatory and immune 
application and any extensions or variations thereof.ion, drug treatment, bone metabolism and inflammatory and immune 
response processes. The nature and format of these tentative analyses will be determined when 
application and any extensions or variations thereof.response processes. The nature and format of these tentative analyses will be determined when 
the results of the main study are made available. A separate ICF will be required for those 
application and any extensions or variations thereof.the results of the main study are made available. A separate ICF will be required for those 
cts who agree to participate in the pharmacogenetics substudy. The substudy will be 
application and any extensions or variations thereof.cts who agree to participate in the pharmacogenetics substudy. The substudy will be 
conducted only where ethically accepted and authorized by [CONTACT_397149]. Refusal to 
application and any extensions or variations thereof.conducted only where ethically accepted and authorized by [CONTACT_397149]. Refusal to 
participate in the substudy will not affect a subject’s ability to participate
application and any extensions or variations thereof.participate in the substudy will not affect a subject’s ability to participate
application and any extensions or variations thereof.samples will be stored at application and any extensions or variations thereof.samples will be stored at 
ASSESSMENT OF IMMUNOapplication and any extensions or variations thereof.ASSESSMENT OF IMMUNO
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 64of 136The Investigator or designee will obtain blood samples for these measurements at the time points 
specified in Table 5‒1. When these samples are required at a visit during which the subject is 
dosed with IMP, the blood samples will be drawn prior to dosing. Samples should be drawn at 
the same time of the sampling for clinical laboratory tests. The time and date of collection will be 
recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, labeling, 
and shippi[INVESTIGATOR_58911]. The presence of antibodies to bimekizumab or CZP will be determined using a validated bioanalytical method. Detailed information on sample analysis will be provided in a bioanalytical report.
12 ASSESSMENT OF SAFETY
12.1 Adverse events
12.1.1 Definitions
[IP_ADDRESS] Adverse event
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period. 
[IP_ADDRESS] Serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:
Death
Life-threatening
(Life -threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)
Significant or persistent disability/incapacity
Congenital anomaly/birth defect (including that occurring in a fetus)
Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of seriousPUBLIC COPY relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
PUBLIC COPY relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated
PUBLIC COPY (including an abnormal laboratory finding), symptom, or disease temporally associated
use of a medicinal (investigational) product, whether or not related to the medicinal 
PUBLIC COPY use of a medicinal (investigational) product, whether or not related to the medicinal 
In order to ensure complete safety data collection, all AEs occurring during the study (ie,
PUBLIC COPY In order to ensure complete safety data collection, all AEs occurring during the study (ie,
form), including any pretreatment and posttreatment periods 
PUBLIC COPY form), including any pretreatment and posttreatment periods 
required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
PUBLIC COPY required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
PUBLIC COPY study procedures were conducted. This includes all AEs not present prior to the initial visit and 
AEs that recurred or worsened after the initial visit.PUBLIC COPY AEs that recurred or worsened after the initial visit.
This document cannot be used to support any marketing authorization An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
This document cannot be used to support any marketing authorization An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
administered a pharmaceutical product that does not necessarily have a causal 
This document cannot be used to support any marketing authorization administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
This document cannot be used to support any marketing authorization relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated
This document cannot be used to support any marketing authorization (including an abnormal laboratory finding), symptom, or disease temporally associated
use of a medicinal (investigational) product, whether or not related to the medicinal 
This document cannot be used to support any marketing authorization use of a medicinal (investigational) product, whether or not related to the medicinal 
In order to ensure complete safety data collection, all AEs occurring during the study (ie,
This document cannot be used to support any marketing authorization In order to ensure complete safety data collection, all AEs occurring during the study (ie,
form), including any pretreatment and posttreatment periods 
This document cannot be used to support any marketing authorization form), including any pretreatment and posttreatment periods 
required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
This document cannot be used to support any marketing authorization required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
This document cannot be used to support any marketing authorization study procedures were conducted. This includes all AEs not present prior to the initial visit and 
AEs that recurred or worsened after the initial visit.
This document cannot be used to support any marketing authorization AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
This document cannot be used to support any marketing authorization Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
This document cannot be used to support any marketing authorization recorded as AEs only if their nature changes considerably or their frequency or intensity 
ly significant manner as compared to the clinical profile known to the 
This document cannot be used to support any marketing authorization ly significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period. 
This document cannot be used to support any marketing authorization Investigator from the subject’s history or the Baseline Period. 
Serious adverse event
This document cannot be used to support any marketing authorization Serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
This document cannot be used to support any marketing authorization Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
ed. An SAE must meet 1 or more of the following criteria:
This document cannot be used to support any marketing authorization ed. An SAE must meet 1 or more of the following criteria:
Life
This document cannot be used to support any marketing authorization Life-
This document cannot be used to support any marketing authorization -threatening
This document cannot be used to support any marketing authorization threatening
(Life
This document cannot be used to support any marketing authorization (Life -
This document cannot be used to support any marketing authorization -threatening does not include a reaction that might have caused death had it occurred in 
This document cannot be used to support any marketing authorization threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)
This document cannot be used to support any marketing authorization a more severe form.)

This document cannot be used to support any marketing authorization Significant or persistent disability/incapacity
This document cannot be used to support any marketing authorization Significant or persistent disability/incapacityapplication and any extensions or variations thereof.An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
application and any extensions or variations thereof.An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
administered a pharmaceutical product that does not necessarily have a causal 
application and any extensions or variations thereof.administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
application and any extensions or variations thereof.relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated
application and any extensions or variations thereof.(including an abnormal laboratory finding), symptom, or disease temporally associated
use of a medicinal (investigational) product, whether or not related to the medicinal 
application and any extensions or variations thereof.use of a medicinal (investigational) product, whether or not related to the medicinal 
In order to ensure complete safety data collection, all AEs occurring during the study (ie,
application and any extensions or variations thereof.In order to ensure complete safety data collection, all AEs occurring during the study (ie,
form), including any pretreatment and posttreatment periods 
application and any extensions or variations thereof.form), including any pretreatment and posttreatment periods 
required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
application and any extensions or variations thereof.required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
application and any extensions or variations thereof.study procedures were conducted. This includes all AEs not present prior to the initial visit and 
AEs that recurred or worsened after the initial visit.
application and any extensions or variations thereof.AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
application and any extensions or variations thereof.Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
application and any extensions or variations thereof.recorded as AEs only if their nature changes considerably or their frequency or intensity 
ly significant manner as compared to the clinical profile known to the 
application and any extensions or variations thereof.ly significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period. 
application and any extensions or variations thereof.Investigator from the subject’s history or the Baseline Period. 
Serious adverse event
application and any extensions or variations thereof.Serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
application and any extensions or variations thereof.Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
ed. An SAE must meet 1 or more of the following criteria:
application and any extensions or variations thereof.ed. An SAE must meet 1 or more of the following criteria:
threatening
application and any extensions or variations thereof.threatening
threatening does not include a reaction that might have caused death had it occurred in 
application and any extensions or variations thereof.threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)application and any extensions or variations thereof.a more severe form.)
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 65of 136(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section [IP_ADDRESS]], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.)
Initial inpatient hospi[INVESTIGATOR_318]
(A patient admitted to a hospi[INVESTIGATOR_307], even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospi[INVESTIGATOR_059]. An emergency room visit that results in 
admission to the hospi[INVESTIGATOR_58912]. However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_352178], instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening adverse experience, important medical event].
Hospi[INVESTIGATOR_58913] [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
since there is no AE upon which to assess the serious criteria. Please note that, if the pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)
[IP_ADDRESS].[ADDRESS_764696] does not change the Investigator’s obligation to report allSAEs (including Anticipated 
SAEs) as detailed in Section [IP_ADDRESS].
Table 12‒1: Anticipated serious adverse events for the population of subjects 
with AS
MedDRA system organ class MedDRA preferred term
Skin and subcutaneous tissue disorders Psoriasis
Eye disorders Uveitis
Musculoskeletal and connective tissue disorders Dactylitis
Tendonitis
Atlantoaxial instability
Gastrointestinal disorders Colitis ulcerativeCrohn's diseasePUBLIC COPY for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
PUBLIC COPY for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
e there is no AE upon which to assess the serious criteria. Please note that, if the 
PUBLIC COPY e there is no AE upon which to assess the serious criteria. Please note that, if the 
existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
PUBLIC COPY existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the even
PUBLIC COPY this would then qualify as an AE and, if necessary, the seriousness of the even
Anticipated serious adverse events
PUBLIC COPY Anticipated serious adverse events
The following Anticipated SAEs are anticipated to occur in the population studied in this 
PUBLIC COPY The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. 
PUBLIC COPY protocol at some frequency that is independent of drug exposure. 
This list does not change the Inv PUBLIC COPY This list does not change the Inv estigator’s obligation to report PUBLIC COPY estigator’s obligation to report 
This document cannot be used to support any marketing authorization nt hospi[INVESTIGATOR_383803]. 
This document cannot be used to support any marketing authorization nt hospi[INVESTIGATOR_383803]. 
However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_581552], emergency room visits that do not result in admission to the hospi[INVESTIGATOR_352178], instead, should be evaluated for 1 of the other criteria in the 
This document cannot be used to support any marketing authorization qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
adverse experience, important medical event].
This document cannot be used to support any marketing authorization adverse experience, important medical event].
Hospi[INVESTIGATOR_58913] [eg,
This document cannot be used to support any marketing authorization Hospi[INVESTIGATOR_58913] [eg, preplanned 
This document cannot be used to support any marketing authorization preplanned 
existing condition that has not worsened or manifested 
This document cannot be used to support any marketing authorization existing condition that has not worsened or manifested 
ristic manner] do not qualify for reporting. For example, if a 
This document cannot be used to support any marketing authorization ristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
This document cannot be used to support any marketing authorization subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
This document cannot be used to support any marketing authorization for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
e there is no AE upon which to assess the serious criteria. Please note that, if the 
This document cannot be used to support any marketing authorization e there is no AE upon which to assess the serious criteria. Please note that, if the 
existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
This document cannot be used to support any marketing authorization existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the even
This document cannot be used to support any marketing authorization this would then qualify as an AE and, if necessary, the seriousness of the even
Anticipated serious adverse events
This document cannot be used to support any marketing authorization Anticipated serious adverse events
The following Anticipated SAEs are anticipated to occur in the population studied in this 
This document cannot be used to support any marketing authorization The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. 
This document cannot be used to support any marketing authorization protocol at some frequency that is independent of drug exposure. 
estigator’s obligation to report 
This document cannot be used to support any marketing authorization estigator’s obligation to report 
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS] .
This document cannot be used to support any marketing authorization .
Anticipated serious adverse events for the population of subjects 
This document cannot be used to support any marketing authorization Anticipated serious adverse events for the population of subjects 
This document cannot be used to support any marketing authorization MedDRA system organ class
This document cannot be used to support any marketing authorization MedDRA system organ class
This document cannot be used to support any marketing authorization Skin and subcutaneous tissue disorders
This document cannot be used to support any marketing authorization Skin and subcutaneous tissue disorders
This document cannot be used to support any marketing authorization Eye disorders
This document cannot be used to support any marketing authorization Eye disorders
This document cannot be used to support any marketing authorization Musculoskeletal and connective tissue disorders
This document cannot be used to support any marketing authorization Musculoskeletal and connective tissue disorders
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Gastrointestinal disorders
This document cannot be used to support any marketing authorization Gastrointestinal disorders
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
application and any extensions or variations thereof.qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
adverse experience, important medical event].
application and any extensions or variations thereof.adverse experience, important medical event].
preplanned 
application and any extensions or variations thereof.preplanned 
existing condition that has not worsened or manifested 
application and any extensions or variations thereof.existing condition that has not worsened or manifested 
ristic manner] do not qualify for reporting. For example, if a 
application and any extensions or variations thereof.ristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
application and any extensions or variations thereof.subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
application and any extensions or variations thereof.for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
e there is no AE upon which to assess the serious criteria. Please note that, if the 
application and any extensions or variations thereof.e there is no AE upon which to assess the serious criteria. Please note that, if the 
existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
application and any extensions or variations thereof.existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the even
application and any extensions or variations thereof.this would then qualify as an AE and, if necessary, the seriousness of the even
Anticipated serious adverse events
application and any extensions or variations thereof.Anticipated serious adverse events
The following Anticipated SAEs are anticipated to occur in the population studied in this 
application and any extensions or variations thereof.The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. 
application and any extensions or variations thereof.protocol at some frequency that is independent of drug exposure. 
estigator’s obligation to report 
application and any extensions or variations thereof.estigator’s obligation to report 
Anticipated serious adverse events for the population of subjects 
application and any extensions or variations thereof.Anticipated serious adverse events for the population of subjects 
application and any extensions or variations thereof.MedDRA system organ class
application and any extensions or variations thereof.MedDRA system organ class
application and any extensions or variations thereof.Skin and subcutaneous tissue disorders
application and any extensions or variations thereof.Skin and subcutaneous tissue disorders
application and any extensions or variations thereof.application and any extensions or variations thereof.Musculoskeletal and connective tissue disorders
application and any extensions or variations thereof.Musculoskeletal and connective tissue disorders
application and any extensions or variations thereof.application and any extensions or variations thereof.Gastrointestinal disorders application and any extensions or variations thereof.Gastrointestinal disorders application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 66of 136Table 12‒1: Anticipated serious adverse events for the population of subjects 
with AS
MedDRA system organ class MedDRA preferred term
Cardiac disorders Aortic valve incompetence
Atrial tachycardiaAtrioventricular blockBundle branch blockCardiomyopathy
Vascular disorders Aortitis
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders Pulmonary fibrosis
Nervous system disorders Cauda equina syndrome
Injury, poisoning and procedural complications Spi[INVESTIGATOR_581553]=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse 
event
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
result in the death of the study subject.
[IP_ADDRESS] Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound. Potential Hy’s Law, defined as ≥3xULN ALT or 
AST with coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of special interest (AESI) (ie, without waiting for any additional etiologic investigations to have 
been concluded). Follow-up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.
In addition, events that are considered as Adverse Events of Interest for CZP include:
Serious infections including opportunistic infections
Malignancies including lymphoma
Congestive heart failure
Demyelinating-like disorders
Aplastic anaemia, pancytopenia, thrombocytopenia, neutropenia and leucopeniaPUBLIC COPY Spi[INVESTIGATOR_581554]=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory
PUBLIC COPY AS=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they PUBLIC COPY Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Cauda equina syndrome
This document cannot be used to support any marketing authorization Cauda equina syndrome
This document cannot be used to support any marketing authorization Spi[INVESTIGATOR_581555]=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory
This document cannot be used to support any marketing authorization AS=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
This document cannot be used to support any marketing authorization Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
result in the death of the study subject.
This document cannot be used to support any marketing authorization result in the death of the study subject.
This document cannot be used to support any marketing authorization Adverse events of special interest
This document cannot be used to support any marketing authorization Adverse events of special interest
This document cannot be used to support any marketing authorization An AE of special interest i
This document cannot be used to support any marketing authorization An AE of special interest i
This document cannot be used to support any marketing authorization s any AE that a regulatory authority has mandated be reported on an 
This document cannot be used to support any marketing authorization s any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
This document cannot be used to support any marketing authorization expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. 
This document cannot be used to support any marketing authorization administration of a UCB product/compound. 
h coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
This document cannot be used to support any marketing authorization h coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of 
This document cannot be used to support any marketing authorization explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of 
special interest (AESI) (ie, without waiting for any additional etiologic investig
This document cannot be used to support any marketing authorization special interest (AESI) (ie, without waiting for any additional etiologic investig
been concluded). Follow
This document cannot be used to support any marketing authorization been concluded). Follow
This document cannot be used to support any marketing authorization identified during investigation and monitoring of the subject.
This document cannot be used to support any marketing authorization identified during investigation and monitoring of the subject.
In addition, events that are considered as Adverse Events of Interest for CZP include
This document cannot be used to support any marketing authorization In addition, events that are considered as Adverse Events of Interest for CZP include

This document cannot be used to support any marketing authorization Serious infections including opportunistic infections
This document cannot be used to support any marketing authorization Serious infections including opportunistic infections

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Cervical Vertebral fracture
application and any extensions or variations thereof.Cervical Vertebral fracture
Lumbar Vertebral fracture
application and any extensions or variations thereof.Lumbar Vertebral fracture
Thoracic Vertebral fracture
application and any extensions or variations thereof.Thoracic Vertebral fracture
application and any extensions or variations thereof.Amyloidosis
application and any extensions or variations thereof.Amyloidosis
application and any extensions or variations thereof.application and any extensions or variations thereof.Depression
application and any extensions or variations thereof.Depression
application and any extensions or variations thereof.AS=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory
application and any extensions or variations thereof.AS=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
application and any extensions or variations thereof.Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
application and any extensions or variations thereof.Adverse events of special interest
application and any extensions or variations thereof.Adverse events of special interest
application and any extensions or variations thereof.s any AE that a regulatory authority has mandated be reported on an 
application and any extensions or variations thereof.s any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
application and any extensions or variations thereof.expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. 
application and any extensions or variations thereof.administration of a UCB product/compound. 
h coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
application and any extensions or variations thereof.h coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of 
application and any extensions or variations thereof.explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of 
special interest (AESI) (ie, without waiting for any additional etiologic investig
application and any extensions or variations thereof.special interest (AESI) (ie, without waiting for any additional etiologic investig
been concluded). Follow
application and any extensions or variations thereof.been concluded). Follow -
application and any extensions or variations thereof.-
application and any extensions or variations thereof.up information should then be reported if an alternative etiology is 
application and any extensions or variations thereof.up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.
application and any extensions or variations thereof.identified during investigation and monitoring of the subject.
In addition, events that are considered as Adverse Events of Interest for CZP includeapplication and any extensions or variations thereof.In addition, events that are considered as Adverse Events of Interest for CZP include
Serious infections including opportunistic infectionsapplication and any extensions or variations thereof.Serious infections including opportunistic infections
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 67of 136Serious bleeding events
Lupus and lupus-like illness
Serious skin reactions (e.g. Stevens Johnson syndrome, toxic epi[INVESTIGATOR_194], and 
erythema multiforme)
[IP_ADDRESS] Adverse events for special monitoring
UCB has identified AEs for special monitoring (AESM). An AESM is an AE or safety topic for 
which special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB), are considered appropriate. Identified AESM can be of particular concern based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
study population.
Adverse events for special monitoring for this study include: infections (serious, opportunistic, 
fungal, and TB, see Sectio n 12.7.5), neutropenia, hypersensitivity, suicidal ideation and behavior 
(assessed using the C-SSRS), depression, (assessed using the HADS, see Section 9.10), major 
cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; see Section 12.6.1), malignancies, and inflammatory bowel diseases (with gastroenterology 
referral as appropriate).
12.1.[ADDRESS_764697] AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study.
[IP_ADDRESS] Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be clarified in the source documentation.
When recording the intensity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator should use the following criteria:
Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
his/her usual activities and/or is of no clinical consequence
Moderate: the AE interferes with the usual activities of the subject or it is of some clinical consequence
Severe: the subject is unable to work normally or to carry out his/her usual activities, or the AE is of definite clinical consequency
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) are described in the eCRF Completion Guidelines.PUBLIC COPY cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
PUBLIC COPY cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
), malignancies, and inflammatory bowel diseases (with gastroenterology 
PUBLIC COPY ), malignancies, and inflammatory bowel diseases (with gastroenterology 
Procedures for reporting and recording adverse events 
PUBLIC COPY Procedures for reporting and recording adverse events 
The subject will be given the opportunity to report AEs 
PUBLIC COPY The subject will be given the opportunity to report AEs 
also be given at each study visit to detect AEs. For example:
PUBLIC COPY also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
PUBLIC COPY “Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any selfPUBLIC COPY In addition, the Investigator should review any self
This document cannot be used to support any marketing authorization UCB has identified AEs for special monitoring (AESM). An AESM is an AE or safety topic for 
This document cannot be used to support any marketing authorization UCB has identified AEs for special monitoring (AESM). An AESM is an AE or safety topic for 
ch special monitoring, additional data collection activities, and/or enhanced signal detection 
This document cannot be used to support any marketing authorization ch special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB), are considered appropriate. Identified AESM can be of particular 
This document cannot be used to support any marketing authorization activities (within UCB), are considered appropriate. Identified AESM can be of particular 
ial risks generally 
This document cannot be used to support any marketing authorization ial risks generally 
associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
This document cannot be used to support any marketing authorization associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
: infections (serious, opportunistic, 
This document cannot be used to support any marketing authorization : infections (serious, opportunistic, 
), neutropenia, hypersensitivity, suicidal ideation and behavior 
This document cannot be used to support any marketing authorization ), neutropenia, hypersensitivity, suicidal ideation and behavior 
SSRS), depression, (assessed using the HADS, see 
This document cannot be used to support any marketing authorization SSRS), depression, (assessed using the HADS, see Section
This document cannot be used to support any marketing authorization Section
cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
This document cannot be used to support any marketing authorization cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
), malignancies, and inflammatory bowel diseases (with gastroenterology 
This document cannot be used to support any marketing authorization ), malignancies, and inflammatory bowel diseases (with gastroenterology 
Procedures for reporting and recording adverse events 
This document cannot be used to support any marketing authorization Procedures for reporting and recording adverse events 
The subject will be given the opportunity to report AEs 
This document cannot be used to support any marketing authorization The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
This document cannot be used to support any marketing authorization spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
This document cannot be used to support any marketing authorization also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
This document cannot be used to support any marketing authorization “Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self
This document cannot be used to support any marketing authorization In addition, the Investigator should review any self
Description of adverse events
This document cannot be used to support any marketing authorization Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
This document cannot be used to support any marketing authorization When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
This document cannot be used to support any marketing authorization standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
e documents should be consistent. Any discrepancies between the subject’s own words 
This document cannot be used to support any marketing authorization e documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg,
This document cannot be used to support any marketing authorization on his/her own records (eg,
This document cannot be used to support any marketing authorization clarified in the source documentation.
This document cannot be used to support any marketing authorization clarified in the source documentation.
When recording the intensity of an AE in 
This document cannot be used to support any marketing authorization When recording the intensity of an AE in 
Investigator should use the following criteria:
This document cannot be used to support any marketing authorization Investigator should use the following criteria:
Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
This document cannot be used to support any marketing authorization Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
his/her usual activities and/or is of no clinical consequence
This document cannot be used to support any marketing authorization his/her usual activities and/or is of no clinical consequence

This document cannot be used to support any marketing authorization Moderat
This document cannot be used to support any marketing authorization Moderatapplication and any extensions or variations thereof.associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
application and any extensions or variations thereof.associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
: infections (serious, opportunistic, 
application and any extensions or variations thereof.: infections (serious, opportunistic, 
), neutropenia, hypersensitivity, suicidal ideation and behavior 
application and any extensions or variations thereof.), neutropenia, hypersensitivity, suicidal ideation and behavior 
Section
application and any extensions or variations thereof.Section 9.[ADDRESS_764698] changes/enzyme elevations (ALT, AST, and bilirubin; 
application and any extensions or variations thereof.cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
), malignancies, and inflammatory bowel diseases (with gastroenterology 
application and any extensions or variations thereof.), malignancies, and inflammatory bowel diseases (with gastroenterology 
Procedures for reporting and recording adverse events 
application and any extensions or variations thereof.Procedures for reporting and recording adverse events 
spontaneously. A general prompt will 
application and any extensions or variations thereof.spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
application and any extensions or variations thereof.also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
application and any extensions or variations thereof.“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self
application and any extensions or variations thereof.In addition, the Investigator should review any self -
application and any extensions or variations thereof.- In addition, the Investigator should review any self - In addition, the Investigator should review any self
application and any extensions or variations thereof.In addition, the Investigator should review any self - In addition, the Investigator should review any self assessment procedures (eg,
application and any extensions or variations thereof.assessment procedures (eg,
Description of adverse events
application and any extensions or variations thereof.Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
application and any extensions or variations thereof.When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
application and any extensions or variations thereof.standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
e documents should be consistent. Any discrepancies between the subject’s own words 
application and any extensions or variations thereof.e documents should be consistent. Any discrepancies between the subject’s own words 
diary card) and the corresponding medical terminology should be 
application and any extensions or variations thereof.diary card) and the corresponding medical terminology should be 
application and any extensions or variations thereof.clarified in the source documentation.
application and any extensions or variations thereof.clarified in the source documentation.
When recording the intensity of an AE in 
application and any extensions or variations thereof.When recording the intensity of an AE in 
Investigator should use the following criteria:
application and any extensions or variations thereof.Investigator should use the following criteria:
Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
application and any extensions or variations thereof.Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
his/her usual activities and/or is of no clinical consequenceapplication and any extensions or variations thereof.his/her usual activities and/or is of no clinical consequence
Moderatapplication and any extensions or variations thereof. Moderat e: the AE interferes with the usual activities of the subject or it is of some clinical application and any extensions or variations thereof.e: the AE interferes with the usual activities of the subject or it is of some clinical 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 68of [ZIP_CODE].1.2.2 Rule for repetition of an adverse event 
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:
The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”
The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
[IP_ADDRESS] Additional procedures for reporting serious adverse events 
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
[CONTACT_779] (see contact [CONTACT_67596]). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by [CONTACT_18338], even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.
An Investigator SAE Report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English. 
It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an expedited manner.
Additional information (eg,autopsy or laboratory reports) received by [CONTACT_18399] [ADDRESS_764699] and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
[ADDRESS_764700]; further details regarding follow up of PDILI events is provided in Section [IP_ADDRESS]. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is PUBLIC COPY provided to the Investigator. The Investigator SAE 
PUBLIC COPY provided to the Investigator. The Investigator SAE 
It is important for the Investigator, when completing the SAE Report form, to include the 
PUBLIC COPY It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP admi
PUBLIC COPY assessment as to a causal relationship between the SAE and the IMP admi
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
PUBLIC COPY from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
PUBLIC COPY and in determining whether the SAE requires reporting to the regulatory authorities in an 
autopsy or laboratory reports) received by [CONTACT_581634]) received by [CONTACT_18399] [ADDRESS_764701] be informed within 24 hours of receipt of this information by 
[CONTACT_581635]). The Investigator must forward to UCB (or its representative) 
This document cannot be used to support any marketing authorization section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
This document cannot be used to support any marketing authorization a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by [CONTACT_18338], even if the data are incomplete, or if it is obvious that more data will be 
This document cannot be used to support any marketing authorization provided by [CONTACT_18338], even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
This document cannot be used to support any marketing authorization needed in order to draw any conclusions. Information recorded on this form will be entered into 
provided to the Investigator. The Investigator SAE 
This document cannot be used to support any marketing authorization provided to the Investigator. The Investigator SAE 
It is important for the Investigator, when completing the SAE Report form, to include the 
This document cannot be used to support any marketing authorization It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP admi
This document cannot be used to support any marketing authorization assessment as to a causal relationship between the SAE and the IMP admi
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
This document cannot be used to support any marketing authorization from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
This document cannot be used to support any marketing authorization and in determining whether the SAE requires reporting to the regulatory authorities in an 
autopsy or laboratory reports) received by [CONTACT_581636]) received by [CONTACT_18399] [ADDRESS_764702] and report to UCB (or its representative) any 
This document cannot be used to support any marketing authorization The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
This document cannot be used to support any marketing authorization SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
end of the study for each subject, and to also inform participating subjects of 
This document cannot be used to support any marketing authorization end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
This document cannot be used to support any marketing authorization the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless o
This document cannot be used to support any marketing authorization Investigator thinks may be associated with the IMP must be reported to UCB regardless o
time between the event and the end of the study.
This document cannot be used to support any marketing authorization time between the event and the end of the study.
Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
This document cannot be used to support any marketing authorization Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
This document cannot be used to support any marketing authorization reported SAE. The assessment of the expectedness of the SAE is based on the IB.
This document cannot be used to support any marketing authorization reported SAE. The assessment of the expectedness of the SAE is based on the IB.
12.1.[ADDRESS_764703] be informed within 24 hours of receipt of this information by 
[CONTACT_581637].tion for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
application and any extensions or variations thereof.section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
application and any extensions or variations thereof.a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by [CONTACT_18338], even if the data are incomplete, or if it is obvious that more data will be 
application and any extensions or variations thereof.provided by [CONTACT_18338], even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
application and any extensions or variations thereof.needed in order to draw any conclusions. Information recorded on this form will be entered into 
provided to the Investigator. The Investigator SAE 
application and any extensions or variations thereof.provided to the Investigator. The Investigator SAE 
It is important for the Investigator, when completing the SAE Report form, to include the 
application and any extensions or variations thereof.It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP admi
application and any extensions or variations thereof.assessment as to a causal relationship between the SAE and the IMP admi
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
application and any extensions or variations thereof.from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
application and any extensions or variations thereof.and in determining whether the SAE requires reporting to the regulatory authorities in an 
autopsy or laboratory reports) received by [CONTACT_581638].autopsy or laboratory reports) received by [CONTACT_18399] [ADDRESS_764704] and report to UCB (or its representative) any 
application and any extensions or variations thereof.The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
application and any extensions or variations thereof.SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
end of the study for each subject, and to also inform participating subjects of 
application and any extensions or variations thereof.end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
application and any extensions or variations thereof.the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless o
application and any extensions or variations thereof.Investigator thinks may be associated with the IMP must be reported to UCB regardless o
time between the event and the end of the study.
application and any extensions or variations thereof.time between the event and the end of the study.
Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
application and any extensions or variations thereof.Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
application and any extensions or variations thereof.reported SAE. The assessment of the expectedness of the SAE is based on the IB.
application and any extensions or variations thereof.reported SAE. The assessment of the expectedness of the SAE is based on the IB.
Follow up of adverse eventsapplication and any extensions or variations thereof.Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the Investigator application and any extensions or variations thereof. An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
UCB [ADDRESS_764705] has discontinued his/her IMP.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.
12.[ADDRESS_764706] immediately notify UCB’s PS department by [CONTACT_352255] (for contact [CONTACT_58969]). The subject should be withdrawn from the study as soon as pregnancy is known (by [CONTACT_18463]), and the following should be completed:
The subject should return for an early discontinuation visit.
The subject should immediately stop the intake of the IMP 
A Safety Follow-Up Visit should be scheduled [ADDRESS_764707] has discontinued 
his/her IMP.
The Investigator must inform the subject of information currently known about potential risks and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_764708] to follow up and/or refuses to give information, written documentation of 
attempts to contact [CONTACT_58970]. UCB’s PS department is the primary contact [CONTACT_581639], eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact [CONTACT_397156]/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the Investigator may contact [CONTACT_58973]/Contract Research Organization (CRO) contract monitor for 
the study. The Investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact [CONTACT_58969]) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS department is also the primary 
contact [CONTACT_58974], eventual birth, and follow up.
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital PUBLIC COPY The Investigator must inform the subject of information currently 
PUBLIC COPY The Investigator must inform the subject of information currently 
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
PUBLIC COPY The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
PUBLIC COPY Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
PUBLIC COPY followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
PUBLIC COPY report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_764709] immediately notify UCB’s PS department by [CONTACT_581640]’s PS department by [CONTACT_581641]). The subject should be withdrawn from the study as soon as 
This document cannot be used to support any marketing authorization beginning of this protocol). The subject should be withdrawn from the study as soon as 
pregnancy is known (by [CONTACT_18463]), and the following should be completed:
This document cannot be used to support any marketing authorization pregnancy is known (by [CONTACT_18463]), and the following should be completed:
Up Visit should be scheduled [ADDRESS_764710] of information currently known about potential risks 
This document cannot be used to support any marketing authorization known about potential risks 
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
This document cannot be used to support any marketing authorization The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
This document cannot be used to support any marketing authorization Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
This document cannot be used to support any marketing authorization followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
This document cannot be used to support any marketing authorization report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_764711] to follow up and/or refuses to give information, written documentation of 
This document cannot be used to support any marketing authorization the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact [CONTACT_581642]. 
This document cannot be used to support any marketing authorization ds to be provided by [CONTACT_352257]. 
UCB’s PS department is the primary contact [CONTACT_581643]’s PS department is the primary contact [CONTACT_261545], eventual birth, and follow up.
This document cannot be used to support any marketing authorization the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled
This document cannot be used to support any marketing authorization In cases where the partner of a male subject enrolled
This document cannot be used to support any marketing authorization Investigator or designee is asked to contact [CONTACT_581644]/IEC and should 
This document cannot be used to support any marketing authorization Partner Pregnancy Consent form that has been approved by [CONTACT_22846]/IEC and should 
be available in the In
This document cannot be used to support any marketing authorization be available in the In vestigator site file. In case of questions about the consent process, the 
This document cannot be used to support any marketing authorization vestigator site file. In case of questions about the consent process, the 
Investigator may contact [CONTACT_58973]/Contract Research Organization (CRO) contract monitor for 
This document cannot be used to support any marketing authorization Investigator may contact [CONTACT_58973]/Contract Research Organization (CRO) contract monitor for 
the study. The Investigator will complete the Pregnancy Report and Outcome form and send it
This document cannot be used to support any marketing authorization the study. The Investigator will complete the Pregnancy Report and Outcome form and send it
UCB’s PS department (for contact [CONTACT_581645]’s PS department (for contact [CONTACT_417714]) only after the partner has agreed that additional information can be captured and has 
This document cannot be used to support any marketing authorization protocol) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS
This document cannot be used to support any marketing authorization provided the signed Partner Pregnancy Consent form. UCB’s PS
contact [CONTACT_58974], eventual birth, 
This document cannot be used to support any marketing authorization contact [CONTACT_58974], eventual birth, 
and follow up.This document cannot be used to support any marketing authorization and follow up.application and any extensions or variations thereof.ct details see SAE reporting information at the 
application and any extensions or variations thereof.ct details see SAE reporting information at the 
pregnancy is known (by [CONTACT_18463]), and the following should be completed:
application and any extensions or variations thereof.pregnancy is known (by [CONTACT_18463]), and the following should be completed:
Up Visit should be scheduled [ADDRESS_764712] has discontinued 
known about potential risks 
application and any extensions or variations thereof.known about potential risks 
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
application and any extensions or variations thereof.The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
application and any extensions or variations thereof.Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
application and any extensions or variations thereof.followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
application and any extensions or variations thereof.report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_764713] to follow up and/or refuses to give information, written documentation of 
application and any extensions or variations thereof.the subject is lost to follow up and/or refuses to give information, written documentation of 
ds to be provided by [CONTACT_352257]. 
application and any extensions or variations thereof.ds to be provided by [CONTACT_352257]. 
UCB’s PS department is the primary contact [CONTACT_581646].UCB’s PS department is the primary contact [CONTACT_261545], eventual birth, and follow up.
application and any extensions or variations thereof.the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled
application and any extensions or variations thereof.In cases where the partner of a male subject enrolled
application and any extensions or variations thereof.Investigator or designee is asked to contact [CONTACT_581647].Investigator or designee is asked to contact [CONTACT_397156]/IEC and should 
application and any extensions or variations thereof.Partner Pregnancy Consent form that has been approved by [CONTACT_22846]/IEC and should 
vestigator site file. In case of questions about the consent process, the 
application and any extensions or variations thereof.vestigator site file. In case of questions about the consent process, the 
Investigator may contact [CONTACT_58973]/Contract Research Organization (CRO) contract monitor for 
application and any extensions or variations thereof.Investigator may contact [CONTACT_58973]/Contract Research Organization (CRO) contract monitor for 
the study. The Investigator will complete the Pregnancy Report and Outcome form and send it
application and any extensions or variations thereof.the study. The Investigator will complete the Pregnancy Report and Outcome form and send it
UCB’s PS department (for contact [CONTACT_581648].UCB’s PS department (for contact [CONTACT_417714]) only after the partner has agreed that additional information can be captured and has application and any extensions or variations thereof.protocol) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS application and any extensions or variations thereof. provided the signed Partner Pregnancy Consent form. UCB’s PS
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 70of 136anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report form.
12.[ADDRESS_764714] should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.
12.[ADDRESS_764715]
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
12.[ADDRESS_764716] as early as possible any safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory authorities, and IRBs/IECs will be informed appropriately and as early as possible.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.
In addition, an independent DMC will periodically review and monitor the safety data from this 
study and advise UCB. The DMC membership includes clinicians knowledgeable about the disease or the treatment. All members have experience and expertise in clinical trials. Board 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the DMC will be inclusive of planned analyses for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The DMC procedures will ensure that data remain blind to the study team and 
Investigators at all times throughout the conduct of the study. The detailed role, scope, 
responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
described in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
Committee will be in place for this study. Specific procedures will be outlined in the charter, which will be developed by [CONTACT_58975].
12.[ADDRESS_764717] of serum chemistry, hematology, and urinalysis, and pregnancy tests (serum or urine) ( Table 12‒2). A centralized laboratory will be used to supply all 
laboratory test supplies and analyze all blood and urine samples for hematology, biochemistry and urinalysis measurements. Any unscheduled laboratory testing should also be collected using PUBLIC COPY riodically to detect as early as possible any 
PUBLIC COPY riodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
PUBLIC COPY safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
PUBLIC COPY authorities, and IRBs/IECs will be informed appropriately and as early as possible.
ly qualified designee/equivalent will conduct an ongoing review 
PUBLIC COPY ly qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
PUBLIC COPY of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
PUBLIC COPY As appropriate for the stage of development and accumulated experience with the IMP, 
ified personnel at UCB may identify additional safety measures (eg,PUBLIC COPY ified personnel at UCB may identify additional safety measures (eg,
signs, laboratory or ECG results) for which data will be periodically reviewed during the course PUBLIC COPY signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
This document cannot be used to support any marketing authorization he AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
This document cannot be used to support any marketing authorization he AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
This document cannot be used to support any marketing authorization particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
This document cannot be used to support any marketing authorization Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
This document cannot be used to support any marketing authorization recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
e events are only considered AEs or SAEs if 
This document cannot be used to support any marketing authorization e events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
This document cannot be used to support any marketing authorization there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
riodically to detect as early as possible any 
This document cannot be used to support any marketing authorization riodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
This document cannot be used to support any marketing authorization safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
This document cannot be used to support any marketing authorization authorities, and IRBs/IECs will be informed appropriately and as early as possible.
ly qualified designee/equivalent will conduct an ongoing review 
This document cannot be used to support any marketing authorization ly qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
This document cannot be used to support any marketing authorization of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
This document cannot be used to support any marketing authorization As appropriate for the stage of development and accumulated experience with the IMP, 
ified personnel at UCB may identify additional safety measures (eg,
This document cannot be used to support any marketing authorization ified personnel at UCB may identify additional safety measures (eg,
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
This document cannot be used to support any marketing authorization signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
In addition, an independent DMC will periodically review and monit
This document cannot be used to support any marketing authorization In addition, an independent DMC will periodically review and monit
study and advise UCB. The DMC membership includes clinicians knowledgeable about the 
This document cannot be used to support any marketing authorization study and advise UCB. The DMC membership includes clinicians knowledgeable about the 
disease or the treatment. All members have experience and expertise in clinical trials. Board 
This document cannot be used to support any marketing authorization disease or the treatment. All members have experience and expertise in clinical trials. Board 
members may not participate in the study as prin
This document cannot be used to support any marketing authorization members may not participate in the study as prin
care physicians. The duration of membership for the DMC will be inclusive of planned analyses 
This document cannot be used to support any marketing authorization care physicians. The duration of membership for the DMC will be inclusive of planned analyses 
for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
This document cannot be used to support any marketing authorization for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The DMC pr
This document cannot be used to support any marketing authorization appropriate. The DMC pr
Investigators at all times throughout the conduct of the study. The detailed role, scope, 
This document cannot be used to support any marketing authorization Investigators at all times throughout the conduct of the study. The detailed role, scope, 
This document cannot be used to support any marketing authorization responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
This document cannot be used to support any marketing authorization responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
descr
This document cannot be used to support any marketing authorization descr ibed in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
This document cannot be used to support any marketing authorization ibed in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
Committee will be in place for this study. Specific procedures will be outlined in the charter, 
This document cannot be used to support any marketing authorization Committee will be in place for this study. Specific procedures will be outlined in the charter, 
which will be developed by [CONTACT_58975].
This document cannot be used to support any marketing authorization which will be developed by [CONTACT_58975].
12.6
This document cannot be used to support any marketing authorization 12.6application and any extensions or variations thereof.Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
application and any extensions or variations thereof.Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
application and any extensions or variations thereof.recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
e events are only considered AEs or SAEs if 
application and any extensions or variations thereof.e events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
application and any extensions or variations thereof.there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
riodically to detect as early as possible any 
application and any extensions or variations thereof.riodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
application and any extensions or variations thereof.safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
application and any extensions or variations thereof.authorities, and IRBs/IECs will be informed appropriately and as early as possible.
ly qualified designee/equivalent will conduct an ongoing review 
application and any extensions or variations thereof.ly qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
application and any extensions or variations thereof.of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
application and any extensions or variations thereof.As appropriate for the stage of development and accumulated experience with the IMP, 
ified personnel at UCB may identify additional safety measures (eg,
application and any extensions or variations thereof.ified personnel at UCB may identify additional safety measures (eg,
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
application and any extensions or variations thereof.signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
In addition, an independent DMC will periodically review and monit
application and any extensions or variations thereof.In addition, an independent DMC will periodically review and monit
study and advise UCB. The DMC membership includes clinicians knowledgeable about the 
application and any extensions or variations thereof.study and advise UCB. The DMC membership includes clinicians knowledgeable about the 
disease or the treatment. All members have experience and expertise in clinical trials. Board 
application and any extensions or variations thereof.disease or the treatment. All members have experience and expertise in clinical trials. Board 
members may not participate in the study as prin
application and any extensions or variations thereof.members may not participate in the study as prin
care physicians. The duration of membership for the DMC will be inclusive of planned analyses 
application and any extensions or variations thereof.care physicians. The duration of membership for the DMC will be inclusive of planned analyses 
for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
application and any extensions or variations thereof.for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The DMC pr
application and any extensions or variations thereof.appropriate. The DMC pr ocedures will ensure that data remain blind to the study team and 
application and any extensions or variations thereof.ocedures will ensure that data remain blind to the study team and 
Investigators at all times throughout the conduct of the study. The detailed role, scope, 
application and any extensions or variations thereof.Investigators at all times throughout the conduct of the study. The detailed role, scope, 
application and any extensions or variations thereof.responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
application and any extensions or variations thereof.responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
ibed in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
application and any extensions or variations thereof.ibed in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
Committee will be in place for this study. Specific procedures will be outlined in the charter, application and any extensions or variations thereof.Committee will be in place for this study. Specific procedures will be outlined in the charter, 
which will be developed by [CONTACT_58975]. application and any extensions or variations thereof. which will be developed by [CONTACT_58975].
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 71of 136the central laboratory. Testing to rule out hepatitis B, hepatitis C, and HIV (see Exclusion 
Criterion #12, Section 6.2) will be performed at Screening in addition to those measurements 
listed in Table 12‒2.
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.
The following laboratory parameters will be measured:
Table 12‒2: Laboratory measurements
Hematology Chemistry Urinalysis Serology
Basophils Bicarbonate Albumin HIV
Eosinophils Calcium Bacteria HLA -B27
Lymphocytes Chloride Crystals Hepatitis B
Atypi[INVESTIGATOR_581556]-CRPaGlucose Hepatitis C
Monocytes Magnesium pH
Neutrophils Potassium RBC
Hematocrit Sodium WBC
Hemoglobin Glucose Urine dipstick for 
pregnancy testingb
MCH BUN
MCHC Creatinine
MCV AST
Platelet count ALT
RBC count ALP
WBC count GGT
Total bilirubinc
LDH
Uric acid
Total cholesterol
Serum FSH testingd
Serum pregnancy testingbPUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY Glucose
PUBLIC COPY Glucose
PUBLIC COPY BUN
PUBLIC COPY BUN
PUBLIC COPY CreatininePUBLIC COPY CreatininePUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization Serology
This document cannot be used to support any marketing authorization Serology
This document cannot be used to support any marketing authorization HIV
This document cannot be used to support any marketing authorization HIV
This document cannot be used to support any marketing authorization HLA
This document cannot be used to support any marketing authorization HLA
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Glucose
This document cannot be used to support any marketing authorization Glucose
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization pH
This document cannot be used to support any marketing authorization pH
This document cannot be used to support any marketing authorization RBC
This document cannot be used to support any marketing authorization RBC
This document cannot be used to support any marketing authorization WBC
This document cannot be used to support any marketing authorization WBC
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Urine dipstick for 
This document cannot be used to support any marketing authorization Urine dipstick for 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Creatinine
This document cannot be used to support any marketing authorization Creatinine
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization AST
This document cannot be used to support any marketing authorization AST
This document cannot be used to support any marketing authorization ALT
This document cannot be used to support any marketing authorization ALT
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.HLA
application and any extensions or variations thereof.HLA -
application and any extensions or variations thereof.-B27
application and any extensions or variations thereof.B27
application and any extensions or variations thereof.Hepatitis B
application and any extensions or variations thereof.Hepatitis B
application and any extensions or variations thereof.Hepatitis C
application and any extensions or variations thereof.Hepatitis C
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.WBC
application and any extensions or variations thereof.WBC
application and any extensions or variations thereof.Urine dipstick for 
application and any extensions or variations thereof.Urine dipstick for 
pregnancy testing
application and any extensions or variations thereof.pregnancy testing
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.ALT
application and any extensions or variations thereof.ALT
application and any extensions or variations thereof.ALP
application and any extensions or variations thereof.ALP
application and any extensions or variations thereof.GGT
application and any extensions or variations thereof.GGT
application and any extensions or variations thereof.Total bilirubin
application and any extensions or variations thereof.Total bilirubin
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 72of 136Table 12‒2: Laboratory measurements
Hematology Chemistry Urinalysis Serology
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; FSH=follicle -stimulating hormone; GGT=gamma glutamyltransferase; HIV=human 
immunodeficiency virus; HLA-B27=human leukocyte antigen B27; hs- CRP=high sensitivity C -reactive 
protein; IMP=investigational medicinal product; LDH=lactate dehydrogenase; MCH=mean corpuscular 
hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood cell; ULN=upper l imit of normal; WBC=white blood cell
ahs-CRP will be tested at specified visits per Table 5‒[ADDRESS_764718] will be conducted at Screening – all other pregnancy tests will be performed on urine. Pregnancy results must be negative prior to administering IMP.
cIf total bilirubin is >ULN, a direct bilirubin estimation (%) will be performed.
dA serum FSH test will be performed at Screening for all female subjects whose last menstrual cycle occurred 
between [ADDRESS_764719] be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section [IP_ADDRESS] ), and, if applicable, also reported as an 
SAE (see Section [IP_ADDRESS] ). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in Table 12‒4 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section [IP_ADDRESS] ). The local 
hepatologist is the expert usually consulted by [CONTACT_58983]. This would usually be a hepatologist, but may be a gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section [IP_ADDRESS]). 
The results of all monitoring, including laboratory testing and other testing, should be madeavailable to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the 
[ADDRESS_764720] be reported as an AE and reported to the study site and sponsor within 24 hours of
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
PUBLIC COPY of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
Section
PUBLIC COPY Section [IP_ADDRESS]
PUBLIC COPY [IP_ADDRESS]
Evaluation of PDILI consists of the diagnostic testing and con
PUBLIC COPY Evaluation of PDILI consists of the diagnostic testing and con
(specific tests dependent on laboratory results and corresponding symptoms) and 
PUBLIC COPY (specific tests dependent on laboratory results and corresponding symptoms) and 
ologist (if applicable; discussed in PUBLIC COPY ologist (if applicable; discussed in 
hepatologist is the expert usually consulted by [CONTACT_581649]. 
This document cannot be used to support any marketing authorization all other pregnancy tests will be performed on urine. 
all female subjects whose last menstrual cycle occurred 
This document cannot be used to support any marketing authorization all female subjects whose last menstrual cycle occurred 
The PDILI IMP discontinuation criteria for this study are provided in 
This document cannot be used to support any marketing authorization The PDILI IMP discontinuation criteria for this study are provided in Section
This document cannot be used to support any marketing authorization Section
up investigation and monitoring detailed below. All PDILI events 
This document cannot be used to support any marketing authorization up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within [ADDRESS_764721] be reported as an AE and reported to the study site and sponsor within 24 hours of
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
This document cannot be used to support any marketing authorization of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS] ), and, if applicable, also reported as an 
This document cannot be used to support any marketing authorization ), and, if applicable, also reported as an 
Evaluation of PDILI consists of the diagnostic testing and con
This document cannot be used to support any marketing authorization Evaluation of PDILI consists of the diagnostic testing and con
(specific tests dependent on laboratory results and corresponding symptoms) and 
This document cannot be used to support any marketing authorization (specific tests dependent on laboratory results and corresponding symptoms) and 
ologist (if applicable; discussed in 
This document cannot be used to support any marketing authorization ologist (if applicable; discussed in 
hepatologist is the expert usually consulted by [CONTACT_581650]. This would usually be a hepatologist, but may be a 
This document cannot be used to support any marketing authorization management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
This document cannot be used to support any marketing authorization gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormalit
This document cannot be used to support any marketing authorization on the diagnosis after the cause of the liver injury/abnormalit
The results of all monitoring, including laboratory testing and other testing, should be made
This document cannot be used to support any marketing authorization The results of all monitoring, including laboratory testing and other testing, should be made
available to the study site and sponsor.
This document cannot be used to support any marketing authorization available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
This document cannot be used to support any marketing authorization All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
This document cannot be used to support any marketing authorization appropriate medical action must not be delayed waiting for the repeat result.
This document cannot be used to support any marketing authorization appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid 
This document cannot be used to support any marketing authorization If tests are done locally for more rapid 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
This document cannot be used to support any marketing authorization central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the 
This document cannot be used to support any marketing authorization most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the 
[ADDRESS_764722] be reported as an AE and reported to the study site and sponsor within 24 hours of
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
application and any extensions or variations thereof.of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
), and, if applicable, also reported as an 
application and any extensions or variations thereof.), and, if applicable, also reported as an 
Evaluation of PDILI consists of the diagnostic testing and con
application and any extensions or variations thereof.Evaluation of PDILI consists of the diagnostic testing and con tinued monitoring included in 
application and any extensions or variations thereof.tinued monitoring included in 
(specific tests dependent on laboratory results and corresponding symptoms) and 
application and any extensions or variations thereof.(specific tests dependent on laboratory results and corresponding symptoms) and 
ologist (if applicable; discussed in 
application and any extensions or variations thereof.ologist (if applicable; discussed in 
hepatologist is the expert usually consulted by [CONTACT_581651].hepatologist is the expert usually consulted by [CONTACT_581652]. This would usually be a hepatologist, but may be a 
application and any extensions or variations thereof.management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
application and any extensions or variations thereof.gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormalit
application and any extensions or variations thereof.on the diagnosis after the cause of the liver injury/abnormalit
The results of all monitoring, including laboratory testing and other testing, should be made
application and any extensions or variations thereof.The results of all monitoring, including laboratory testing and other testing, should be made
available to the study site and sponsor.
application and any extensions or variations thereof.available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
application and any extensions or variations thereof.All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
application and any extensions or variations thereof.appropriate medical action must not be delayed waiting for the repeat result.
application and any extensions or variations thereof.appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid 
application and any extensions or variations thereof.If tests are done locally for more rapid 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
application and any extensions or variations thereof.central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the application and any extensions or variations thereof.most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the 
atory tests are significantly different. Data from the local and central laboratory are to be application and any extensions or variations thereof.atory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.application and any extensions or variations thereof.recorded on the applicable eCRF pages.
UCB [ADDRESS_764723] not occur.
Table 12‒3 summarizes the approach to investigate PDILI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 74of 136Table 12‒3: Required investigations and follow- up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consult.c
Medical Monitor must be notified 
within 24 hours 
(eg,by [CONTACT_67600]) and subject 
discussed with 
Medical Monitor ASAP.Immediate IMP discontinuation
d.Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed 
ASAP (see Section [IP_ADDRESS] ); 
recommended to 
occur at the site with 
HCP.Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.e
Monitoring of liver chemistry 
values at least twice per week for 2 weeks.
e
Immediate IMP ≥3xULN NA Yes
≥5xULN NA NA Need for hepatology consult to be 
discussed. (required 
if ALT or AST 
≥8xULN). Medical 
Monitor must be notified within 
24hours (eg, by 
[CONTACT_58980]) and 
subject discussed 
with Medical Monitor ASAP.PUBLIC COPY PUBLIC COPY Need for hepatology 
PUBLIC COPY Need for hepatology 
discussed. (required 
PUBLIC COPY discussed. (required 
if ALT or AST PUBLIC COPY if ALT or AST 
≥8xULN). PUBLIC COPY ≥8xULN). Medical PUBLIC COPY Medical PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Essential: Must have 
This document cannot be used to support any marketing authorization Essential: Must have 
repeat liver chemistry 
This document cannot be used to support any marketing authorization repeat liver chemistry 
values and additional 
This document cannot be used to support any marketing authorization values and additional 
testing completed 
This document cannot be used to support any marketing authorization testing completed 
ASAP (see 
This document cannot be used to support any marketing authorization ASAP (see 
Section
This document cannot be used to support any marketing authorization Section
recommended to 
This document cannot be used to support any marketing authorization recommended to 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialMedical 
This document cannot be used to support any marketing authorization Medical 
Monitor must be 
This document cannot be used to support any marketing authorization Monitor must be 
notified within 
This document cannot be used to support any marketing authorization notified within 
24hours (eg, by 
[CONTACT_581653] 24hours (eg, by 
[CONTACT_58980]) and 
This document cannot be used to support any marketing authorization laboratory alert) and 
subject discussed 
This document cannot be used to support any marketing authorization subject discussed 
with Medical Monitor 
This document cannot be used to support any marketing authorization with Medical Monitor 
ASAP.
This document cannot be used to support any marketing authorization ASAP.
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
Essential: Must have 
application and any extensions or variations thereof.Essential: Must have 
repeat liver chemistry 
application and any extensions or variations thereof.repeat liver chemistry 
values and additional 
application and any extensions or variations thereof.values and additional 
testing completed 
application and any extensions or variations thereof.testing completed 
ASAP (see 
application and any extensions or variations thereof.ASAP (see 
Section
application and any extensions or variations thereof.Section [IP_ADDRESS]
application and any extensions or variations thereof.[IP_ADDRESS] ); 
application and any extensions or variations thereof.); 
recommended to 
application and any extensions or variations thereof.recommended to 
occur at the site with 
application and any extensions or variations thereof.occur at the site with 
HCP.
application and any extensions or variations thereof.HCP.Monitoring of liver chemistry 
application and any extensions or variations thereof.Monitoring of liver chemistry 
values at least twice per week 
application and any extensions or variations thereof.values at least twice per week 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.laboratory alert) and 
application and any extensions or variations thereof.laboratory alert) and 
subject discussed 
application and any extensions or variations thereof.subject discussed 
with Medical Monitor 
application and any extensions or variations thereof.with Medical Monitor 
ASAP.
application and any extensions or variations thereof.ASAP.
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 75of 136Table 12‒3: Required investigations and follow- up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x baseline)<2xULN No Discussion with Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence of resolution (see 
Follow-up 
requirements) 
cFurther investigation – immediate IMP 
discontinuation not 
required (see 
Section [IP_ADDRESS] ).
IMP discontinuation required if any of 
the following occur:
Subject cannot 
comply with monitoring 
schedule. 
Liver chemistry 
values continue to increase 
Liver chemistry values remain ≥3xULN (and ≥2xbaseline ) 
after 2 weeks of monitoring without 
evidence of 
resolutionEssential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional testing completed 
within 48hours at 
the site with HCP 
(see Section 
[IP_ADDRESS] ).discontinuation required if 
liver chemistry values 
continue to increase. After 2 
weeks of monitoring liver chemistry values: 
Discontinue IMP if levels remain ≥3xULN (and ≥2x baseline) without evidence of resolution
e
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuese.PUBLIC COPY [IP_ADDRESS]
PUBLIC COPY [IP_ADDRESS]
IMP discontinuation 
PUBLIC COPY IMP discontinuation 
required if any of 
PUBLIC COPY required if any of 
the following occur:
PUBLIC COPY the following occur:

PUBLIC COPY 
PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Essential: Every 
This document cannot be used to support any marketing authorization Essential: Every 
attempt must be 
This document cannot be used to support any marketing authorization attempt must be 
made to have 
This document cannot be used to support any marketing authorization made to have 
repeat liver 
This document cannot be used to support any marketing authorization repeat liver 
chemistry values 
This document cannot be used to support any marketing authorization chemistry values 
and additional 
This document cannot be used to support any marketing authorization and additional 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization IMP discontinuation 
This document cannot be used to support any marketing authorization IMP discontinuation 
required if any of 
This document cannot be used to support any marketing authorization required if any of 
the following occur:
This document cannot be used to support any marketing authorization the following occur:
Subject cannot 
This document cannot be used to support any marketing authorization Subject cannot 
comply with 
This document cannot be used to support any marketing authorization comply with 
monitoring 
This document cannot be used to support any marketing authorization monitoring 
schedule. 
This document cannot be used to support any marketing authorization schedule. 
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
discontinuation required if 
application and any extensions or variations thereof.discontinuation required if 
application and any extensions or variations thereof.application and any extensions or variations thereof.Essential: Every 
application and any extensions or variations thereof.Essential: Every 
attempt must be 
application and any extensions or variations thereof.attempt must be 
made to have 
application and any extensions or variations thereof.made to have 
repeat liver 
application and any extensions or variations thereof.repeat liver 
chemistry values 
application and any extensions or variations thereof.chemistry values 
and additional 
application and any extensions or variations thereof.and additional 
testing completed 
application and any extensions or variations thereof.testing completed 
within 48hours at 
application and any extensions or variations thereof.within 48hours at 
the site with HCP 
application and any extensions or variations thereof.the site with HCP 
application and any extensions or variations thereof.the following occur:
application and any extensions or variations thereof.the following occur:
Subject cannot 
application and any extensions or variations thereof.Subject cannot 
comply with 
application and any extensions or variations thereof.comply with 
monitoring 
application and any extensions or variations thereof.monitoring 
schedule. 
application and any extensions or variations thereof.schedule. 

application and any extensions or variations thereof.Liver chemistry 
application and any extensions or variations thereof.Liver chemistry 
values continue 
application and any extensions or variations thereof.values continue 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 76of 136Table 12‒3: Required investigations and follow- up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc are practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug- induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
cDetails provided in Section [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would usually be a hepatologist, but may be a gastroenterologist. 
dDetails are provided in Section [IP_ADDRESS].[ADDRESS_764724] (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY . The local hepatologist is the expert usually consulted by [CONTACT_581654] . The local hepatologist is the expert usually consulted by [CONTACT_581655], but may be a gastroenterologist. 
PUBLIC COPY hepatologist, but may be a gastroenterologist. 
by [CONTACT_352315]. Determination of stabilization is at the discretion of the 
PUBLIC COPY by [CONTACT_352315]. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
This document cannot be used to support any marketing authorization ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
induced liver injury; ULN=upper limit of normal 
This document cannot be used to support any marketing authorization induced liver injury; ULN=upper limit of normal 
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
This document cannot be used to support any marketing authorization Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
This document cannot be used to support any marketing authorization If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
. The local hepatologist is the expert usually consulted by [CONTACT_581656] . The local hepatologist is the expert usually consulted by [CONTACT_581655], but may be a gastroenterologist. 
This document cannot be used to support any marketing authorization hepatologist, but may be a gastroenterologist. 
by [CONTACT_352315]. Determination of stabilization is at the discretion of the 
This document cannot be used to support any marketing authorization by [CONTACT_352315]. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
application and any extensions or variations thereof.ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
induced liver injury; ULN=upper limit of normal 
application and any extensions or variations thereof.induced liver injury; ULN=upper limit of normal 
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
application and any extensions or variations thereof.Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
application and any extensions or variations thereof.If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
. The local hepatologist is the expert usually consulted by [CONTACT_581657].. The local hepatologist is the expert usually consulted by [CONTACT_581658]. Determination of stabilization is at the discretion of the 
application and any extensions or variations thereof.by [CONTACT_352315]. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
application and any extensions or variations thereof.Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
application and any extensions or variations thereof.
UCB [ADDRESS_764725] 
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24hours (eg, by [CONTACT_58980]), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The local hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full hepatology assessment (see Section [IP_ADDRESS]) and SAE report (if applicable).
[IP_ADDRESS] Immediate action: Determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to immediate discontinuation (see Section 6.3.1 and Table 12‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
[IP_ADDRESS].1 IMP restart/rechallenge
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
[IP_ADDRESS] Testing: Identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by [CONTACT_58985] 12‒4 (laboratory measurements) and Table 12‒5 (additional 
information). Results of the laboratory measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
indicates a requirement for other assessments not included below, these additional assessments 
should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
Table 12‒4: PDILI laboratory measurements
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb- IgM
Hepatitis C RNAPUBLIC COPY medically necessary should also be discontinued. The Investigator should also consider 
PUBLIC COPY medically necessary should also be discontinued. The Investigator should also consider 
reduction for medically necessary concomitant medication and consider changing any medically 
PUBLIC COPY reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
PUBLIC COPY required concomitant medication known to be hepatotoxic to a suitable alternative. 
Rechallenge with a substance potentially causing d
PUBLIC COPY Rechallenge with a substance potentially causing d
Testing: Identification/exclusion of alternative etiology
PUBLIC COPY Testing: Identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when PUBLIC COPY The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by [CONTACT_581659] a reasonable possibility that they may have been caused by [CONTACT_581660] (followed by [CONTACT_58984]) to 
This document cannot be used to support any marketing authorization hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to 
details).
This document cannot be used to support any marketing authorization details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
This document cannot be used to support any marketing authorization When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider 
This document cannot be used to support any marketing authorization medically necessary should also be discontinued. The Investigator should also consider 
reduction for medically necessary concomitant medication and consider changing any medically 
This document cannot be used to support any marketing authorization reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
This document cannot be used to support any marketing authorization required concomitant medication known to be hepatotoxic to a suitable alternative. 
Rechallenge with a substance potentially causing d
This document cannot be used to support any marketing authorization Rechallenge with a substance potentially causing d rug
This document cannot be used to support any marketing authorization rug-
This document cannot be used to support any marketing authorization -induced liver injury is dangerous, may be 
This document cannot be used to support any marketing authorization induced liver injury is dangerous, may be 
Testing: Identification/exclusion of alternative etiology
This document cannot be used to support any marketing authorization Testing: Identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
This document cannot be used to support any marketing authorization The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by [CONTACT_581661] a reasonable possibility that they may have been caused by [CONTACT_581662] 
‒
This document cannot be used to support any marketing authorization ‒4
This document cannot be used to support any marketing authorization 4(laboratory measurements) and 
This document cannot be used to support any marketing authorization (laboratory measurements) and 
of the laboratory measurements and information collected are to be 
This document cannot be used to support any marketing authorization of the laboratory measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
This document cannot be used to support any marketing authorization submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
indicates a requirement for other assessments not included below, these additional assessments 
This document cannot be used to support any marketing authorization indicates a requirement for other assessments not included below, these additional assessments 
uld be completed and submitted, as applicable.
This document cannot be used to support any marketing authorization uld be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
This document cannot be used to support any marketing authorization All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
This document cannot be used to support any marketing authorization concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed
This document cannot be used to support any marketing authorization The following measurements are to be assessed
Table
This document cannot be used to support any marketing authorization Table 12
This document cannot be used to support any marketing authorization 12‒
This document cannot be used to support any marketing authorization ‒4
This document cannot be used to support any marketing authorization 4:
This document cannot be used to support any marketing authorization :
Virology
This document cannot be used to support any marketing authorization Virology
related
This document cannot be used to support any marketing authorization related
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.atory values and symptoms of hepatitis or 
application and any extensions or variations thereof.atory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to 
application and any extensions or variations thereof.hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to 
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
application and any extensions or variations thereof.When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider 
application and any extensions or variations thereof.medically necessary should also be discontinued. The Investigator should also consider 
reduction for medically necessary concomitant medication and consider changing any medically 
application and any extensions or variations thereof.reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
application and any extensions or variations thereof.required concomitant medication known to be hepatotoxic to a suitable alternative. 
induced liver injury is dangerous, may be 
application and any extensions or variations thereof.induced liver injury is dangerous, may be 
Testing: Identification/exclusion of alternative etiology
application and any extensions or variations thereof.Testing: Identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
application and any extensions or variations thereof.The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by [CONTACT_581663].there is a reasonable possibility that they may have been caused by [CONTACT_581662] 
(laboratory measurements) and 
application and any extensions or variations thereof.(laboratory measurements) and 
of the laboratory measurements and information collected are to be 
application and any extensions or variations thereof.of the laboratory measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
application and any extensions or variations thereof.submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
indicates a requirement for other assessments not included below, these additional assessments 
application and any extensions or variations thereof.indicates a requirement for other assessments not included below, these additional assessments 
uld be completed and submitted, as applicable.
application and any extensions or variations thereof.uld be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
application and any extensions or variations thereof.All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
application and any extensions or variations thereof.concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed
application and any extensions or variations thereof.The following measurements are to be assessed
PDILI laboratory measurements
application and any extensions or variations thereof.PDILI laboratory measurements
Hepatitis A IgM antibodyapplication and any extensions or variations thereof.Hepatitis A IgM antibodyapplication and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 78of 136Table 12‒4: PDILI laboratory measurements
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Eosinophil count
Urinalysis Toxicology screen
Chemistry Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Additional Prothrombin time/INRa
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb -
IgM=hepatitis B core antibody -IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; 
PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
aMeasured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:PUBLIC COPY If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
PUBLIC COPY If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
PUBLIC COPY Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
PUBLIC COPY Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb
PUBLIC COPY ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb
IgM; HBsAg=hepatitis B surface antigen; PUBLIC COPY IgM; HBsAg=hepatitis B surface antigen; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug PUBLIC COPY INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization cholesterol, albumin
This document cannot be used to support any marketing authorization cholesterol, albumin
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb
This document cannot be used to support any marketing authorization ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb
IgM; HBsAg=hepatitis B surface antigen; 
This document cannot be used to support any marketing authorization IgM; HBsAg=hepatitis B surface antigen; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug
This document cannot be used to support any marketing authorization INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug
PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
This document cannot be used to support any marketing authorization PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
This document cannot be used to support any marketing authorization Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
This document cannot be used to support any marketing authorization hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms includ
This document cannot be used to support any marketing authorization tenderness; hypersensitivity symptoms includ
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization The following additional information is to be collected:
This document cannot be used to support any marketing authorization The following additional information is to be collected:
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.cholesterol, albumin
application and any extensions or variations thereof.cholesterol, albumin
application and any extensions or variations thereof.application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb
application and any extensions or variations thereof.ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb
IgM; HBsAg=hepatitis B surface antigen; 
application and any extensions or variations thereof.IgM; HBsAg=hepatitis B surface antigen; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug
application and any extensions or variations thereof.INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug
PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
application and any extensions or variations thereof.PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
application and any extensions or variations thereof.Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
application and any extensions or variations thereof.hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms includ
application and any extensions or variations thereof.tenderness; hypersensitivity symptoms includ e eosinophilia (>5%), rash, and fever (without clear alternative 
application and any extensions or variations thereof.e eosinophilia (>5%), rash, and fever (without clear alternative 
application and any extensions or variations thereof.application and any extensions or variations thereof.The following additional information is to be collected:
application and any extensions or variations thereof.The following additional information is to be collected:
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 79of 136Table 12‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
Adverse reactions to drugs
Allergies
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)
Recent travel 
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury
[IP_ADDRESS] Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
12.7 Other saf ety measurements
12.7.1 Vital signs
The Investigator or designee should measure all vital signs (systolic and diastolic blood pressure (BP), temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting for at least [ADDRESS_764726] should remain seated during the measurements. Body 
temperature should be obtained prior to dosing with IMP at study visits when IMP is 
administered. At Baseline/Day 1, pulse and BP should be collected prior to IMP administration and then at [ADDRESS_764727] or hepatology consult, if done
PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
This document cannot be used to support any marketing authorization disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha
This document cannot be used to support any marketing authorization Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -
This document cannot be used to support any marketing authorization -1 antitrypsin 
This document cannot be used to support any marketing authorization 1 antitrypsin 
ogression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
This document cannot be used to support any marketing authorization ogression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)
This document cannot be used to support any marketing authorization should not be used as an explanation for significant AST and/or ALT elevations.)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization The appearance or worsening of clinical symptoms of hepatitis or hypersensitivi
This document cannot be used to support any marketing authorization The appearance or worsening of clinical symptoms of hepatitis or hypersensitivi
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
This document cannot be used to support any marketing authorization vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
This document cannot be used to support any marketing authorization Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
This document cannot be used to support any marketing authorization Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Results of any specialist or hepatology consult, if done
This document cannot be used to support any marketing authorization Results of any specialist or hepatology consult, if done
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug
This document cannot be used to support any marketing authorization ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug
This document cannot be used to support any marketing authorization up evaluation
This document cannot be used to support any marketing authorization up evaluation
induced liver injury events require follow
This document cannot be used to support any marketing authorization induced liver injury events require follow
Monitoring should cont
This document cannot be used to support any marketing authorization Monitoring should cont
This document cannot be used to support any marketing authorization return to baseline. Determination of stabilization is at the discretion of the Investigator in 
This document cannot be used to support any marketing authorization return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Other saf
This document cannot be used to support any marketing authorization Other saf
12.7.1
This document cannot be used to support any marketing authorization 12.7.1
The Investigator or designee should measure all vital signs (systolic and diastolic blood 
This document cannot be used to support any marketing authorization The Investigator or designee should measure all vital signs (systolic and diastolic blood 
pressure
This document cannot be used to support any marketing authorization pressure
for at least [ADDRESS_764728] 5
temperature should be obtained prior to dosing with IMP at study visits when IMP is This document cannot be used to support any marketing authorization temperature should be obtained prior to dosing with IMP at study visits when IMP is application and any extensions or variations thereof.1 antitrypsin 
application and any extensions or variations thereof.1 antitrypsin 
ogression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
application and any extensions or variations thereof.ogression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)
application and any extensions or variations thereof.should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivi
application and any extensions or variations thereof.The appearance or worsening of clinical symptoms of hepatitis or hypersensitivi ty (eg, fatigue, nausea, 
application and any extensions or variations thereof.ty (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
application and any extensions or variations thereof.vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
application and any extensions or variations thereof.Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
application and any extensions or variations thereof.Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Results of any specialist or hepatology consult, if done
application and any extensions or variations thereof.Results of any specialist or hepatology consult, if done
application and any extensions or variations thereof.application and any extensions or variations thereof.ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug
application and any extensions or variations thereof.ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug
application and any extensions or variations thereof.up evaluation
application and any extensions or variations thereof.up evaluation
induced liver injury events require follow
application and any extensions or variations thereof.induced liver injury events require follow
Monitoring should cont
application and any extensions or variations thereof.Monitoring should cont
application and any extensions or variations thereof.inue until liver chemistry values normalize, stabilize, or 
application and any extensions or variations thereof.inue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in 
application and any extensions or variations thereof.return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
application and any extensions or variations thereof.consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Other saf
application and any extensions or variations thereof.Other saf
Vital signs
application and any extensions or variations thereof.Vital signs
The Investigator or designee should measure all vital signs (systolic and diastolic blood application and any extensions or variations thereof.The Investigator or designee should measure all vital signs (systolic and diastolic blood 
(BP), temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting application and any extensions or variations thereof.(BP), temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 80of [ZIP_CODE].7.2 Body weight and height
Height is collected at the Screening Visit only. Body weight will be measured by [CONTACT_581664] 5‒1. The Investigator or designee will measure the 
height of the subject with shoes removed in meters and the weight of the subject in kilograms. 
The same scale should be utilized throughout the study where possible.
12.7.3 Physical examination
The physical examination should be conducted by [CONTACT_58986] 5‒1 and will include general appearance; ear, nose, and throat; eyes, hair, and 
skin; respi[INVESTIGATOR_696]; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.
12.7.4 12-lead electrocardiogram
The Investigator or designee will perform the ECG at time points specified in Table 5‒1. The 
ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
12.7.5 Tuberculosis and TB risk factor assessment and management
All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
Table 5‒[ADDRESS_764729] 
(Section [IP_ADDRESS]), laboratory testing ( Section [IP_ADDRESS] ), and subject questionnaire 
(Section [IP_ADDRESS]). 
At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
recommended), a chest X-ray or CT (unless already performed within 3 months of screening) 
and an examination for signs and symptoms of TB. In addition, each subject will complete a TB questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
Exclusion Criteria at Screening
Subjects with known TB infection, at high risk of acquiring TB infection, with LTBI, or current 
or history of NTMB infection.
a.Known TB infection whether present or past is defined as:
Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
extra-pulmonary)
History of active TB infection involving any organ system or findings in other organ systems consistent with TB infection, unless adequately treated and proven to be fully recovered upon consult with a TB specialist.
Any evidence by [CONTACT_581665]’s medical historyPUBLIC COPY Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
PUBLIC COPY Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
factor assessment and management
PUBLIC COPY factor assessment and management
All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
PUBLIC COPY All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
cal examination for signs and symptoms of TB, chest X
PUBLIC COPY cal examination for signs and symptoms of TB, chest X
Section 
PUBLIC COPY Section [IP_ADDRESS]
PUBLIC COPY [IP_ADDRESS]
At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
PUBLIC COPY At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
ray or CT (unless already performed within 3 months of screening) PUBLIC COPY ray or CT (unless already performed within 3 months of screening) 
tion for signs and symptoms of TB. In addition, each subject will complete a TB PUBLIC COPY tion for signs and symptoms of TB. In addition, each subject will complete a TB 
This document cannot be used to support any marketing authorization The physical examination should be conducted by [CONTACT_581666]; ear, nose, and throat; eyes, hair, and 
This document cannot be used to support any marketing authorization and will include general appearance; ear, nose, and throat; eyes, hair, and 
skin; respi[INVESTIGATOR_696]; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
This document cannot be used to support any marketing authorization skin; respi[INVESTIGATOR_696]; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Findings considered clinically significant changes sinc
This document cannot be used to support any marketing authorization reflexes); and mental status. Findings considered clinically significant changes sinc e the physical 
This document cannot be used to support any marketing authorization e the physical 
The Investigator or designee will perform the ECG at time points specified in 
This document cannot be used to support any marketing authorization The Investigator or designee will perform the ECG at time points specified in Table
This document cannot be used to support any marketing authorization Table
ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
This document cannot be used to support any marketing authorization ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
This document cannot be used to support any marketing authorization Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
factor assessment and management
This document cannot be used to support any marketing authorization factor assessment and management
All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
This document cannot be used to support any marketing authorization All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
cal examination for signs and symptoms of TB, chest X
This document cannot be used to support any marketing authorization cal examination for signs and symptoms of TB, chest X
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS] ), and subject questionnaire 
This document cannot be used to support any marketing authorization ), and subject questionnaire 
At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
This document cannot be used to support any marketing authorization At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
ray or CT (unless already performed within 3 months of screening) 
This document cannot be used to support any marketing authorization ray or CT (unless already performed within 3 months of screening) 
tion for signs and symptoms of TB. In addition, each subject will complete a TB 
This document cannot be used to support any marketing authorization tion for signs and symptoms of TB. In addition, each subject will complete a TB 
questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
This document cannot be used to support any marketing authorization questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
Exclusion Criteria at Screening
This document cannot be used to support any marketing authorization Exclusion Criteria at Screening
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Subjects with known TB infection, at high risk of acquiri
This document cannot be used to support any marketing authorization Subjects with known TB infection, at high risk of acquiri
or history of NTMB infection.
This document cannot be used to support any marketing authorization or history of NTMB infection.
Known TB infection whether present or past is defined as:
This document cannot be used to support any marketing authorization Known TB infection whether present or past is defined as:
Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
This document cannot be used to support any marketing authorization Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
extra
This document cannot be used to support any marketing authorization extra -
This document cannot be used to support any marketing authorization -pulmonary)
This document cannot be used to support any marketing authorization pulmonary)
History of active TB infectio
This document cannot be used to support any marketing authorization History of active TB infectio
systems consistent with TB infection, unless adequately treated and proven to be fully 
This document cannot be used to support any marketing authorization systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.
This document cannot be used to support any marketing authorization recovered upon consult with a TB specialist.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.e the physical 
application and any extensions or variations thereof.e the physical 
Table
application and any extensions or variations thereof.Table 5
application and any extensions or variations thereof.5‒
application and any extensions or variations thereof.‒1
application and any extensions or variations thereof.1
ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
application and any extensions or variations thereof.ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
application and any extensions or variations thereof.Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
factor assessment and management
application and any extensions or variations thereof.factor assessment and management
All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
application and any extensions or variations thereof.All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
cal examination for signs and symptoms of TB, chest X
application and any extensions or variations thereof.cal examination for signs and symptoms of TB, chest X
), and subject questionnaire 
application and any extensions or variations thereof.), and subject questionnaire 
At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
application and any extensions or variations thereof.At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
ray or CT (unless already performed within 3 months of screening) 
application and any extensions or variations thereof.ray or CT (unless already performed within 3 months of screening) 
tion for signs and symptoms of TB. In addition, each subject will complete a TB 
application and any extensions or variations thereof.tion for signs and symptoms of TB. In addition, each subject will complete a TB 
questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
application and any extensions or variations thereof.questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
application and any extensions or variations thereof.Subjects with known TB infection, at high risk of acquiri
application and any extensions or variations thereof.Subjects with known TB infection, at high risk of acquiri
Known TB infection whether present or past is defined as:
application and any extensions or variations thereof.Known TB infection whether present or past is defined as:
Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
application and any extensions or variations thereof.Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
pulmonary)
application and any extensions or variations thereof.pulmonary)
History of active TB infectio
application and any extensions or variations thereof.History of active TB infectio
systems consistent with TB infection, unless adequately treated and proven to be fully 
application and any extensions or variations thereof.systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.application and any extensions or variations thereof.recovered upon consult with a TB specialist.
Any evidence by [CONTACT_581667]. Any evidence by [CONTACT_581668] w
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 81of 136b. High risk of acquiring TB infection is defined as:
Known exposure to another person with active TB infection within the 3 months prior to 
Screening
Time spent in a healthcare delivery setting or institution where individuals infected with TB are housed and where the risk of transmission of infection is high
c.Latent TB infection is defined as:
The absence of signs, symptoms (ie, evidence of organ-specific involvement), or physical 
findings suggestive of TB infection with a positive IGRA test (or [ADDRESS_764730] results) and a chest X-ray (or other imaging) without evidence of TB infection. If the result of the IGRA test is indeterminate, the particular IGRA test previously performed 
may be repeated once; if positive or indeterminate on retest, the subject may not be 
randomized to IMP without further evaluation, treatment and discussion with Study Physician, if Latent TB infection is identified. The retest must be done during the protocol-defined Screening window.
Note: If available, respi[INVESTIGATOR_368738] (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) http://www.cdc.gov/TB/topic /testing/default.htm)
d. Current or history of NTMB infection despi[INVESTIGATOR_58919].
Signs and Symptoms
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
patients and/or patients treated with TNF inhibitors, extra-pulmonary manifestations of TB are 
common compared to normal population.
Some common symptoms that the subject may present are dependent on the primary focus of 
infection and may include cough, blood in sputum, night sweats, lymphadenitis, joint 
pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal pain (mimicking inflammatory bowel disease), etc. Unusual presentations should always be considered.
Latent tuberculosis infection is defined in the “Exclusion Criteria” above. If the result of the 
IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without further 
evaluation by a TB specialist. If LTBI or active TB is identified, subject must undergo 
appropriate study specified withdrawal procedures. The retest must be done during the protocol-defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria cultu re 
media (or if available by [CONTACT_581669] [MTB] rifampin [RIF] test) and result must be negative for TB inducing pathogens.PUBLIC COPY Note: If available, respi[INVESTIGATOR_581557]: If available, respi[INVESTIGATOR_397122] (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
PUBLIC COPY TB (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
http://www.cdc.gov/TB/topic /testing/default.htm)
PUBLIC COPY http://www.cdc.gov/TB/topic /testing/default.htm)
Current or history of NTMB infection despi[INVESTIGATOR_58919].
PUBLIC COPY Current or history of NTMB infection despi[INVESTIGATOR_58919].
The Investigator should consider all potential sites of infection when assessing for TB during the 
PUBLIC COPY The Investigator should consider all potential sites of infection when assessing for TB during the 
ion, and other evaluations, and based on the subject’s medical or social history. 
PUBLIC COPY ion, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal PUBLIC COPY The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised PUBLIC COPY system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
This document cannot be used to support any marketing authorization physical 
This document cannot be used to support any marketing authorization physical 
findings suggestive of TB infection with a positive IGRA test (or [ADDRESS_764731] (or 2 indeterminate IGRA 
ray (or other imaging) without evidence of TB infection. If the 
This document cannot be used to support any marketing authorization ray (or other imaging) without evidence of TB infection. If the 
previously performed 
This document cannot be used to support any marketing authorization previously performed 
may be repeated once; if positive or indeterminate on retest, the subject may not be 
This document cannot be used to support any marketing authorization may be repeated once; if positive or indeterminate on retest, the subject may not be 
randomized to IMP without further evaluation, treatment and discussion with Study 
This document cannot be used to support any marketing authorization randomized to IMP without further evaluation, treatment and discussion with Study 
Physician, if Latent TB infection is identified. The retest must be 
This document cannot be used to support any marketing authorization Physician, if Latent TB infection is identified. The retest must be done during the 
This document cannot be used to support any marketing authorization done during the 
Note: If available, respi[INVESTIGATOR_581558]: If available, respi[INVESTIGATOR_397122] (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
This document cannot be used to support any marketing authorization TB (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
Current or history of NTMB infection despi[INVESTIGATOR_58919].
This document cannot be used to support any marketing authorization Current or history of NTMB infection despi[INVESTIGATOR_58919].
The Investigator should consider all potential sites of infection when assessing for TB during the 
This document cannot be used to support any marketing authorization The Investigator should consider all potential sites of infection when assessing for TB during the 
ion, and other evaluations, and based on the subject’s medical or social history. 
This document cannot be used to support any marketing authorization ion, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
This document cannot be used to support any marketing authorization The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
This document cannot be used to support any marketing authorization system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
patients and/or patients treated with TNF inhibitors, extra
This document cannot be used to support any marketing authorization patients and/or patients treated with TNF inhibitors, extra
common compared to normal population.
This document cannot be used to support any marketing authorization common compared to normal population.
Some common symptoms that the subject may present are dependent on the primary focus of 
This document cannot be used to support any marketing authorization Some common symptoms that the subject may present are dependent on the primary focus of 
infection and may include cough, b
This document cannot be used to support any marketing authorization infection and may include cough, b
pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal pain (mimicking inflammatory 
This document cannot be used to support any marketing authorization pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal pain (mimicking inflammatory 
This document cannot be used to support any marketing authorization bowel disease), etc. Unusual presentations should always be considered.
This document cannot be used to support any marketing authorization bowel disease), etc. Unusual presentations should always be considered.
Latent tuberculosis infection is defined 
This document cannot be used to support any marketing authorization Latent tuberculosis infection is defined 
IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
This document cannot be used to support any marketing authorization IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without further 
This document cannot be used to support any marketing authorization positive or indeterminate on retest, the subject may not be randomized to IMP without further 
evaluation by a T
This document cannot be used to support any marketing authorization evaluation by a T
appropriate study specified withdrawal procedures. The retest must be done during the protocol
This document cannot be used to support any marketing authorization appropriate study specified withdrawal procedures. The retest must be done during the protocol
defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria cultu
This document cannot be used to support any marketing authorization defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria cultu
media (or if available by [CONTACT_581670] (or if available by [CONTACT_58988] [MTB] rifampin [RIF] test) and result must be negative for TB 
This document cannot be used to support any marketing authorization mycobacterium tuberculosis [MTB] rifampin [RIF] test) and result must be negative for TB application and any extensions or variations thereof.ray (or other imaging) without evidence of TB infection. If the 
application and any extensions or variations thereof.ray (or other imaging) without evidence of TB infection. If the 
previously performed 
application and any extensions or variations thereof.previously performed 
may be repeated once; if positive or indeterminate on retest, the subject may not be 
application and any extensions or variations thereof.may be repeated once; if positive or indeterminate on retest, the subject may not be 
randomized to IMP without further evaluation, treatment and discussion with Study 
application and any extensions or variations thereof.randomized to IMP without further evaluation, treatment and discussion with Study 
done during the 
application and any extensions or variations thereof.done during the 
Note: If available, respi[INVESTIGATOR_581559].Note: If available, respi[INVESTIGATOR_397122] (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
application and any extensions or variations thereof.TB (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
Current or history of NTMB infection despi[INVESTIGATOR_58919].
application and any extensions or variations thereof.Current or history of NTMB infection despi[INVESTIGATOR_58919].
The Investigator should consider all potential sites of infection when assessing for TB during the 
application and any extensions or variations thereof.The Investigator should consider all potential sites of infection when assessing for TB during the 
ion, and other evaluations, and based on the subject’s medical or social history. 
application and any extensions or variations thereof.ion, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
application and any extensions or variations thereof.The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
application and any extensions or variations thereof.system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
patients and/or patients treated with TNF inhibitors, extra
application and any extensions or variations thereof.patients and/or patients treated with TNF inhibitors, extra
common compared to normal population.
application and any extensions or variations thereof.common compared to normal population.
Some common symptoms that the subject may present are dependent on the primary focus of 
application and any extensions or variations thereof.Some common symptoms that the subject may present are dependent on the primary focus of 
infection and may include cough, b
application and any extensions or variations thereof.infection and may include cough, b lood in sputum, night sweats, lymphadenitis, joint 
application and any extensions or variations thereof.lood in sputum, night sweats, lymphadenitis, joint 
pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal pain (mimicking inflammatory 
application and any extensions or variations thereof.pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal pain (mimicking inflammatory 
application and any extensions or variations thereof.bowel disease), etc. Unusual presentations should always be considered.
application and any extensions or variations thereof.bowel disease), etc. Unusual presentations should always be considered.
Latent tuberculosis infection is defined 
application and any extensions or variations thereof.Latent tuberculosis infection is defined 
IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
application and any extensions or variations thereof.IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without further 
application and any extensions or variations thereof.positive or indeterminate on retest, the subject may not be randomized to IMP without further 
evaluation by a T
application and any extensions or variations thereof.evaluation by a T B specialist. If LTBI or active TB is identified, subject must undergo 
application and any extensions or variations thereof.B specialist. If LTBI or active TB is identified, subject must undergo 
appropriate study specified withdrawal procedures. The retest must be done during the protocolapplication and any extensions or variations thereof.appropriate study specified withdrawal procedures. The retest must be done during the protocol
defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria cultu application and any extensions or variations thereof. defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria cultu
UCB [ADDRESS_764732] (eg, pulmonologist, infectious disease specialist) for further evaluation. If test conversion indicates LTBI, active TB, or NTMB then, per UCB TB working instructions, 
TB test conversion (confirmed) should be classified adequately, either as due to LTBI, active TB 
infection, or NTMB, respectively. Additional assessments (eg, blood tests or IGRA, chest X-rays, or other imaging) should be performed where medically relevant and documented. Such conversions should be reported to the UCB PS function.
Latent TB
In case the evaluation by [CONTACT_18405] a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the subject must be withdrawn.
Every related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
WD Visit assessments, and complete a SFU Visit (20 weeks after the final dose of IMP).
Active TB or NTMB infection 
Subjects who develop active TB or NTMB infection during the study must be withdrawn from 
the study. The subject must be immediately discontinued from IMP and an WD Visit must be 
scheduled as soon as possible, but no later than the next scheduled visit. The subject should be 
encouraged to keep the SFU Visit as specified by [CONTACT_760]. Treatment should be started 
immediately.
Note that subjects with history of NTMB or active NTMB infection are excluded from the study 
regardless of prior or current therapy for this condition. 
[IP_ADDRESS] Tuberculosis assessment by [CONTACT_58989], the TB assessment by [CONTACT_18406] (QuantiFERON TB test is 
recommended) will be performed at Screening and should be repeated at the SFU Visit for all subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
recommends that a TB specialist be consulted where TB (latent or active) is suspected or if there 
are doubts regarding test results. If latent or active TB is identified, subject must undergo 
appropriate study-specified withdrawal procedures. The retest during Screening must be done 
during the protocol-defined Screening window.
[IP_ADDRESS] Chest X-ray for tuberculosis
A plain posteroanterior chest X-ray must be performed during the Screening Period unless one 
has been performed within [ADDRESS_764733] X-ray (or, if done, 
Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or current) before first IMP administration. All chest imaging (particularly X-rays) should be available for review by [CONTACT_397160]. The chest X- ray 
should be repeated only if the TB test was confirmed positive or any further evidence is suggestive of potential lung TB infection (eg, exposure). Radiographic findings suggestive of PUBLIC COPY Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
PUBLIC COPY Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
Visit assessments, and complete a SFU Visit (20 weeks after the f
PUBLIC COPY Visit assessments, and complete a SFU Visit ([ADDRESS_764734] conversion (confirmed) should be classified adequately, either as due to LTBI, active TB 
This document cannot be used to support any marketing authorization TB test conversion (confirmed) should be classified adequately, either as due to LTBI, active TB 
infection, or NTMB, respectively. Additional assessments (eg, blood tests or IGRA, chest 
This document cannot be used to support any marketing authorization infection, or NTMB, respectively. Additional assessments (eg, blood tests or IGRA, chest 
lly relevant and documented. Such 
This document cannot be used to support any marketing authorization lly relevant and documented. Such 
In case the evaluation by [CONTACT_18405] a new LTBI during the study, a 
This document cannot be used to support any marketing authorization In case the evaluation by [CONTACT_18405] a new LTBI during the study, a 
ust be withdrawn.
This document cannot be used to support any marketing authorization ust be withdrawn.
Every related action should be discussed in advance with the Medical Monitor. 
This document cannot be used to support any marketing authorization Every related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
This document cannot be used to support any marketing authorization Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
Visit assessments, and complete a SFU Visit (20 weeks after the f
This document cannot be used to support any marketing authorization Visit assessments, and complete a SFU Visit ([ADDRESS_764735] of the study, the TB assessment by [CONTACT_18406] (QuantiFERON TB 
This document cannot be used to support any marketing authorization During conduct of the study, the TB assessment by [CONTACT_18406] (QuantiFERON TB 
recommended) will be performed at Screening and should be repeated at the SFU
This document cannot be used to support any marketing authorization recommended) will be performed at Screening and should be repeated at the SFU
subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
This document cannot be used to support any marketing authorization subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
recommends that a
This document cannot be used to support any marketing authorization recommends that a TB specialist be consulted
This document cannot be used to support any marketing authorization TB specialist be consulted
are doubts regarding test results. If latent or active TB is identified, subject must undergo 
This document cannot be used to support any marketing authorization are doubts regarding test results. If latent or active TB is identified, subject must undergo 
appropriate study
This document cannot be used to support any marketing authorization appropriate study
This document cannot be used to support any marketing authorization during the protocol
This document cannot be used to support any marketing authorization during the protocol
[IP_ADDRESS]
This document cannot be used to support any marketing authorization [IP_ADDRESS]
A plain posteroanterior chest X
This document cannot be used to support any marketing authorization A plain posteroanterior chest X
has been performed within [ADDRESS_764736] be withdrawn.
Every related action should be discussed in advance with the Medical Monitor. 
application and any extensions or variations thereof.Every related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
application and any extensions or variations thereof.Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
Visit assessments, and complete a SFU Visit (20 weeks after the f
application and any extensions or variations thereof.Visit assessments, and complete a SFU Visit (20 weeks after the f inal dose of IMP).
application and any extensions or variations thereof.inal dose of IMP). Visit assessments, and complete a SFU Visit (20 weeks after the f inal dose of IMP). Visit assessments, and complete a SFU Visit (20 weeks after the f
application and any extensions or variations thereof.Visit assessments, and complete a SFU Visit (20 weeks after the f inal dose of IMP). Visit assessments, and complete a SFU Visit ([ADDRESS_764737] of the study, the TB assessment by [CONTACT_18406] (QuantiFERON TB 
application and any extensions or variations thereof.During conduct of the study, the TB assessment by [CONTACT_18406] (QuantiFERON TB 
recommended) will be performed at Screening and should be repeated at the SFU
application and any extensions or variations thereof.recommended) will be performed at Screening and should be repeated at the SFU
subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
application and any extensions or variations thereof.subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
TB specialist be consulted
application and any extensions or variations thereof.TB specialist be consulted
are doubts regarding test results. If latent or active TB is identified, subject must undergo 
application and any extensions or variations thereof.are doubts regarding test results. If latent or active TB is identified, subject must undergo 
application and any extensions or variations thereof.appropriate study
application and any extensions or variations thereof.appropriate study specified withdrawal procedures. The retest during Screening must be done 
application and any extensions or variations thereof.specified withdrawal procedures. The retest during Screening must be done 
during the protocol
application and any extensions or variations thereof.during the protocol -
application and any extensions or variations thereof.-defined Screen
application and any extensions or variations thereof.defined Screen
Chest Xapplication and any extensions or variations thereof.Chest X
A plain posteroanterior chest X application and any extensions or variations thereof. A plain posteroanterior chest X
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 83of 136inactive TB or active TB may include but are not limited to: api[INVESTIGATOR_18304], pleural thickening, 
pulmonary nodules, fibrotic scars, calcified granulomas, upper lobe infiltrates, cavitations and 
pleural effusions, calcified lung nodules, calcified hilar lymph nodes, and pericardial calcification.
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. Any new clinically significant findings post Baseline on chest X-ray must be documented in the source documents and the eCRF as an AE.
[IP_ADDRESS] Tuberculosis questionnaire 
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed at the Screening Visit, Weeks 12, 24, and36, and the SFU Visit. The questionnaire will assist with the identification of subjects who 
may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been in close contact [CONTACT_41022], or an individual who has recently been treated for TB?” at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
LTB or active TB (see Exclusion Criterion #13, Section 6.2). A “Yes” response to any of the 
questions during the study should trigger further assessments to determine if the subject has either LTB or active TB infection. 
Subjects with a latent or active TB infection must be withdrawn from the study.
[IP_ADDRESS] Tuberculosis management
LTB infection and active TB identified during study
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects diagnosed with active TB or LTB infection should be withdrawn from the study and receive appropriate TB or prophylaxis therapy. 
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB follow-up 
Form provided.
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and scheduled to return for the WD Visit as soon as possible but no 
later than the next scheduled study visit and complete all WD Visit assessments. 
The subject should be encouraged to complete a SFU Visit (20 weeks after the final dose of 
IMP).PUBLIC COPY Section
PUBLIC COPY Section
r assessments to determine if the subject has 
PUBLIC COPY r assessments to determine if the subject has 
Subjects with a latent or active TB infection must be withdrawn from the study.
PUBLIC COPY Subjects with a latent or active TB infection must be withdrawn from the study.
Tuberculosis management
PUBLIC COPY Tuberculosis management
LTB infection and active TB identified during study
PUBLIC COPY LTB infection and active TB identified during study
PUBLIC COPY During the study, subjects who develop evidence of LTB infection or active TB must 
PUBLIC COPY During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB PUBLIC COPY immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. PUBLIC COPY specialist (pulmonologist or infectious disease specialist) for further evaluation. 
This document cannot be used to support any marketing authorization ray must be documented in the source documents and the eCRF as an AE.
This document cannot be used to support any marketing authorization ray must be documented in the source documents and the eCRF as an AE.
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
This document cannot be used to support any marketing authorization The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed at the Screening Visit, Weeks
This document cannot be used to support any marketing authorization source document. The questionnaire will be completed at the Screening Visit, Weeks 12, 24, 
This document cannot be used to support any marketing authorization 12, 24, 
identification of subjects who 
This document cannot be used to support any marketing authorization identification of subjects who 
may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been 
This document cannot be used to support any marketing authorization may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been 
in close contact [CONTACT_41022], or an individual who has recently been treated 
This document cannot be used to support any marketing authorization in close contact [CONTACT_41022], or an individual who has recently been treated 
d. A “Yes” response to any of the other questions within the 
This document cannot be used to support any marketing authorization d. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
This document cannot be used to support any marketing authorization questionnaire at Screening should trigger further careful assessment to determine if subject has 
). A “Yes” response to any of the 
This document cannot be used to support any marketing authorization ). A “Yes” response to any of the 
r assessments to determine if the subject has 
This document cannot be used to support any marketing authorization r assessments to determine if the subject has 
Subjects with a latent or active TB infection must be withdrawn from the study.
This document cannot be used to support any marketing authorization Subjects with a latent or active TB infection must be withdrawn from the study.
LTB infection and active TB identified during study
This document cannot be used to support any marketing authorization LTB infection and active TB identified during study
This document cannot be used to support any marketing authorization During the study, subjects who develop evidence of LTB infection or active TB must 
This document cannot be used to support any marketing authorization During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
This document cannot be used to support any marketing authorization immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. 
This document cannot be used to support any marketing authorization specialist (pulmonologist or infectious disease specialist) for further evaluation. 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
This document cannot be used to support any marketing authorization LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
This document cannot be used to support any marketing authorization confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evi
This document cannot be used to support any marketing authorization indicates that TB infection or exposure may have occurred. Evi
This document cannot be used to support any marketing authorization addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
This document cannot be used to support any marketing authorization addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
This document cannot be used to support any marketing authorization situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infectio
This document cannot be used to support any marketing authorization diagnosed with active TB or LTB infectio
appropriate TB or prophylaxis therapy. 
This document cannot be used to support any marketing authorization appropriate TB or prophylaxis therapy. 
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
This document cannot be used to support any marketing authorization Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and sub
This document cannot be used to support any marketing authorization TB must be reported as an SAE. The Investigator is to complete and sub
This document cannot be used to support any marketing authorization Form provided.
This document cannot be used to support any marketing authorization Form provided.
The subject should be transferred to the care of his/her physician and managed according to the 
This document cannot be used to support any marketing authorization The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
This document cannot be used to support any marketing authorization best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and
This document cannot be used to support any marketing authorization study must be withdrawn and
later than the next scheduled study visit and complete all WD Visit assessments. 
This document cannot be used to support any marketing authorization later than the next scheduled study visit and complete all WD Visit assessments. application and any extensions or variations thereof.12, 24, 
application and any extensions or variations thereof.12, 24, 
identification of subjects who 
application and any extensions or variations thereof.identification of subjects who 
may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been 
application and any extensions or variations thereof.may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been 
in close contact [CONTACT_41022], or an individual who has recently been treated 
application and any extensions or variations thereof.in close contact [CONTACT_41022], or an individual who has recently been treated 
d. A “Yes” response to any of the other questions within the 
application and any extensions or variations thereof.d. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
application and any extensions or variations thereof.questionnaire at Screening should trigger further careful assessment to determine if subject has 
). A “Yes” response to any of the 
application and any extensions or variations thereof.). A “Yes” response to any of the 
r assessments to determine if the subject has 
application and any extensions or variations thereof.r assessments to determine if the subject has 
Subjects with a latent or active TB infection must be withdrawn from the study.
application and any extensions or variations thereof.Subjects with a latent or active TB infection must be withdrawn from the study.
During the study, subjects who develop evidence of LTB infection or active TB must 
application and any extensions or variations thereof.During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
application and any extensions or variations thereof.immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. 
application and any extensions or variations thereof.specialist (pulmonologist or infectious disease specialist) for further evaluation. 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
application and any extensions or variations thereof.LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
application and any extensions or variations thereof.confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evi
application and any extensions or variations thereof.indicates that TB infection or exposure may have occurred. Evi
application and any extensions or variations thereof.addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
application and any extensions or variations thereof.addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
application and any extensions or variations thereof.situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infectio
application and any extensions or variations thereof.diagnosed with active TB or LTB infectio
appropriate TB or prophylaxis therapy. 
application and any extensions or variations thereof.appropriate TB or prophylaxis therapy. 
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
application and any extensions or variations thereof.Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and sub
application and any extensions or variations thereof.TB must be reported as an SAE. The Investigator is to complete and sub
application and any extensions or variations thereof.Form provided.
application and any extensions or variations thereof.Form provided.
The subject should be transferred to the care of his/her physician and managed according to the application and any extensions or variations thereof.The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the application and any extensions or variations thereof. best available standard of care. Subjects identified as having converted to active TB during the 
UCB [ADDRESS_764738] be followed.
12.7.6 Pregnancy testing
A serum human chorionic gonadotropin (hCG) pregnancy test for all women of childbearing 
potential will be performed at the Screening Visit. This recommendation also applies to women 
of childbearing potential with infrequent or irregular menstrual cycles and women during 
menopause. Natural menopause is recognized to have occurred after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause (International Menopause Society, 2015).
Pregnancy testing will performed on urine at all other visits. Pregnancy test results (serum and 
urine) must be negative prior to administering IMP.
12.7.7 Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed by [CONTACT_207276] C- SSRS. 
This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
The visits at which the C-SSRS assessments will be performed are specified in the schedule of study assessments ( Table 5‒1).
The C-SSRS is a standardized and validated instrument developed for the assessment of the severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
C-SSRS defines [ADDRESS_764739] demographic information for all subjects according to 
local rules and regulations. This will include age, gender, race, and ethnicity. Information will 
also be collected on Baseline characteristics for subjects including lifestyle, child bearing potential, as applicable, height, weight, and body mass index (BMI). Demographic and baseline characteristics information will be recorded in the eCRF.
13.[ADDRESS_764740] these in the eCRF. PUBLIC COPY SSRS assessments will be performed are specified in the schedule of 
PUBLIC COPY SSRS assessments will be performed are specified in the schedule of 
SSRS is a standardized and validated instrument developed for the assessment of the 
PUBLIC COPY SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
PUBLIC COPY severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are present
PUBLIC COPY Subjects respond to standardized clinical questions that are present
SSRS defines [ADDRESS_764741] results (serum and 
This document cannot be used to support any marketing authorization Pregnancy testing will performed on urine at all other visits. Pregnancy test results (serum and 
Suicidal ideation and behavior will be assessed by [CONTACT_207276] C
This document cannot be used to support any marketing authorization Suicidal ideation and behavior will be assessed by [CONTACT_207276] C
This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
This document cannot be used to support any marketing authorization This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
SSRS assessments will be performed are specified in the schedule of 
This document cannot be used to support any marketing authorization SSRS assessments will be performed are specified in the schedule of 
SSRS is a standardized and validated instrument developed for the assessment of the 
This document cannot be used to support any marketing authorization SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
This document cannot be used to support any marketing authorization severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are present
This document cannot be used to support any marketing authorization Subjects respond to standardized clinical questions that are present
SSRS defines [ADDRESS_764742] results (serum and 
application and any extensions or variations thereof.Pregnancy testing will performed on urine at all other visits. Pregnancy test results (serum and 
Suicidal ideation and behavior will be assessed by [CONTACT_207276] C
application and any extensions or variations thereof.Suicidal ideation and behavior will be assessed by [CONTACT_207276] C -
application and any extensions or variations thereof.-SSRS. 
application and any extensions or variations thereof.SSRS. 
This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
application and any extensions or variations thereof.This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
SSRS assessments will be performed are specified in the schedule of 
application and any extensions or variations thereof.SSRS assessments will be performed are specified in the schedule of 
SSRS is a standardized and validated instrument developed for the assessment of the 
application and any extensions or variations thereof.SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
application and any extensions or variations thereof.severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are present
application and any extensions or variations thereof.Subjects respond to standardized clinical questions that are present ed in a uniform fashion. The 
application and any extensions or variations thereof.ed in a uniform fashion. The 
SSRS defines [ADDRESS_764743] demographic informati
local rules and regulations. This will include age, gender, race, and ethnicity. Information will 
application and any extensions or variations thereof.local rules and regulations. This will include age, gender, race, and ethnicity. Information will 
also be collected on Baseline characteristics for subjects including lifestyle, child bearing 
application and any extensions or variations thereof.also be collected on Baseline characteristics for subjects including lifestyle, child bearing 
potential, as applicable, heigh
application and any extensions or variations thereof.potential, as applicable, heigh t, weight, and body mass index (BMI). Demographic and baseline 
application and any extensions or variations thereof.t, weight, and body mass index (BMI). Demographic and baseline 
characteristics information will be recorded in the eCRF.
application and any extensions or variations thereof.characteristics information will be recorded in the eCRF.
Medical history
application and any extensions or variations thereof.Medical history
The Investigator or designee will obtain a complete medical history of AS as part of the 
application and any extensions or variations thereof.The Investigator or designee will obtain a complete medical history of AS as part of the 
screening assessment and inclu
application and any extensions or variations thereof.screening assessment and inclu
responses to AS treatment as available, and surgeries. Findings will be recorded in the eCRF.
application and any extensions or variations thereof.responses to AS treatment as available, and surgeries. Findings will be recorded in the eCRF.
Ankylosing spondylitis historyapplication and any extensions or variations thereof.Ankylosing spondylitis history
UCB [ADDRESS_764744] to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
sponsor.
After implementation of such measure, the Investigator must notify the EPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
14.2 Monitoring
Monitoring of the study will be delegated by [CONTACT_18410] a CRO. The CRO will monitor the study to 
meet the CRO’s monitoring Standard Operating Procedures (SOPs), ICH-GCP guideline, and 
applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are adequate. 
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospi[INVESTIGATOR_58921]). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.
14.2.[ADDRESS_764745] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] (such as removable self-stick notes). Photocopi[INVESTIGATOR_13265]/or printouts of eCRFs are not considered acceptable source documents. 
Source documents are original records in which raw data are first recorded. These may include 
hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, X-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of lif e 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.
Source documents that are computer-generated and stored electronically must be printed for 
review by [CONTACT_2037] (eg, ECG reports). Once printed, these copi[INVESTIGATOR_581560] a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.PUBLIC COPY The Investigator and his/her staff are expected to cooperate with UCB
PUBLIC COPY The Investigator and his/her staff are expected to cooperate with UCB
available during the monitoring visits to answer questions sufficiently and to provide any 
PUBLIC COPY available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
PUBLIC COPY missing information. The Investigator(s)/institution(s) will permit direct access to source 
related monitoring, aud
PUBLIC COPY related monitoring, aud its, IRB/IEC review, and regulatory 
PUBLIC COPY its, IRB/IEC review, and regulatory 
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
PUBLIC COPY The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg,
PUBLIC COPY corresponding source documents (eg, hospi[INVESTIGATOR_58921]). 
PUBLIC COPY hospi[INVESTIGATOR_58921]). 
ovide UCB (or designee) with the opportunity to evaluate the progress PUBLIC COPY ovide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol PUBLIC COPY of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
This document cannot be used to support any marketing authorization IRB/IEC, or 
This document cannot be used to support any marketing authorization IRB/IEC, or 
lementation of such measure, the Investigator must notify the EPM of the sponsor 
This document cannot be used to support any marketing authorization lementation of such measure, the Investigator must notify the EPM of the sponsor 
Monitoring of the study will be delegated by [CONTACT_18410] a CRO. The CRO will monitor the study to 
This document cannot be used to support any marketing authorization Monitoring of the study will be delegated by [CONTACT_18410] a CRO. The CRO will monitor the study to 
CRO’s monitoring Standard Operating Procedures (SOPs), ICH
This document cannot be used to support any marketing authorization CRO’s monitoring Standard Operating Procedures (SOPs), ICH -
This document cannot be used to support any marketing authorization -GCP guideline, and 
This document cannot be used to support any marketing authorization GCP guideline, and 
applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are 
This document cannot be used to support any marketing authorization applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are 
The Investigator and his/her staff are expected to cooperate with UCB
This document cannot be used to support any marketing authorization The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
This document cannot be used to support any marketing authorization (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
This document cannot be used to support any marketing authorization available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
This document cannot be used to support any marketing authorization missing information. The Investigator(s)/institution(s) will permit direct access to source 
its, IRB/IEC review, and regulatory 
This document cannot be used to support any marketing authorization its, IRB/IEC review, and regulatory 
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
This document cannot be used to support any marketing authorization The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
hospi[INVESTIGATOR_58921]). 
This document cannot be used to support any marketing authorization hospi[INVESTIGATOR_58921]). 
ovide UCB (or designee) with the opportunity to evaluate the progress 
This document cannot be used to support any marketing authorization ovide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
This document cannot be used to support any marketing authorization of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator’s obligations are being 
This document cannot be used to support any marketing authorization requirements, applicable authorities regulations, and Investigator’s obligations are being 
, and resolve any inconsistencies in the study records.
This document cannot be used to support any marketing authorization , and resolve any inconsistencies in the study records.
Definition of source data 
This document cannot be used to support any marketing authorization Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
This document cannot be used to support any marketing authorization All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], 
This document cannot be used to support any marketing authorization audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], 
This document cannot be used to support any marketing authorization optical disc). They should not be obscured by [CONTACT_581671]). They should not be obscured by [CONTACT_18411] 
(such as removable self
This document cannot be used to support any marketing authorization (such as removable self
acceptable source documents. 
This document cannot be used to support any marketing authorization acceptable source documents. 
Source documents are origina
This document cannot be used to support any marketing authorization Source documents are origina
hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, X
This document cannot be used to support any marketing authorization hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, X
pharmacy records, care records, ECG or other printouts, completed scales, quality of lif
This document cannot be used to support any marketing authorization pharmacy records, care records, ECG or other printouts, completed scales, quality of lif
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
This document cannot be used to support any marketing authorization questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.
This document cannot be used to support any marketing authorization access area.
Source documents that are computer
This document cannot be used to support any marketing authorization Source documents that are computerapplication and any extensions or variations thereof.Monitoring of the study will be delegated by [CONTACT_18410] a CRO. The CRO will monitor the study to 
application and any extensions or variations thereof.Monitoring of the study will be delegated by [CONTACT_18410] a CRO. The CRO will monitor the study to 
GCP guideline, and 
application and any extensions or variations thereof.GCP guideline, and 
applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are 
application and any extensions or variations thereof.applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are 
(or designee) and to be 
application and any extensions or variations thereof.(or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
application and any extensions or variations thereof.available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
application and any extensions or variations thereof.missing information. The Investigator(s)/institution(s) will permit direct access to source 
its, IRB/IEC review, and regulatory 
application and any extensions or variations thereof.its, IRB/IEC review, and regulatory 
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
application and any extensions or variations thereof.The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
hospi[INVESTIGATOR_58921]). 
application and any extensions or variations thereof.hospi[INVESTIGATOR_58921]). 
ovide UCB (or designee) with the opportunity to evaluate the progress 
application and any extensions or variations thereof.ovide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
application and any extensions or variations thereof.of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator’s obligations are being 
application and any extensions or variations thereof.requirements, applicable authorities regulations, and Investigator’s obligations are being 
, and resolve any inconsistencies in the study records.
application and any extensions or variations thereof., and resolve any inconsistencies in the study records.
Definition of source data 
application and any extensions or variations thereof.Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
application and any extensions or variations thereof.All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], 
application and any extensions or variations thereof.audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], 
application and any extensions or variations thereof.optical disc). They should not be obscured by [CONTACT_581672].optical disc). They should not be obscured by [CONTACT_18411] 
(such as removable self
application and any extensions or variations thereof.(such as removable self stick notes). Photocopi[INVESTIGATOR_13265]/or printouts of eCRFs are not considered 
application and any extensions or variations thereof.stick notes). Photocopi[INVESTIGATOR_13265]/or printouts of eCRFs are not considered 
acceptable source documents. 
application and any extensions or variations thereof.acceptable source documents. 
Source documents are origina
application and any extensions or variations thereof.Source documents are origina
hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, X
application and any extensions or variations thereof.hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, X
pharmacy records, care records, ECG or other printouts, completed scales, quality of lifapplication and any extensions or variations thereof.pharmacy records, care records, ECG or other printouts, completed scales, quality of lif
questionnaires, or video, for example. Source documents should be kept in a secure, limited application and any extensions or variations thereof.questionnaires, or video, for example. Source documents should be kept in a secure, limited 
UCB [ADDRESS_764746] to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], X-ray films, laboratory notes). All data reported on the eCRF should be supported by [CONTACT_18412], unless otherwise specified in Section 14.2.1 .
14.3 Data handling
14.3.1 Case Report Form completion
The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
reporting of accurate, complete, and legible data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) will be reapproved by [CONTACT_737].
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. Access to the EDC will be given after training has been received. A training certificate 
will be provided and filed.
Serious AE reporting will be done using the SAE Report Form (see Section [IP_ADDRESS] ) while also 
entering the event in the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
Detailed instructions will be provided in the eCRF Completion Guidelines.
14.3.2 Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
study is performed using electronic data capture.
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
14.3.[ADDRESS_764747] Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s participation.PUBLIC COPY The Investigator should maintain a list of personnel authorized to enter data into the electronic 
PUBLIC COPY The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. Access to the EDC will be given after training has been received. A training certif
PUBLIC COPY eCRF. Access to the EDC will be given after training has been received. A training certif
Serious AE reporting will be done using the SAE Report Form (see 
PUBLIC COPY Serious AE reporting will be done using the SAE Report Form (see 
the appropriate eCRF section. The safety database and the clinical database 
PUBLIC COPY the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
PUBLIC COPY will be reconciled during the study and discrepancies will be corrected as needed.
Detailed instructions will be provided in the eCRF Completion Guidelines.
PUBLIC COPY Detailed instructions will be provided in the eCRF Completion Guidelines.
Database entry and rec PUBLIC COPY Database entry and rec
This document cannot be used to support any marketing authorization The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
This document cannot be used to support any marketing authorization The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
accurate, complete, and legible data in the eCRFs and in all required reports.
This document cannot be used to support any marketing authorization accurate, complete, and legible data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
This document cannot be used to support any marketing authorization Any change or correction to the eCRF after saving must be accompanied by a reason for the 
Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
This document cannot be used to support any marketing authorization Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
ssword/electronic signature) will be reapproved by [CONTACT_737].
This document cannot be used to support any marketing authorization ssword/electronic signature) will be reapproved by [CONTACT_737].
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
This document cannot be used to support any marketing authorization The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. Access to the EDC will be given after training has been received. A training certif
This document cannot be used to support any marketing authorization eCRF. Access to the EDC will be given after training has been received. A training certif
Serious AE reporting will be done using the SAE Report Form (see 
This document cannot be used to support any marketing authorization Serious AE reporting will be done using the SAE Report Form (see 
the appropriate eCRF section. The safety database and the clinical database 
This document cannot be used to support any marketing authorization the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
This document cannot be used to support any marketing authorization will be reconciled during the study and discrepancies will be corrected as needed.
Detailed instructions will be provided in the eCRF Completion Guidelines.
This document cannot be used to support any marketing authorization Detailed instructions will be provided in the eCRF Completion Guidelines.
Database entry and rec
This document cannot be used to support any marketing authorization Database entry and rec onciliation
This document cannot be used to support any marketing authorization onciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
This document cannot be used to support any marketing authorization Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
This document cannot be used to support any marketing authorization database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for disc
This document cannot be used to support any marketing authorization will be used in addition to manual review to check for disc
the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
This document cannot be used to support any marketing authorization the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
study is performed using electronic data capture.
This document cannot be used to support any marketing authorization study is performed using electronic data capture.
An electronic audit trail system will be maintained within the CDMS to 
This document cannot be used to support any marketing authorization An electronic audit trail system will be maintained within the CDMS to 
the database once the data have been saved initially into the system or electronically loaded. 
This document cannot be used to support any marketing authorization the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
This document cannot be used to support any marketing authorization Regular backups of the electronic data will be performed.
Subject Screening and Enrollment log/Subject Identification Code list
This document cannot be used to support any marketing authorization Subject Screening and Enrollment log/Subject Identification Code list
The sub
This document cannot be used to support any marketing authorization The sub ject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
This document cannot be used to support any marketing authorization ject’s screening and enrollment will be recorded in the Subject Screening and Enrollment The sub ject’s screening and enrollment will be recorded in the Subject Screening and Enrollment The sub
This document cannot be used to support any marketing authorization The sub ject’s screening and enrollment will be recorded in the Subject Screening and Enrollment The sub
log.
This document cannot be used to support any marketing authorization log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
This document cannot be used to support any marketing authorization The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
This document cannot be used to support any marketing authorization Investigator and is used for unambiguous identification of each subject.application and any extensions or variations thereof.The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
application and any extensions or variations thereof.The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
application and any extensions or variations thereof.Any change or correction to the eCRF after saving must be accompanied by a reason for the 
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
application and any extensions or variations thereof.The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. Access to the EDC will be given after training has been received. A training certif
application and any extensions or variations thereof.eCRF. Access to the EDC will be given after training has been received. A training certif
Serious AE reporting will be done using the SAE Report Form (see 
application and any extensions or variations thereof.Serious AE reporting will be done using the SAE Report Form (see Section
application and any extensions or variations thereof.Section
the appropriate eCRF section. The safety database and the clinical database 
application and any extensions or variations thereof.the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
application and any extensions or variations thereof.will be reconciled during the study and discrepancies will be corrected as needed.
Detailed instructions will be provided in the eCRF Completion Guidelines.
application and any extensions or variations thereof.Detailed instructions will be provided in the eCRF Completion Guidelines.
onciliation
application and any extensions or variations thereof.onciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
application and any extensions or variations thereof.Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
application and any extensions or variations thereof.database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for disc
application and any extensions or variations thereof.will be used in addition to manual review to check for disc
the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
application and any extensions or variations thereof.the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
study is performed using electronic data capture.
application and any extensions or variations thereof.study is performed using electronic data capture.
An electronic audit trail system will be maintained within the CDMS to 
application and any extensions or variations thereof.An electronic audit trail system will be maintained within the CDMS to 
the database once the data have been saved initially into the system or electronically loaded. 
application and any extensions or variations thereof.the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
application and any extensions or variations thereof.Regular backups of the electronic data will be performed.
Subject Screening and Enrollment log/Subject Identification Code list
application and any extensions or variations thereof.Subject Screening and Enrollment log/Subject Identification Code list
application and any extensions or variations thereof.ject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
application and any extensions or variations thereof.ject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
The Investigator will keep a Subject Identification Code list. This list remains with the application and any extensions or variations thereof.The Investigator will keep a Subject Identification Code list. This list remains with the 
UCB [ADDRESS_764748] to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the termination or suspension by [CONTACT_581673]/institution, as specified by [CONTACT_12926](s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
14.[ADDRESS_764749] elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_58993] (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The Investigator will contact 
[CONTACT_463203]. The Investigator will also notify UCB should he/she 
relocate or move the study-related files to a location other than that specified in the sponsor’s 
trial master file.
14.[ADDRESS_764750] been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).PUBLIC COPY reports, information regarding participants who discontinued, and other pertinent data.
PUBLIC COPY reports, information regarding participants who discontinued, and other pertinent data.
ocuments are to be retained by [CONTACT_31201] [ADDRESS_764751] elap
formal discontinuation of clinical development of the IMP. These documents should be retained 
PUBLIC COPY formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_581674] a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_58993] (CPMP/ICH/135/95, 2002 [Section
PUBLIC COPY agreement with UCB (CPMP/ICH/135/95, 2002 [Section
UCB for authorization prior to the destruction of any study records or in the event of accidental PUBLIC COPY UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The Investigator will also notify UCB should he/she PUBLIC COPY loss or destruction of any study records. The Investigator will also notify UCB should he/she 
This document cannot be used to support any marketing authorization If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
This document cannot be used to support any marketing authorization If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
This document cannot be used to support any marketing authorization Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
s) for the termination or suspension, in accordance with applicable regulatory 
This document cannot be used to support any marketing authorization s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
This document cannot be used to support any marketing authorization requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by [CONTACT_581673]/institution, as specified
This document cannot be used to support any marketing authorization termination or suspension by [CONTACT_581673]/institution, as specified by [CONTACT_581675](s). In addition, arrangements will be made for the return of all 
This document cannot be used to support any marketing authorization applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
This document cannot be used to support any marketing authorization unused IMP and other material in accordance with UCB procedures for the study.
records for the study, including eCRFs, medical records, 
This document cannot be used to support any marketing authorization records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
This document cannot be used to support any marketing authorization laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
This document cannot be used to support any marketing authorization reports, information regarding participants who discontinued, and other pertinent data.
ocuments are to be retained by [CONTACT_31201] [ADDRESS_764752] elap
formal discontinuation of clinical development of the IMP. These documents should be retained 
This document cannot be used to support any marketing authorization formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_581676] a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_58993] (CPMP/ICH/135/95, 2002 [Section
This document cannot be used to support any marketing authorization agreement with UCB (CPMP/ICH/135/95, 2002 [Section
UCB for authorization prior to the destruction of any study records or in the event of accidental 
This document cannot be used to support any marketing authorization UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The Investigator will also notify UCB should he/she 
This document cannot be used to support any marketing authorization loss or destruction of any study records. The Investigator will also notify UCB should he/she 
related files to a location other than that specified in the sponsor’s 
This document cannot be used to support any marketing authorization related files to a location other than that specified in the sponsor’s 
Audit and inspection
This document cannot be used to support any marketing authorization Audit and inspection
This document cannot be used to support any marketing authorization The Investigator will permit study
This document cannot be used to support any marketing authorization The Investigator will permit study
inspections by [CONTACT_581677], that enrolled subjects (ie,
This document cannot be used to support any marketing authorization subjects enrolled have been protected, that enrolled subjects (ie,
study procedures) are appropriate for the study, and
This document cannot be used to support any marketing authorization study procedures) are appropriate for the study, and
IMP have been processed and reported in compliance with the planned arrangements, the 
This document cannot be used to support any marketing authorization IMP have been processed and reported in compliance with the planned arrangements, the 
This document cannot be used to support any marketing authorization protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
This document cannot be used to support any marketing authorization protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
This document cannot be used to support any marketing authorization requirements.
The Investigator will
This document cannot be used to support any marketing authorization The Investigator will
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
This document cannot be used to support any marketing authorization data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).This document cannot be used to support any marketing authorization inform UCB (or designee).application and any extensions or variations thereof.by [CONTACT_581616].by [CONTACT_12926](s). In addition, arrangements will be made for the return of all 
application and any extensions or variations thereof.applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
records for the study, including eCRFs, medical records, 
application and any extensions or variations thereof.records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
application and any extensions or variations thereof.laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
application and any extensions or variations thereof.reports, information regarding participants who discontinued, and other pertinent data.
ocuments are to be retained by [CONTACT_31201] [ADDRESS_764753] elap
formal discontinuation of clinical development of the IMP. These documents should be retained 
application and any extensions or variations thereof.formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_581678].for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_58993] (CPMP/ICH/135/95, 2002 [Section
application and any extensions or variations thereof.agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.
application and any extensions or variations thereof.4.9.5]). The Investigator will contact 
[INVESTIGATOR_581504].9.5]). The Investigator will contact 
[CONTACT_581679].UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The Investigator will also notify UCB should he/she 
application and any extensions or variations thereof.loss or destruction of any study records. The Investigator will also notify UCB should he/she 
related files to a location other than that specified in the sponsor’s 
application and any extensions or variations thereof.related files to a location other than that specified in the sponsor’s 
Audit and inspection
application and any extensions or variations thereof.Audit and inspection
application and any extensions or variations thereof.The Investigator will permit study
application and any extensions or variations thereof.The Investigator will permit study -
application and any extensions or variations thereof.-related audits mandated by [CONTACT_18338], after reasonable notice, and 
application and any extensions or variations thereof.related audits mandated by [CONTACT_18338], after reasonable notice, and 
inspections by [CONTACT_581680].inspections by [CONTACT_581681].The main purposes of an audit or inspection are to confirm that the rights and wellbeing of the 
subjects enrolled have been protected, that enrolled subjects (ie,
application and any extensions or variations thereof.subjects enrolled have been protected, that enrolled subjects (ie,
study procedures) are appropriate for the study, and
application and any extensions or variations thereof.study procedures) are appropriate for the study, and
IMP have been processed and reported in compliance with the planned arrangements, the 
application and any extensions or variations thereof.IMP have been processed and reported in compliance with the planned arrangements, the 
application and any extensions or variations thereof.protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
application and any extensions or variations thereof.protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.application and any extensions or variations thereof.requirements.
The Investigator will application and any extensions or variations thereof. The Investigator will
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 88of [ZIP_CODE].7 Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by [CONTACT_3786], institution, institution staff, or designees of the sponsor will lead to prompt action by [CONTACT_18418]. Continued noncompliance may result in the termination of the site’s involvement in the study.
15 STATISTICS
A description of statistical methods follows and will be described in more detail in the SAP. Deviations from the original SAP will be documented in the clinical study report (CSR).
15.1 Definition of analysis sets
The Enrolled Set (ES) will consist of all subjects who have given informed consent.
The Randomized Set (RS) will consist of all randomized subjects.
The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least [ADDRESS_764754]-baseline efficacy assessment. 
The Per-Protocol Set (PPS) will consist of all subjects in the FAS who have no important 
protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi ng 
of the data.
The Pharmacokinetics Per-Protocol Set (PK-PPS) will consist of all randomized subjects who 
receive at least [ADDRESS_764755]-dose plasma 
concentration. 
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at least 
[ADDRESS_764756]-Baseline assessments.
Further details of each analysis set along with specifications of analyses by [CONTACT_581682].
15.2 General statistical considerations
Statistical evaluation will be performed by [CONTACT_581683].
All analyses will be performed using SAS
®Version 9.2 or later (SAS Institute, Cary, NC, [LOCATION_003]) 
or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.[ADDRESS_764757] deviation (SD), median, minimum, and maximum. Two-PUBLIC COPY of the IMP and have a valid measurement of the primary efficacy variable at Baseline and at 
PUBLIC COPY of the IMP and have a valid measurement of the primary efficacy variable at Baseline and at 
S) will consist of all subjects in the FAS who have no important 
PUBLIC COPY S) will consist of all subjects in the FAS who have no important 
protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
PUBLIC COPY protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi
PUBLIC COPY deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi
Protocol Set (PK
PUBLIC COPY Protocol Set (PK
receive at least [ADDRESS_764758]
This document cannot be used to support any marketing authorization A description of statistical methods follows and will be described in more detail in the SAP. 
This document cannot be used to support any marketing authorization A description of statistical methods follows and will be described in more detail in the SAP. 
Deviations from the original SAP will be documented in the clinical study report (CSR).
This document cannot be used to support any marketing authorization Deviations from the original SAP will be documented in the clinical study report (CSR).
will consist of all subjects who have given informed consent.
This document cannot be used to support any marketing authorization will consist of all subjects who have given informed consent.
The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
This document cannot be used to support any marketing authorization The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least 1 dose 
This document cannot be used to support any marketing authorization The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least [ADDRESS_764759] a valid measurement of the primary efficacy variable at Baseline and at 
S) will consist of all subjects in the FAS who have no important 
This document cannot be used to support any marketing authorization S) will consist of all subjects in the FAS who have no important 
protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
This document cannot be used to support any marketing authorization protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi
This document cannot be used to support any marketing authorization deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi
Protocol Set (PK
This document cannot be used to support any marketing authorization Protocol Set (PK -
This document cannot be used to support any marketing authorization -PPS) will consist of all randomized subjects who 
This document cannot be used to support any marketing authorization PPS) will consist of all randomized subjects who 
receive at least [ADDRESS_764760]
PPS) will consist 
This document cannot be used to support any marketing authorization PPS) will consist 
dose of the IMP and have evaluable PET
This document cannot be used to support any marketing authorization dose of the IMP and have evaluable PET
Baseline assessments.
This document cannot be used to support any marketing authorization Baseline assessments.
Further details of each analysis set along with specifications of analyses by a
This document cannot be used to support any marketing authorization Further details of each analysis set along with specifications of analyses by a
provided in the SAP.
This document cannot be used to support any marketing authorization provided in the SAP.
General statistical considerations
This document cannot be used to support any marketing authorization General statistical considerations
Statistical evaluation will be performed by [CONTACT_581684].
This document cannot be used to support any marketing authorization Statistics and Global Statistical Sciences Departments of UCB.
All analyses will be performed 
This document cannot be used to support any marketing authorization All analyses will be performed 
or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.6 or later.
This document cannot be used to support any marketing authorization or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.6 or later.
Descriptive statistics will be used to provide an overview of the Baseline, efficacy and safety 
This document cannot be used to support any marketing authorization Descriptive statistics will be used to provide an overview of the Baseline, efficacy and safety 
resul
This document cannot be used to support any marketing authorization resul
be presented by [CONTACT_1570]. The denominator for the percentages will be based on the This document cannot be used to support any marketing authorization be presented by [CONTACT_1570]. The denominator for the percentages will be based on the application and any extensions or variations thereof.The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
application and any extensions or variations thereof.The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least 1 dose 
application and any extensions or variations thereof.The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least [ADDRESS_764761] a valid measurement of the primary efficacy variable at Baseline and at 
S) will consist of all subjects in the FAS who have no important 
application and any extensions or variations thereof.S) will consist of all subjects in the FAS who have no important 
protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
application and any extensions or variations thereof.protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi
application and any extensions or variations thereof.deviations will be predefined and evaluated during a data evaluation meeting prior to unblindi
PPS) will consist of all randomized subjects who 
application and any extensions or variations thereof.PPS) will consist of all randomized subjects who 
receive at least [ADDRESS_764762]
PPS) will consist 
application and any extensions or variations thereof.PPS) will consist of all randomized subjects who receive at least 
application and any extensions or variations thereof.of all randomized subjects who receive at least 
dose of the IMP and have evaluable PET
application and any extensions or variations thereof.dose of the IMP and have evaluable PET -
application and any extensions or variations thereof.-CT or PET
application and any extensions or variations thereof.CT or PET
Baseline assessments.
application and any extensions or variations thereof.Baseline assessments.
Further details of each analysis set along with specifications of analyses by a
application and any extensions or variations thereof.Further details of each analysis set along with specifications of analyses by a
General statistical considerations
application and any extensions or variations thereof.General statistical considerations
Statistical evaluation will be performed by [CONTACT_581685].Statistical evaluation will be performed by [CONTACT_581685].Statistics and Global Statistical Sciences Departments of UCB.
application and any extensions or variations thereof.Statistics and Global Statistical Sciences Departments of UCB.
All analyses will be performed 
application and any extensions or variations thereof.All analyses will be performed 
or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.6 or later.application and any extensions or variations thereof.or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.6 or later.
Descriptive statistics will be used to provide an overview of the Baseline, efficacy and safety application and any extensions or variations thereof. Descriptive statistics will be used to provide an overview of the Baseline, efficacy and safety 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 89of 136sided 95% confidence intervals, geometric means, and coefficient of variation (CV) will be 
presented for selected variables as appropriate.
Baseline for each assessment is defined as either the value obtained at Baseline (Visit 2) or the 
last available value obtained prior to treatment administration at the Screening Visit (Visit 1) (details to be specified in the SAP).
Formal statistical testing will be conducted for this study for the primary efficacy variable. Other 
efficacy variables will be summarized descriptively by [CONTACT_1570]. Additional exploratory analyses will be conducted as deemed appropriate. 
15.[ADDRESS_764763] disposition 
The number of subjects who were screened, subjects included in each analysis set, and subjects 
who completed/prematurely discontinued the study, as well as the primary reason for 
discontinuation, will be presented by [CONTACT_1570], and overall using frequency counts and percentages.
15.[ADDRESS_764764] characteristics will summarized and listed as appropriate:
Demographics (including gender, age, race, and ethnicity)
Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
Medical/procedure history
Prior and concomitant medications/medical procedures 
Baseline disease characteristics
15.5 Planned efficacy analyses
The primary efficacy analyses will be based on the PPS.
15.5.1 Analysis of the primary efficacy variable
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by [CONTACT_581686]. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [- 1.78, var=0.0605]). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in the 
SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
Baseline ASDAS (mean centered).
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment PUBLIC COPY The following subject characteristics will summarized and listed as appropriate:
PUBLIC COPY The following subject characteristics will summarized and listed as appropriate:
Demographics (including gender, age, race, and 
PUBLIC COPY Demographics (including gender, age, race, and ethnicity)
PUBLIC COPY ethnicity)
Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
PUBLIC COPY Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
Prior and concomitant medications/medical procedures 
PUBLIC COPY Prior and concomitant medications/medical procedures 
Baseline disease characteristics
PUBLIC COPY Baseline disease characteristics
Planned efficacy analyses PUBLIC COPY Planned efficacy analyses
This document cannot be used to support any marketing authorization Formal statistical testing will be conducted for this study for the primary efficacy variable. Other 
This document cannot be used to support any marketing authorization Formal statistical testing will be conducted for this study for the primary efficacy variable. Other 
efficacy variables will be summarized descriptively by [CONTACT_1570]. Additional exploratory 
This document cannot be used to support any marketing authorization efficacy variables will be summarized descriptively by [CONTACT_1570]. Additional exploratory 
The number of subjects who were screened, subjects included in each analysis set, and subjects 
This document cannot be used to support any marketing authorization The number of subjects who were screened, subjects included in each analysis set, and subjects 
who completed/prematurely discontinued the study, as well as the primary reason for 
This document cannot be used to support any marketing authorization who completed/prematurely discontinued the study, as well as the primary reason for 
uation, will be presented by [CONTACT_1570], and overall using frequency counts and 
This document cannot be used to support any marketing authorization uation, will be presented by [CONTACT_1570], and overall using frequency counts and 
The following subject characteristics will summarized and listed as appropriate:
This document cannot be used to support any marketing authorization The following subject characteristics will summarized and listed as appropriate:
ethnicity)
This document cannot be used to support any marketing authorization ethnicity)
Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
This document cannot be used to support any marketing authorization Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
Prior and concomitant medications/medical procedures 
This document cannot be used to support any marketing authorization Prior and concomitant medications/medical procedures 
Planned efficacy analyses
This document cannot be used to support any marketing authorization Planned efficacy analyses
ry efficacy analyses will be based on the PPS.
This document cannot be used to support any marketing authorization ry efficacy analyses will be based on the PPS.
Analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization Analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
This document cannot be used to support any marketing authorization The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
12 in the bimekizumab treatment group versus the CZP treatment group.
This document cannot be used to support any marketing authorization 12 in the bimekizumab treatment group versus the CZP treatment group.
statistics will be presented by [CONTACT_581687]. 
This document cannot be used to support any marketing authorization changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
This document cannot be used to support any marketing authorization The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior 
This document cannot be used to support any marketing authorization paradigm. An informative prior 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
This document cannot be used to support any marketing authorization primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [
This document cannot be used to support any marketing authorization centered Baseline is observed at its mean of zero (βCZP ~ Normal [
This document cannot be used to support any marketing authorization priors will be
This document cannot be used to support any marketing authorization priors will be
SAP and in the interim analysis SAP.
This document cannot be used to support any marketing authorization SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and This document cannot be used to support any marketing authorization The Bayesian analysis will employ a linear regression model including treatment group and application and any extensions or variations thereof.The number of subjects who were screened, subjects included in each analysis set, and subjects 
application and any extensions or variations thereof.The number of subjects who were screened, subjects included in each analysis set, and subjects 
uation, will be presented by [CONTACT_1570], and overall using frequency counts and 
application and any extensions or variations thereof.uation, will be presented by [CONTACT_1570], and overall using frequency counts and 
The following subject characteristics will summarized and listed as appropriate:
application and any extensions or variations thereof.The following subject characteristics will summarized and listed as appropriate:
Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
application and any extensions or variations thereof.Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 
Prior and concomitant medications/medical procedures 
application and any extensions or variations thereof.Prior and concomitant medications/medical procedures 
Planned efficacy analyses
application and any extensions or variations thereof.Planned efficacy analyses
ry efficacy analyses will be based on the PPS.
application and any extensions or variations thereof.ry efficacy analyses will be based on the PPS.
Analysis of the primary efficacy variable
application and any extensions or variations thereof.Analysis of the primary efficacy variable
application and any extensions or variations thereof.The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
application and any extensions or variations thereof.The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
12 in the bimekizumab treatment group versus the CZP treatment group.
application and any extensions or variations thereof.12 in the bimekizumab treatment group versus the CZP treatment group.
statistics will be presented by [CONTACT_581688].statistics will be presented by [CONTACT_581686]. 
application and any extensions or variations thereof.changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
application and any extensions or variations thereof.The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior 
application and any extensions or variations thereof.paradigm. An informative prior 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
application and any extensions or variations thereof.primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [application and any extensions or variations thereof.centered Baseline is observed at its mean of zero (βCZP ~ Normal [
priors will be application and any extensions or variations thereof. priors will be used for all other model coefficients. All priors will be fully documented in the application and any extensions or variations thereof.used for all other model coefficients. All priors will be fully documented in the 
SAP and in the interim analysis SAP.application and any extensions or variations thereof.
SAP and in the interim analysis SAP.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 90of 136groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than zero will also be presented. The posterior probability that bimekizumab achieves a lower ASDAS score at Week 12 compared to CZP will be derived from this distribution.
The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible interval of the difference between treatment groups in the mean change from Baseline in ASDAS is zero or greater).
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will not be updated based upon accrued study data at any time point.
15.5.2 Supportive analysis of the primary efficacy variable
A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
conducted by [CONTACT_581689]. 
Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
Further analyses may be performed for the primary efficacy variable adjusting for other Baseline 
covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
substitute for the planned analyses, but may be used as supplemental information for the CSR.
15.5.3 Analysis of the secondary efficacy variables
The secondary efficacy variables are listed in Section 4.1.2.
All secondary efficacy variables will be summarized descriptively by [CONTACT_359432]. Estimated effects relating to the categorical variables ASDAS-MI and ASDAS-ID will be 
derived from the primary Bayesian analysis. Further details of the analysis methods for secondary efficacy variables will be included in the SAP.
15.5.4 Analysis of the other efficacy variables
The other efficacy variables are listed in Section 4.1.3 .
The other efficacy variables will be listed and summarized descriptively by [CONTACT_169191]. Any formal statistical analyses of the other efficacy variables will be described in 
more detail in the SAP.
Details of the summaries and analyses of efficacy data assessed during the Treatment Extension 
Period, will be provided in the SAP.
15.6 Pharmacokinetic analyses
Bimekizumab and CZP trough plasma concentrations will be listed and summarized by [CONTACT_581690]-PPS using descriptive statistics. PUBLIC COPY A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
PUBLIC COPY A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
imary analysis assuming vague priors for all parameters of the 
PUBLIC COPY imary analysis assuming vague priors for all parameters of the 
Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
PUBLIC COPY Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
Further analyses may be performed for the primary efficacy variable adjusting for other B
PUBLIC COPY Further analyses may be performed for the primary efficacy variable adjusting for other B
covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
PUBLIC COPY covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
substitute for the planned analyses, but may be used as supplemental information for the CSR.
PUBLIC COPY substitute for the planned analyses, but may be used as supplemental information for the CSR.
Analysis of the secondary efficacy variablesPUBLIC COPY Analysis of the secondary efficacy variables
This document cannot be used to support any marketing authorization treatment groups (CZP 
This document cannot be used to support any marketing authorization treatment groups (CZP -
This document cannot be used to support any marketing authorization -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible 
This document cannot be used to support any marketing authorization bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible 
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
This document cannot be used to support any marketing authorization interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
on (independent to this study) regarding the CZP treatment group response 
This document cannot be used to support any marketing authorization on (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
This document cannot be used to support any marketing authorization comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that th
This document cannot be used to support any marketing authorization unblinding, and details of this will be supplied in the SAP and the CSR. Note that th
Supportive analysis of the primary efficacy variable
This document cannot be used to support any marketing authorization Supportive analysis of the primary efficacy variable
A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
This document cannot be used to support any marketing authorization A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
imary analysis assuming vague priors for all parameters of the 
This document cannot be used to support any marketing authorization imary analysis assuming vague priors for all parameters of the 
Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
This document cannot be used to support any marketing authorization Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
Further analyses may be performed for the primary efficacy variable adjusting for other B
This document cannot be used to support any marketing authorization Further analyses may be performed for the primary efficacy variable adjusting for other B
covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
This document cannot be used to support any marketing authorization covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
substitute for the planned analyses, but may be used as supplemental information for the CSR.
This document cannot be used to support any marketing authorization substitute for the planned analyses, but may be used as supplemental information for the CSR.
Analysis of the secondary efficacy variables
This document cannot be used to support any marketing authorization Analysis of the secondary efficacy variables
ry efficacy variables are listed in 
This document cannot be used to support any marketing authorization ry efficacy variables are listed in 
All secondary efficacy variables will be summarized descriptively by [CONTACT_581691]. Estimated effects relating to the categorical variables ASDAS
This document cannot be used to support any marketing authorization point. Estimated effects relating to the categorical variables ASDAS
derived from the primary Bayesian analysis. Further details of the analysis methods for 
This document cannot be used to support any marketing authorization derived from the primary Bayesian analysis. Further details of the analysis methods for 
secondary efficacy variables will be included in the SAP.
This document cannot be used to support any marketing authorization secondary efficacy variables will be included in the SAP.
Analysis of the o
This document cannot be used to support any marketing authorization Analysis of the o
This document cannot be used to support any marketing authorization The other efficacy variables are listed in 
This document cannot be used to support any marketing authorization The other efficacy variables are listed in 
The other efficacy variables will be listed and summarized descrip
This document cannot be used to support any marketing authorization The other efficacy variables will be listed and summarized descrip
time point. Any formal statistical analyses of the other efficacy variables will be described in 
This document cannot be used to support any marketing authorization time point. Any formal statistical analyses of the other efficacy variables will be described in 
more detail in the SAP.
This document cannot be used to support any marketing authorization more detail in the SAP.
Details of the summaries and analyses of efficacy data assessed during the Treatment Extension 
This document cannot be used to support any marketing authorization Details of the summaries and analyses of efficacy data assessed during the Treatment Extension 
Period, 
This document cannot be used to support any marketing authorization Period, 
15.6This document cannot be used to support any marketing authorization 15.6application and any extensions or variations thereof.on (independent to this study) regarding the CZP treatment group response 
application and any extensions or variations thereof.on (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
application and any extensions or variations thereof.comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that th
application and any extensions or variations thereof.unblinding, and details of this will be supplied in the SAP and the CSR. Note that th e prior will 
application and any extensions or variations thereof.e prior will 
Supportive analysis of the primary efficacy variable
application and any extensions or variations thereof.Supportive analysis of the primary efficacy variable
A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
application and any extensions or variations thereof.A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
imary analysis assuming vague priors for all parameters of the 
application and any extensions or variations thereof.imary analysis assuming vague priors for all parameters of the 
Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
application and any extensions or variations thereof.Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
Further analyses may be performed for the primary efficacy variable adjusting for other B
application and any extensions or variations thereof.Further analyses may be performed for the primary efficacy variable adjusting for other B
covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
application and any extensions or variations thereof.covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
substitute for the planned analyses, but may be used as supplemental information for the CSR.
application and any extensions or variations thereof.substitute for the planned analyses, but may be used as supplemental information for the CSR.
Analysis of the secondary efficacy variables
application and any extensions or variations thereof.Analysis of the secondary efficacy variables
ry efficacy variables are listed in 
application and any extensions or variations thereof.ry efficacy variables are listed in Section
application and any extensions or variations thereof.Section
All secondary efficacy variables will be summarized descriptively by [CONTACT_581692].All secondary efficacy variables will be summarized descriptively by [CONTACT_359432]. Estimated effects relating to the categorical variables ASDAS
application and any extensions or variations thereof.point. Estimated effects relating to the categorical variables ASDAS
derived from the primary Bayesian analysis. Further details of the analysis methods for 
application and any extensions or variations thereof.derived from the primary Bayesian analysis. Further details of the analysis methods for 
secondary efficacy variables will be included in the SAP.
application and any extensions or variations thereof.secondary efficacy variables will be included in the SAP.
Analysis of the o
application and any extensions or variations thereof.Analysis of the o ther efficacy variables
application and any extensions or variations thereof.ther efficacy variables
application and any extensions or variations thereof.The other efficacy variables are listed in 
application and any extensions or variations thereof.The other efficacy variables are listed in 
The other efficacy variables will be listed and summarized descrip
application and any extensions or variations thereof.The other efficacy variables will be listed and summarized descrip
time point. Any formal statistical analyses of the other efficacy variables will be described in 
application and any extensions or variations thereof.time point. Any formal statistical analyses of the other efficacy variables will be described in 
more detail in the SAP.
application and any extensions or variations thereof.more detail in the SAP.
Details of the summaries and analyses of efficacy data assessed during the Treatment Extension application and any extensions or variations thereof.Details of the summaries and analyses of efficacy data assessed during the Treatment Extension 
will be provided in the SAP.application and any extensions or variations thereof.will be provided in the SAP.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 91of [ZIP_CODE].7 Immunological analyses
Immunological variables will be analyzed for all subjects in the PK- PPS.
Anti-bimekizumab and anti-CZP antibody data will be summarized at each scheduled visit, and 
the rate of ADA positive subjects for each treatment group will be calculated and presented.
15.8 Planned safety and other analyses
15.8.1 Safety analyses
All safety variables will be analyzed for all subjects in the SS.
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA®, version 19.0). The incidence of treatment-emergent adverse events (TEAEs) will be 
summarized descriptively by [CONTACT_11189], preferred term, and treatment group. 
Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
presented descriptively by [CONTACT_1570]. The C-SSRS data will be listed only.
15.[ADDRESS_764765] been verified/coded/entered into a database, a data review will be performed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
quality of the data. The review will also help decide how to manage problems in the subjects’ data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the Study Master File. After the pre-analysis review, resolution of all issues, and 
documentation of all decisions, the database will be locked.
15.10 Handling of dropouts or missing data
Appropriate missing data imputation methods will be used according to the variable being analyz ed. Details will be included in the SAP.
15.11 Planned interim analysis and data monitoring
This study will include 3 informal unblinded interim analyses; the first after approximately [ADDRESS_764766]’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes 
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
of the interim analyses will lead to any formal decision to alter or terminate the study. 
Interim analyses will be conducted by [CONTACT_581693]. This 
process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team PUBLIC COPY SSRS data will be listed only.
PUBLIC COPY SSRS data will be listed only.
deviations
PUBLIC COPY deviations
After all data have been verified/coded/entered into a database, a data review will be performed. 
PUBLIC COPY After all data have been verified/coded/entered into a database, a data review will be performed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
PUBLIC COPY The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
quality of the data. The review will also help 
PUBLIC COPY quality of the data. The review will also help decide how to manage problems in the subjects’ 
PUBLIC COPY decide how to manage problems in the subjects’ 
data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
PUBLIC COPY data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
Accepted deviations from theoretical time points will be described in the appropriate documents 
PUBLIC COPY Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the Study Master FilePUBLIC COPY and included in the Study Master File . After the prePUBLIC COPY . After the pre
documentation of all decisions, the database will be locked. PUBLIC COPY documentation of all decisions, the database will be locked.
This document cannot be used to support any marketing authorization Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
This document cannot be used to support any marketing authorization Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
emergent adverse events (TEAEs) will be 
This document cannot be used to support any marketing authorization emergent adverse events (TEAEs) will be 
summarized descriptively by [CONTACT_11189], preferred term, and treatment group. 
This document cannot be used to support any marketing authorization summarized descriptively by [CONTACT_11189], preferred term, and treatment group. 
Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
This document cannot be used to support any marketing authorization Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
, serious TEAEs, and deaths. All AE information will be listed.
This document cannot be used to support any marketing authorization , serious TEAEs, and deaths. All AE information will be listed.
Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
This document cannot be used to support any marketing authorization Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
SSRS data will be listed only.
This document cannot be used to support any marketing authorization SSRS data will be listed only.
After all data have been verified/coded/entered into a database, a data review will be performed. 
This document cannot be used to support any marketing authorization After all data have been verified/coded/entered into a database, a data review will be performed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
This document cannot be used to support any marketing authorization The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
decide how to manage problems in the subjects’ 
This document cannot be used to support any marketing authorization decide how to manage problems in the subjects’ 
data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
This document cannot be used to support any marketing authorization data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
Accepted deviations from theoretical time points will be described in the appropriate documents 
This document cannot be used to support any marketing authorization Accepted deviations from theoretical time points will be described in the appropriate documents 
. After the pre
This document cannot be used to support any marketing authorization . After the pre
documentation of all decisions, the database will be locked.
This document cannot be used to support any marketing authorization documentation of all decisions, the database will be locked.
Handling of dropouts or missing data
This document cannot be used to support any marketing authorization Handling of dropouts or missing data
Appropriate missing data imputation methods will be used according to the variable being 
This document cannot be used to support any marketing authorization Appropriate missing data imputation methods will be used according to the variable being 
ed. Details will be included in the SAP.
This document cannot be used to support any marketing authorization ed. Details will be included in the SAP.
Planned interim analysis and data monitoring
This document cannot be used to support any marketing authorization Planned interim analysis and data monitoring
This document cannot be used to support any marketing authorization This study will include 3 informal unblinded interim analyses; the first after approximately 
This document cannot be used to support any marketing authorization This study will include 3 informal unblinded interim analyses; the first after approximately 
subjects have completed [ADDRESS_764767]’s participation has ended prematurely. 
This document cannot be used to support any marketing authorization or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
This document cannot be used to support any marketing authorization The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary 
This document cannot be used to support any marketing authorization primary efficacy analysis and a subset of the analyses of secondary 
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
This document cannot be used to support any marketing authorization to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none application and any extensions or variations thereof.emergent adverse events (TEAEs) will be 
application and any extensions or variations thereof.emergent adverse events (TEAEs) will be 
summarized descriptively by [CONTACT_11189], preferred term, and treatment group. 
application and any extensions or variations thereof.summarized descriptively by [CONTACT_11189], preferred term, and treatment group. 
Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
application and any extensions or variations thereof.Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
, serious TEAEs, and deaths. All AE information will be listed.
application and any extensions or variations thereof., serious TEAEs, and deaths. All AE information will be listed.
Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
application and any extensions or variations thereof.Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
SSRS data will be listed only.
application and any extensions or variations thereof.SSRS data will be listed only.
After all data have been verified/coded/entered into a database, a data review will be performed. 
application and any extensions or variations thereof.After all data have been verified/coded/entered into a database, a data review will be performed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
application and any extensions or variations thereof.The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
decide how to manage problems in the subjects’ 
application and any extensions or variations thereof.decide how to manage problems in the subjects’ 
data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
application and any extensions or variations thereof.data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
Accepted deviations from theoretical time points will be described in the appropriate documents 
application and any extensions or variations thereof.Accepted deviations from theoretical time points will be described in the appropriate documents 
. After the pre
application and any extensions or variations thereof.. After the pre -
application and any extensions or variations thereof.-analysis review, resolution of all issues, and 
application and any extensions or variations thereof.analysis review, resolution of all issues, and 
documentation of all decisions, the database will be locked.
application and any extensions or variations thereof.documentation of all decisions, the database will be locked.
Handling of dropouts or missing data
application and any extensions or variations thereof.Handling of dropouts or missing data
Appropriate missing data imputation methods will be used according to the variable being 
application and any extensions or variations thereof.Appropriate missing data imputation methods will be used according to the variable being 
ed. Details will be included in the SAP.
application and any extensions or variations thereof.ed. Details will be included in the SAP.
Planned interim analysis and data monitoring
application and any extensions or variations thereof.Planned interim analysis and data monitoring
application and any extensions or variations thereof.This study will include 3 informal unblinded interim analyses; the first after approximately 
application and any extensions or variations thereof.This study will include 3 informal unblinded interim analyses; the first after approximately 
subjects have completed [ADDRESS_764768]’s participation has ended prematurely. 
application and any extensions or variations thereof.or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the application and any extensions or variations thereof. The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary application and any extensions or variations thereof.
primary efficacy analysis and a subset of the analyses of secondary 
UCB [ADDRESS_764769]/MRI substudy.
Subjects will be randomized in a 2:[ADDRESS_764770] 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
change from Baseline for CZP and bimekizumab being -1.78 and -2.67 respectively) with a common standard deviation of 1.[ADDRESS_764771] methods for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (-
1.78,var=0.0605), contributes an effective sample size of approximately [ADDRESS_764772]’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by [CONTACT_737] (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with the Investigator.
Prior to participation in the study, the Informed Consent form should be signed and personally 
dated by [CONTACT_233791] 
(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
Consent form. As part of the consent process, each subject must consent to direct access to 
his/her medical records for study-related monitoring, auditing, IRB/IEC review, and regulatory inspection.
If the Informed Consent form is amended during the study, the Investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the amended Informed Consent form by [CONTACT_1201]/IEC and use of the amended form.
All studies conducted at centers in the [LOCATION_002] must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.PUBLIC COPY covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
PUBLIC COPY covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ASDAS was assumed to be 0.35. Note that the informati
PUBLIC COPY ASDAS was assumed to be 0.35. Note that the informati ve prior for the model intercept to be 
PUBLIC COPY ve prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
PUBLIC COPY used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
PUBLIC COPY 1.78,var=0.0605), contributes an effective sample size of approximately [ADDRESS_764773]’s informed consent must be obtained and documented in accordance with local PUBLIC COPY Subject’s informed consent must be obtained and documented in accordance with local 
This document cannot be used to support any marketing authorization zumab 
This document cannot be used to support any marketing authorization zumab 
Subjects will be randomized in a 2:1 ratio to receive bimekizumab or CZP respectively. 
This document cannot be used to support any marketing authorization Subjects will be randomized in a 2:1 ratio to receive bimekizumab or CZP respectively. 
difference between 
This document cannot be used to support any marketing authorization difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
This document cannot be used to support any marketing authorization treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
2.67 respectively) with a 
This document cannot be used to support any marketing authorization 2.67 respectively) with a 
for the comparison of the 
This document cannot be used to support any marketing authorization for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
This document cannot be used to support any marketing authorization treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
This document cannot be used to support any marketing authorization covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ve prior for the model intercept to be 
This document cannot be used to support any marketing authorization ve prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
This document cannot be used to support any marketing authorization used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
This document cannot be used to support any marketing authorization 1.78,var=0.0605), contributes an effective sample size of approximately [ADDRESS_764774]’s informed consent must be obtained and documented in accordance with local 
This document cannot be used to support any marketing authorization Subject’s informed consent must be obtained and documented in accordance with local 
GCP requirements, and the ethical principles that have their origin in the 
This document cannot be used to support any marketing authorization GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
This document cannot be used to support any marketing authorization principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
This document cannot be used to support any marketing authorization Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandabl
This document cannot be used to support any marketing authorization complexity understandabl e to the subject in both oral and written form by [CONTACT_737] (or 
This document cannot be used to support any marketing authorization e to the subject in both oral and written form by [CONTACT_737] (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
This document cannot be used to support any marketing authorization designee). Each subject will have the opportunity to discuss the study and its alternatives with 
Prior to participation in the study, the Informed Consent form should 
This document cannot be used to support any marketing authorization Prior to participation in the study, the Informed Consent form should 
dated by [CONTACT_581694] 
(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
This document cannot be used to support any marketing authorization (Investigator or designee). The subject must receive a copy of the signed and dated Informed 
This document cannot be used to support any marketing authorization Consent form. As part of the consent process, each su
This document cannot be used to support any marketing authorization Consent form. As part of the consent process, each su
his/her medical records for study
This document cannot be used to support any marketing authorization his/her medical records for study
inspection.
This document cannot be used to support any marketing authorization inspection.
If the Informed Consent form is amended during the study, the Investigator (or the sponsor, if 
This document cannot be used to support any marketing authorization If the Informed Consent form is amended during the study, the Investigator (or the sponsor, if 
applicable) musThis document cannot be used to support any marketing authorization applicable) musapplication and any extensions or variations thereof.difference between 
application and any extensions or variations thereof.difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
application and any extensions or variations thereof.treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
2.67 respectively) with a 
application and any extensions or variations thereof.2.67 respectively) with a 
for the comparison of the 
application and any extensions or variations thereof.for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
application and any extensions or variations thereof.treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
application and any extensions or variations thereof.covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ve prior for the model intercept to be 
application and any extensions or variations thereof.ve prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
application and any extensions or variations thereof.used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
application and any extensions or variations thereof.1.78,var=0.0605), contributes an effective sample size of approximately [ADDRESS_764775]’s informed consent must be obtained and documented in accordance with local 
application and any extensions or variations thereof.Subject’s informed consent must be obtained and documented in accordance with local 
GCP requirements, and the ethical principles that have their origin in the 
application and any extensions or variations thereof.GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
application and any extensions or variations thereof.principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
application and any extensions or variations thereof.Prior to obtaining informed consent, information should be given in a language and at a level of 
e to the subject in both oral and written form by [CONTACT_737] (or 
application and any extensions or variations thereof.e to the subject in both oral and written form by [CONTACT_737] (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
application and any extensions or variations thereof.designee). Each subject will have the opportunity to discuss the study and its alternatives with 
Prior to participation in the study, the Informed Consent form should 
application and any extensions or variations thereof.Prior to participation in the study, the Informed Consent form should 
dated by [CONTACT_581695].dated by [CONTACT_233791] 
(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
application and any extensions or variations thereof.(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
application and any extensions or variations thereof.Consent form. As part of the consent process, each su
application and any extensions or variations thereof.Consent form. As part of the consent process, each su
his/her medical records for studyapplication and any extensions or variations thereof.his/her medical records for study
inspection. application and any extensions or variations thereof.inspection.
UCB [ADDRESS_764776] may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent Form. An 
eCRF must not be started, nor may any study specific procedure be performed for a given subject, without having obtained his/her written consent to participate in the study.
16.[ADDRESS_764777] with him/her at all times.
16.3 Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to initiation of the study, the Investigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
and all other subject-related documents to be used for the study to the IRB/IEC for its review and approval.
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by [CONTACT_18424], it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. PUBLIC COPY be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
PUBLIC COPY be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
GCP, and in accordance with the ethical principles that have their origin in the Declaration 
PUBLIC COPY GCP, and in accordance with the ethical principles that have their origin in the Declaration 
The Investigator/UCB will ensure that an appropriately constitute
PUBLIC COPY The Investigator/UCB will ensure that an appropriately constitute
GCP version or applicable country
PUBLIC COPY GCP version or applicable country
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
PUBLIC COPY be responsible for the initial and continuing review and approval of the clinical study. Prior to 
stigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
PUBLIC COPY stigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
PUBLIC COPY Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
related documents to be used for the study to the IRB/IEC for its review and PUBLIC COPY related documents to be used for the study to the IRB/IEC for its review and 
This document cannot be used to support any marketing authorization Upon signing the Informed Consent form, the subject will be provided with a subject 
This document cannot be used to support any marketing authorization Upon signing the Informed Consent form, the subject will be provided with a subject 
will fill in the subject 
This document cannot be used to support any marketing authorization will fill in the subject 
identifying information and medical emergency contact [CONTACT_3031]. The Investigator will 
This document cannot be used to support any marketing authorization identifying information and medical emergency contact [CONTACT_3031]. The Investigator will 
Institutional Review Boards and Independent Ethics 
This document cannot be used to support any marketing authorization Institutional Review Boards and Independent Ethics 
be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
This document cannot be used to support any marketing authorization be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
GCP, and in accordance with the ethical principles that have their origin in the Declaration 
This document cannot be used to support any marketing authorization GCP, and in accordance with the ethical principles that have their origin in the Declaration 
The Investigator/UCB will ensure that an appropriately constitute
This document cannot be used to support any marketing authorization The Investigator/UCB will ensure that an appropriately constitute
GCP version or applicable country
This document cannot be used to support any marketing authorization GCP version or applicable country
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
This document cannot be used to support any marketing authorization be responsible for the initial and continuing review and approval of the clinical study. Prior to 
stigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
This document cannot be used to support any marketing authorization stigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
This document cannot be used to support any marketing authorization Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
related documents to be used for the study to the IRB/IEC for its review and 
This document cannot be used to support any marketing authorization related documents to be used for the study to the IRB/IEC for its review and 
Before initiating a study, the Investigator will have written and dated full approval from the 
This document cannot be used to support any marketing authorization Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
This document cannot be used to support any marketing authorization responsible IRB/IEC for the protocol.
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
This document cannot be used to support any marketing authorization The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems in
This document cannot be used to support any marketing authorization unanticipated problems in volving risks to human subjects or others, and any protocol deviations, 
This document cannot be used to support any marketing authorization volving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
This document cannot be used to support any marketing authorization to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
This document cannot be used to support any marketing authorization The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate appar
This document cannot be used to support any marketing authorization approval, except where necessary to eliminate appar
minor changes to a previously approved protocol during the period covered by [CONTACT_581696] a previously approved protocol during the period covered by [CONTACT_18424], it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
This document cannot be used to support any marketing authorization approval, it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
allowed.
This document cannot be used to support any marketing authorization allowed.
As part of the I
This document cannot be used to support any marketing authorization As part of the I
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
This document cannot be used to support any marketing authorization will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, bu
This document cannot be used to support any marketing authorization requirements), at intervals appropriate to the degree of subject risk involved, buapplication and any extensions or variations thereof.identifying information and medical emergency contact [CONTACT_3031]. The Investigator will 
application and any extensions or variations thereof.identifying information and medical emergency contact [CONTACT_3031]. The Investigator will 
Institutional Review Boards and Independent Ethics 
application and any extensions or variations thereof.Institutional Review Boards and Independent Ethics 
be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
application and any extensions or variations thereof.be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
GCP, and in accordance with the ethical principles that have their origin in the Declaration 
application and any extensions or variations thereof.GCP, and in accordance with the ethical principles that have their origin in the Declaration 
The Investigator/UCB will ensure that an appropriately constitute
application and any extensions or variations thereof.The Investigator/UCB will ensure that an appropriately constitute d IRB/IEC that complies with 
application and any extensions or variations thereof.d IRB/IEC that complies with 
GCP version or applicable country
application and any extensions or variations thereof.GCP version or applicable country
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
application and any extensions or variations thereof.be responsible for the initial and continuing review and approval of the clinical study. Prior to 
stigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
application and any extensions or variations thereof.stigator/UCB will forward copi[INVESTIGATOR_18280], Informed 
Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
application and any extensions or variations thereof.Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
related documents to be used for the study to the IRB/IEC for its review and 
application and any extensions or variations thereof.related documents to be used for the study to the IRB/IEC for its review and 
Before initiating a study, the Investigator will have written and dated full approval from the 
application and any extensions or variations thereof.Before initiating a study, the Investigator will have written and dated full approval from the 
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
application and any extensions or variations thereof.The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
volving risks to human subjects or others, and any protocol deviations, 
application and any extensions or variations thereof.volving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
application and any extensions or variations thereof.to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
application and any extensions or variations thereof.The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate appar
application and any extensions or variations thereof.approval, except where necessary to eliminate appar
minor changes to a previously approved protocol during the period covered by [CONTACT_581697].minor changes to a previously approved protocol during the period covered by [CONTACT_18424], it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
application and any extensions or variations thereof.approval, it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
As part of the I application and any extensions or variations thereof.As part of the I RB/IEC requirements for continuing review of approved studies, the Investigator application and any extensions or variations thereof.RB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC application and any extensions or variations thereof.will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 94of 136The appropriate IRB/IEC will also be informed by [CONTACT_352292], as specified 
by [CONTACT_59002]. Where applicable, 
Investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC notification.
16.[ADDRESS_764778] privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_579682].
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of th e 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_18281] a subject’s study participation, and autopsy reports for deaths occurring during the study).
16.[ADDRESS_764779] 
be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being implemented.
17 FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
18 REFERENCES
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody 
infliximab. Arthritis Rheum. 2000;43:1346-52.
Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. Clin Exp 
Rheumatol. 2012;30:S132-5.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-90.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 
2010 update of the ASAS/EULAR recommendations for the management of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896-904.
Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin 
Rheumatol. 2002;16:573-604.PUBLIC COPY Protocol changes may affect the legal and ethical status of the study and may also affect the 
PUBLIC COPY Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its p
PUBLIC COPY statistical evaluations of sample size and the likelihood of the study fulfilling its p
Significant changes to the protocol will only be made as an amendment to the protocol and must 
PUBLIC COPY Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
PUBLIC COPY be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
FINANCE, INSURANCE, PUBLIC COPY FINANCE, INSURANCE, 
Insurance coverage will be handled according to local requirements. PUBLIC COPY Insurance coverage will be handled according to local requirements.
This document cannot be used to support any marketing authorization entified only by [CONTACT_581698], its designee, representatives of the relevant 
This document cannot be used to support any marketing authorization The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of th
This document cannot be used to support any marketing authorization IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of th
subject’s primary medical records that directly concerns this study (including, but not limited to, 
This document cannot be used to support any marketing authorization subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_581561], ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_581562] p
This document cannot be used to support any marketing authorization statistical evaluations of sample size and the likelihood of the study fulfilling its p
Significant changes to the protocol will only be made as an amendment to the protocol and must 
This document cannot be used to support any marketing authorization Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
This document cannot be used to support any marketing authorization be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
FINANCE, INSURANCE, 
This document cannot be used to support any marketing authorization FINANCE, INSURANCE, AND PUBLICATION
This document cannot be used to support any marketing authorization AND PUBLICATION
Insurance coverage will be handled according to local requirements.
This document cannot be used to support any marketing authorization Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
This document cannot be used to support any marketing authorization Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
REFERENCES
This document cannot be used to support any marketing authorization REFERENCES
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
This document cannot be used to support any marketing authorization Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
active ankylosing spondylitis with the anti
This document cannot be used to support any marketing authorization active ankylosing spondylitis with the anti
infliximab. Arthritis Rheum. 2000;43:1346
This document cannot be used to support any marketing authorization infliximab. Arthritis Rheum. 2000;43:1346
Braun J. Axial spondyloarthr
This document cannot be used to support any marketing authorization Braun J. Axial spondyloarthr
Rheumatol. 2012;30:S132
This document cannot be used to support any marketing authorization Rheumatol. 2012;30:S132
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379
This document cannot be used to support any marketing authorization Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos
This document cannot be used to support any marketing authorization Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos
2
This document cannot be used to support any marketing authorization 2010 update of the ASAS/EULAR recommendations for the management of ankylosing 
This document cannot be used to support any marketing authorization 010 update of the ASAS/EULAR recommendations for the management of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896
This document cannot be used to support any marketing authorization spondylitis. Ann Rheum Dis. 2011;70:896application and any extensions or variations thereof.The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
application and any extensions or variations thereof.The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of th
application and any extensions or variations thereof.IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of th e 
application and any extensions or variations thereof.e 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
application and any extensions or variations thereof.subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_581563].laboratory test result reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_581564].utopsy reports for deaths 
Protocol changes may affect the legal and ethical status of the study and may also affect the 
application and any extensions or variations thereof.Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its p
application and any extensions or variations thereof.statistical evaluations of sample size and the likelihood of the study fulfilling its p
Significant changes to the protocol will only be made as an amendment to the protocol and must 
application and any extensions or variations thereof.Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
application and any extensions or variations thereof.be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
AND PUBLICATION
application and any extensions or variations thereof.AND PUBLICATION
Insurance coverage will be handled according to local requirements.
application and any extensions or variations thereof.Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
application and any extensions or variations thereof.Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
REFERENCES
application and any extensions or variations thereof.REFERENCES
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
application and any extensions or variations thereof.Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
active ankylosing spondylitis with the anti
application and any extensions or variations thereof.active ankylosing spondylitis with the anti
infliximab. Arthritis Rheum. 2000;43:1346
application and any extensions or variations thereof.infliximab. Arthritis Rheum. 2000;43:1346
Braun J. Axial spondyloarthr
application and any extensions or variations thereof.Braun J. Axial spondyloarthr
Rheumatol. 2012;30:S132
application and any extensions or variations thereof.Rheumatol. 2012;30:S132
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379
application and any extensions or variations thereof.Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos application and any extensions or variations thereof.Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos
010 update of the ASAS/EULAR recommendations for the management of ankylosing application and any extensions or variations thereof.010 update of the ASAS/EULAR recommendations for the management of ankylosing 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 95of 136Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of 
sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis 
and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006;65:1147-53.
Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;2:2281-5.
Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-
articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis 
Res. 2001;3:168–77. 
CPMP/ICH/135/95. Note for guidance on good clinical practice. July 2002. 
CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
NSAIDs for treatment of rheumatoid arthritis. Mar 2015. 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient-reported outcomes in moderate- to-severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23(12):1374-82.
Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764780] report No.: UCB- MBMA -AS-164.
Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83-100. 
Even-Sapir E, Mishani E, Flusser G, Metser U: 18F-Fluoride positron emission tomography and 
positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Activity Index. J Rheumatol. 1994;21:2286-91.
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann 
Rheum Dis. 2007;66:419-21.
Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124-6.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the [LOCATION_002]. Part I. Arthritis Rheum. 2008;58:15-25.
International Menopause Society. Cornwall, [LOCATION_006]: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed 25 Jan 2016.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of 
certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing PUBLIC COPY severe psoriasis patients receiving continuous or 
PUBLIC COPY severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Ac
PUBLIC COPY paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Ac
Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
PUBLIC COPY Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764781] 
PUBLIC COPY modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764782] 
avis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
PUBLIC COPY avis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83
PUBLIC COPY bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83
Sapir E, Mishani E, Flusser G, Metser U: 18F PUBLIC COPY Sapir E, Mishani E, Flusser G, Metser U: 18F
This document cannot be used to support any marketing authorization 17 derived from juxta
This document cannot be used to support any marketing authorization 17 derived from juxta -
This document cannot be used to support any marketing authorization -
articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis 
This document cannot be used to support any marketing authorization articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis 
CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
This document cannot be used to support any marketing authorization CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. 
This document cannot be used to support any marketing authorization Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. 
severe psoriasis patients receiving continuous or 
This document cannot be used to support any marketing authorization severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Ac
This document cannot be used to support any marketing authorization paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Ac
Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
This document cannot be used to support any marketing authorization Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764783] 
This document cannot be used to support any marketing authorization modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764784] 
avis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
This document cannot be used to support any marketing authorization avis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83
This document cannot be used to support any marketing authorization bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83
Sapir E, Mishani E, Flusser G, Metser U: 18F
This document cannot be used to support any marketing authorization Sapir E, Mishani E, Flusser G, Metser U: 18F
emission tomography/computed tomography. Semin Nucl Med. 2007;37:462
This document cannot be used to support any marketing authorization emission tomography/computed tomography. Semin Nucl Med. 2007;37:[ADDRESS_764785] P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
This document cannot be used to support any marketing authorization defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Rheumatol. 1994;21:2286
This document cannot be used to support any marketing authorization Rheumatol. 1994;21:2286
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
This document cannot be used to support any marketing authorization Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
This document cannot be used to support any marketing authorization subcutaneous methotrexate in active ankylosing spondylitis: a 16
This document cannot be used to support any marketing authorization subcutaneous methotrexate in active ankylosing spondylitis: a 16
Rheum Dis. 2007;66:419
This document cannot be used to support any marketing authorization Rheum Dis. 2007;66:419
Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
This document cannot be used to support any marketing authorization Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124
This document cannot be used to support any marketing authorization ankylosing spondylitis. Ann Rheum Dis. 2005;64:124
This document cannot be used to support any marketing authorization Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
This document cannot be used to support any marketing authorization Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis an
This document cannot be used to support any marketing authorization prevalence of arthritis an
Rheum. 2008;58:15
This document cannot be used to support any marketing authorization Rheum. 2008;58:15
International Menopause Society. Cornwall, [LOCATION_006]: Menopause Terminology; c2015. 
This document cannot be used to support any marketing authorization International Menopause Society. Cornwall, [LOCATION_006]: Menopause Terminology; c2015. application and any extensions or variations thereof.CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
application and any extensions or variations thereof.CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. 
application and any extensions or variations thereof.Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
application and any extensions or variations thereof.Improvements 
severe psoriasis patients receiving continuous or 
application and any extensions or variations thereof.severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Ac
application and any extensions or variations thereof.paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Ac ad Dermatol 
application and any extensions or variations thereof.ad Dermatol 
Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
application and any extensions or variations thereof.Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764786] 
application and any extensions or variations thereof.modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_764787] 
avis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
application and any extensions or variations thereof.avis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83
application and any extensions or variations thereof.bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83
Sapir E, Mishani E, Flusser G, Metser U: 18F
application and any extensions or variations thereof.Sapir E, Mishani E, Flusser G, Metser U: 18F -
application and any extensions or variations thereof.-Fluoride positron emission tomography and 
application and any extensions or variations thereof.Fluoride positron emission tomography and 
emission tomography/computed tomography. Semin Nucl Med. 2007;37:462
application and any extensions or variations thereof.emission tomography/computed tomography. Semin Nucl Med. 2007;37:[ADDRESS_764788] P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
application and any extensions or variations thereof.defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Rheumatol. 1994;21:2286
application and any extensions or variations thereof.Rheumatol. 1994;21:2286
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
application and any extensions or variations thereof.Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
application and any extensions or variations thereof.subcutaneous methotrexate in active ankylosing spondylitis: a 16
application and any extensions or variations thereof.subcutaneous methotrexate in active ankylosing spondylitis: a 16
Rheum Dis. 2007;66:419
application and any extensions or variations thereof.Rheum Dis. 2007;66:419 -
application and any extensions or variations thereof.-21.
application and any extensions or variations thereof.21.
Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
application and any extensions or variations thereof.Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124
application and any extensions or variations thereof.ankylosing spondylitis. Ann Rheum Dis. 2005;64:124
application and any extensions or variations thereof.Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
application and any extensions or variations thereof.Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis anapplication and any extensions or variations thereof.prevalence of arthritis an
Rheum. 2008;58:15 application and any extensions or variations thereof. Rheum. 2008;58:15
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 96of 136spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann 
Rheum Dis. 2014;73:39-47.
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab 
significantly improves symptoms of anxiety, depression, and skin-related quality of life in 
patients with moderate- to-severe psoriasis: Results from a randomized, double-blind, placebo-
controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457-65. 
Lories RJU, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone 
formation in spondyloarthritis. Arthritis Res Ther. 2009;11:221.
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an 
ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann 
Rheum Dis. 2009;68:18-24.
Mease PJ, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, et al. Long -term 
safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
prior anti-tumor necrosis factor exposure: 96-week outcomes from the RAPID-PsA trial. 
Presented at the European League Against Rheumatism (EULAR) [ADDRESS_764789] 
#OP0077.
Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and 
implication for clinical practice. RMD Open. 2017;3(1):e000284). 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer-Automated Columbia-Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224-8.
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis 
Rheum. 2010;62:1576-82.
Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
proportions. Biometrics. 1987;43(3):701-5.
National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
2010. Ogdie A, Weiss P. The Epi[INVESTIGATOR_58931]. Rheum Dis Clin North Am. 
2015;41(4):545-68.
Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. IL-17-producing γδ T cells 
enhance bone regeneration. Nat Commun. 2016;11;7:[ZIP_CODE].
Osta B, Lavocat F, Eljaafari A, et al. Effects of interleukin-17A on osteogenic differentiation of 
isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
Overall J, Starbuck R. Sample size estimation for randomized pre-post designs. Journal of 
Psychiatric Research. 1979;15(1):51-5. 
Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the 
bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32:80-5.
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet 
Dis. 2013;5:45-54.PUBLIC COPY 17: a role in the pathogenesis of inflammatory arthritis and 
PUBLIC COPY 17: a role in the pathogenesis of inflammatory arthritis and 
RMD Open. 2017;3(1):e000284). 
PUBLIC COPY RMD Open. 2017;3(1):e000284). 
elnick DJ, Jefferson JW, Modell JG. 
PUBLIC COPY elnick DJ, Jefferson JW, Modell JG. 
Automated Columbia
PUBLIC COPY Automated Columbia
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224
PUBLIC COPY Voice Response Technology. J Psychiatr Res. 2010;44(16):1224
Myasoedova E, Crowson CS, Kremers HM, Therneau T
PUBLIC COPY Myasoedova E, Crowson CS, Kremers HM, Therneau T
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955PUBLIC COPY rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955
This document cannot be used to support any marketing authorization Development of an 
This document cannot be used to support any marketing authorization Development of an 
endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. 
This document cannot be used to support any marketing authorization endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann 
This document cannot be used to support any marketing authorization Ann 
ladman D, Hoepken B, et al. 
This document cannot be used to support any marketing authorization ladman D, Hoepken B, et al. 
safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
This document cannot be used to support any marketing authorization safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
week outcomes from the RAPID
This document cannot be used to support any marketing authorization week outcomes from the RAPID
inst Rheumatism (EULAR) [ADDRESS_764790] Rheumatism (EULAR) [ADDRESS_764791] 
17: a role in the pathogenesis of inflammatory arthritis and 
This document cannot be used to support any marketing authorization 17: a role in the pathogenesis of inflammatory arthritis and 
RMD Open. 2017;3(1):e000284). 
This document cannot be used to support any marketing authorization RMD Open. 2017;3(1):e000284). 
elnick DJ, Jefferson JW, Modell JG. 
This document cannot be used to support any marketing authorization elnick DJ, Jefferson JW, Modell JG. 
Suicide severity Rating Scale Using Interactive 
This document cannot be used to support any marketing authorization Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224
This document cannot be used to support any marketing authorization Voice Response Technology. J Psychiatr Res. 2010;44(16):1224
Myasoedova E, Crowson CS, Kremers HM, Therneau T
This document cannot be used to support any marketing authorization Myasoedova E, Crowson CS, Kremers HM, Therneau T
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955
This document cannot be used to support any marketing authorization rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955
Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
This document cannot be used to support any marketing authorization Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
ometrics. 1987;43(3):701
This document cannot be used to support any marketing authorization ometrics. 1987;43(3):701
This document cannot be used to support any marketing authorization National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
This document cannot be used to support any marketing authorization National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
This document cannot be used to support any marketing authorization and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
2010. Ogdie A, Weiss P. The Epi[INVESTIGATOR_14849] P
This document cannot be used to support any marketing authorization 2010. Ogdie A, Weiss P. The Epi[INVESTIGATOR_14849] P
68.
This document cannot be used to support any marketing authorization 68.
Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. 
This document cannot be used to support any marketing authorization Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. 
enhance bone regeneration. 
This document cannot be used to support any marketing authorization enhance bone regeneration. 
Osta B, Lavocat F, Eljaafari A, et al. 
This document cannot be used to support any marketing authorization Osta B, Lavocat F, Eljaafari A, et al. 
isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
This document cannot be used to support any marketing authorization isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
Overall J, Starbuck R. Sample size estimation for randomized pre
This document cannot be used to support any marketing authorization Overall J, Starbuck R. Sample size estimation for randomized pre
Psychiatric Research. 1979;15(1):51
This document cannot be used to support any marketing authorization Psychiatric Research. 1979;15(1):51application and any extensions or variations thereof.Ann 
application and any extensions or variations thereof.Ann 
ladman D, Hoepken B, et al. 
application and any extensions or variations thereof.ladman D, Hoepken B, et al. Long
application and any extensions or variations thereof.Long
safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
application and any extensions or variations thereof.safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
week outcomes from the RAPID
application and any extensions or variations thereof.week outcomes from the RAPID -
application and any extensions or variations thereof.-PsA trial. 
application and any extensions or variations thereof.PsA trial. 
inst Rheumatism (EULAR) [ADDRESS_764792] Rheumatism (EULAR) [ADDRESS_764793] 
17: a role in the pathogenesis of inflammatory arthritis and 
application and any extensions or variations thereof.17: a role in the pathogenesis of inflammatory arthritis and 
RMD Open. 2017;3(1):e000284). 
application and any extensions or variations thereof.RMD Open. 2017;3(1):e000284). 
elnick DJ, Jefferson JW, Modell JG. 
application and any extensions or variations thereof.elnick DJ, Jefferson JW, Modell JG. 
Suicide severity Rating Scale Using Interactive 
application and any extensions or variations thereof.Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224
application and any extensions or variations thereof.Voice Response Technology. J Psychiatr Res. 2010;44(16):1224
Myasoedova E, Crowson CS, Kremers HM, Therneau T
application and any extensions or variations thereof.Myasoedova E, Crowson CS, Kremers HM, Therneau T M, Gabriel SE. Is the incidence of 
application and any extensions or variations thereof.M, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955
application and any extensions or variations thereof.rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955
Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
application and any extensions or variations thereof.Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
ometrics. 1987;43(3):701
application and any extensions or variations thereof.ometrics. 1987;43(3):701
application and any extensions or variations thereof.-
application and any extensions or variations thereof.-5.
application and any extensions or variations thereof.5.
National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
application and any extensions or variations thereof.National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
application and any extensions or variations thereof.and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
2010. Ogdie A, Weiss P. The Epi[INVESTIGATOR_14849] P
application and any extensions or variations thereof.2010. Ogdie A, Weiss P. The Epi[INVESTIGATOR_14849] P
Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. 
application and any extensions or variations thereof.Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. 
enhance bone regeneration. 
application and any extensions or variations thereof.enhance bone regeneration. 
Osta B, Lavocat F, Eljaafari A, et al. 
application and any extensions or variations thereof.Osta B, Lavocat F, Eljaafari A, et al. 
isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.application and any extensions or variations thereof.isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
Overall J, Starbuck R. Sample size estimation for randomized pre application and any extensions or variations thereof. Overall J, Starbuck R. Sample size estimation for randomized pre
UCB [ADDRESS_764794] of 
non-steroidal anti-inflammatory drugs on radiographic spi[INVESTIGATOR_58932]: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616-22.
Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. 
Higher disease activity leads to more structural damage in the spi[INVESTIGATOR_581565]: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455-61.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266-77.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the [LOCATION_002]: 
estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905-10.
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
spondyloarthritis. Curr Opin Rheumatol. 2010;22:375-80.
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early 
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Cohort. Arthritis Rheum. 2009a;60:717-27.
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31.
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development 
of Assessment of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_18287]. Ann Rheum Dis. 2009b;68:770-6.
Shah et al. unpublished data/abstract submitted European League Against Rheumatism; 14–17 
June 2017. 
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment 
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Supple 2):ii1-44.
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
improvements in patient-reported outcomes with certolizumab pegol in patients with axial 
spondyloarthritis, including ankylosing spondylitis: 24-Week results of RAPID-axSpA trial. 
European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
Sieper J, Rudwaleit M, van der Heijde D. Long-term safety and efficacy of certolizumab pegol in 
patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial 
spondyloarthritis: 96-week outcomes of the RAPID-axSpA trial. Presented at the European 
League Against Rheumatism (EULAR) [ADDRESS_764795] #SAT0351.
Snaith RP, Zigmond AS. The hospi[INVESTIGATOR_56105], with the irritability-
depression-anxiety scale and the Leeds situational anxiety scale manual. 1994.PUBLIC COPY Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker
PUBLIC COPY Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
PUBLIC COPY disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
PUBLIC COPY Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
is International Society classification criteria for peripheral 
PUBLIC COPY is International Society classification criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. 
PUBLIC COPY spondyloarthritis and for spondyloarthritis in general. 
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. 
PUBLIC COPY Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. 
nt of SpondyloArthritis international Society classification criteria for axial 
PUBLIC COPY nt of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_581566] (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_18287]. Ann Rheum Dis. 2009b;68:770 PUBLIC COPY appraisal. Ann Rheum Dis. 2009b;68:770
This document cannot be used to support any marketing authorization Findings From 
This document cannot be used to support any marketing authorization Findings From 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266
This document cannot be used to support any marketing authorization Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the [LOCATION_002]: 
This document cannot be used to support any marketing authorization Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the [LOCATION_002]: 
e Res (Hoboken). 2012;64:905
This document cannot be used to support any marketing authorization e Res (Hoboken). 2012;64:905
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
This document cannot be used to support any marketing authorization Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
Hermann E, Zeidler H, et al.
This document cannot be used to support any marketing authorization Hermann E, Zeidler H, et al.
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
This document cannot be used to support any marketing authorization disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
This document cannot be used to support any marketing authorization Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
is International Society classification criteria for peripheral 
This document cannot be used to support any marketing authorization is International Society classification criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. 
This document cannot be used to support any marketing authorization spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25
This document cannot be used to support any marketing authorization Ann Rheum Dis. 2011;70:25
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. 
This document cannot be used to support any marketing authorization Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. 
nt of SpondyloArthritis international Society classification criteria for axial 
This document cannot be used to support any marketing authorization nt of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_581567] (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_18287]. Ann Rheum Dis. 2009b;68:770
This document cannot be used to support any marketing authorization appraisal. Ann Rheum Dis. 2009b;68:770 -
This document cannot be used to support any marketing authorization -6.
This document cannot be used to support any marketing authorization 6.
Shah et al. unpublished data/abst
This document cannot be used to support any marketing authorization Shah et al. unpublished data/abst ract submitted European League Against Rheumatism; [ADDRESS_764796] Rheumatism; 14
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos
This document cannot be used to support any marketing authorization Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
This document cannot be used to support any marketing authorization of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
This document cannot be used to support any marketing authorization tis. Ann Rheum Dis. 2009;68(Supple 2):ii1
This document cannot be used to support any marketing authorization tis. Ann Rheum Dis. 2009;68(Supple 2):ii1
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
This document cannot be used to support any marketing authorization Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
improvements in patient
This document cannot be used to support any marketing authorization improvements in patient
spondyloarthritis, including ankylosin
This document cannot be used to support any marketing authorization spondyloarthritis, including ankylosin
European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
This document cannot be used to support any marketing authorization European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
Sieper J, Rudwaleit M, van der Heijde D. Long
This document cannot be used to support any marketing authorization Sieper J, Rudwaleit M, van der Heijde D. Long
This document cannot be used to support any marketing authorization patients with axial sp
This document cannot be used to support any marketing authorization patients with axial sp
spondyloarthritis: 96
This document cannot be used to support any marketing authorization spondyloarthritis: [ADDRESS_764797] Rheumatism (EULAR) [ADDRESS_764798] #SAT0351.
This document cannot be used to support any marketing authorization League Against Rheumatism (EULAR) [ADDRESS_764799] #SAT0351.application and any extensions or variations thereof.Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266
application and any extensions or variations thereof.Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266 -
application and any extensions or variations thereof.-77.
application and any extensions or variations thereof.77.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the [LOCATION_002]: 
application and any extensions or variations thereof.Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the [LOCATION_002]: 
10.
application and any extensions or variations thereof.10.
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
application and any extensions or variations thereof.Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
Hermann E, Zeidler H, et al.
application and any extensions or variations thereof.Hermann E, Zeidler H, et al.
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
application and any extensions or variations thereof.disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
application and any extensions or variations thereof.Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
is International Society classification criteria for peripheral 
application and any extensions or variations thereof.is International Society classification criteria for peripheral 
Ann Rheum Dis. 2011;70:25
application and any extensions or variations thereof.Ann Rheum Dis. 2011;70:25
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. 
application and any extensions or variations thereof.Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. 
nt of SpondyloArthritis international Society classification criteria for axial 
application and any extensions or variations thereof.nt of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_581568].spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_581569]; [ADDRESS_764800] Rheumatism; 14
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos
application and any extensions or variations thereof.Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
application and any extensions or variations thereof.of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
application and any extensions or variations thereof.tis. Ann Rheum Dis. 2009;68(Supple 2):ii1
application and any extensions or variations thereof.tis. Ann Rheum Dis. 2009;68(Supple 2):ii1
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
application and any extensions or variations thereof.Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
improvements in patient
application and any extensions or variations thereof.improvements in patient -
application and any extensions or variations thereof.-reported outcomes with certolizumab pegol in patients with axial 
application and any extensions or variations thereof.reported outcomes with certolizumab pegol in patients with axial 
spondyloarthritis, including ankylosin
application and any extensions or variations thereof.spondyloarthritis, including ankylosin
European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
application and any extensions or variations thereof.European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
Sieper J, Rudwaleit M, van der Heijde D. Longapplication and any extensions or variations thereof.Sieper J, Rudwaleit M, van der Heijde D. Longapplication and any extensions or variations thereof. patients with axial sp application and any extensions or variations thereof. patients with axial sp
spondyloarthritis: 96application and any extensions or variations thereof.
spondyloarthritis: [ADDRESS_764801], Tamborrini G, Kyburz D, Stumpe KD, Hesselmann RG, Johayem A, von 
Schulthess GK, Michel BA, Ciurea A. 18F-fluoride PET/CT for detection of sacroiliitis in 
ankylosing spondylitis. Eur J Nucl Med Mol Imaging. 2010; 37:1760–65.
van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. 
Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of 
America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum. 2005;52:386-94.
van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. 
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063-70.
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: 
long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
spondylitis. A proposal for modification of the [LOCATION_001] criteria. Arthritis Rheum. 1984;27:361-68.
van Tubergen A, Black PM, Coteur G. Are patient-reported outcome instruments for ankylosing 
spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometric Analysis. Rheum. 2015;54:1842-51.
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum. 2002a;47:242-8.
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 2002b;47:8-16.
Wein MN, Jones DC, Shim JH, et al. Control of bone resorption in mice by [CONTACT_581699]-3. Proc Natl 
Acad Sci. 2012;109:8173–8. 
PUBLIC COPY van Tubergen A, Black PM, Coteur G. Are patient
PUBLIC COPY van Tubergen A, Black PM, Coteur G. Are patient -
PUBLIC COPY -reported outcome instruments for ankylosing 
PUBLIC COPY reported outcome instruments for ankylosing 
spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometr
PUBLIC COPY spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometr
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos
PUBLIC COPY van Tubergen A, Debats I, Ryser L, Londoño J, Burgos
numerical rating scale as an answer modality in ankylosing spondylitis
PUBLIC COPY numerical rating scale as an answer modality in ankylosing spondylitis
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment PUBLIC COPY van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. PUBLIC COPY of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
This document cannot be used to support any marketing authorization van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al
This document cannot be used to support any marketing authorization van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al . 
This document cannot be used to support any marketing authorization . 
Radiographic findings following two years of infliximab therapy in patients with ankylosing 
This document cannot be used to support any marketing authorization Radiographic findings following two years of infliximab therapy in patients with ankylosing 
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
This document cannot be used to support any marketing authorization van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
ent of ankylosing spondylitis is maintained for up to 2 years: 
This document cannot be used to support any marketing authorization ent of ankylosing spondylitis is maintained for up to 2 years: 
9.
This document cannot be used to support any marketing authorization 9.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
This document cannot be used to support any marketing authorization van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
ication of the [LOCATION_001] criteria. Arthritis Rheum. 
This document cannot be used to support any marketing authorization ication of the [LOCATION_001] criteria. Arthritis Rheum. 
reported outcome instruments for ankylosing 
This document cannot be used to support any marketing authorization reported outcome instruments for ankylosing 
spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometr
This document cannot be used to support any marketing authorization spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometr
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos
This document cannot be used to support any marketing authorization van Tubergen A, Debats I, Ryser L, Londoño J, Burgos -
This document cannot be used to support any marketing authorization -Vargas R, Cardiel MH, et al. Use of a 
This document cannot be used to support any marketing authorization Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spondylitis
This document cannot be used to support any marketing authorization numerical rating scale as an answer modality in ankylosing spondylitis
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
This document cannot be used to support any marketing authorization van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
This document cannot be used to support any marketing authorization of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
Wein MN, Jones DC, Shim JH, et al. Control of bone resor
This document cannot be used to support any marketing authorization Wein MN, Jones DC, Shim JH, et al. Control of bone resor
–
This document cannot be used to support any marketing authorization –8. 
This document cannot be used to support any marketing authorization 8. 
application and any extensions or variations thereof.van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
application and any extensions or variations thereof.van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
ent of ankylosing spondylitis is maintained for up to 2 years: 
application and any extensions or variations thereof.ent of ankylosing spondylitis is maintained for up to 2 years: 
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
application and any extensions or variations thereof.van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
ication of the [LOCATION_001] criteria. Arthritis Rheum. 
application and any extensions or variations thereof.ication of the [LOCATION_001] criteria. Arthritis Rheum. 
reported outcome instruments for ankylosing 
application and any extensions or variations thereof.reported outcome instruments for ankylosing 
spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometr
application and any extensions or variations thereof.spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometr
Vargas R, Cardiel MH, et al. Use of a 
application and any extensions or variations thereof.Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spondylitis
application and any extensions or variations thereof.numerical rating scale as an answer modality in ankylosing spondylitis
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
application and any extensions or variations thereof.van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
application and any extensions or variations thereof.of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
Wein MN, Jones DC, Shim JH, et al. Control of bone resor
application and any extensions or variations thereof.Wein MN, Jones DC, Shim JH, et al. Control of bone resor
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 99of [ZIP_CODE] APPENDICES
19.1 Modified [LOCATION_001] (mNY) Classification Criteria for AS
Table 19‒1: Modified [LOCATION_001] (mNY) Classification Criteria for AS
Diagnosis
1. Clinical criteria:
a. Low back pain and stiffness for more than [ADDRESS_764802] expansion relative to normal values corrected for age and sex.
2. Radiologic criterion:
Sacroiliitis grade ≥[ADDRESS_764803] 1 
clinical criterion
AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
applicable for this study. It is included here for completeness. The grading will be probable ankylosing 
spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
PUBLIC COPY Definite ankylosing spondylitis if the radiologic criterion is associated wit
PUBLIC COPY Definite ankylosing spondylitis if the radiologic criterion is associated wit
PUBLIC COPY PUBLIC COPY AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria
PUBLIC COPY AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
PUBLIC COPY Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
applicable for this study. It is included here for 
PUBLIC COPY applicable for this study. It is included here for completeness. The grading will be probable ankylosing 
PUBLIC COPY completeness. The grading will be probable ankylosing 
spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
PUBLIC COPY spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
PUBLIC COPY symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Low back pain and stiffness for more than [ADDRESS_764804] expansion relative to normal values corrected for age and sex.
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Definite ankylosing spondylitis if the radiologic criterion is associated wit
This document cannot be used to support any marketing authorization Definite ankylosing spondylitis if the radiologic criterion is associated wit
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria
This document cannot be used to support any marketing authorization AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
This document cannot be used to support any marketing authorization Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
completeness. The grading will be probable ankylosing 
This document cannot be used to support any marketing authorization completeness. The grading will be probable ankylosing 
spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
This document cannot be used to support any marketing authorization spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
This document cannot be used to support any marketing authorization symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Limitation of chest expansion relative to normal values corrected for age and sex.
application and any extensions or variations thereof.Limitation of chest expansion relative to normal values corrected for age and sex.
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Definite ankylosing spondylitis if the radiologic criterion is associated wit
application and any extensions or variations thereof.Definite ankylosing spondylitis if the radiologic criterion is associated wit
application and any extensions or variations thereof.application and any extensions or variations thereof.Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
application and any extensions or variations thereof.Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
completeness. The grading will be probable ankylosing 
application and any extensions or variations thereof.completeness. The grading will be probable ankylosing 
spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
application and any extensions or variations thereof.spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
application and any extensions or variations thereof.symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 100of [ZIP_CODE].2 Markedly abnormal laboratory values
Table 19‒2: Definitions of markedly abnormal hematology values
Parameter (SI units)Markedly Abnormal Definition
Low High
Hemoglobin (g/dL) <LLN 
AND 
>2.0 decrease from baselineN/A
Hemoglobin (g/dL) <8.0 N/A
Leukocytes (total x 1000) <2.0 N/A
Lymphocytes (x 1000) <0.5 N/A
Neutrophils (x 1000) <1.0 N/A
Platelets (x 1000) <50 N/A
LLN=lower limit of normal; N/A = Not Applicable: SI=standard international
Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
Woodworth etal, 2007
aWithdrawal criteria for neutrophils is <0.5 ( Section 6.3)
Table 19‒3: Definitions of markedly abnormal biochemistry values
Parameter (SI units)Markedly Abnormal Definition
Low High
Alkaline Phosphatase N/A >[ADDRESS_764805]
ALT N/A >[ADDRESS_764806] N/A >[ADDRESS_764807]
Calcium (mg/dL) <7.0 >12.5
Creatinine (mg/dL) N/A >1.[ADDRESS_764808]
Glucose (mg/dL) <40 >250
Potassium (mmol/L) <3.0 >6.4
Sodium (mmol/L) <125 N/A
Total bilirubin N/A ≥[ADDRESS_764809]
Uric acid N/A ≥[ADDRESS_764810]
ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; SI=standard international; 
ULN=upper limit of normalPUBLIC COPY Applicable: SI=standard international
PUBLIC COPY Applicable: SI=standard international
Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
PUBLIC COPY Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
)
PUBLIC COPY )
Definitions of markedly abnormal biochemistry values
PUBLIC COPY Definitions of markedly abnormal biochemistry values
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization N/A
This document cannot be used to support any marketing authorization N/A
This document cannot be used to support any marketing authorization N/A
This document cannot be used to support any marketing authorization N/A
This document cannot be used to support any marketing authorization N/A
This document cannot be used to support any marketing authorization N/A
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Applicable: SI=standard international
This document cannot be used to support any marketing authorization Applicable: SI=standard international
Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
This document cannot be used to support any marketing authorization Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Definitions of markedly abnormal biochemistry values
This document cannot be used to support any marketing authorization Definitions of markedly abnormal biochemistry values
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Calcium (mg/dL)
This document cannot be used to support any marketing authorization Calcium (mg/dL)
This document cannot be used to support any marketing authorization Creatinine (mg/dL)
This document cannot be used to support any marketing authorization Creatinine (mg/dL)
This document cannot be used to support any marketing authorization Glucose (mg/dL)
This document cannot be used to support any marketing authorization Glucose (mg/dL)
This document cannot be used to support any marketing authorization Potassium (mmol/L)
This document cannot be used to support any marketing authorization Potassium (mmol/L)
This document cannot be used to support any marketing authorization Sodium (mmol/L)
This document cannot be used to support any marketing authorization Sodium (mmol/L)
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; SI=standard international; 
This document cannot be used to support any marketing authorization ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; SI=standard international; 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
application and any extensions or variations thereof.Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
application and any extensions or variations thereof.Definitions of markedly abnormal biochemistry values
application and any extensions or variations thereof.Definitions of markedly abnormal biochemistry values
Markedly Abnormal 
application and any extensions or variations thereof.Markedly Abnormal 
application and any extensions or variations thereof.Low 
application and any extensions or variations thereof.Low 
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.N/A
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Glucose (mg/dL)
application and any extensions or variations thereof.Glucose (mg/dL)
application and any extensions or variations thereof.Potassium (mmol/L)
application and any extensions or variations thereof.Potassium (mmol/L)
application and any extensions or variations thereof.Sodium (mmol/L)
application and any extensions or variations thereof.Sodium (mmol/L)
application and any extensions or variations thereof.Total bilirubinapplication and any extensions or variations thereof.Total bilirubinapplication and any extensions or variations thereof.Uric acidapplication and any extensions or variations thereof.Uric acidapplication and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 101of [ZIP_CODE].3 Protocol Amendment 1
Rationale for the amendment
The purpose of this protocol amendment is the following: 
Sections summarizing the use of concomitant DMARDs have been updated for internal 
consistency.
hs-CRP was added to the assessments at Screening.
In addition, minor clarifications were made and typographical errors were corrected.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #1 
Section 1, Summary, paragraph 8
Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
Has been changed to:
Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. PUBLIC COPY Bimekizumab 160mg sc Q2W from Week 0 through Week
PUBLIC COPY Bimekizumab 160mg sc Q2W from Week 0 through Week
eceive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
PUBLIC COPY eceive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
PUBLIC COPY order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
This document cannot be used to support any marketing authorization Bimekizumab 160mg sc Q2W from Week 0 through Week
This document cannot be used to support any marketing authorization Bimekizumab 160mg sc Q2W from Week 0 through Week
eceive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
This document cannot be used to support any marketing authorization eceive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
This document cannot be used to support any marketing authorization order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
Bimekizumab 160mg sc Q2W from Week 0 through Week
This document cannot be used to support any marketing authorization Bimekizumab 160mg sc Q2W from Week 0 through Week
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 
This document cannot be used to support any marketing authorization receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 
This document cannot be used to support any marketing authorization order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
This document cannot be used to support any marketing authorization order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
application and any extensions or variations thereof.Bimekizumab 160mg sc Q2W from Week 0 through Week
application and any extensions or variations thereof.Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
application and any extensions or variations thereof.10. In addition, subjects will 
eceive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
application and any extensions or variations thereof.eceive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
application and any extensions or variations thereof.order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
Bimekizumab 160mg sc Q2W from Week 0 through Week
application and any extensions or variations thereof.Bimekizumab 160mg sc Q2W from Week 0 through Week
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 
application and any extensions or variations thereof.receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 
application and any extensions or variations thereof.order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
application and any extensions or variations thereof.order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 102of 136Change #2
Table 5-1, Schedule of assessmen ts, Screening
Study Period S
C
rTreatment Period Treatment Extension Period SF
Ua
Visitb/Week 
(Visit window 
±3 days)V
1V
2V
3V
4V
5V
6V7 V8 V9 V1
0V1
1V1
2V1
3V1
4V1
5V1
6V1
7V1
8
Procedures S
VB
L 
W
0W
2W
4W
6W
8W
10W12W16W20W24W28W32W36W40W44W
48
/
W
DW
64
Blood sample for hs -CRP
kX X X X X X X X X X X X X X
Has been changed to:
Study Period S
C
rTreatment Period Treatment Extension Period SF
Ua
Visitb/Week 
(Visit window ±3 days)V
1V
2V
3V
4V
5V
6V7 V8 V9 V1
0V1
1V1
2V1
3V1
4V1
5V1
6V1
7V1
8
Procedures S
VB
L 
W
0W
2W
4W
6W
8W10W12W16W20W24W28W32W36W40W44W48
/
W
DW64
Blood sample 
for hs -CRPkX X X X X X X X X X X X X X X
Change #3
Table 5-1, Schedule of assessments, footnote g
gThe physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, 
height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
Has been changed to:
gThe physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, 
height (Screening only) and weight ( Screening , Week 12 and Week 48/WD only).PUBLIC COPY PUBLIC COPY PUBLIC COPY V7
PUBLIC COPY V7 V8
PUBLIC COPY V8
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY W
PUBLIC COPY W
6PUBLIC COPY 6W
PUBLIC COPY W
8PUBLIC COPY 8PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization V1
This document cannot be used to support any marketing authorization V1
8
This document cannot be used to support any marketing authorization 8
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W
This document cannot be used to support any marketing authorization W
44
This document cannot be used to support any marketing authorization 44W
This document cannot be used to support any marketing authorization W
48
This document cannot be used to support any marketing authorization 48
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization Treatment Extension Period
This document cannot be used to support any marketing authorization V9
This document cannot be used to support any marketing authorization V9 V1
This document cannot be used to support any marketing authorization V1
0
This document cannot be used to support any marketing authorization 0
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization W
This document cannot be used to support any marketing authorization W
10
This document cannot be used to support any marketing authorization 10W
This document cannot be used to support any marketing authorization W
12
This document cannot be used to support any marketing authorization 12W
This document cannot be used to support any marketing authorization W
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization X
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization 1, Schedule of assessments, footnote g
This document cannot be used to support any marketing authorization 1, Schedule of assessments, footnote g
The physical examination includes the evaluation of
This document cannot be used to support any marketing authorization The physical examination includes the evaluation of
height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
This document cannot be used to support any marketing authorization height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
Has been changed to:
This document cannot be used to support any marketing authorization Has been changed to:
g
This document cannot be used to support any marketing authorization gThe physical examination includes the evaluation of signs and symptoms of active TB, risk for 
This document cannot be used to support any marketing authorization The physical examination includes the evaluation of signs and symptoms of active TB, risk for 
height (Screening only) and weight (
This document cannot be used to support any marketing authorization height (Screening only) and weight ( application and any extensions or variations thereof.48
application and any extensions or variations thereof.48
/
application and any extensions or variations thereof./
W
application and any extensions or variations thereof.W
D
application and any extensions or variations thereof.D64
application and any extensions or variations thereof.64
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Treatment Extension Period
application and any extensions or variations thereof.Treatment Extension Period
application and any extensions or variations thereof.V1
application and any extensions or variations thereof.V1
1
application and any extensions or variations thereof.1V1
application and any extensions or variations thereof.V1
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.W
application and any extensions or variations thereof.W
16
application and any extensions or variations thereof.16W
application and any extensions or variations thereof.W
20
application and any extensions or variations thereof.20
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.X
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.1, Schedule of assessments, footnote g
application and any extensions or variations thereof.1, Schedule of assessments, footnote g
The physical examination includes the evaluation of
application and any extensions or variations thereof.The physical examination includes the evaluation of
height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
application and any extensions or variations thereof.height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
Has been changed to:
application and any extensions or variations thereof.Has been changed to:
application and any extensions or variations thereof.The physical examination includes the evaluation of signs and symptoms of active TB, risk for application and any extensions or variations thereof.The physical examination includes the evaluation of signs and symptoms of active TB, risk for 
height (Screening only) and weight ( application and any extensions or variations thereof.height (Screening only) and weight (
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 103of 136Change #4
Section 7.8.1 Permitted concomitant treatments (medications and 
therapi[INVESTIGATOR_014])
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:
Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:
Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12
Subjects may use sulfasalazine and/or hydroxychloroquine under the following conditions:
Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
allowed. No change in dose or dose regimen is allowed during the study except for reasons of intolerance, where the DMARD dose may be reduced or discontinued.
Subjects may use MTX under the following conditions:
No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
intolerance/AEs. No increase of the MTX dose is permitted. No change is permitted in the 
route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
that subjects taking MTX are also taking folic acid supplements. No combinations of DMARDs are permitted during the study.
Has been changed to: 
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:
Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:
Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after Week 12
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following conditions:PUBLIC COPY r hydroxychloroquine under the following conditions:
PUBLIC COPY r hydroxychloroquine under the following conditions:
Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
PUBLIC COPY Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
PUBLIC COPY allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
D dose may be reduced or discontinued.
PUBLIC COPY D dose may be reduced or discontinued.
Subjects may use MTX under the following conditions:
PUBLIC COPY Subjects may use MTX under the following conditions:
No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
PUBLIC COPY No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
intolerance/AEs. No increase of the MTX dose is permitted. No change is pPUBLIC COPY intolerance/AEs. No increase of the MTX dose is permitted. No change is p
route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended PUBLIC COPY route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
This document cannot be used to support any marketing authorization Subjects who are already receiving an established NSAID regimen and have been on a stable 
This document cannot be used to support any marketing authorization Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least [ADDRESS_764811] 2 weeks prior to Baseline may continue their use during the study. However, 
ase in dosage of NSAIDs during the study (especially in subjects with a 
This document cannot be used to support any marketing authorization ase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
This document cannot be used to support any marketing authorization history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
—
This document cannot be used to support any marketing authorization —subjects are permitted to 
This document cannot be used to support any marketing authorization subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
This document cannot be used to support any marketing authorization decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
r hydroxychloroquine under the following conditions:
This document cannot be used to support any marketing authorization r hydroxychloroquine under the following conditions:
Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
This document cannot be used to support any marketing authorization Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
This document cannot be used to support any marketing authorization allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
D dose may be reduced or discontinued.
This document cannot be used to support any marketing authorization D dose may be reduced or discontinued.
Subjects may use MTX under the following conditions:
This document cannot be used to support any marketing authorization Subjects may use MTX under the following conditions:
No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
This document cannot be used to support any marketing authorization No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
intolerance/AEs. No increase of the MTX dose is permitted. No change is p
This document cannot be used to support any marketing authorization intolerance/AEs. No increase of the MTX dose is permitted. No change is p
route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
This document cannot be used to support any marketing authorization route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
that subjects taking MTX are also taking folic acid supplements. No combinations of 
This document cannot be used to support any marketing authorization that subjects taking MTX are also taking folic acid supplements. No combinations of 
DMARDs are permitted during the study.
This document cannot be used to support any marketing authorization DMARDs are permitted during the study.
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
he following concomitant medications are permitted during the study:
This document cannot be used to support any marketing authorization he following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:
This document cannot be used to support any marketing authorization Subjects may use NSAIDs under the following conditions:
Subjects who are already receiving an established NSAID regimen and have been on a stable 
This document cannot be used to support any marketing authorization Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least [ADDRESS_764812] 2 weeks prior to Baseli
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
This document cannot be used to support any marketing authorization initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
This document cannot be used to support any marketing authorization history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not 
This document cannot be used to support any marketing authorization caution and must not 
This document cannot be used to support any marketing authorization Subjects may use corticosteroids under the following conditions:
This document cannot be used to support any marketing authorization Subjects may use corticosteroids under the following conditions:

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.ase in dosage of NSAIDs during the study (especially in subjects with a 
application and any extensions or variations thereof.ase in dosage of NSAIDs during the study (especially in subjects with a 
subjects are permitted to 
application and any extensions or variations thereof.subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
application and any extensions or variations thereof.decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
r hydroxychloroquine under the following conditions:
application and any extensions or variations thereof.r hydroxychloroquine under the following conditions:
Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
application and any extensions or variations thereof.Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
application and any extensions or variations thereof.allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
D dose may be reduced or discontinued.
application and any extensions or variations thereof.D dose may be reduced or discontinued.
No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
application and any extensions or variations thereof.No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
intolerance/AEs. No increase of the MTX dose is permitted. No change is p
application and any extensions or variations thereof.intolerance/AEs. No increase of the MTX dose is permitted. No change is p
route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
application and any extensions or variations thereof.route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
that subjects taking MTX are also taking folic acid supplements. No combinations of 
application and any extensions or variations thereof.that subjects taking MTX are also taking folic acid supplements. No combinations of 
DMARDs are permitted during the study.
application and any extensions or variations thereof.DMARDs are permitted during the study.
he following concomitant medications are permitted during the study:
application and any extensions or variations thereof.he following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:
application and any extensions or variations thereof.Subjects may use NSAIDs under the following conditions:
Subjects who are already receiving an established NSAID regimen and have been on a stable 
application and any extensions or variations thereof.Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least [ADDRESS_764813] 2 weeks prior to Baseli
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
application and any extensions or variations thereof.initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
application and any extensions or variations thereof.history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not 
application and any extensions or variations thereof.caution and must not 
application and any extensions or variations thereof. Subjects may use corticosteroids under the following conditions: application and any extensions or variations thereof. Subjects may use corticosteroids under the following conditions:
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 104of 136No change in dose or dose regimen of these agents is allowed during the study except for 
reasons of intolerance/AEs. No increase of the dose is permitted. No change is permitted in the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
combinations of DMARDs are permitted during the study.
Change #5 
Table 7-2, Prohibited or restricted medications and required wash-out 
periods prior to Baseline (MTX, SSZ, and HCQ)
Drug class Dose Exclusion criteria
…
MTX Any dose regimen Use within 12 weeks prior to the Baseline 
Visit 
SSZ Any dose Use within 12 weeks prior to the Baseline 
Visit 
HCQ Any dose Use within 12 weeks prior to the Baseline Visit 
…
ADA=adalimumab; COX -2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
ia=intra -articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfa salazine; TNF=tumor necrosis factor 
Has been changed to:
Drug class Dose Exclusion criteria
…
MTX Any dose regimen Use within 12 weeks prior to the Baseline 
Visit 
SSZ Any dose Use within 12 weeks prior to the Baseline 
Visit 
MTX, SSZ, and HCQ Maximum allowed: 
SSZ ≤3g daily 
HCQ ≤400mg daily MTX ≤25mg weeklyUse initiated and/or any change in the 
dose regimen in the 28 days prior to the 
Baseline Visit. No change is permitted in 
the route of administration for MTX (im, 
sc, or oral) in the 28 days prior to the Baseline Visit.
HCQ Any dose Use within 12 weeks prior to the Baseline 
Visit 
…PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 2=cyclooxygenase 2; 
PUBLIC COPY 2=cyclooxygenase 2; CZP=certolizumab pegol; 
PUBLIC COPY CZP=certolizumab pegol; 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
PUBLIC COPY antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal PUBLIC COPY articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
inflammatory drug; sc=subcutaneous; SSZ=sulfa PUBLIC COPY inflammatory drug; sc=subcutaneous; SSZ=sulfa PUBLIC COPY 
This document cannot be used to support any marketing authorization out 
This document cannot be used to support any marketing authorization out 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Use within 12 weeks prior to the Baseline 
This document cannot be used to support any marketing authorization Use within 12 weeks prior to the Baseline 
This document cannot be used to support any marketing authorization Use within 12 weeks prior to the Baseline 
This document cannot be used to support any marketing authorization Use within 12 weeks prior to the Baseline 
Visit 
This document cannot be used to support any marketing authorization Visit 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Use within 12 weeks prior to the Baseline 
This document cannot be used to support any marketing authorization Use within 12 weeks prior to the Baseline 
Visit 
This document cannot be used to support any marketing authorization Visit 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization CZP=certolizumab pegol; 
This document cannot be used to support any marketing authorization CZP=certolizumab pegol; 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
This document cannot be used to support any marketing authorization antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
This document cannot be used to support any marketing authorization articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
inflammatory drug; sc=subcutaneous; SSZ=sulfa
This document cannot be used to support any marketing authorization inflammatory drug; sc=subcutaneous; SSZ=sulfa
This document cannot be used to support any marketing authorization Dose
This document cannot be used to support any marketing authorization Dose
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization MTX, SSZ, and HCQ
This document cannot be used to support any marketing authorization MTX, SSZ, and HCQ
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization HCQ
This document cannot be used to support any marketing authorization HCQ
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Use within 12 weeks prior to the Baseline 
application and any extensions or variations thereof.Use within 12 weeks prior to the Baseline 
application and any extensions or variations thereof.Use within 12 weeks prior to the Baseline 
application and any extensions or variations thereof.Use within 12 weeks prior to the Baseline 
application and any extensions or variations thereof.Use within 12 weeks prior to the Baseline 
application and any extensions or variations thereof.Use within 12 weeks prior to the Baseline 
Visit 
application and any extensions or variations thereof.Visit 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.CZP=certolizumab pegol; 
application and any extensions or variations thereof.CZP=certolizumab pegol; 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
application and any extensions or variations thereof.antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
application and any extensions or variations thereof.articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
inflammatory drug; sc=subcutaneous; SSZ=sulfa
application and any extensions or variations thereof.inflammatory drug; sc=subcutaneous; SSZ=sulfa salazine; TNF=tumor necrosis factor 
application and any extensions or variations thereof.salazine; TNF=tumor necrosis factor 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Dose
application and any extensions or variations thereof.Dose
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Any dose regimen
application and any extensions or variations thereof.Any dose regimen
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.MTX, SSZ, and HCQ
application and any extensions or variations thereof.MTX, SSZ, and HCQ
application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 105of 136Drug class Dose Exclusion criteria
ADA=adalimumab; COX -2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
ia=intra -articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Change #6
Section 8.1, Screening Vis it (Visit 1)
The following bullet has been added:
Collect samples for hs- CRP.
Change #7
Section 8.1, Screening Visit (Visit 1)
Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Has been changed to:
Measure vital signs (temperature, pulse, and blood pressure).
Change #8
Section 8.2, Baseline (Visit 2, Week 0)
Measure vital signs (temperature, pulse, and blood pressure).
Has been changed to:
Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Change #9
Section 12.7.5, Tuberculosis and TB risk factor assessment and 
management), latent TB
Latent TB
In case the evaluation by [CONTACT_18405] a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the IMP can be continued no sooner than [ADDRESS_764814] be withdrawn.
Has been changed to:PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
Measure vital signs (temperature, pulse, and blood pressure).
PUBLIC COPY Measure vital signs (temperature, pulse, and blood pressure).
Section 8.2, Baseline (Visit 2, Week 0) PUBLIC COPY Section 8.2, Baseline (Visit 2, Week 0)
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
Section 8.2, Baseline (Visit 2, Week 0)
This document cannot be used to support any marketing authorization Section 8.2, Baseline (Visit 2, Week 0)
Measure vital signs (temperature, pulse, and blood pressure).
This document cannot be used to support any marketing authorization Measure vital signs (temperature, pulse, and blood pressure).
(temperature, pulse, and blood pressure) prior to IMP administration and 
This document cannot be used to support any marketing authorization (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
This document cannot be used to support any marketing authorization then at 30 minutes and 1 hour after dosing.
Change #9
This document cannot be used to support any marketing authorization Change #9
Section 12.7.5, Tuberculosis and TB risk factor assessment and 
This document cannot be used to support any marketing authorization Section 12.7.5, Tuberculosis and TB risk factor assessment and 
management), latent TB
This document cannot be used to support any marketing authorization management), latent TB
Latent TB
This document cannot be used to support any marketing authorization Latent TB
This document cannot be used to support any marketing authorization In case the evaluation by [CONTACT_581700] 4 
This document cannot be used to support any marketing authorization prophylactic TB treatment should be initiated and the IMP can be continued no sooner than 4 
weeks after start of prophylactic TB treatment, if it is deemed likely by [CONTACT_581701], if it is deemed likely by [CONTACT_581702].Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
Section 8.2, Baseline (Visit 2, Week 0)
application and any extensions or variations thereof.Section 8.2, Baseline (Visit 2, Week 0)
Measure vital signs (temperature, pulse, and blood pressure).
application and any extensions or variations thereof.Measure vital signs (temperature, pulse, and blood pressure).
(temperature, pulse, and blood pressure) prior to IMP administration and 
application and any extensions or variations thereof.(temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
application and any extensions or variations thereof.then at 30 minutes and 1 hour after dosing.
Section 12.7.5, Tuberculosis and TB risk factor assessment and 
application and any extensions or variations thereof.Section 12.7.5, Tuberculosis and TB risk factor assessment and 
management), latent TB
application and any extensions or variations thereof.management), latent TB
In case the evaluation by [CONTACT_581703]. In case the evaluation by [CONTACT_581704] [ADDRESS_764815] be withdrawn.
Change #10
Section [IP_ADDRESS], Tuberculosis management, LTB infection and active TB 
identified during study, paragraph [ADDRESS_764816] scans for subjects at selected sites 
participating in the substudy will be performed at Screening and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #[ADDRESS_764817] been 
changed:
Sponsor Study Physician
Name:
[CONTACT_2761]: UCB Celltech, [ADDRESS_764818], Slough, Berkshire, SL1 3WE, [LOCATION_006]
Phone:
Fax:PUBLIC COPY Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
PUBLIC COPY Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
STUDY CONTACT [CONTACT_581705]. The rationale for this is that the observed pattern of 
This document cannot be used to support any marketing authorization estimation was revised. The rationale for this is that the observed pattern of 
subject recruitment is not as expected at the time of study planning. Consequently, an insufficient 
This document cannot be used to support any marketing authorization subject recruitment is not as expected at the time of study planning. Consequently, an insufficient 
have completed the Week [ADDRESS_764819] scans for subjects at selected sites 
This document cannot be used to support any marketing authorization subjects at selected sites 
participating in the substudy will be performed at Screening and during the study at Week
This document cannot be used to support any marketing authorization participating in the substudy will be performed at Screening and during the study at Week
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
This document cannot be used to support any marketing authorization Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
STUDY CONTACT [CONTACT_581706]:
This document cannot be used to support any marketing authorization Address:
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Phone:
This document cannot be used to support any marketing authorization Phone:
This document cannot be used to support any marketing authorization Fax:
This document cannot be used to support any marketing authorization Fax:
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.have completed the Week [ADDRESS_764820] interim analysis. The risk of performing an analysis with a very small amount of 
committing a 
application and any extensions or variations thereof.committing a 
II error will be inflated. To mitigate these risks it was decided to remove the formal futility 
application and any extensions or variations thereof.II error will be inflated. To mitigate these risks it was decided to remove the formal futility 
subjects at selected sites 
application and any extensions or variations thereof.subjects at selected sites 
participating in the substudy will be performed at Screening and during the study at Week
application and any extensions or variations thereof.participating in the substudy will be performed at Screening and during the study at Week
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
application and any extensions or variations thereof.Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
The Sponsor study physician and Clinical Trial Biostatistician have been 
application and any extensions or variations thereof.The Sponsor study physician and Clinical Trial Biostatistician have been 
application and any extensions or variations thereof.application and any extensions or variations thereof.UCB Celltech, [ADDRESS_764821], Slough, 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 108of 136Clinical Trial Biostatistician
Name:
[CONTACT_2761]: UCB Celltech, [ADDRESS_764822], Slough, Berkshire, SL1 3WE, [LOCATION_006]
Phone:
Fax:
Change #2 
Section 5.1, Study description
A new paragraph has been added at the end of this section:
In approximately [ADDRESS_764823] scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET positive 
lesions were observed in the previous scan.
Change #3 
Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
treatments: 
Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the CZP loading dose at these visits. 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Weeks 6to10.
Study treatments will be prepared and administered by [CONTACT_581707]. 
A formal unblinded interim analysis will be conducted when approximately [ADDRESS_764824] has discontinued prematurely from the study. Further 
details on the interim analyses planned for this study are included in Section 15.11 and in the 
interim Statistical Analysis Plan (SAP).
Has been changed to: 
Eligible subjects will be randomized in a 2:1 ratio to to receive the following blinded study 
treatments: 
Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to mai ntain the blind vs the CZP loading dose at these visits. PUBLIC COPY Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
PUBLIC COPY Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
PUBLIC COPY Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
Bimekizumab 160mg sc Q2W from Week 0 through Week
PUBLIC COPY Bimekizumab 160mg sc Q2W from Week 0 through Week
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in PUBLIC COPY placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the CZP loading dose at these visits. PUBLIC COPY order to maintain the blind vs the CZP loading dose at these visits. 
This document cannot be used to support any marketing authorization CT scan will be performed at 
This document cannot be used to support any marketing authorization CT scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if
This document cannot be used to support any marketing authorization Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if
Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
This document cannot be used to support any marketing authorization Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
This document cannot be used to support any marketing authorization Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
Bimekizumab 160mg sc Q2W from Week 0 through Week
This document cannot be used to support any marketing authorization Bimekizumab 160mg sc Q2W from Week 0 through Week
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
This document cannot be used to support any marketing authorization placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the CZP loading dose at these visits. 
This document cannot be used to support any marketing authorization order to maintain the blind vs the CZP loading dose at these visits. 
Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
This document cannot be used to support any marketing authorization Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Study treatments will be prepared and administered by [CONTACT_581708] 
A formal unblinded interim analysis will be conducted when 
This document cannot be used to support any marketing authorization A formal unblinded interim analysis will be conducted when 
completed the Week [ADDRESS_764825] has 
completed the Week 12 Visit or the s
This document cannot be used to support any marketing authorization completed the Week 12 Visit or the s
details on the interim analyses planned for this study are included in Section 15.11 and in the 
This document cannot be used to support any marketing authorization details on the interim analyses planned for this study are included in Section 15.11 and in the 
This document cannot be used to support any marketing authorization interim Statistical Analysis Plan (SAP).
This document cannot be used to support any marketing authorization interim Statistical Analysis Plan (SAP).
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
Eligible subjects will be randomized 
This document cannot be used to support any marketing authorization Eligible subjects will be randomized application and any extensions or variations thereof.CT scan will be performed at 
application and any extensions or variations thereof.CT scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if
application and any extensions or variations thereof.Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET positive 
application and any extensions or variations thereof.PET positive 
Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
application and any extensions or variations thereof.Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
application and any extensions or variations thereof.Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
Bimekizumab 160mg sc Q2W from Week 0 through Week
application and any extensions or variations thereof.Bimekizumab 160mg sc Q2W from Week 0 through Week
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
application and any extensions or variations thereof.placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the CZP loading dose at these visits. 
application and any extensions or variations thereof.order to maintain the blind vs the CZP loading dose at these visits. 
Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
application and any extensions or variations thereof.Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Study treatments will be prepared and administered by [CONTACT_581585].Study treatments will be prepared and administered by [CONTACT_581709] 
A formal unblinded interim analysis will be conducted when 
application and any extensions or variations thereof.A formal unblinded interim analysis will be conducted when 
completed the Week [ADDRESS_764826] has 
completed the Week 12 Visit or the s
application and any extensions or variations thereof.completed the Week 12 Visit or the s
details on the interim analyses planned for this study are included in Section 15.11 and in the 
application and any extensions or variations thereof.details on the interim analyses planned for this study are included in Section 15.11 and in the 
application and any extensions or variations thereof.interim Statistical Analysis Plan (SAP).
application and any extensions or variations thereof.interim Statistical Analysis Plan (SAP).
Has been changed to: application and any extensions or variations thereof. Has been changed to: 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 109of 136CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Weeks 6to10.
Study treatments will be prepared and administered by [CONTACT_581583]. 
Change #[ADDRESS_764827] scan of the entire spi[INVESTIGATOR_581500] 25 subjects at Screening, Week 12, and at Week 48/Early 
Withdrawal Visit. 
Has been changed to: 
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spi[INVESTIGATOR_581498] 25 subjects at Screening, and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan. 
Change #5 
Section 5.7, Schedule of assessments, Table 5-1, footnote c
A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 
1) with biomarker, pharmacogenomic and nonhereditary pharmacogenomic blood-samples and 
2) PET-MRI or PET-CT scans.
Has been changed to: 
A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 
1) with biomarker, pharmacogenetic and nonhereditary pharmacogenomic blood-samples and 
2) PET-MRI or PET-CT scans.
Change #[ADDRESS_764828] scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit. If a subject withdraws from the study early, the PET-MRI or 
PET-CT scan must be repeated at the WD visit only, if the prior examination was done more than 12 weeks prior to the WD visit.
Has been changed to: 
A PET-MRI or P ET-CT scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit if PET -positive lesions are observed in the previous scan . If 
a subject withdraws from the study early, the PET-MRI or PET-CT scan must be repeated at the WD visit only, if the prior examination was done more than [ADDRESS_764829] scan of the entire spi[INVESTIGATOR_581570] 
12, and at Week 48/Early 
This document cannot be used to support any marketing authorization 12, and at Week 48/Early 
CT scan of the entire spi[INVESTIGATOR_581571] [ADDRESS_764830] scans.
Section 5.7, Schedule of assessments, Table 5
This document cannot be used to support any marketing authorization Section 5.7, Schedule of assessments, Table 5
MRI or Pet
This document cannot be used to support any marketing authorization MRI or Pet
after the W12 and W48/WD Visit. If a s
This document cannot be used to support any marketing authorization after the W12 and W48/WD Visit. If a s
-
This document cannot be used to support any marketing authorization -CT scan must be repeated at the WD visit only, if the prior examination was done more 
This document cannot be used to support any marketing authorization CT scan must be repeated at the WD visit only, if the prior examination was done more 
than 12 weeks prior to the WD visit.
This document cannot be used to support any marketing authorization than 12 weeks prior to the WD visit.
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
A PET
This document cannot be used to support any marketing authorization A PETapplication and any extensions or variations thereof.CT scan of the entire spi[INVESTIGATOR_581501].CT scan of the entire spi[INVESTIGATOR_581570] 
12, and at Week 48/Early 
application and any extensions or variations thereof.12, and at Week 48/Early 
CT scan of the entire spi[INVESTIGATOR_581501].CT scan of the entire spi[INVESTIGATOR_581500] [ADDRESS_764831] scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit. If a s
application and any extensions or variations thereof.after the W12 and W48/WD Visit. If a s
CT scan must be repeated at the WD visit only, if the prior examination was done more 
application and any extensions or variations thereof.CT scan must be repeated at the WD visit only, if the prior examination was done more 
than 12 weeks prior to the WD visit.application and any extensions or variations thereof.than 12 weeks prior to the WD visit.
Has been changed to: application and any extensions or variations thereof.Has been changed to: 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 110of 136Change #7
Section 5.7, Table 5-1 Schedule of assessments, footnote p
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in 
Weeks [ADDRESS_764832] been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3). 
Has been changed to: 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200mg sc Q2W in Weeks [ADDRESS_764833] been completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4).
Change #8
Section 6.3, Withdrawal criteria
The following was added to the withdrawal criteria:
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:
Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist
Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use clinical judgement in deciding whether the subject should continue in the study and contact [CONTACT_580666]'s suitability for continued participation in the study.
Change #[ADDRESS_764834]:PUBLIC COPY Subjects with newly diagnosed IBD or with IBD flares during the study must:
Be referred, as appropriate, to a health care professional treating IBD, such as a PUBLIC COPY Be referred, as appropriate, to a health care professional treating IBD, such as a 
This document cannot be used to support any marketing authorization Weeks [ADDRESS_764835] been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
This document cannot be used to support any marketing authorization completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200m
This document cannot be used to support any marketing authorization CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by [CONTACT_18322] 200m g sc Q2W in 
This document cannot be used to support any marketing authorization g sc Q2W in 
Weeks [ADDRESS_764836] been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
This document cannot be used to support any marketing authorization completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
criteria:
This document cannot be used to support any marketing authorization criteria:
Subjects with newly diagnosed IBD or with IBD flares during the study must:
This document cannot be used to support any marketing authorization Subjects with newly diagnosed IBD or with IBD flares during the study must:
Be referred, as appropriate, to a health care professional treating IBD, such as a 
This document cannot be used to support any marketing authorization Be referred, as appropriate, to a health care professional treating IBD, such as a 
Discontinue IMP and be followed
This document cannot be used to support any marketing authorization Discontinue IMP and be followed
If IBD flares increase in severity or frequency during the study, the Investigator should use 
This document cannot be used to support any marketing authorization If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
[CONTACT_581710].
This document cannot be used to support any marketing authorization continued participation in the study.
Change #9
This document cannot be used to support any marketing authorization Change #[ADDRESS_764837]:
application and any extensions or variations thereof.Subjects with newly diagnosed IBD or with IBD flares during the study must:
Be referred, as appropriate, to a health care professional treating IBD, such as a 
application and any extensions or variations thereof.Be referred, as appropriate, to a health care professional treating IBD, such as a 
Discontinue IMP and be followed
application and any extensions or variations thereof.Discontinue IMP and be followed -
application and any extensions or variations thereof.-up until resolution of active IB
application and any extensions or variations thereof.up until resolution of active IB
If IBD flares increase in severity or frequency during the study, the Investigator should use 
application and any extensions or variations thereof.If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
[INVESTIGATOR_581504].clinical judgement in deciding whether the subject should continue in the study and contact 
[CONTACT_581711].the Medical Monitor and UCB study physician to confirm the 
continued participation in the study.
application and any extensions or variations thereof.continued participation in the study.
application and any extensions or variations thereof.Section 7.2, Treatments to be administered, paragraph 1
application and any extensions or variations thereof.Section 7.2, Treatments to be administered, paragraph 1
The IMP is to be administered in the clinic by [CONTACT_581604] 2 sc injections. Suitable application and any extensions or variations thereof. The IMP is to be administered in the clinic by [CONTACT_581604] 2 sc injections. Suitable 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 111of 136Has been changed to: 
The IMP is to be administered in the clinic by [CONTACT_581604] [ADDRESS_764838].
Change #10 
Section 7.9, Blinding, paragraph 1
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in order to maintain the blind vs the CZP loading dose at these visits. 
Has been changed to: 
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Change #[ADDRESS_764839] 2 paragraphs
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analysis. These individuals will be separate from the main blinded study team.
Unblinded programming team at PAREXEL for the purpose of sending unblinded data cuts
Has been changed to: 
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded DMC and interim analy ses. These individuals will be separate from the main blinded study 
team.
Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned interim analyses
Change #12
Section 8.8, Week 12 (Visit 8), bullet #18
Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit.PUBLIC COPY Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
PUBLIC COPY Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bim
PUBLIC COPY be taken to ensure study blinding. Subjects randomized to bim
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 
PUBLIC COPY Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 
Section 7.9.1, Procedures for maintaining and breaking the treatment blind, PUBLIC COPY Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
This document cannot be used to support any marketing authorization Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
This document cannot be used to support any marketing authorization Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
This document cannot be used to support any marketing authorization be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
t 3) in order to maintain the blind vs the 
This document cannot be used to support any marketing authorization t 3) in order to maintain the blind vs the 
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
This document cannot be used to support any marketing authorization Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bim
This document cannot be used to support any marketing authorization be taken to ensure study blinding. Subjects randomized to bim ekizumab will receive placebo at 
This document cannot be used to support any marketing authorization ekizumab will receive placebo at 
4
This document cannot be used to support any marketing authorization 4) in order to maintain the blind vs the 
This document cannot be used to support any marketing authorization ) in order to maintain the blind vs the 
Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
This document cannot be used to support any marketing authorization Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
This document cannot be used to support any marketing authorization Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analysis. These individuals will be separate from the main blinded study 
This document cannot be used to support any marketing authorization DMC and interim analysis. These individuals will be separate from the main blinded study 
This document cannot be used to support any marketing authorization Unblinded programming team at PAREXEL for the purpose 
This document cannot be used to support any marketing authorization Unblinded programming team at PAREXEL for the purpose 
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
This document cannot be used to support any marketing authorization Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analy
This document cannot be used to support any marketing authorization DMC and interim analy
team.
This document cannot be used to support any marketing authorization team.
Unblinded team at P
This document cannot be used to support any marketing authorization Unblinded team at P
interim analyses
This document cannot be used to support any marketing authorization interim analyses
Change #12This document cannot be used to support any marketing authorization Change #12application and any extensions or variations thereof.Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
application and any extensions or variations thereof.Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
application and any extensions or variations thereof.be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
t 3) in order to maintain the blind vs the 
application and any extensions or variations thereof.t 3) in order to maintain the blind vs the 
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
application and any extensions or variations thereof.Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
ekizumab will receive placebo at 
application and any extensions or variations thereof.ekizumab will receive placebo at 
) in order to maintain the blind vs the 
application and any extensions or variations thereof.) in order to maintain the blind vs the 
Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
application and any extensions or variations thereof.Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
application and any extensions or variations thereof.Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analysis. These individuals will be separate from the main blinded study 
application and any extensions or variations thereof.DMC and interim analysis. These individuals will be separate from the main blinded study 
application and any extensions or variations thereof.Unblinded programming team at PAREXEL for the purpose 
application and any extensions or variations thereof.Unblinded programming team at PAREXEL for the purpose 
Has been changed to: 
application and any extensions or variations thereof.Has been changed to: 
Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
application and any extensions or variations thereof.Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analy
application and any extensions or variations thereof.DMC and interim analy ses
application and any extensions or variations thereof.ses
Unblinded team at P
application and any extensions or variations thereof.Unblinded team at P
application and any extensions or variations thereof.interim analysesapplication and any extensions or variations thereof.interim analyses
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 112of 136Has been changed to: 
Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit if PET positive lesions were observed in the previous scan .
Change #13
Section 8.11, Week 48 (Visit 17)/Early Withdrawal Visit, bullet #21
Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after the Week 48/WD Visit. At the WD Visit, the PET-MRI or PET-CT must be 
done only, if the previous imaging evaluation occurred more than 12 weeks ago
Has been changed to: 
Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 2 weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET positive lesions were observed in 
the previous scan .
Change #[ADDRESS_764840] to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, very severe symptoms which are intolerable and inability to carry out normal activities. This assessment by [CONTACT_58964].
Has been changed to: 
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities. This assessment by [CONTACT_58964].
Change #15
Section 10, ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) 
Has been changed to: 
Section 10, ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/PHARMACOGENETIC
VARIABLE(S) PUBLIC COPY and if PET positive lesions were observed in 
PUBLIC COPY and if PET positive lesions were observed in 
Section 9.7, PhGADA, paragraph 1
PUBLIC COPY Section 9.7, PhGADA, paragraph 1
The Investigator will assess the overall status of t
PUBLIC COPY The Investigator will assess the overall status of t
symptoms and functional capacity (considering both joint and skin components) using an NRS in PUBLIC COPY symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, PUBLIC COPY which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
This document cannot be used to support any marketing authorization CT scan in approximately [ADDRESS_764841] to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in 
This document cannot be used to support any marketing authorization symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
This document cannot be used to support any marketing authorization which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
are intolerable and inability to carry out normal activities. This 
This document cannot be used to support any marketing authorization are intolerable and inability to carry out normal activities. This 
assessment by [CONTACT_58964].
This document cannot be used to support any marketing authorization assessment by [CONTACT_58964].
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
The Investigator will assess the overall status of the subject with respect to their AS signs and 
This document cannot be used to support any marketing authorization The Investigator will assess the overall status of the subject with respect to their AS signs and 
mptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
This document cannot be used to support any marketing authorization mptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
This document cannot be used to support any marketing authorization limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
This document cannot be used to support any marketing authorization and inability to carry out normal activities. This assessment by [CONTACT_581712]. This assessment by [CONTACT_581713].
This document cannot be used to support any marketing authorization blind to the PGADA.
Change #15
This document cannot be used to support any marketing authorization Change #15
Section 10,
This document cannot be used to support any marketing authorization Section 10,
PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) 
This document cannot be used to support any marketing authorization PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) 
Has been changed to: This document cannot be used to support any marketing authorization Has been changed to: application and any extensions or variations thereof.CT must be 
application and any extensions or variations thereof.CT must be 
CT scan in approximately [ADDRESS_764842] to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in 
application and any extensions or variations thereof.symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
application and any extensions or variations thereof.which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
are intolerable and inability to carry out normal activities. This 
application and any extensions or variations thereof.are intolerable and inability to carry out normal activities. This 
assessment by [CONTACT_58964].
application and any extensions or variations thereof.assessment by [CONTACT_58964].
The Investigator will assess the overall status of the subject with respect to their AS signs and 
application and any extensions or variations thereof.The Investigator will assess the overall status of the subject with respect to their AS signs and 
mptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
application and any extensions or variations thereof.mptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
application and any extensions or variations thereof.limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
application and any extensions or variations thereof.and inability to carry out normal activities. This assessment by [CONTACT_581714].and inability to carry out normal activities. This assessment by [CONTACT_581713].
application and any extensions or variations thereof.blind to the PGADA.
Change #15
application and any extensions or variations thereof.Change #15
Section 10, application and any extensions or variations thereof.Section 10, ASSESSMENT OF PHARMACOKINETIC/ application and any extensions or variations thereof.ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) application and any extensions or variations thereof.PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 113of 136Change #16
Section [IP_ADDRESS], Table 12-4 PDILI laboratory measurements
Chemistry Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Has been changed to: 
Chemistry Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
And the following was added to the list of abbreviations : 
AST=aspartate aminotransferase;
Change #[ADDRESS_764843] of Baseline ASDAS. These will be derived from an 
internal UCB study (AS0001). A vague prior will be applied to the mean change from Baseline in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
adjusting for Baseline ASDAS.
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than zero will also be presented. The posterior probability that bimekizumab achieves a lower ASDAS score at Week [ADDRESS_764844] of abbreviations
Section 15.5.1, Analysis of the primary efficacy variable 
PUBLIC COPY Section 15.5.1, Analysis of the primary efficacy variable 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
PUBLIC COPY The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
12 in the bimekizumab treatment group versus the CZP treatment group. Summary PUBLIC COPY 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by [CONTACT_581715] ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Section 15.5.1, Analysis of the primary efficacy variable 
This document cannot be used to support any marketing authorization Section 15.5.1, Analysis of the primary efficacy variable 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
This document cannot be used to support any marketing authorization The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
[ADDRESS_764845] of Baseline ASDAS. These will be derived from an 
internal UCB study (AS0001). A vague 
This document cannot be used to support any marketing authorization internal UCB study (AS0001). A vague 
in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP 
This document cannot be used to support any marketing authorization in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP 
and in the interim analysis SAP.
This document cannot be used to support any marketing authorization and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatm
This document cannot be used to support any marketing authorization The Bayesian analysis will employ a linear regression model including treatm
This document cannot be used to support any marketing authorization adjusting for Baseline ASDAS.
This document cannot be used to support any marketing authorization adjusting for Baseline ASDAS.
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
This document cannot be used to support any marketing authorization The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
This document cannot be used to support any marketing authorization bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP 
This document cannot be used to support any marketing authorization groups (CZP 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
This document cannot be used to support any marketing authorization intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than This document cannot be used to support any marketing authorization difference between treatment groups in the mean change from Baseline in ASDAS is greater than application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Section 15.5.1, Analysis of the primary efficacy variable 
application and any extensions or variations thereof.Section 15.5.1, Analysis of the primary efficacy variable 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
application and any extensions or variations thereof.The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
[ADDRESS_764846] of Baseline ASDAS. These will be derived from an 
internal UCB study (AS0001). A vague 
application and any extensions or variations thereof.internal UCB study (AS0001). A vague 
in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP 
application and any extensions or variations thereof.in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP 
and in the interim analysis SAP.
application and any extensions or variations thereof.and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatm
application and any extensions or variations thereof.The Bayesian analysis will employ a linear regression model including treatm
application and any extensions or variations thereof.adjusting for Baseline ASDAS.
application and any extensions or variations thereof.adjusting for Baseline ASDAS.
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
application and any extensions or variations thereof.The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment application and any extensions or variations thereof.bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP application and any extensions or variations thereof. groups (CZP -application and any extensions or variations thereof.-bimekizumab) will bapplication and any extensions or variations thereof.bimekizumab) will b
UCB [ADDRESS_764847] 97.5% (ie, the lower
bound of the 95% credible interval of the difference between treatment groups in the mean 
change from Baseline in ASDAS is greater than zero). 
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will not be updated based upon accrued study data at any time point.
Has been changed to: 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by [CONTACT_581686]. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when centered Baseline is observed at its mean of zero (βCZP ~ Normal [- 1.78, var=0.0605)). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in th e 
SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
Baseline ASDAS (mean centered).
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible interval of the difference between treatment groups in the mean change from Baseline in ASDAS is zero or greater).
If further information (independent to this study) regarding the CZP treatment group respons e 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.PUBLIC COPY centered Baseline is observed at its mean of zero (βCZP ~ Normal [
PUBLIC COPY centered Baseline is observed at its mean of zero (βCZP ~ Normal [
priors will be used for all other model coefficients. All priors will be fully documented in th
PUBLIC COPY priors will be used for all other model coefficients. All priors will be fully documented in th
The Bayesian analysis will employ a linear regression model including treatment group and 
PUBLIC COPY The Bayesian analysis will employ a linear regression model including treatment group and 
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
PUBLIC COPY The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
PUBLIC COPY bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
bimekizumab) will be summarized with means, standard deviations, 95% credible PUBLIC COPY bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior pr PUBLIC COPY intervals and 95% Highest Posterior Density intervals. The posterior pr
This document cannot be used to support any marketing authorization The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
This document cannot be used to support any marketing authorization The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
This document cannot be used to support any marketing authorization 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
oint together with the 
This document cannot be used to support any marketing authorization oint together with the 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
This document cannot be used to support any marketing authorization The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
This document cannot be used to support any marketing authorization paradigm. An informative prior will be used for the model intercept coefficient which in the 
ual to the mean change from Baseline in ASDAS in the CZP group when 
This document cannot be used to support any marketing authorization ual to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [
This document cannot be used to support any marketing authorization centered Baseline is observed at its mean of zero (βCZP ~ Normal [ -
This document cannot be used to support any marketing authorization -1.78, var=0.0605)). Vague 
This document cannot be used to support any marketing authorization 1.78, var=0.0605)). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in th
This document cannot be used to support any marketing authorization priors will be used for all other model coefficients. All priors will be fully documented in th
The Bayesian analysis will employ a linear regression model including treatment group and 
This document cannot be used to support any marketing authorization The Bayesian analysis will employ a linear regression model including treatment group and 
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
This document cannot be used to support any marketing authorization The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
This document cannot be used to support any marketing authorization bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
bimekizumab) will be summarized with means, standard deviations, 95% credible 
This document cannot be used to support any marketing authorization bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior pr
This document cannot be used to support any marketing authorization intervals and 95% Highest Posterior Density intervals. The posterior pr
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
This document cannot be used to support any marketing authorization difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
This document cannot be used to support any marketing authorization zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived
This document cannot be used to support any marketing authorization ASDAS score at Week 12 compared to CZP will be derived
The study will be considered a success if the posterior probability of the difference in the mean 
This document cannot be used to support any marketing authorization The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP 
This document cannot be used to support any marketing authorization change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP 
bimekizumab) being greater than zero is at leas
This document cannot be used to support any marketing authorization bimekizumab) being greater than zero is at leas
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
This document cannot be used to support any marketing authorization interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
is zero or greater).
This document cannot be used to support any marketing authorization is zero or greater).
This document cannot be used to support any marketing authorization If further information (independent to this study) regarding the CZP treatment group respons
This document cannot be used to support any marketing authorization If further information (independent to this study) regarding the CZP treatment group respons
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
This document cannot be used to support any marketing authorization comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
This document cannot be used to support any marketing authorization unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
This document cannot be used to support any marketing authorization not be updated based upon accrued study data at any time po
This document cannot be used to support any marketing authorization not be updated based upon accrued study data at any time po application and any extensions or variations thereof.The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
application and any extensions or variations thereof.The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
oint together with the 
application and any extensions or variations thereof.oint together with the 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
application and any extensions or variations thereof.The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
application and any extensions or variations thereof.paradigm. An informative prior will be used for the model intercept coefficient which in the 
ual to the mean change from Baseline in ASDAS in the CZP group when 
application and any extensions or variations thereof.ual to the mean change from Baseline in ASDAS in the CZP group when 
1.78, var=0.0605)). Vague 
application and any extensions or variations thereof.1.78, var=0.0605)). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in th
application and any extensions or variations thereof.priors will be used for all other model coefficients. All priors will be fully documented in th
The Bayesian analysis will employ a linear regression model including treatment group and 
application and any extensions or variations thereof.The Bayesian analysis will employ a linear regression model including treatment group and 
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
application and any extensions or variations thereof.The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
application and any extensions or variations thereof.bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
bimekizumab) will be summarized with means, standard deviations, 95% credible 
application and any extensions or variations thereof.bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior pr
application and any extensions or variations thereof.intervals and 95% Highest Posterior Density intervals. The posterior pr
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
application and any extensions or variations thereof.difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
application and any extensions or variations thereof.zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived
application and any extensions or variations thereof.ASDAS score at Week 12 compared to CZP will be derived
The study will be considered a success if the posterior probability of the difference in the mean 
application and any extensions or variations thereof.The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP 
application and any extensions or variations thereof.change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP 
bimekizumab) being greater than zero is at leas
application and any extensions or variations thereof.bimekizumab) being greater than zero is at leas
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
application and any extensions or variations thereof.interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
application and any extensions or variations thereof.If further information (independent to this study) regarding the CZP treatment group respons
application and any extensions or variations thereof.If further information (independent to this study) regarding the CZP treatment group respons
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
application and any extensions or variations thereof.comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
application and any extensions or variations thereof.unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
application and any extensions or variations thereof.not be updated based upon accrued study data at any time po application and any extensions or variations thereof.not be updated based upon accrued study data at any time po
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 115of 136Change #[ADDRESS_764848]’s 
participation has ended prematurely. The purpose of this informal interim analysis is for the 
Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
Portfolio Management decisions.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This study will include two unblinded interim analyses, the first after approximately [ADDRESS_764849]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key personnel to review results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to alter or terminate the trial. Interim analyses will be conducted by [CONTACT_581716]. This process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #[ADDRESS_764850] 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means for CZP and bimekizumab change from baseline being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.[ADDRESS_764851] methods for the comparison of group 
means with baseline as covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week [ADDRESS_764852]’s 
PUBLIC COPY study has completed the Week [ADDRESS_764853]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
PUBLIC COPY participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
results from the primary efficacy analysis and a subset of the analyses of 
PUBLIC COPY results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
PUBLIC COPY secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decis PUBLIC COPY Management decisions; consequently, neither analysis and will lead to any formal decis
This document cannot be used to support any marketing authorization The study may be stopped for futility. Futility rules and operating characteristics will be detailed 
This document cannot be used to support any marketing authorization The study may be stopped for futility. Futility rules and operating characteristics will be detailed 
y 
This document cannot be used to support any marketing authorization y 
An informal unblinded interim analysis will be performed when the last randomized subject for 
This document cannot be used to support any marketing authorization An informal unblinded interim analysis will be performed when the last randomized subject for 
[ADDRESS_764854]’s 
This document cannot be used to support any marketing authorization [ADDRESS_764855]’s 
f this informal interim analysis is for the 
This document cannot be used to support any marketing authorization f this informal interim analysis is for the 
Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
This document cannot be used to support any marketing authorization Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
This document cannot be used to support any marketing authorization analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
All analyses and unblinding instructions will be prespecified in the interim SAP.
This document cannot be used to support any marketing authorization All analyses and unblinding instructions will be prespecified in the interim SAP.
This study will include two unblinded interim analyses, the first after approximately [ADDRESS_764856]’s 
This document cannot be used to support any marketing authorization study has completed the Week [ADDRESS_764857]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
This document cannot be used to support any marketing authorization participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
results from the primary efficacy analysis and a subset of the analyses of 
This document cannot be used to support any marketing authorization results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
This document cannot be used to support any marketing authorization secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decis
This document cannot be used to support any marketing authorization Management decisions; consequently, neither analysis and will lead to any formal decis
alter or terminate the trial. Interim analyses will be conducted by [CONTACT_581717]. Interim analyses will be conducted by [CONTACT_581718]. This process will ensure that no u
This document cannot be used to support any marketing authorization analysis purposes. This process will ensure that no u
occurs. The unblinded team will not disclose any unblinded information to the blinded study 
This document cannot be used to support any marketing authorization occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
This document cannot be used to support any marketing authorization team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documenta
This document cannot be used to support any marketing authorization the rest of the study documenta
All analyses and unblinding instructions will be prespecified in the interim SAP.
This document cannot be used to support any marketing authorization All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #19
This document cannot be used to support any marketing authorization Change #[ADDRESS_764858] 80% po
This document cannot be used to support any marketing authorization The sample size was calculated to provide at least 80% po
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means 
This document cannot be used to support any marketing authorization treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means 
for CZP and bimekizumab change from baseline being 
This document cannot be used to support any marketing authorization for CZP and bimekizumab change from baseline being application and any extensions or variations thereof.An informal unblinded interim analysis will be performed when the last randomized subject for 
application and any extensions or variations thereof.An informal unblinded interim analysis will be performed when the last randomized subject for 
[ADDRESS_764859]’s 
application and any extensions or variations thereof.[ADDRESS_764860]’s 
f this informal interim analysis is for the 
application and any extensions or variations thereof.f this informal interim analysis is for the 
Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
application and any extensions or variations thereof.Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
application and any extensions or variations thereof.analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
All analyses and unblinding instructions will be prespecified in the interim SAP.
application and any extensions or variations thereof.All analyses and unblinding instructions will be prespecified in the interim SAP.
This study will include two unblinded interim analyses, the first after approximately [ADDRESS_764861]’s 
application and any extensions or variations thereof.study has completed the Week [ADDRESS_764862]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
application and any extensions or variations thereof.participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
results from the primary efficacy analysis and a subset of the analyses of 
application and any extensions or variations thereof.results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
application and any extensions or variations thereof.secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decis
application and any extensions or variations thereof.Management decisions; consequently, neither analysis and will lead to any formal decis
alter or terminate the trial. Interim analyses will be conducted by [CONTACT_581719].alter or terminate the trial. Interim analyses will be conducted by [CONTACT_581720].will follow internal SOPs for the formal process to control the unblinding of the study for interim 
analysis purposes. This process will ensure that no u
application and any extensions or variations thereof.analysis purposes. This process will ensure that no u
occurs. The unblinded team will not disclose any unblinded information to the blinded study 
application and any extensions or variations thereof.occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
application and any extensions or variations thereof.team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documenta
application and any extensions or variations thereof.the rest of the study documenta tion and outputs up until the end of the study.
application and any extensions or variations thereof.tion and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
application and any extensions or variations thereof.All analyses and unblinding instructions will be prespecified in the interim SAP.
Section 15.12, Determination of sample size, paragraph [ADDRESS_764863] 80% po application and any extensions or variations thereof.The sample size was calculated to provide at least 80% po
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means application and any extensions or variations thereof.treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 116of 136as the Bayesian analysis with the informative priors described in Section 15.5.1 will improve the 
probability of study success for an effective drug.
Has been changed to: 
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
change from Baseline for CZP and bimekizumab being -1.78 and -2.67 respectively) with a common standard deviation of 1.[ADDRESS_764864] methods for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (-
1.78,var=0.0605), contributes an effective sample size of approximately [ADDRESS_764865].
PUBLIC COPY 
This document cannot be used to support any marketing authorization t group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
This document cannot be used to support any marketing authorization t group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
This document cannot be used to support any marketing authorization covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to
This document cannot be used to support any marketing authorization ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
This document cannot be used to support any marketing authorization be 
This document cannot be used to support any marketing authorization used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
This document cannot be used to support any marketing authorization used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
This document cannot be used to support any marketing authorization 1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
This document cannot be used to support any marketing authorization 1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
This document cannot be used to support any marketing authorization ed for the model intercept 
This document cannot be used to support any marketing authorization ed for the model intercept 
application and any extensions or variations thereof.be 
application and any extensions or variations thereof.be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (
application and any extensions or variations thereof.used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal ( -
application and any extensions or variations thereof.-
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
application and any extensions or variations thereof.1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
application and any extensions or variations thereof.ed for the model intercept 
application and any extensions or variations thereof.ed for the model intercept 
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 117of [ZIP_CODE].5 Protocol Amendment 3
Rationale for the amendment
The major purpose of this protocol amendment is the following: 
Secondary and other study objectives and variables have been updated to evaluate the effect 
of bimekizumab or CZP on changes in bone formation as an “other” exploratory variable. 
It is convention that clinical study research is divided into [ADDRESS_764866] areas of evaluations: 
1) prospectively declared analyses and 2) hypothesis-generating or exploratory analyses. Prospectively declared evaluations are partitioned into primary analyses (where type I error is 
conserved) and secondary analyses that are prospectively declared in order to offer 
unambiguous interpretation. Owing to the novelty of PET-CT/MRI assessments within this 
disease indication, it is not possible to prospectively define the analyses as we are continuing 
to develop UCB’s understanding of the specific data and endpoints yielded from the imaging 
software, the distribution and covariance of these endpoints and the hypothesized difference owing to treatment. As a result, the analyses of the PET-CT/MRI data in this study will 
primarily be descriptive and exploratory and this is now updated in the study objectives, ie, 
the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an other exploratory objective or variable instead of a secondary objective or variable.
A clarification regarding the sample size is required in this protocol amendment. The planned sample size of [ADDRESS_764867]/MRI substudy. However, due to complexities in the initiation of sites capable of performing PET-CT or PET-MRI scans, more than the planned [ADDRESS_764868]/MRI 
substudy subjects were screened and randomized before it was possible to close enrolment at the sites not participating in the substudy. Owing to the novelty of the PET-CT/MRI outcomes within this disease area, it is considered important to ensure at least [ADDRESS_764869] a difference in the 
primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target number of subjects are included in the exploratory analysis of changes in bone formation at 
Week [ADDRESS_764870]/MRI data are exploratory and 
treatment effect sizes are unknown, formal power calculations were not performed. Clinical expertise does, however, indicate that a sample size of at least [ADDRESS_764871] differences between treatment groups.
Objectives related to PK and immunogenicity were downgraded from “secondary” objectives 
to “other” objectives for consistency with the classification of the corresponding variables.
Nonhereditary pharmacogenomic variables and pharmacogenetic variables are considered exploratory in nature and have been labelled as “other”.
A PFS as described in Section 7.1is available for administration in addition to the vial and 
corresponding text has been added. The PFS use is expected to improve the subject experience.PUBLIC COPY the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
PUBLIC COPY the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
other exploratory objective or variable instead of a secondary objective or variable.
PUBLIC COPY other exploratory objective or variable instead of a secondary objective or variable.
on regarding the sample size is required in this protocol amendment. The planned 
PUBLIC COPY on regarding the sample size is required in this protocol amendment. The planned 
sample size of [ADDRESS_764872]/MRI substudy. However, due to complexities in the initiation of sites capable of 
PUBLIC COPY CT/MRI substudy. However, due to complexities in the initiation of sites capable of 
MRI scans, more than the planned 35 non
PUBLIC COPY MRI scans, more than the planned 35 non
substudy subjects were screened and randomized before it was possible to close enrolmenPUBLIC COPY substudy subjects were screened and randomized before it was possible to close enrolmen
the sites not participating in the substudy. Owing to the novelty of the PET PUBLIC COPY the sites not participating in the substudy. Owing to the novelty of the PET
This document cannot be used to support any marketing authorization generating or exploratory analyses. 
This document cannot be used to support any marketing authorization generating or exploratory analyses. 
Prospectively declared evaluations are partitioned into primary analyses (where type I error is 
This document cannot be used to support any marketing authorization Prospectively declared evaluations are partitioned into primary analyses (where type I error is 
y declared in order to offer 
This document cannot be used to support any marketing authorization y declared in order to offer 
CT/MRI assessments within this 
This document cannot be used to support any marketing authorization CT/MRI assessments within this 
disease indication, it is not possible to prospectively define the analyses as we are continuing 
This document cannot be used to support any marketing authorization disease indication, it is not possible to prospectively define the analyses as we are continuing 
fic data and endpoints yielded from the imaging 
This document cannot be used to support any marketing authorization fic data and endpoints yielded from the imaging 
software, the distribution and covariance of these endpoints and the hypothesized difference 
This document cannot be used to support any marketing authorization software, the distribution and covariance of these endpoints and the hypothesized difference 
CT/MRI data in this study will 
This document cannot be used to support any marketing authorization CT/MRI data in this study will 
d exploratory and this is now updated in the study objectives, ie, 
This document cannot be used to support any marketing authorization d exploratory and this is now updated in the study objectives, ie, 
the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
This document cannot be used to support any marketing authorization the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
other exploratory objective or variable instead of a secondary objective or variable.
This document cannot be used to support any marketing authorization other exploratory objective or variable instead of a secondary objective or variable.
on regarding the sample size is required in this protocol amendment. The planned 
This document cannot be used to support any marketing authorization on regarding the sample size is required in this protocol amendment. The planned 
sample size of [ADDRESS_764873]/MRI substudy. However, due to complexities in the initiation of sites capable of 
This document cannot be used to support any marketing authorization CT/MRI substudy. However, due to complexities in the initiation of sites capable of 
MRI scans, more than the planned [ADDRESS_764874] the pow
primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
This document cannot be used to support any marketing authorization primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
number of subjects are included in the exploratory analysis of changes in bone formation at 
This document cannot be used to support any marketing authorization number of subjects are included in the exploratory analysis of changes in bone formation at 
This document cannot be used to support any marketing authorization Week [ADDRESS_764875] diff
Objectives related to PK and immunogenicity were downgraded from “secondary” objectives 
This document cannot be used to support any marketing authorization Objectives related to PK and immunogenicity were downgraded from “secondary” objectives 
to “other” objectives for consistency with the classification of the corresponding variables.
This document cannot be used to support any marketing authorization to “other” objectives for consistency with the classification of the corresponding variables.

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.CT/MRI assessments within this 
application and any extensions or variations thereof.CT/MRI assessments within this 
disease indication, it is not possible to prospectively define the analyses as we are continuing 
application and any extensions or variations thereof.disease indication, it is not possible to prospectively define the analyses as we are continuing 
fic data and endpoints yielded from the imaging 
application and any extensions or variations thereof.fic data and endpoints yielded from the imaging 
software, the distribution and covariance of these endpoints and the hypothesized difference 
application and any extensions or variations thereof.software, the distribution and covariance of these endpoints and the hypothesized difference 
CT/MRI data in this study will 
application and any extensions or variations thereof.CT/MRI data in this study will 
d exploratory and this is now updated in the study objectives, ie, 
application and any extensions or variations thereof.d exploratory and this is now updated in the study objectives, ie, 
the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
application and any extensions or variations thereof.the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
other exploratory objective or variable instead of a secondary objective or variable.
application and any extensions or variations thereof.other exploratory objective or variable instead of a secondary objective or variable.
on regarding the sample size is required in this protocol amendment. The planned 
application and any extensions or variations thereof.on regarding the sample size is required in this protocol amendment. The planned 
sample size of [ADDRESS_764876]/MRI substudy. However, due to complexities in the initiation of sites capable of 
application and any extensions or variations thereof.CT/MRI substudy. However, due to complexities in the initiation of sites capable of 
MRI scans, more than the planned [ADDRESS_764877] the pow
primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
application and any extensions or variations thereof.primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
number of subjects are included in the exploratory analysis of changes in bone formation at 
application and any extensions or variations thereof.number of subjects are included in the exploratory analysis of changes in bone formation at 
application and any extensions or variations thereof.Week [ADDRESS_764878] diff
Objectives related to PK and immunogenicity were downgraded from “secondary” objectives application and any extensions or variations thereof.Objectives related to PK and immunogenicity were downgraded from “secondary” objectives 
to “other” objectives for consistency with the classification of the corresponding variables.application and any extensions or variations thereof. to “other” objectives for consistency with the classification of the corresponding variables.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 118of 136The section describing AEs of special monitoring have been updated to reflect the 
development process and to maintain co nsistency with other protocols. 
A third informal unblinded interim analysis when the last randomized subject has completed 
the Week [ADDRESS_764879]’s participation has ended 
prematurely, has been added to facili tate additional Clinical Planning or Portfolio 
Management decisions. 
Study contact [CONTACT_579684].
In addition, a few minor updates including consistency changes for PDILI -related text and a few 
clarifications and corrections of typographical e rrors have been made. The occurrence of 
abbreviations was updated.
Modifications and changes
Global changes
The specification of the IGRA TB test has been changed from “QuantiFERON TB GOLD test” 
to “QuantiFERON TB test”.
Specific changes
Change #1
Sponsor Study Physician
Name:
[CONTACT_2761]: UCB Celltech, [ADDRESS_764880], Slough, Berkshire, SL1 3WE, [LOCATION_006]
Phone:
Fax:
Has been changed to: 
Name:
[CONTACT_2761]: UCB Celltech, [ADDRESS_764881], Slough, Berkshire, SL1 3WE, [LOCATION_006]
Phone:
Fax:
Change #2
Section 1, Summary, paragraphs 3, 4, and 5
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for [ADDRESS_764882] has been changed from “QuantiFERON TB GOLD test” 
This document cannot be used to support any marketing authorization The specification of the IGRA TB test has been changed from “QuantiFERON TB GOLD test” 
This document cannot be used to support any marketing authorization UCB Celltech, [ADDRESS_764883], Slough, Berkshire, SL1 3WE, [LOCATION_006]
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Address:
This document cannot be used to support any marketing authorization Address:
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Phone:
This document cannot be used to support any marketing authorization Phone:
This document cannot be used to support any marketing authorization Fax:
This document cannot be used to support any marketing authorization Fax:
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Change #2
This document cannot be used to support any marketing authorization Change #[ADDRESS_764884] has been changed from “QuantiFERON TB GOLD test” 
application and any extensions or variations thereof.The specification of the IGRA TB test has been changed from “QuantiFERON TB GOLD test” 
application and any extensions or variations thereof.UCB Celltech, [ADDRESS_764885], Slough, Berkshire, 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
Change #2application and any extensions or variations thereof.
Change #2application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 119of 136Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objectives 
of the study are to evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity, 
to assess the safety and tolerability of bimekizumab, and to assess the pharmacokinetics (PK) and immunogenicity of bimekizumab. The secondary efficacy variables include the 
determination of ASDAS inactive disease (ASDAS-ID) at Week 12, ASDAS major 
improvement (ASDAS-MI) at Week 12, and osteoblastic activity as detected by [CONTACT_176089]-emission tomography-magnetic resonance imaging (PET-MRI) or positron-emission 
tomography computed tomography (PET-CT) at Week 12 and Week 48. Primary safety variables include the incidence of adverse events (AEs), serious adverse events (SAEs), and withdrawal due to AEs.
Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize 
approximately 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Has been changed to: 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objective 
of the study isto assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS-ID) andASDAS major 
improvement (ASDAS-MI) at Week 12. Primary safety variables include the incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
investigational medicinal product (IMP).
Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP 
on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
bimekizumab, to obtain additional biomarkers and clinical and imaging data as applicable, and 
to assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Treatment Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize at 
least 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Change #3
Section 3.2, Secondary objectives
The secondary objectives of the study are as follows:
To evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity 
To assess the safety and tolerability of bimekizumab
To assess the PK and immunogenicity of bimekizumabPUBLIC COPY The primary objective of the study is to evaluate the efficacy of bimek
PUBLIC COPY The primary objective of the study is to evaluate the efficacy of bimek
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
PUBLIC COPY subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
PUBLIC COPY subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score
PUBLIC COPY Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week
PUBLIC COPY (ASDAS) at Week
to assess the safety and tolerability of bimekizumab. The secondary efficacy 
PUBLIC COPY to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS
PUBLIC COPY variables include the determination of ASDAS inactive disease (ASDAS
MI) at Week 12. Primary sa
PUBLIC COPY MI) at Week 12. Primary sa
adverse events (AEs), serious adverse events (SAEs), and PUBLIC COPY adverse events (AEs), serious adverse events (SAEs), and 
investigational medicinal product (IMP). PUBLIC COPY investigational medicinal product (IMP).
This document cannot be used to support any marketing authorization CT) at Week [ADDRESS_764886]) at Week 12 and Week 48. Primary safety variables 
ts (SAEs), and withdrawal 
This document cannot be used to support any marketing authorization ts (SAEs), and withdrawal 
Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
This document cannot be used to support any marketing authorization Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
This document cannot be used to support any marketing authorization applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
Pacific (APAC) region will randomize 
This document cannot be used to support any marketing authorization Pacific (APAC) region will randomize 
subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
This document cannot be used to support any marketing authorization subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
The primary objective of the study is to evaluate the efficacy of bimek
This document cannot be used to support any marketing authorization The primary objective of the study is to evaluate the efficacy of bimek
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
This document cannot be used to support any marketing authorization subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
This document cannot be used to support any marketing authorization subjects with active AS. The primary efficacy variable is the change from Baseline in 
(ASDAS) at Week
This document cannot be used to support any marketing authorization (ASDAS) at Week
to assess the safety and tolerability of bimekizumab. The secondary efficacy 
This document cannot be used to support any marketing authorization to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS
This document cannot be used to support any marketing authorization variables include the determination of ASDAS inactive disease (ASDAS
MI) at Week 12. Primary sa
This document cannot be used to support any marketing authorization MI) at Week 12. Primary sa
adverse events (AEs), serious adverse events (SAEs), and 
This document cannot be used to support any marketing authorization adverse events (AEs), serious adverse events (SAEs), and 
investigational medicinal product (IMP).
This document cannot be used to support any marketing authorization investigational medicinal product (IMP).
objectives of the study are 
This document cannot be used to support any marketing authorization objectives of the study are 
This document cannot be used to support any marketing authorization on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
This document cannot be used to support any marketing authorization on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
obtain additional biomarkers and clinical and imaging data as applicable, and 
This document cannot be used to support any marketing authorization obtain additional biomarkers and clinical and imaging data as applicable, and 
to assess the efficacy and safety of bimekizumab or CZP during the Tre
This document cannot be used to support any marketing authorization to assess the efficacy and safety of bimekizumab or CZP during the Tre
Extension Period.
This document cannot be used to support any marketing authorization Extension Period.
Multiple sites in North America, Europe, and the Asian
This document cannot be used to support any marketing authorization Multiple sites in North America, Europe, and the Asian
subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
This document cannot be used to support any marketing authorization subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Change #3
This document cannot be used to support any marketing authorization Change #[ADDRESS_764887]
The secondary objectives of the study are as follows:
This document cannot be used to support any marketing authorization The secondary objectives of the study are as follows:

This document cannot be used to support any marketing authorization To evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity 
This document cannot be used to support any marketing authorization To evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity application and any extensions or variations thereof.Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
application and any extensions or variations thereof.Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
application and any extensions or variations thereof.applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
Pacific (APAC) region will randomize 
application and any extensions or variations thereof.Pacific (APAC) region will randomize 
subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
application and any extensions or variations thereof.subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
The primary objective of the study is to evaluate the efficacy of bimek
application and any extensions or variations thereof.The primary objective of the study is to evaluate the efficacy of bimek izumab administered 
application and any extensions or variations thereof.izumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
application and any extensions or variations thereof.subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
application and any extensions or variations thereof.subjects with active AS. The primary efficacy variable is the change from Baseline in 
(ASDAS) at Week
application and any extensions or variations thereof.(ASDAS) at Week 12. The secondary objective 
application and any extensions or variations thereof.12. The secondary objective 
to assess the safety and tolerability of bimekizumab. The secondary efficacy 
application and any extensions or variations thereof.to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS
application and any extensions or variations thereof.variables include the determination of ASDAS inactive disease (ASDAS
MI) at Week 12. Primary sa
application and any extensions or variations thereof.MI) at Week 12. Primary sa fety variables include the incidence of 
application and any extensions or variations thereof.fety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and 
application and any extensions or variations thereof.adverse events (AEs), serious adverse events (SAEs), and 
objectives of the study are 
application and any extensions or variations thereof.objectives of the study are to 
application and any extensions or variations thereof.to evaluate the effect of bimekizumab or 
application and any extensions or variations thereof.evaluate the effect of bimekizumab or 
application and any extensions or variations thereof.on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
application and any extensions or variations thereof.on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
obtain additional biomarkers and clinical and imaging data as applicable, and 
application and any extensions or variations thereof.obtain additional biomarkers and clinical and imaging data as applicable, and 
to assess the efficacy and safety of bimekizumab or CZP during the Tre
application and any extensions or variations thereof.to assess the efficacy and safety of bimekizumab or CZP during the Tre
Multiple sites in North America, Europe, and the Asian
application and any extensions or variations thereof.Multiple sites in North America, Europe, and the Asian
subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
application and any extensions or variations thereof.subjects in a 2:[ADDRESS_764888]
The secondary objectives of the study are as follows: application and any extensions or variations thereof.The secondary objectives of the study are as follows:
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 120of 136Has been changed to: 
Section 3.2, Secondary objective
The secondary objective of the study isas follows:
To assess the safety and tolerability of bimekizumab
Change #4
Section 3.3, Other objectives
The other objectives of the study are as follows:
To assess additional biomarker, clinical, and imaging data as available
To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
Has been changed to: 
Section 3.3, Other exploratory objectives
The other exploratory objectives of the study are as follows:
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
Change #5
Section 4.1.2, Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
ASDAS-ID at Week 12
ASDAS-MI at Week 12
Osteoblastic activity as detected by [CONTACT_10052]-MRI or PET-CT at Week 12 and Week 48 
Has been changed to: 
The secondary efficacy variables for this study are as follows:ASDAS-ID at Week 12
ASDAS-MI at Week 12PUBLIC COPY of the study are as follows:
PUBLIC COPY of the study are as follows:
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
PUBLIC COPY To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
PUBLIC COPY To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
PUBLIC COPY To assess additional biomarker, clinical, and imaging data as available
safety of bimekizumab or CZP during the Treatment Extension 
PUBLIC COPY safety of bimekizumab or CZP during the Treatment Extension 
This document cannot be used to support any marketing authorization To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
This document cannot be used to support any marketing authorization To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
of the study are as follows:
This document cannot be used to support any marketing authorization of the study are as follows:
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
This document cannot be used to support any marketing authorization To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
This document cannot be used to support any marketing authorization To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
This document cannot be used to support any marketing authorization To assess additional biomarker, clinical, and imaging data as available
safety of bimekizumab or CZP during the Treatment Extension 
This document cannot be used to support any marketing authorization safety of bimekizumab or CZP during the Treatment Extension 
Section 4.1.2, Secondary efficacy variables
This document cannot be used to support any marketing authorization Section 4.1.2, Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
This document cannot be used to support any marketing authorization The secondary efficacy variables for this study are as follows:
ID at Week [ADDRESS_764889]
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
The secondary efficacy variables for this study are as follows:
This document cannot be used to support any marketing authorization The secondary efficacy variables for this study are as follows:

This document cannot be used to support any marketing authorization ASDAS
This document cannot be used to support any marketing authorization ASDAS

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
application and any extensions or variations thereof.To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
To evaluate the effect of bimekizumab or CZP on changes in bone formation 
application and any extensions or variations thereof.To evaluate the effect of bimekizumab or CZP on changes in bone formation 
To assess the PK and immunogenicity of bimekizumab
application and any extensions or variations thereof.To assess the PK and immunogenicity of bimekizumab
To assess additional biomarker, clinical, and imaging data as available
application and any extensions or variations thereof.To assess additional biomarker, clinical, and imaging data as available
safety of bimekizumab or CZP during the Treatment Extension 
application and any extensions or variations thereof.safety of bimekizumab or CZP during the Treatment Extension 
Section 4.1.2, Secondary efficacy variables
application and any extensions or variations thereof.Section 4.1.2, Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
application and any extensions or variations thereof.The secondary efficacy variables for this study are as follows:
MI at Week [ADDRESS_764890]
Has been changed to: 
application and any extensions or variations thereof.Has been changed to: 
The secondary efficacy variables for this study are as follows:
application and any extensions or variations thereof.The secondary efficacy variables for this study are as follows:
ASDASapplication and any extensions or variations thereof. ASDAS -application and any extensions or variations thereof.-ID at Week 12application and any extensions or variations thereof.ID at Week 12
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 121of 136Change #6
Section 4.1.3, Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1. Other efficacy 
variables are as follows:
Change from Baseline in ASD AS
ASAS20 response
ASAS40 response
Time to ASAS20 response
Time to ASAS40 response
ASAS partial remission
Change from Baseline in BASDAI
Has been changed to: 
Section 4.1.3, Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1. The following 
efficacy variables are exploratory and are assessed over the Treatment Period and 
Treatment Extension Period, as applicable:
Change from Baseline in ASDAS
ASAS20 response
ASAS40 response
Time to ASAS20 response
Time to ASAS40 response
ASAS partial remission
Change from Baseline in BASDAI
Changes in bone formation as measured by [CONTACT_581721] (SUV AUC) and derived from PET-MRI or PET-CT at Baseline, Week 12, and 
Week 48 
Change #7, Primary safety variables
The primary safety variables for this study are as follows:
Incidence of AEs and SAEs
Withdrawal due to AEs
Has been changed to: 
The primary safety variables for this study are as follows:PUBLIC COPY Assessment time points for the other efficacy variables are specified in 
PUBLIC COPY Assessment time points for the other efficacy variables are specified in 
efficacy variables are exploratory and are assessed ov
PUBLIC COPY efficacy variables are exploratory and are assessed ov
Treatment Extension Period, as applicable:
PUBLIC COPY Treatment Extension Period, as applicable:
This document cannot be used to support any marketing authorization Assessment time points for the other efficacy variables are specified in 
This document cannot be used to support any marketing authorization Assessment time points for the other efficacy variables are specified in 
efficacy variables are exploratory and are assessed ov
This document cannot be used to support any marketing authorization efficacy variables are exploratory and are assessed ov er the Treatment Period and 
This document cannot be used to support any marketing authorization er the Treatment Period and 
Time to ASAS40 response
This document cannot be used to support any marketing authorization Time to ASAS40 response
ASAS partial remission
This document cannot be used to support any marketing authorization ASAS partial remission
Change from Baseline in BASDAI
This document cannot be used to support any marketing authorization Change from Baseline in BASDAI
Changes in bone forma
This document cannot be used to support any marketing authorization Changes in bone forma
the curve (SUV
This document cannot be used to support any marketing authorization the curve (SUV
This document cannot be used to support any marketing authorization AUC
This document cannot be used to support any marketing authorization AUC
Week 48 
This document cannot be used to support any marketing authorization Week 48 
Change #7, Primary safety variables
This document cannot be used to support any marketing authorization Change #7, Primary safety variables
The primary safety variables for this study are as follows:
This document cannot be used to support any marketing authorization The primary safety variables for this study are as follows:

This document cannot be used to support any marketing authorization Incidence 
This document cannot be used to support any marketing authorization Incidence 

This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Assessment time points for the other efficacy variables are specified in 
application and any extensions or variations thereof.Assessment time points for the other efficacy variables are specified in Table
application and any extensions or variations thereof.Table
er the Treatment Period and 
application and any extensions or variations thereof.er the Treatment Period and 
Change from Baseline in BASDAI
application and any extensions or variations thereof.Change from Baseline in BASDAI
Changes in bone forma
application and any extensions or variations thereof.Changes in bone forma tion as measured by [CONTACT_581722].tion as measured by [CONTACT_581722].AUC
application and any extensions or variations thereof.AUC) and derived from PET
application and any extensions or variations thereof.) and derived from PET
Change #7, Primary safety variables
application and any extensions or variations thereof.Change #7, Primary safety variables
The primary safety variables for this study are as follows:application and any extensions or variations thereof.The primary safety variables for this study are as follows:
Incidence application and any extensions or variations thereof.Incidence of AEs and SAEsapplication and any extensions or variations thereof.of AEs and SAEs
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 122of 136Incidence of AEs and SAEs
Adverse events leading to withdrawal from IMP
Change #8, Section header
4.5 Nonhereditary pharmacogenomic variables
Has been changed to: 
4.5 Other nonhereditary pharmacogenomic variables
Change #9, Section header
4.6 Pharmacogenetic variables
Has been changed to: 
4.6 Other pharmacogenetic variables 
Change #10
Section 5.1, Study description, paragraph 3
Approximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
receive either bimekizumab or CZP up to Week 44 (final dose of IMP). 
Has been changed to: 
At least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will receive 
either bimekizumab or CZP up to Week 44 (final dose of IMP). 
Change #11
Section 5.5, Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
60 subjects at multiple sites.
Has been changed to: 
It is anticipated that approximately [ADDRESS_764891] or PET-MRI substudy 
at multiple sites.PUBLIC COPY Section 5.1, Study description, paragraph 3
PUBLIC COPY Section 5.1, Study description, paragraph 3
oximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
PUBLIC COPY oximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
receive either bimekizumab or CZP up to Week
PUBLIC COPY receive either bimekizumab or CZP up to Week 44 (final dose of IMP). 
PUBLIC COPY 44 (final dose of IMP). 
subjects will be randomized to 1 of 2 treatment arms in a 2:1 
PUBLIC COPY subjects will be randomized to 1 of 2 treatment arms in a 2:1 
either bimekizumab or CZP up to Week
PUBLIC COPY either bimekizumab or CZP up to Week
This document cannot be used to support any marketing authorization oximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
This document cannot be used to support any marketing authorization oximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
44 (final dose of IMP). 
This document cannot be used to support any marketing authorization 44 (final dose of IMP). 
subjects will be randomized to 1 of 2 treatment arms in a 2:1 
This document cannot be used to support any marketing authorization subjects will be randomized to 1 of 2 treatment arms in a 2:1 
44 (final dose of IMP). 
This document cannot be used to support any marketing authorization 44 (final dose of IMP). 
Section 5.5, Planned number of subjects and site(s)
This document cannot be used to support any marketing authorization Section 5.5, Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
This document cannot be used to support any marketing authorization It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
cts at multiple sites.
This document cannot be used to support any marketing authorization cts at multiple sites.
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
It is anticipated that approximately 120 subjects will be screened in order to enroll 
This document cannot be used to support any marketing authorization It is anticipated that approximately 120 subjects will be screened in order to enroll 
This document cannot be used to support any marketing authorization in the main study and
This document cannot be used to support any marketing authorization in the main study and
at multiple sites.
This document cannot be used to support any marketing authorization at multiple sites.
application and any extensions or variations thereof.oximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
application and any extensions or variations thereof.oximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
44 (final dose of IMP). 
application and any extensions or variations thereof.44 (final dose of IMP). 
subjects will be randomized to 1 of 2 treatment arms in a 2:1 
application and any extensions or variations thereof.subjects will be randomized to 1 of 2 treatment arms in a 2:1 
44 (final dose of IMP). 
application and any extensions or variations thereof.44 (final dose of IMP). 
Section 5.5, Planned number of subjects and site(s)
application and any extensions or variations thereof.Section 5.5, Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
application and any extensions or variations thereof.It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
It is anticipated that approximately 120 subjects will be screened in order to enroll 
application and any extensions or variations thereof.It is anticipated that approximately 120 subjects will be screened in order to enroll 
application and any extensions or variations thereof.in the main study and
application and any extensions or variations thereof.in the main study and
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 123of 136Change #12
Section 6.3.1, Potential drug -induced liver injury IMP discontinuation 
criteria, paragraph 2
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
Subjects with either of the following:
ALT or AST ≥5ULN
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), 
rash, or eosinophilia (ie, >5%).
Has been changed to: 
The PDILI criteria below require immediate discontinuation of IMP: 
Subjects with either of the following:
ALT or AST ≥5ULN
ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitiv ity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
Change #[ADDRESS_764892](s), 
paragraphs 1 and 2
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
preservative -free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
with a rubber stopper and sealed with an aluminum cap overseal. Each single -use dose vial will 
contain 160mg/mL bimekizumab in mM sodium acetate, mM glycine and  (w/v) 
polysorbate 80 at pH .PUBLIC COPY and coexisting total bilirubin ≥2xULN 
PUBLIC COPY and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
PUBLIC COPY Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
PUBLIC COPY hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitiv
PUBLIC COPY upper quadrant pain or tenderness. Hypersensitiv
alternative cause), rash, or eosinophilia (ie, >5%).PUBLIC COPY alternative cause), rash, or eosinophilia (ie, >5%).
This document cannot be used to support any marketing authorization Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
This document cannot be used to support any marketing authorization Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
This document cannot be used to support any marketing authorization hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
symptoms include fever (without clear alternative cause), 
This document cannot be used to support any marketing authorization symptoms include fever (without clear alternative cause), 
The PDILI criteria below require immediate discontinuation of IMP: 
This document cannot be used to support any marketing authorization The PDILI criteria below require immediate discontinuation of IMP: 
and coexisting total bilirubin ≥2xULN 
This document cannot be used to support any marketing authorization and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
This document cannot be used to support any marketing authorization Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
This document cannot be used to support any marketing authorization hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitiv
This document cannot be used to support any marketing authorization upper quadrant pain or tenderness. Hypersensitiv
alternative cause), rash, or eosinophilia (ie, >5%).
This document cannot be used to support any marketing authorization alternative cause), rash, or eosinophilia (ie, >5%).
Section 7.1, Description of investigational medicinal product(s), 
This document cannot be used to support any marketing authorization Section 7.1, Description of investigational medicinal product(s), 
The IMPs used in this study are bimekizumab and CZP.
This document cannot be used to support any marketing authorization The IMPs used in this study are bimekizumab and CZP.
will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
This document cannot be used to support any marketing authorization will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
This document cannot be used to support any marketing authorization free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
with a rubber stopper and sealed with an aluminum cap overseal. Each single
This document cannot be used to support any marketing authorization with a rubber stopper and sealed with an aluminum cap overseal. Each single
contain 160mg/mL bimekizumab in mM sodium acetate, mM glycine and  (w/v) 
This document cannot be used to support any marketing authorization contain 160mg/mL bimekizumab in mM sodium acetate, mM glycine and  (w/v) 
This document cannot be used to support any marketing authorization polysorbate [ADDRESS_764893] ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
application and any extensions or variations thereof.Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
application and any extensions or variations thereof.hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
symptoms include fever (without clear alternative cause), 
application and any extensions or variations thereof.symptoms include fever (without clear alternative cause), 
and coexisting total bilirubin ≥2xULN 
application and any extensions or variations thereof.and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
application and any extensions or variations thereof.Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
application and any extensions or variations thereof.hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitiv
application and any extensions or variations thereof.upper quadrant pain or tenderness. Hypersensitiv ity symptoms include fever (without clear 
application and any extensions or variations thereof.ity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
application and any extensions or variations thereof.alternative cause), rash, or eosinophilia (ie, >5%).
Section 7.1, Description of investigational medicinal product(s), 
application and any extensions or variations thereof.Section 7.1, Description of investigational medicinal product(s), 
The IMPs used in this study are bimekizumab and CZP.
application and any extensions or variations thereof.The IMPs used in this study are bimekizumab and CZP.
will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
application and any extensions or variations thereof.will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
application and any extensions or variations thereof.free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
with a rubber stopper and sealed with an aluminum cap overseal. Each single
application and any extensions or variations thereof.with a rubber stopper and sealed with an aluminum cap overseal. Each single
contain 160mg/mL bimekizumab in mM sodium acetate, mM glycine and  (w/v) 
application and any extensions or variations thereof.contain 160mg/mL bimekizumab in mM sodium acetate, mM glycine and  (w/v) 
application and any extensions or variations thereof.polysorbate 80 at pH .
application and any extensions or variations thereof.polysorbate 80 at pH .
application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 124of 136Has been changed to: 
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a vial or in a pre -filled syringe (PFS) form as described 
below: 
Vial: a clear to opalescent, colorless to slightly brown, sterile, preservative -free solution in 
2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
and sealed with an aluminum cap overseal. Each single -use dose vial will c ontain 160mg/mL 
bimekizumab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
pH 
PFS: 1mL PFS at a concentration of 160mg/mL mM sodium acetate, mM 
glycine,  polysorbate 80 at pH ) for sc injection.
Change #14
Secti on 8.8, Week 12 (Visit 8), PET -MRI/PET -CT scan bullet
Perform a PET -MRI or PET -CT scan in approximately 25 subjects at selected sites within 
2weeks after Week 12 Visit if PET positive lesions were observed in the previous scan.
Has been changed to: 
Perfo rm a PET -MRI or PET -CT scan in at least 25 subjects at selected sites within 2 weeks 
after Week 12 Visit if PET -positive lesions were observed in the previous scan.
Change #15
Section 8.11, Week 48 (Visit 17), PET -MRI/PET -CT scan bullet
Perform a PET -MRI o r PET -CT scan in approximately 25 subjects at selected sites within 2 
weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET -MRI or PET -CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET positive lesions were observed in the 
previous scan.
Has been changed to: 
Perform a PET -MRI or PET -CT scan in at least 25 subjects at selected sites within 2 weeks 
after the Week 48/WD Visit if PET -positive lesions were observed in the previous scan. At 
the WD Visit, the PET -MRI or PET -CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET -positive lesions were observed in 
the previous scan.
Change #[ADDRESS_764894] paragraph
The 18F -fluoride PET -MRIs of the whole spi[INVESTIGATOR_581572] a whole -body 
PET/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
PET-CT system permitting the acquisitio n of co -registered CT and PET images in the same PUBLIC COPY CT scan in approximately [ADDRESS_764895]
positive lesions were observed in the previous scan.
PUBLIC COPY positive lesions were observed in the previous scan.
Section 8.11, Week 48 (Visit 17), PET PUBLIC COPY Section 8.11, Week 48 (Visit 17), PET
This document cannot be used to support any marketing authorization 2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
This document cannot be used to support any marketing authorization 2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
ontain 160mg/mL 
This document cannot be used to support any marketing authorization ontain 160mg/mL 
bimekizumab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
This document cannot be used to support any marketing authorization bimekizumab in mM sodium acetate, mM glycine, and  (w/v) polysorbate 80 at 
PFS: 1mL PFS at a concentration of 160mg/mL mM sodium acetate, mM 
This document cannot be used to support any marketing authorization PFS: 1mL PFS at a concentration of 160mg/mL mM sodium acetate, mM 
CT scan bullet
This document cannot be used to support any marketing authorization CT scan bullet
CT scan in approximately [ADDRESS_764896] 25 subjects at selected sites within 2
This document cannot be used to support any marketing authorization 25 subjects at selected sites within 2
positive lesions were observed in the previous scan.
This document cannot be used to support any marketing authorization positive lesions were observed in the previous scan.
Section 8.11, Week 48 (Visit 17), PET
This document cannot be used to support any marketing authorization Section 8.11, Week 48 (Visit 17), PET -
This document cannot be used to support any marketing authorization -MRI/PET
This document cannot be used to support any marketing authorization MRI/PET
CT scan in approximately [ADDRESS_764897] scan in approximately 25 subjects at selected sites within 2 
This document cannot be used to support any marketing authorization weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
This document cannot be used to support any marketing authorization weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET
This document cannot be used to support any marketing authorization scan. At the WD Visit, the PET -
This document cannot be used to support any marketing authorization -MRI or PET
This document cannot be used to support any marketing authorization MRI or PET
occurred more than 12 weeks ago and if PET positive lesions were observed in the 
This document cannot be used to support any marketing authorization occurred more than 12 weeks ago and if PET positive lesions were observed in the 
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
Perform a PET
This document cannot be used to support any marketing authorization Perform a PET -
This document cannot be used to support any marketing authorization -MRI or PET
This document cannot be used to support any marketing authorization MRI or PET
after the Week 48/WD Visit if PET
This document cannot be used to support any marketing authorization after the Week 48/WD Visit if PET
the WD Visit, the PET
This document cannot be used to support any marketing authorization the WD Visit, the PET
evaluation occurred more than 12 weeks ago and if PET
This document cannot be used to support any marketing authorization evaluation occurred more than 12 weeks ago and if PET
the previous scan.
This document cannot be used to support any marketing authorization the previous scan.
Change #16
This document cannot be used to support any marketing authorization Change #16
Section 9.11This document cannot be used to support any marketing authorization Section 9.11This document cannot be used to support any marketing authorization application and any extensions or variations thereof.PFS: 1mL PFS at a concentration of 160mg/mL mM sodium acetate, mM 
application and any extensions or variations thereof.PFS: 1mL PFS at a concentration of 160mg/mL mM sodium acetate, mM 
CT scan in approximately [ADDRESS_764898] scan in approximately 25 subjects at selected sites within 
positive lesions were observed in the previous scan.
application and any extensions or variations thereof.positive lesions were observed in the previous scan.
25 subjects at selected sites within 2
application and any extensions or variations thereof.25 subjects at selected sites within 2
positive lesions were observed in the previous scan.
application and any extensions or variations thereof.positive lesions were observed in the previous scan.
MRI/PET
application and any extensions or variations thereof.MRI/PET
CT scan in approximately [ADDRESS_764899] scan in approximately 25 subjects at selected sites within 2 
application and any extensions or variations thereof.weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
application and any extensions or variations thereof.weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
MRI or PET
application and any extensions or variations thereof.MRI or PET
occurred more than 12 weeks ago and if PET positive lesions were observed in the 
application and any extensions or variations thereof.occurred more than 12 weeks ago and if PET positive lesions were observed in the 
Has been changed to: 
application and any extensions or variations thereof.Has been changed to: 
MRI or PET
application and any extensions or variations thereof.MRI or PET
after the Week 48/WD Visit if PET
application and any extensions or variations thereof.after the Week 48/WD Visit if PET
the WD Visit, the PET
application and any extensions or variations thereof.the WD Visit, the PET
evaluation occurred more than 12 weeks ago and if PET
application and any extensions or variations thereof.evaluation occurred more than 12 weeks ago and if PET
the previous scan.application and any extensions or variations thereof.the previous scan.
Change #16application and any extensions or variations thereof.Change #[ADDRESS_764900] scan will be performed at time points provided in Table 5‒1
in approximately 25 subjects at selected sites.
Has been changed to: 
The 18F-fluoride PET-MRIs of the whole spi[INVESTIGATOR_581538] a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supi[INVESTIGATOR_435945] a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒[ADDRESS_764901] 25 subjects at selected sites.
Change #17
Section 12.1.14, Adverse events for special monitoring, section header and 
paragraph 2
[IP_ADDRESS] Adverse events for special monitoring
Adverse events for special monitoring for this study include: serious infections (including 
opportunistic infections and TB, see Section 12.7.5), cytopenias, hypersensitivities, suicide 
ideation or behavior (assessed using the C-SSRS), depression and anxiety (assessed using the 
HADS, see Section 9.10), major cardiovascular events and liver function test changes/enzyme 
elevations (ALT, AST, and bilirubin; see Section 12.6.1 ), malignancies, and inflammatory bowel 
diseases.
Has been changed to: 
[IP_ADDRESS] Adverse events for special monitoring
Adverse events for special monitoring for this study include: infections (serious , opportunistic, 
fungal , and TB, see Section 12.7.5), neutropenia, hypersensitivit y, suicid alideation and
behavior (assessed using the C-SSRS), depression, (assessed using the HADS, see Section 9.10), 
major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
bilirubin; see Section 12.6.1 ), malignancies, and inflammatory bowel diseases (with 
gastroenterology referral as appropriate).PUBLIC COPY ), cyt
PUBLIC COPY ), cyt
SSRS), depression and anxiety (assessed using the 
PUBLIC COPY SSRS), depression and anxiety (assessed using the 
), major cardiovascular events and liver function test changes/enzyme 
PUBLIC COPY ), major cardiovascular events and liver function test changes/enzyme 
Section
PUBLIC COPY Section 12.6.1
PUBLIC COPY 12.6.1
PUBLIC COPY Adverse events for special monitoring
PUBLIC COPY Adverse events for special monitoring
Adverse events for special monitoring for this study includePUBLIC COPY Adverse events for special monitoring for this study include
12.7.5PUBLIC COPY 12.7.5 ), PUBLIC COPY ), 
This document cannot be used to support any marketing authorization 5
This document cannot be used to support any marketing authorization 5‒
This document cannot be used to support any marketing authorization ‒1
This document cannot be used to support any marketing authorization 1
Section 12.1.14, Adverse events for special monitoring, section header and 
This document cannot be used to support any marketing authorization Section 12.1.14, Adverse events for special monitoring, section header and 
Adverse events for special monitoring for this study include: serious infections (including 
This document cannot be used to support any marketing authorization Adverse events for special monitoring for this study include: serious infections (including 
openias, hypersensitivities, suicide 
This document cannot be used to support any marketing authorization openias, hypersensitivities, suicide 
SSRS), depression and anxiety (assessed using the 
This document cannot be used to support any marketing authorization SSRS), depression and anxiety (assessed using the 
), major cardiovascular events and liver function test changes/enzyme 
This document cannot be used to support any marketing authorization ), major cardiovascular events and liver function test changes/enzyme 
), malignancies, and
This document cannot be used to support any marketing authorization ), malignancies, and
This document cannot be used to support any marketing authorization Adverse events for special monitoring
This document cannot be used to support any marketing authorization Adverse events for special monitoring
Adverse events for special monitoring for this study include
This document cannot be used to support any marketing authorization Adverse events for special monitoring for this study include
neutropenia,
This document cannot be used to support any marketing authorization neutropenia,
This document cannot be used to support any marketing authorization SSRS), depression, (assessed using the HADS, see 
This document cannot be used to support any marketing authorization SSRS), depression, (assessed using the HADS, see 
major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
This document cannot be used to support any marketing authorization major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
), malignancies, and inflammatory bowel diseases 
This document cannot be used to support any marketing authorization ), malignancies, and inflammatory bowel diseases 
gastroenterology referral as appropriate).
This document cannot be used to support any marketing authorization gastroenterology referral as appropriate).
application and any extensions or variations thereof.Section 12.1.14, Adverse events for special monitoring, section header and 
application and any extensions or variations thereof.Section 12.1.14, Adverse events for special monitoring, section header and 
Adverse events for special monitoring for this study include: serious infections (including 
application and any extensions or variations thereof.Adverse events for special monitoring for this study include: serious infections (including 
openias, hypersensitivities, suicide 
application and any extensions or variations thereof.openias, hypersensitivities, suicide 
SSRS), depression and anxiety (assessed using the 
application and any extensions or variations thereof.SSRS), depression and anxiety (assessed using the 
), major cardiovascular events and liver function test changes/enzyme 
application and any extensions or variations thereof.), major cardiovascular events and liver function test changes/enzyme 
), malignancies, and
application and any extensions or variations thereof.), malignancies, and
application and any extensions or variations thereof.Adverse events for special monitoring for this study include
application and any extensions or variations thereof.Adverse events for special monitoring for this study include
neutropenia,
application and any extensions or variations thereof.neutropenia, hypersensitivit
application and any extensions or variations thereof.hypersensitivit
application and any extensions or variations thereof.SSRS), depression, (assessed using the HADS, see 
application and any extensions or variations thereof.SSRS), depression, (assessed using the HADS, see 
major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
application and any extensions or variations thereof.major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
), malignancies, and inflammatory bowel diseases 
application and any extensions or variations thereof.), malignancies, and inflammatory bowel diseases 
gastroenterology referral as appropriate).
application and any extensions or variations thereof.gastroenterology referral as appropriate).
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 126of 136Change #18
Section 12.6.1, Evaluation of PDILI, Table 12-3
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consult.b
Medical Monitor must be notified 
within 24 hours (eg,by [CONTACT_67600]) and subject discussed with 
Medical Monitor 
ASAP.Immediate, 
permanent IMP 
discontinuation.Essential: Must 
have repeat liver 
chemistry values 
and additional testing completed 
ASAP (see 
Section [IP_ADDRESS] ); 
recommended to occur at the site 
with HCP.Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline values.
b
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.d
Immediate IMP 
discontinuation required if 
liver chemistry values≥3xULN NA Yes
≥5xULN NA NA Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST ≥8xULN) Medical 
Monitor must be 
notified within 
24hours (eg, by 
[CONTACT_58980]) and 
subject discussed 
with Medical Monitor 
ASAP.Immediate, 
permanent IMP 
discontinuation PUBLIC COPY Medical Monitor 
PUBLIC COPY Medical Monitor permanent IMP 
PUBLIC COPY permanent IMP 
discontinuation.
PUBLIC COPY discontinuation.
PUBLIC COPY PUBLIC COPY Need for hepatology PUBLIC COPY Need for hepatology 
consult to be PUBLIC COPY consult to be PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Testing
This document cannot be used to support any marketing authorization Testing
This document cannot be used to support any marketing authorization discontinuation.
This document cannot be used to support any marketing authorization discontinuation.Essential: Must 
This document cannot be used to support any marketing authorization Essential: Must 
have repeat liver 
This document cannot be used to support any marketing authorization have repeat liver 
chemistry values 
This document cannot be used to support any marketing authorization chemistry values 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Need for hepatology 
This document cannot be used to support any marketing authorization Need for hepatology 
discussed. (required 
This document cannot be used to support any marketing authorization discussed. (required 
if ALT or AST 
This document cannot be used to support any marketing authorization if ALT or AST 
≥8xULN) Medical 
This document cannot be used to support any marketing authorization ≥8xULN) Medical 
Monitor must be 
This document cannot be used to support any marketing authorization Monitor must be 
notified within 
This document cannot be used to support any marketing authorization notified within 
24hours (eg, by 
[CONTACT_581653] 24hours (eg, by 
[CONTACT_58980]) and 
This document cannot be used to support any marketing authorization laboratory alert) and 
subject discussed 
This document cannot be used to support any marketing authorization subject discussed Immediate, 
This document cannot be used to support any marketing authorization Immediate, 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Follow up
application and any extensions or variations thereof.Follow up
application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.application and any extensions or variations thereof.Essential: Must 
application and any extensions or variations thereof.Essential: Must 
have repeat liver 
application and any extensions or variations thereof.have repeat liver 
chemistry values 
application and any extensions or variations thereof.chemistry values 
and additional 
application and any extensions or variations thereof.and additional 
testing completed 
application and any extensions or variations thereof.testing completed 
ASAP (see 
application and any extensions or variations thereof.ASAP (see 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Immediate, 
application and any extensions or variations thereof.Immediate, 
permanent IMP 
application and any extensions or variations thereof.permanent IMP 
discontinuation
application and any extensions or variations thereof.discontinuation
application and any extensions or variations thereof.application and any extensions or variations thereof.≥8xULN) Medical 
application and any extensions or variations thereof.≥8xULN) Medical 
Monitor must be 
application and any extensions or variations thereof.Monitor must be 
notified within 
application and any extensions or variations thereof.notified within 
24hours (eg, by 
[INVESTIGATOR_581504].24hours (eg, by 
[CONTACT_58980]) and 
application and any extensions or variations thereof.laboratory alert) and 
subject discussed 
application and any extensions or variations thereof.subject discussed 
with 
application and any extensions or variations thereof.with Medical Monitor 
application and any extensions or variations thereof.Medical Monitor 
ASAP.
application and any extensions or variations thereof.ASAP.
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 127of 136Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and <5xULN 
(and ≥2x 
baseline)<2xULN No Discussion with Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) 
cFurther investigation – immediate IMP 
discontinuation not 
required (see 
Section [IP_ADDRESS] ).
IMP discontinuation required if any of 
the following occur:
Subject cannot 
comply with monitoring 
schedule. 
Liver chemistry 
values continue to increase 
Liver chemistry values remain ≥3xULN (and 
≥2xbaseline ) 
after 2 weeks of 
monitoring 
without 
evidence of resolution Essential: Every 
attempt must be 
made to have 
repeat liver chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP (see Section 
[IP_ADDRESS] ).continue to increase. After 2 
weeks of monitoring liver 
chemistry values:
Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutiond 
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuesd.
PUBLIC COPY IMP discontinuation 
PUBLIC COPY IMP discontinuation 
required if any of 
PUBLIC COPY required if any of 
the following occur:
PUBLIC COPY the following occur:

PUBLIC COPY Subject cannot 
PUBLIC COPY Subject cannot 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialFollow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization IMP discontinuation 
This document cannot be used to support any marketing authorization IMP discontinuation 
required if any of 
This document cannot be used to support any marketing authorization required if any of 
the following occur:
This document cannot be used to support any marketing authorization the following occur:
Subject cannot 
This document cannot be used to support any marketing authorization Subject cannot 
comply with 
This document cannot be used to support any marketing authorization comply with 
monitoring 
This document cannot be used to support any marketing authorization monitoring 
schedule. 
This document cannot be used to support any marketing authorization schedule. 

This document cannot be used to support any marketing authorization Essential: Every 
This document cannot be used to support any marketing authorization Essential: Every 
attempt must be 
This document cannot be used to support any marketing authorization attempt must be 
made to have 
This document cannot be used to support any marketing authorization made to have 
repeat liver 
This document cannot be used to support any marketing authorization repeat liver 
chemistry values 
This document cannot be used to support any marketing authorization chemistry values 
and additional 
This document cannot be used to support any marketing authorization and additional 
testing completed 
This document cannot be used to support any marketing authorization testing completed 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
continue to increase. After [ADDRESS_764902] 
repeat liver 
application and any extensions or variations thereof.repeat liver 
chemistry values 
application and any extensions or variations thereof.chemistry values 
and additional 
application and any extensions or variations thereof.and additional 
testing completed 
application and any extensions or variations thereof.testing completed 
within 48hours at 
application and any extensions or variations thereof.within 48hours at 
the site with HCP 
application and any extensions or variations thereof.the site with HCP 
(see 
application and any extensions or variations thereof.(see 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 128of 136Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc are practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug- induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
cDetails provided in Section [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would usually be a hepatologist, but may be a gastroenterologist. 
dUnless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Has been changed to: 
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNb NA Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg,by [CONTACT_67600]) and subject 
discussed with 
Medical Monitor 
ASAP.Immediate IMP discontinuation
d.Essential: Must have repeat liver 
chemistry values 
and additional 
testing completed ASAP (see 
Section [IP_ADDRESS] ); 
recommended to occur at the site Monitoring of liver chemistry values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.
e≥3xULN NA YesPUBLIC COPY . The local hepatologist is the expert usually consulted by [CONTACT_581654] . The local hepatologist is the expert usually consulted by [CONTACT_581723] a gastroenterologist. 
PUBLIC COPY ay be a gastroenterologist. 
Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
PUBLIC COPY Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
le) and UCB responsible physician, as needed.
PUBLIC COPY le) and UCB responsible physician, as needed.
up for PDILI
PUBLIC COPY up for PDILI
PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
This document cannot be used to support any marketing authorization ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
induced liver injury; ULN=upper limit of normal 
This document cannot be used to support any marketing authorization induced liver injury; ULN=upper limit of normal 
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
This document cannot be used to support any marketing authorization Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
This document cannot be used to support any marketing authorization If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
. The local hepatologist is the expert usually consulted by [CONTACT_581656] . The local hepatologist is the expert usually consulted by [CONTACT_581723] a gastroenterologist. 
This document cannot be used to support any marketing authorization ay be a gastroenterologist. 
Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
This document cannot be used to support any marketing authorization Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
le) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization le) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization Immediate
This document cannot be used to support any marketing authorization Immediate
This document cannot be used to support any marketing authorization Consultation 
This document cannot be used to support any marketing authorization Consultation 
requirements
This document cannot be used to support any marketing authorization requirements
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Hepatology consult.c
This document cannot be used to support any marketing authorization Hepatology consult.c
Medical Monitor 
This document cannot be used to support any marketing authorization Medical Monitor 
must be notified 
This document cannot be used to support any marketing authorization must be notified 
within 24
This document cannot be used to support any marketing authorization within 24
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
application and any extensions or variations thereof.ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc
induced liver injury; ULN=upper limit of normal 
application and any extensions or variations thereof.induced liver injury; ULN=upper limit of normal 
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
application and any extensions or variations thereof.Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
application and any extensions or variations thereof.If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi
. The local hepatologist is the expert usually consulted by [CONTACT_581657].. The local hepatologist is the expert usually consulted by [CONTACT_581724]. Determination of stabi
application and any extensions or variations thereof.Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
le) and UCB responsible physician, as needed.
application and any extensions or variations thereof.le) and UCB responsible physician, as needed.
application and any extensions or variations thereof.Immediate
application and any extensions or variations thereof.Immediate
application and any extensions or variations thereof.Actions
application and any extensions or variations thereof.Actions
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Hepatology consult.c
application and any extensions or variations thereof.Hepatology consult.c
Medical Monitor 
application and any extensions or variations thereof.Medical Monitor 
must be notified 
application and any extensions or variations thereof.must be notified 
within 24
application and any extensions or variations thereof.within 24 hours 
application and any extensions or variations thereof.hours 
(eg,
application and any extensions or variations thereof.(eg,by [CONTACT_581725].by [CONTACT_67600]) and subject 
application and any extensions or variations thereof.alert) and subject 
discussed with 
application and any extensions or variations thereof.discussed with 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 129of 136Table 12-3:Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥5xULN NA NA Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST ≥8xULN). Medical 
Monitor must be 
notified within 
24hours (eg, by 
[CONTACT_58980]) and subject discussed 
with Medical Monitor 
ASAP.with HCP.
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.e
Immediate IMP 
PUBLIC COPY with Medical Monitor 
PUBLIC COPY with Medical Monitor 
PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization with HCP.
This document cannot be used to support any marketing authorization with HCP.
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 130of 136Table 12-3:Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and <5xULN 
(and ≥2x 
baseline)<2xULN No Discussion with Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) 
cFurther investigation – immediate IMP 
discontinuation not 
required (see 
Section [IP_ADDRESS] ).
IMP discontinuation required if any of 
the following occu r:
Subject cannot 
comply with monitoring 
schedule. 
Liver chemistry 
values continue to increase 
Liver chemistry values remain ≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of resolution Essential: Every 
attempt must be 
made to hav e 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP (see Section 
[IP_ADDRESS] ).discontinuation required if 
liver chemistry values
continue to increase. After 2 
weeks of monitoring liver 
chemistry values:
Discontinue IMP if levels remain ≥3xULN (and ≥2x baseline) without evidence of resolution
e
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuese.
PUBLIC COPY IMP discontinuation 
PUBLIC COPY IMP discontinuation 
required if any of 
PUBLIC COPY required if any of 
the following occu
PUBLIC COPY the following occu

PUBLIC COPY Subject cannot 
PUBLIC COPY Subject cannot 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization ConfidentialFollow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization IMP discontinuation 
This document cannot be used to support any marketing authorization IMP discontinuation 
required if any of 
This document cannot be used to support any marketing authorization required if any of 
the following occu
This document cannot be used to support any marketing authorization the following occu r:
This document cannot be used to support any marketing authorization r:
Subject cannot 
This document cannot be used to support any marketing authorization Subject cannot 
comply with 
This document cannot be used to support any marketing authorization comply with 
monitoring 
This document cannot be used to support any marketing authorization monitoring 
schedule. 
This document cannot be used to support any marketing authorization schedule. 

This document cannot be used to support any marketing authorization Essential: Every 
This document cannot be used to support any marketing authorization Essential: Every 
attempt must be 
This document cannot be used to support any marketing authorization attempt must be 
made to hav
This document cannot be used to support any marketing authorization made to hav
repeat liver 
This document cannot be used to support any marketing authorization repeat liver 
chemistry values 
This document cannot be used to support any marketing authorization chemistry values 
and additional 
This document cannot be used to support any marketing authorization and additional 
testing completed 
This document cannot be used to support any marketing authorization testing completed 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
discontinuation required if 
application and any extensions or variations thereof.discontinuation required if 
application and any extensions or variations thereof.application and any extensions or variations thereof.Subject cannot 
application and any extensions or variations thereof.Subject cannot 
comply with 
application and any extensions or variations thereof.comply with 
monitoring 
application and any extensions or variations thereof.monitoring 
schedule. 
application and any extensions or variations thereof.schedule. 
Liver chemistry 
application and any extensions or variations thereof.Liver chemistry 
values continue 
application and any extensions or variations thereof.values continue 
to increase 
application and any extensions or variations thereof.to increase attempt must be 
application and any extensions or variations thereof.attempt must be 
e 
application and any extensions or variations thereof.e 
repeat liver 
application and any extensions or variations thereof.repeat liver 
chemistry values 
application and any extensions or variations thereof.chemistry values 
and additional 
application and any extensions or variations thereof.and additional 
testing completed 
application and any extensions or variations thereof.testing completed 
within 48hours at 
application and any extensions or variations thereof.within 48hours at 
the site with HCP 
application and any extensions or variations thereof.the site with HCP 
(see 
application and any extensions or variations thereof.(see 
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 131of 136Table 12-3:Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal bilirubinSymptoms
aof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio ner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug- induced liver injury; ULN=upper limit of normal
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
cDetails provided in Section [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would usually be a hepatologist, but may be a gastroenterologist. 
dDetails are provided in Section [IP_ADDRESS].[ADDRESS_764903] (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY tologist is the expert usually consulted by [CONTACT_581726]. This would usually be a hepatologist, but may be a gastroenterologist. 
PUBLIC COPY potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
PUBLIC COPY Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization 27 Feb 2019
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Follow up
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization Evaluation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization ConfidentialThis document cannot be used to support any marketing authorization Confidentialphosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio
This document cannot be used to support any marketing authorization phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio
induced liver injury; ULN=upper limit of normal
This document cannot be used to support any marketing authorization induced liver injury; ULN=upper limit of normal
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
This document cannot be used to support any marketing authorization Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
bility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
This document cannot be used to support any marketing authorization bility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
tologist is the expert usually consulted by [CONTACT_581727]. This would usually be a hepatologist, but may be a gastroenterologist. 
This document cannot be used to support any marketing authorization potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
This document cannot be used to support any marketing authorization Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.Evaluation
application and any extensions or variations thereof.phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio
application and any extensions or variations thereof.phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio
induced liver injury; ULN=upper limit of normal
application and any extensions or variations thereof.induced liver injury; ULN=upper limit of normal
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
application and any extensions or variations thereof.Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms 
bility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
application and any extensions or variations thereof.bility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
tologist is the expert usually consulted by [CONTACT_581657].tologist is the expert usually consulted by [CONTACT_581724]. Determination of stabi
application and any extensions or variations thereof.Unless an alternative monitoring schedule is agreed by [CONTACT_352315]. Determination of stabi
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
application and any extensions or variations thereof.Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
application and any extensions or variations thereof.
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 132of 136Change #19
Section [IP_ADDRESS], Immediate action: Determination of IMP discontinuation, 
paragraph 2
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to immediate and permanent discontinuation (see Section 6.3.1 and Table 12‒3 for details).
Has been changed to: 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to immediate discontinuation (see Section 6.3.1 and Table 12‒3 for details).
Change #20
Section [IP_ADDRESS], Testing: Identification/exclusion of alternative etiology, 
Table 12-4, chemistry
Chemistry Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Has been changed to: 
Chemistry Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Change #21
Section 15.1, Definition of analysis sets
The following analysis set has been added: 
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at 
least [ADDRESS_764904]-Baseline assessments.
Change #[ADDRESS_764905] recent version of the Medical Dictionary for 
Regulatory Activities (MedDRA®). The incidence of treatment-emergent adverse events PUBLIC COPY PUBLIC COPY PUBLIC COPY If total bilirubin ≥1.5xULN, obtain fractionated bilirubin
PUBLIC COPY If total bilirubin ≥1.5xULN, obtain fractionated bilirubin
PUBLIC COPY Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
PUBLIC COPY Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
This document cannot be used to support any marketing authorization The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
mmediate investigation) to 
This document cannot be used to support any marketing authorization mmediate investigation) to 
Section [IP_ADDRESS], Testing: Identification/exclusion of alternative etiology, 
This document cannot be used to support any marketing authorization Section [IP_ADDRESS], Testing: Identification/exclusion of alternative etiology, 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin
This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Sodium, potassium, chloride, glucose, BUN, creatinine
This document cannot be used to support any marketing authorization Sodium, potassium, chloride, glucose, BUN, creatinine
This document cannot be used to support any marketing authorization Total bilirubin, ALP, AST, ALT, GGT, 
This document cannot be used to support any marketing authorization Total bilirubin, ALP, AST, ALT, GGT, 
This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
This document cannot be used to support any marketing authorization If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Section 15.1, Definition of analysis sets
This document cannot be used to support any marketing authorization Section 15.1, Definition of analysis sets
The following analysis set has been added: 
This document cannot be used to support any marketing authorization The following analysis set has been added: 
The PET Per
This document cannot be used to support any marketing authorization The PET Per
least [ADDRESS_764906]
Change #2This document cannot be used to support any marketing authorization Change #2application and any extensions or variations thereof.mmediate investigation) to 
application and any extensions or variations thereof.mmediate investigation) to 
Section [IP_ADDRESS], Testing: Identification/exclusion of alternative etiology, 
application and any extensions or variations thereof.Section [IP_ADDRESS], Testing: Identification/exclusion of alternative etiology, 
application and any extensions or variations thereof.application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin
application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.to obtain % direct bilirubin
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Sodium, potassium, chloride, glucose, BUN, creatinine
application and any extensions or variations thereof.Sodium, potassium, chloride, glucose, BUN, creatinine
application and any extensions or variations thereof.Total bilirubin, ALP, AST, ALT, GGT, 
application and any extensions or variations thereof.Total bilirubin, ALP, AST, ALT, GGT, 
application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
application and any extensions or variations thereof.application and any extensions or variations thereof.Section 15.1, Definition of analysis sets
application and any extensions or variations thereof.Section 15.1, Definition of analysis sets
The following analysis set has been added: 
application and any extensions or variations thereof.The following analysis set has been added: 
The PET Per
application and any extensions or variations thereof.The PET Per -
application and any extensions or variations thereof.-
application and any extensions or variations thereof.Protocol Set (PET
application and any extensions or variations thereof.Protocol Set (PET
dose of the IMP and have evaluable PETapplication and any extensions or variations thereof.dose of the IMP and have evaluable PET
[ADDRESS_764907]
UCB 27 Feb 2019
Clinical Study Protocol Bimekizumab AS0013
Confidential Page 133of 136(TEAEs) will be summarized descriptively by [CONTACT_11189], preferred term, and 
treatment group. Additional tables will summarize TEAEs by [CONTACT_58998], 
TEAEs leading to withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Has been changed to: 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA
®, version 19.0 ). The incidence of treatment-emergent adverse events (TEAEs) will be 
summarized descriptively by [CONTACT_11189], preferred term, and treatment group. Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Change #[ADDRESS_764908]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
alter or terminate the trial. Interim analyses will be conducted by [CONTACT_581728]. This process will ensure that no unnecessary or unintentional unblinding 
occurs. The unblinded team will not disclose any unblinded information to the blinded study team and the storage of all unblinded documentation will be held securely and separately from the rest of the study documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This study will include 3 informal unblinded interim analyses; the first after approximately 
[ADDRESS_764909]’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
of the interim analyses will lead to any formal decision to alter or terminate the study . 
Interim analyses will be conducted by [CONTACT_581729]. This 
process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team 
will not disclose any unblinded information to the blinded study team and the storage of all PUBLIC COPY study has completed the Week [ADDRESS_764910]’s 
PUBLIC COPY study has completed the Week [ADDRESS_764911]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
PUBLIC COPY participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis
PUBLIC COPY personnel to review results from the primary efficacy analysis
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
PUBLIC COPY secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
PUBLIC COPY Management decisions; consequently, neither analysis and will lead to any formal decision to 
im analyses will be conducted by [CONTACT_581730]. This process will ensure that no unnecessary or unintentional unblinding 
PUBLIC COPY analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
urs. The unblinded team will not disclose any unblinded information to the blinded study PUBLIC COPY urs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from PUBLIC COPY team and the storage of all unblinded documentation will be held securely and separately from 
This document cannot be used to support any marketing authorization emergent adverse events (TEAEs) will be 
This document cannot be used to support any marketing authorization emergent adverse events (TEAEs) will be 
iptively by [CONTACT_11189], preferred term, and treatment group. 
This document cannot be used to support any marketing authorization iptively by [CONTACT_11189], preferred term, and treatment group. 
Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
This document cannot be used to support any marketing authorization Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
withdrawal from the study, serious TEAEs, and deaths. All AE information will be liste
This document cannot be used to support any marketing authorization withdrawal from the study, serious TEAEs, and deaths. All AE information will be liste d.
This document cannot be used to support any marketing authorization d.
Section 15.11, Planned interim analysis and data monitoring
This document cannot be used to support any marketing authorization Section 15.11, Planned interim analysis and data monitoring
This study will include two unblinded interim analyses, the first after approximately [ADDRESS_764912]’s 
This document cannot be used to support any marketing authorization study has completed the Week [ADDRESS_764913]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
This document cannot be used to support any marketing authorization participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis
This document cannot be used to support any marketing authorization personnel to review results from the primary efficacy analysis and a subset of the analyses of 
This document cannot be used to support any marketing authorization and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
This document cannot be used to support any marketing authorization secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
This document cannot be used to support any marketing authorization Management decisions; consequently, neither analysis and will lead to any formal decision to 
im analyses will be conducted by [CONTACT_581731]. This process will ensure that no unnecessary or unintentional unblinding 
This document cannot be used to support any marketing authorization analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
urs. The unblinded team will not disclose any unblinded information to the blinded study 
This document cannot be used to support any marketing authorization urs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
This document cannot be used to support any marketing authorization team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the s
This document cannot be used to support any marketing authorization the rest of the study documentation and outputs up until the end of the s
All analyses and unblinding instructions will be prespecified in the interim SAP.
This document cannot be used to support any marketing authorization All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This document cannot be used to support any marketing authorization Has been changed to: 
This study will include 
This document cannot be used to support any marketing authorization This study will include [ADDRESS_764914]’s participation has ended prematurely. 
This document cannot be used to support any marketing authorization Treatment Period or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
This document cannot be used to support any marketing authorization The purpose of these interim analyses is for Sponsor key personnel to review results from the 
This document cannot be used to support any marketing authorization primary efficacy analysis and a subset of th
This document cannot be used to support any marketing authorization primary efficacy analysis and a subset of th
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, 
This document cannot be used to support any marketing authorization to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, 
of the interim analyses
This document cannot be used to support any marketing authorization of the interim analysesapplication and any extensions or variations thereof.Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
application and any extensions or variations thereof.Additional tables will summarize TEAEs by [CONTACT_58998], TEAEs leading to 
This study will include two unblinded interim analyses, the first after approximately [ADDRESS_764915]’s 
application and any extensions or variations thereof.study has completed the Week [ADDRESS_764916]’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
application and any extensions or variations thereof.participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
and a subset of the analyses of 
application and any extensions or variations thereof.and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
application and any extensions or variations thereof.secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
application and any extensions or variations thereof.Management decisions; consequently, neither analysis and will lead to any formal decision to 
im analyses will be conducted by [CONTACT_581719].im analyses will be conducted by [CONTACT_581720].will follow internal SOPs for the formal process to control the unblinding of the study for interim 
analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
application and any extensions or variations thereof.analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
urs. The unblinded team will not disclose any unblinded information to the blinded study 
application and any extensions or variations thereof.urs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
application and any extensions or variations thereof.team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the s
application and any extensions or variations thereof.the rest of the study documentation and outputs up until the end of the s
All analyses and unblinding instructions will be prespecified in the interim SAP.
application and any extensions or variations thereof.All analyses and unblinding instructions will be prespecified in the interim SAP.
3 informal
application and any extensions or variations thereof.3 informal unblinded interim analyses; the first after approximately 
application and any extensions or variations thereof.unblinded interim analyses; the first after approximately 
subjects have completed [ADDRESS_764917]’s participation has ended prematurely. 
application and any extensions or variations thereof.Treatment Period or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the application and any extensions or variations thereof.The purpose of these interim analyses is for Sponsor key personnel to review results from the application and any extensions or variations thereof.primary efficacy analysis and a subset of th application and any extensions or variations thereof.primary efficacy analysis and a subset of th
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, application and any extensions or variations thereof.to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, 
UCB [ADDRESS_764918] of the study 
documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #[ADDRESS_764919] paragraph
A sufficient number of subjects will be enrolled in order to ensure 60 subjects are available at 
Week 12 to compare the change from Baseline in ASDAS between bimekizumab and CZP.
Has been changed to: 
A sufficient number of subjects will be enrolled in order to ensure at least [ADDRESS_764920]/MRI substudy.
PUBLIC COPY 
This document cannot be used to support any marketing authorization A sufficient number of subjects will be enrolled in order to ensure [ADDRESS_764921]/MRI substudy.
This document cannot be used to support any marketing authorization CT/MRI substudy.
application and any extensions or variations thereof.[ADDRESS_764922]/MRI substudy.
application and any extensions or variations thereof.CT/MRI substudy.
UCB [ADDRESS_764923].
Investigator:
Printed name [CONTACT_1782]/Signature
[CONTACT_581734]/Signature
[CONTACT_581734]/Signature
[CONTACT_581735] 
[CONTACT_581732], unless other agreements were made in a 
This document cannot be used to support any marketing authorization All rights of publication of the results reside with UCB, unless other agreements were made in a 
This document cannot be used to support any marketing authorization Date/Signature
[CONTACT_581736]/Signature
[CONTACT_122253].le to third parties without prior authorization by 
[INVESTIGATOR_581504].le to third parties without prior authorization by 
[INVESTIGATOR_581504].All rights of publication of the results reside with UCB, unless other agreements were made in a 
application and any extensions or variations thereof.All rights of publication of the results reside with UCB, unless other agreements were made in a 
application and any extensions or variations thereof.Date/Signature
[INVESTIGATOR_581504].Date/Signature
[INVESTIGATOR_581504].
UCB [ADDRESS_764924] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
PUBLIC COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.
Approval Signatures
Name: [INVESTIGATOR_17174]0013-protocol-amend-3
Version: 1. 0
Document Number: CLIN-000130278
Title: AS0013 Protocol Amendment 3
Approved Date: [ADDRESS_764925]: ApprovedName: [CONTACT_18469]: MedicalDate of Signature: 05-Mar-2019 09:01:24 GMT[PHONE_006]
ApprovalVerdict: ApprovedName:[CONTACT_18469]: ClinicalDate of Signature: 05-Mar-2019 20:20:19 GMT[PHONE_006]
ApprovalVerdict: ApprovedName:[CONTACT_18469]: ClinicalDate of Signature: 06-Mar-2019 11:03:07 GMT[PHONE_006]PUBLIC COPY PUBLIC COPY Document Approvals
PUBLIC COPY Document Approvals
PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY PUBLIC COPY 
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Document Approvals
This document cannot be used to support any marketing authorization Document Approvals
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization Name: 
[CONTACT_581733]: 
Capacity: Medical
This document cannot be used to support any marketing authorization Capacity: Medical
Date of Signature: 05-Mar-2019 09:01:24 GMT[PHONE_006]
This document cannot be used to support any marketing authorization Date of Signature: 05-Mar-2019 09:01:24 GMT[PHONE_006]
This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization This document cannot be used to support any marketing authorization application and any extensions or variations thereof.application and any extensions or variations thereof.Document Approvals
application and any extensions or variations thereof.Document Approvals
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Capacity: Medical
application and any extensions or variations thereof.Capacity: Medical
Date of Signature: 05-Mar-2019 09:01:24 GMT[PHONE_006]
application and any extensions or variations thereof.Date of Signature: 05-Mar-2019 09:01:24 GMT[PHONE_006]
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.Name:
[INVESTIGATOR_581504].Name:
[CONTACT_18469]: Clinical
application and any extensions or variations thereof.Capacity: Clinical
Date of Signature: 05-Mar-2019 20:20:19 GMT[PHONE_006]
application and any extensions or variations thereof.Date of Signature: 05-Mar-2019 20:20:19 GMT[PHONE_006]
application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.application and any extensions or variations thereof.